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Summary 
Conversion of the essential n-3 (18:3n-3) and n-6 (18:2n-6) fatty acids to longer chain 
polyunsaturated fatty acids (PUFA) involves sequential desaturation and elongation reactions. 
Previous studies have reported gender differences in n-3 PUFA synthesis, whereas the effect of age 
is less clear. n-3 PUFAs are reported to have important effects on immune cell function. A previous 
study reported long chain PUFA synthesis in mitogen stimulated but not quiescent peripheral blood 
mononuclear cells (PBMCs). However, the underlying mechanism is not known. 
PUFA synthesis was investigated in PBMCs incubated with [1-13C]18:3n-3 for 48 h. Activation with 
the T-lymphocyte mitogen concanavalin A (Con A) increased PUFA synthesis. 22:6n-3 synthesis was 
not detected. [1-13C] incorporation was greatest for 20:3n-3 suggesting initial chain elongation is an 
important fate for 18:3n-3. Con A increased expression of three key genes (FADS2, FADS1 and 
ELOVL5) involved in PUFA synthesis, suggesting upregulation of the pathway is controlled at the 
transcriptional level. ELOVL2 expression was negligible, possibly explaining the lack of 22:6n-3 
synthesis. Con A increased methylation of 12 CpGs in the FADS2 promoter contradicting the general 
view that DNA methylation represses transcription. Subsequent 5’RACE analysis verified that 
activated PBMCs were not using an alternative promoter for FADS2 transcription. Contrary to 
expectation, 18:3n-3 conversion in activated PBMCs was not affected by gender or menopausal 
status and there was no clear age effect.  
PUFA synthesis was constitutive in the Jurkat T-lymphocyte leukaemic cell-line and was higher than 
in PBMCs. FADS2, FADS1 and ELOVL5 mRNA expression was also higher in Jurkat cells and was 
associated with 50% lower methylation of 17 CpGs in the FADS2 promoter, suggesting 
transcriptional dysregulation of PUFA synthesis in Jurkat cells involves altered DNA methylation. 
These findings have provided novel insights into the regulation of PUFA biosynthesis in PBMCs and 
upregulation of the pathway in activated PBMCs suggests that newly synthesised PUFAs may be 
important for cell function. 
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Fatty acid nomenclature 
Notation Trivial Name   Systematic name 
18:3n-3 α-Linolenic acid   all-cis-9,12,15-Octadecatrienoic acid 
18:4n-3 Stearidonic acid   all-cis-6,9,12,15-Octadecatetraenoic acid 
20:3n-3 Eicosatrienoic acid   all-cis-11,14,17-Eicosatrienoic acid   
    
20:4n-3 Eicosatetraenoic acid  all-cis-8,11,14,17-Eicosatetraenoic acid 
20:5n-3 Eicosapentaenoic acid  all-cis-5,8,11,14,17-Eicosapentaenoic acid 
22:5n-3 Docosapentaenoic acid  all-cis-7,10,13,16,19-Docosapentaenoic acid 
22:6n-3 Docosahexaenoic acid  all-cis-4,7,10,13,16,19-Docosahexaenoic acid 
24:5n-3 Tetracosapentaenoic acid all-cis-9,12,15,18,21-Tetracosapentaenoic acid 
24:6n-3 Tetracosahexaenoic acid  all-cis-6,9,12,15,18,21-Tetracosahexaenoic acid 
 
18:2n-6 Linoleic acid    all-cis-9,12-Octadecadienoic acid 
18:3n-6 γ-Linolenic acid   all-cis-6,9,12-Octadecatrienoic acid 
20:2n-6 Eicosadienoic acid   all-cis-11,14-Eicosadienoic acid 
20:3n-6 Dihomo-γ-linolenic acid  all-cis-8,11,14-Eicosatrienoic acid 
20:4n-6 Arachidonic acid   all-cis-5,8,11,14-Eicosatetraenoic acid 
22:4n-6 Adrenic acid    all-cis-7,10,13,16-Docosatetraenoic acid 
22:5n-6 Docosapentaenoic acid   all-cis-4,7,10,13,16-Docosapentaenoic acid 
 
16:0  Palmitic acid   Hexadecanoic acid    
17:0  Margaric acid   Heptadecanoic acid 
18:0  Stearic acid    Octadecanoic acid 
 
16:1n-7 Palmitoleic acid   cis-9-Hexadecenoic acid 
18:1n-9 Oleic acid    cis-9-Octadecenoic acid 
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1.1 Fatty acid structure 
Fatty acids consist of a hydrocarbon (acyl) chain with a carboxyl group at one end and a methyl 
group at the other end. The acidic carboxyl group reacts readily to form ester links with hydroxyl 
groups (1). Fatty acids can be esterified to produce more complex lipids such as cholesterol esters 
(CE) and acylglycerols, which include triacylglycerols (TG) and phospholipids. Fatty acids are also 
present in the body as non-esterified fatty acids (NEFA) where they are bound to serum albumin 
for transport to target tissues. Phospholipids are the main constituent of biological membranes. 
Common phospholipids found in membranes include the phosphoglycerides: phosphatidylcholine 
(PC), phosphatidylethanolamine (PE), phospatidylserine (PS), diphosphatidylglycerol and 
phosphatidylinositol. Sphingomyelin is another class of phospholipid found in membranes but in 
contrast to the phosphoglycerides, sphingomyelin is not derived from glycerol (2). 
Long chain fatty acids (>12 carbons) are most common in mammalian plasma and tissues.  They can 
be classified as saturated (SFA), monounsaturated (MUFA) or polyunsaturated (PUFA) fatty acids 
based on the number of double bonds they contain – zero, one or two or more, respectively. Double 
bonds can be in either the cis or trans configuration. The length of the acyl chain and the number, 
position and orientation of the double bonds, all influence the physical and biological properties of 
the fatty acid.  
1.2 Fatty acid nomenclature 
Fatty acids can be named using a trivial name, systematic name, or shorthand notation. The 
traditional systematic name denotes the number of carbons in the acyl chain and, when present, 
the position and configuration of double bonds relative to the carboxyl carbon (carbon 1). 
Therefore, using this naming system, the 18 carbon saturated fatty acid stearic acid (trivial name) 
is written as octadecanoic acid and the 18 carbon PUFA α-linolenic acid (trivial name) is written as 
cis 9, cis 12, cis 15-octadecatrienoic acid or more simply, all-cis-9,12,15-octadecatrienoic. 
Shorthand notation is now regularly used for naming fatty acids and is based on the fatty acid chain 
length and the number and position of double bonds. This naming system lists the first double bond 
counting from the methyl carbon of the fatty acid, which is sometimes referred to as the omega (ω) 
carbon. For example, α-linolenic acid is written as 18:3n-3. This means it has a chain length of 18 
carbons (18), contains three double bonds (:3) and the first double bond occurs on the third carbon 
counting from the methyl end (n-3) of the fatty acid. The shorthand notation for stearic acid is 18:0 
as it consists of 18 carbons and no double bonds. The shorthand notation for naming fatty acids is 
useful when considering fatty acid biosynthesis as they are are elongated from their carboxyl end 
and therefore fatty acids formed in the same biosynthetic pathway have the same ‘n‘ notation. For 
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example, elongation of 18:3n-3 and linoleic acid (18:2n-6) gives rise to the n-3 and n-6 series of 
PUFA, respectively. Therefore, the shorthand notation will be used in this thesis. 
1.3 Biosynthesis of fatty acids 
Fatty acid synthesis (lipogenesis) involves successive addition of two carbon units from acetyl-CoA 
to the fatty acid chain. Glucose breakdown via glycolysis results in the production of pyruvate, 
which is converted to acetyl-CoA by oxidative decarboxylation (3). Synthesis of fatty acids from 
acetyl-CoA requires formation of the activated intermediate malonyl-CoA by the enzyme acetyl-
CoA carboxylase (ACC) and then two carbon units from malonyl-CoA are added to the activated 
carboxyl end of the growing acyl chain by fatty acid synthase (FAS). The primary product of de novo 
synthesis is palmitic acid (16:0) but the action of thioesterases can also result in the release of 
shorter chain fatty acids (2). 
1.4 Fatty acid modification 
Newly synthesised fatty acids and fatty acids obtained from the diet can be further modified by 
elongation and desaturation or by hydroxylation; the latter has been demonstrated in the nervous 
system for the formation of some myelin lipids (2). 16:0 can be converted to 18:0 by the action of 
elongase enzymes. 16:0 or 18:0 can be converted to 16:1n-7 and oleic acid (18:1n-9), respectively, 
by the enzyme delta-9 destaurase, also referred to as stearoyl-CoA desaturase, which catalyses the 
addition of a cis double bond between carbon 9 and 10 relative to the carboxyl end of the fatty 
acid. In mammals, desaturation and elongation of fatty acids occurs in the endoplasmic reticulum 
(3). 
Important substrates for the synthesis of PUFAs are the essential fatty acids 18:2n-6 and 18:3n-3, 
which can only be obtained from the diet. This is because mammals do not have the enzymes that 
introduce double bonds beyond carbon 9 in the acyl chain and consequently cannot synthesise 
18:2n-6 and 18:3n-3. These fatty acids can be obtained from the diet by eating higher plants that 
have the enzymes to insert new double bonds between existing double bonds and the terminal 
methyl group. Plants are able to desaturate 18:1n-9 to yield 18:2n-6 (catalysed by delta-12 
desaturase), which can then be further desaturated by delta-15 desaturase to produce 18:3n-3 (1). 
These fatty acids are the simplest of the n-6 and n-3 series of fatty acids and although they cannot 
be synthesised by mammalian cells they can undergo further desaturation and elongation.  
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1.4.1 Desaturation and elongation of n-3 and n-6 PUFA 
Both n-3 and n-6 PUFA are metabolised by the same series of enzymes (Figure 1.1). This pathway 
was characterised by a number of experiments in rat liver and has been comprehensively reviewed 
(4). The initial reaction, catalysed by delta-6 desaturase, is considered the rate limiting reaction of 
the pathway. Since both n-3 and n-6 PUFA are metabolised by the same series of enzymes there is 
potential for competition. The affinity of delta-6 desaturase is greater for 18:3n-3 than for 18:2n-6 
(4) but because 18:2n-6 is more common than 18:3n-3 in most human diets (5) the conversion of 
n-6 PUFA is greater (6).  
The reactions occur in the endoplasmic reticulum, except the final reaction in the pathway which 
results in the formation of docosahexaenoic acid (22:6n-3) and n-6 docosapentaenoic acid (22:5n-
6). With respect to n-3 PUFA, the initial reaction involves the conversion of 18:3n-3 to stearidonic 
acid (18:4n-3) by delta-6 desaturase. Next, addition of two carbons by elongase-5 activity results in 
the formation of eicosatetraenoic acid (20:4n-3). Delta-5 desaturase catalyses the conversion to 
eicosapentaenoic acid (20:5n-3) and subsequent addition of two carbons by elongase activity yields 
docosapentaenoic acid (22:5n-3). Conversion of 22:5n-3 to docosahexaenoic acid (22:6n-3) is 
generally accepted to occur by the following pathway: elongation of 22:5n-3 to 
tetracosapentaenoic acid (24:5n-3) by elongase-2, followed by delta-6 desaturation of 24:5n-3 to 
form tetracosahexaenoic acid (24:6n-3), which is then translocated from the ER to the peroxisome 
where one cycle of the β-oxidation pathway shortens the chain by two carbons to form 22:6n-3. 
How the translocation steps and β-oxidation are regulated is not entirely known but it could 
represent a point of metabolic control that results in regulation of 22:6n-3 synthesis independently 
from the synthesis of the preceding  long chain n-3 PUFA in the pathway (4). 
The conversion of 22:5n-3 to 22:6n-3 has been a matter of debate and an alternative mechanism, 
whereby 22:5n-3 is converted to 22:6n-3 by delta-4 desaturase activity without peroxisomal 
involvement, has been suggested (7). However, stable isotope experiments in rat liver microsomes 
and hepatocytes and human Y-79 retinoblastoma cells have demonstrated that synthesis of 22:6n-
3 occurs independently of delta-4 desaturation by the pathway detailed above (8, 9). Furthermore, 
in human cells, specific inhibition of delta-6 desaturase by 2,2-diphenyl-5-(4-[[(1 E)-pyridin-3-yl-
methylidene]amino]piperazin-1-yl)pentanenitrile (SC-26196) reduced conversion of stable isotope 
labelled 22:5n-3 and 24:5n-3 to 22:6n-3 by 75% and 84%, respectively, strongly supporting that 
22:6n-3 synthesis involves delta-6 desaturation of 24:5n-3 (10). However, in human cells, the delta-
6 desaturase enzyme was recently demonstrated to have delta-4 desaturase activity and the ability 
to directly catalyse delta-4 desaturation of 22:5n-3 to yield 22:6n-3 (11). This could explain the 
reduced conversion of 22:5n-3 to 22:6n-3 in the presence of SC-26196 shown by Harmon et al., 
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2003, if delta-6 desaturase catalysed delta-4 desaturation of 22:5n-3 to form 22:6n-3 (10). 
However, the reduced conversion of 24:5n-3 to 22:6n-3 in the presence of SC-26196 indicated that 
the pathway involving delta-6 desaturation to form 22:6n-3 was functioning (10).    
 
 
Figure 1.1. The n-3 and n-6 PUFA desaturation and elongation pathway. 
The enzymes that catalyse each conversion are in the centre with their corresponding gene written 
above. Delta is represented by the symbol Δ.  
 
1.4.2 Delta-6 and delta-5 desaturase enzymes 
Desaturase enzymes introduce cis double bonds between particular carbons of the fatty acid chain. 
Delta-6 and delta-5 desaturases introduce a double bond after the sixth and fifth carbon atoms, 
respectively, from the carboxyl end of the fatty acid carbon chain. They are classified as front-end 
desaturases as they are able to insert a double bond between the pre-existing double bond and the 
carboxyl end of the fatty acid. In eukaryotic cells, delta-6 and delta-5 desaturases are anchored in 
the ER membrane. They contain an N-terminal cytochrome b5-like domain and a C-terminal 
desaturation domain (12). Three conserved histidine-rich motifs act at the di-iron catalytic centre 
of the desaturases (13). Cytochrome b5 functions in the electron transfer system in the 
desaturation reaction and mutation or deletion of the cytochrome b5-like domain have 
demonstrated it is essential for the activity of rat delta-6 desaturase, which could not be rescued 
by endogenous cytochrome b5 (14). 
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In humans, delta-6 desaturase is encoded by the FADS2 gene and delta-5 desaturase is encoded by 
the FADS1 gene. Delta-6 and delta-5 desaturase enzymes are expressed in many human tissues 
including the lung, kidney, pancreas and skeletal muscle, with the greatest activities found in the 
liver, heart and brain (15, 16). They are clustered within a 92 kb region on chromosome 11 at 11q12-
q13.1 with a third FADS gene (FADS3) and their similar exon/intron organisation suggests evolution 
from a common ancestor by gene duplication events (17). FADS1 and FADS2 are positioned in head-
to-head orientation with an 11 kb region between the first exons of both genes. It has been 
suggested that, due to the proximity of the FADS1 and FADS2 promoters, the 11 kb intergenic region 
might contain common regulatory sequences that coordinate the transcription of both genes (16, 
18).  
The FADS2 gene product displays both diverse substrate specificity and desaturase activities (11, 
19). It is reported to act on at least seven substrates including 18:2n-6, 18:3n-3, eicosadienoic acid 
(20:2n-6), 20:3n-3, 24:4n-6, 24:5n-3 and 16:0 (20-22) and is capable of introducing double bonds at 
the delta-6, delta-4 and delta-8 positions (11, 19). Whether the same delta-6 desaturase enzyme 
catalyses both the desaturation of 18:3n-3 and 24:5n-3 has been a matter for debate. The idea that 
there may be a distinctive delta-6 desaturase showing selectivity for 24 carbon PUFAs came from 
observations that most cells exhibit delta-6 desaturase activities and the ability to retro-convert 
fatty acids yet few cells have the ability to synthesise significant amounts of 22:6n-3 (9). This idea 
is supported by the existence of different delta-6 desaturase isoforms and experiments in cultured 
human cells that showed an increase delta-6 desaturase activity on 18:3n-3 under certain 
conditions but unchanged or decreased 22:6n-3 synthesis (9). However, this observation might be 
explained by other factors such as the preferential delta-6 desaturation of 18:3n-3 compared with 
24:5n-3, shown by competition studies (23) or differential regulation of the elongation or 
translocation steps involved in synthesis of 22:6n-3. Furthermore, in cloning experiments the same 
rat delta-6 desaturase has been shown to catalyse both the conversion of 18:3n-3 to 18:4n-3 and 
the conversion 24:5n-3 to 22:6n-3 (20). 
1.4.3 Elongase-5 and elongase-2 enzymes 
Elongase enzymes function in extending the acyl chain of long chain fatty acids; an ER-bound 
process involving four enzymes and fatty acyl CoA, malonyl CoA and NADPH as substrates, allowing 
addition of two carbons to the fatty acyl chain per cycle (24). The initial and rate-limiting 
condensation reaction is catalysed by elongase enzymes (25). Elongase enzymes are encoded by 
the ELOVL (elongation of very long chain fatty acid) genes. Proteins encoded by  ELOVL1, ELOVL3, 
ELOVL6 and ELOVL7 are selective for saturated and monounsaturated fatty acids and ELOVL2, 
ELOVL4 and ELOVL5 encoded proteins prefer PUFAs as substrates (25). The elongase-5 and 
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elongase-2 enzymes are encoded by the ELOVL5 and ELOVL2 genes, respectively, and are 
responsible for elongation of n-3 and n-6 PUFAs. Both genes are located on chromosome 6 with 
ELOVL5 at 6p12.1 and ELOVL2 at 6p24.2. ELOVL5 is widely expressed with highest levels reported 
in the adrenal glands and testes (26) whereas ELOVL2 displays more tissue specific expression, 
being found in tissues rich in 22:6n-3, such as the liver, testis and brain (27, 28). There has been 
some uncertainty as to where Elongase-5 and Elongase-2 function in the PUFA synthesis pathway 
and they display some overlap in their functions. Elongase-5 is involved in the elongation of 18 and 
20 carbon PUFAs, while elongase-2 utilises 20 and 22 (to produce 24 carbon precursors for 
formation of 22:6n-3 and 22:5n-6) carbon PUFAs as substrates (26, 29-31). ELOVL5 has been shown 
to be expressed at much higher levels than ELOVL2 in rat liver and heart indicating that it might be 
more important for the conversion of 20:5n-3 and 20:4n-6 (29). However, 20:5n-3 elongation was 
maintained in the liver of ELOVL5 knockout mice and interestingly ELOVL2 was upregulated in these 
mice compared with wild-type (WT) controls (32). This suggests that elongase-2 might be important 
for 20 carbon elongation when elongase-5 is diminished although it is not clear whether one or 
both these enzymes normally contribute to the conversion of 20:5n-3 and 20:4n-6 (29).  
1.4.4 The alternative delta-8 desaturation pathway for n-3 and n-6 PUFA synthesis 
Figure 1.2 shows an alternative pathway for n-3 and n-6 PUFA synthesis consisting of elongation of 
18:3n-3 to eicosatrienoic acid (20:3n-3) and 18:2n-6 to 20:2n-6. This is followed by delta-8 
desaturation of 20:3n-3 and 20:2n-6 to form 20:4n-3 and 20:3n-6, respectively, products in the 
conventional pathway (19, 33). The operation of this pathway has been verified by molecular 
cloning and functional characterisation experiments in unicellular organisms (34, 35). However, the 
occurrence and importance of delta-8 desaturation in mammalian tissues has been a debateable 
issue. (33, 36, 37). Evidence for delta-8 desaturation has been provided from experiments in rat 
(38) and human testes (39). Contradictory to these findings, some experiments in mice liver and rat 
liver and testes have reported delta-8 desaturation as either not occurring or as a questionable 
route for the biosynthesis of PUFAs. An early study found no evidence for delta-8 desaturation in 
rat liver in both in vitro and in vivo experiments (37). Another study found no definitive evidence 
for delta-8 desaturation in rat liver and testes based on measurement of radiolabelled products 
(36). However, inconclusive mass spectrometry data suggested a small amount of 20:2n-6 may have 
been metabolised by delta-8 desaturation (36). Analysis of liver lipids in mice fed deuterated 20:3n-
3 revealed that only a minor percentage (4.4%) of identified products were formed by delta-8 
desaturation (33). A much larger proportion of products were formed by initial delta-5 desaturation 
of 20:3n-3 to form the unusual fatty acid 20:4(5,11,14,17) and further elongation to 22:4(7,13,6,19). 
The position of the double bonds relative to the carboxyl carbon have been given here as 
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20:4(5,11,14,17) has the same shorthand notation as eicosatraenoic acid (20:4n-3). A number of 
other studies in rat liver and testes and cultured rat, mouse and human cell lines, have reported 
metabolism of 20:2n-6 and 20:3n-3 to their respective products, 20:3(5,11,14) and 
20:4(5,11,14,17), by delta-5 desaturation (36, 37, 40-44). 
There is no molecular evidence for a specific gene that encodes delta-8 desaturase activity in 
mammalian cells. A study in Saccharomyces cerevisiae transformed with mammalian FADS2 
demonstrated that the delta-6 desaturase enzyme encoded by FADS2 had the ability to catalyse 
delta-8 desaturation of 20:3n-3 and 20:2n-6 to yield 20:4n-3 and 20:3n-6, respectively (19). 
However, this was an artificial system where endogenous PUFA synthesis capacity was lacking and 
therefore important regulatory factors may have been missing. Equivalent results were reported in 
human breast cancer MCF7 cells which lack delta-6 desaturase activity but do possess delta-5 
desaturase activity (43). FADS2 transfected cells were able to convert 20:3n-3 and 20:2n-6 to 20:4n-
3 and 20:3n-6, respectively, by delta-8 desaturation (43). The elongase enzyme responsible for the 
initial reaction in the alternative deta-8 desaturation pathway (the elongation of 18:3n-3 and 18:2n-
6 to 20:3n-3 and 20:2n-6, respectively), has not been clearly identified. However, heterologous 
expression of human ELOVL5 in S. cerevisiae demonstrated that the ELOVL5 gene product was 
capable of elongating 18:3n-3 to 20:3n-3, indicating that elongase-5 might be the enzyme catalysing 
the elongation step in the alternative pathway (26). 
 
 
Figure 1.2. The alternative delta-8 desaturation pathway for n-3 and n-6 PUFA synthesis. 
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1.5 n-3 Polyunsaturated fatty acids 
1.5.1 Dietary sources of n-3 PUFAs 
The main dietary sources of 18:3n-3 include green leaves, nuts (e.g. walnuts), some seeds (e.g. 
linseeds) and cooking oils such as soybean oil, rapeseed oil and linseed oil. In the UK, daily intake 
of 18:3n-3 is estimated to be 1.7 g for males and 1.2 g for females (1). Intake of the n-6 PUFA 18:2n-
6 is considerably higher at 13.5 g per day for males and 9.3 g per day for females (1). The longer 
chain n-3 PUFAs 20:5n-3, 22:5n-3 and 22:6n-3 are consumed in lower amounts compared with 
18:3n-3 (45) and are mainly obtained by eating fish, particularly oily fish (e.g. mackerel, herring, 
salmon, trout and tuna). There is a large variation in fish consumption between individuals (6) but 
for UK adults consumption of oily fish is estimated to be approximately 50 g/week (46, 47). A 
proposed recommended daily intake for 18:3n-3 by the European Food Safety Authority is 2 g/day 
and for 20:5n-3 and 22:6n-3 combined is 250 mg/day (45). However, intake recommendations 
established by national authorities vary between different European countries ranging from 200 
mg to 500 mg per day for 20:5n-3 plus 22:6n-3 (45). In the UK, the recommended daily intake of 
20:5n-3 and 22:6n-3 endorsed by the Scientific Advisory Committee on Nutrition (SACN) is 450 mg 
(46). The evidence supporting recommendations for 20:5n-3 and 22:6n-3 intake provided by 
different international and national bodies is mostly related to lower risk of cardiovascular disease 
(CVD). However, clinical benefits are not consistent in all studies and the relationship between n-3 
PUFAS and risk of CVD may vary in populations with differing prevalence of CVD, which may explain 
why recommendations differ between countries. Furthermore, recommendations may be 
influenced by dietary habits. For example, in countries with high habitual fish intake, considerations 
for recommended 20:5n-3 and 22:6n-3 consumption may not carry such importance. 
1.5.2 Overview of the health Benefits relating to n-3 PUFA consumption 
n-3 PUFAs have many important effects on cell and tissue function and therefore it is not surprising 
that they have been linked to many health benefits. n-3 PUFAs are critical for optimal structure and 
function of biological membranes. The fatty acid composition of the membrane has a strong 
influence on its fluidity and therefore protein movement, which can ultimately affect cell function 
(48, 49). A high level of 22:6n-3 is found in the membrane phospholipids of the brain and retina 
where is important in signalling pathways and neurological function (50, 51). Furthermore, n-3 
PUFAs have important effects on the production of inflammatory mediators, such as eicosanoids 
(52) and the regulation of gene expression (53), consequently influencing cell function. These 
mechanisms of action of n-3 PUFAs are discussed in more detail in section 1.10. 
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The first evidence for the health benefits associated with n-3 PUFA consumption came from studies 
on Inuit populations in Greenland, Northern Canada and Alaska where it was documented that they 
had much lower cardiovascular mortality (54, 55). It was suggested that the high levels of longer 
chain n-3 PUFA consumed in their diet, as a result of the regular intake of seal meat and whale 
blubber, was having a protective action (56). Evidence reviewed from epidemiological studies and 
intervention trials suggests that long chain n-3 PUFA consumption may lower the risk of 
cardiovascular disease (CVD) (57). Supplementation with 20:5n-3 and 22:6n-3 was reported to 
reduce the rate of death from cardiac causes by 20% in a meta-analysis of randomised control trials 
involving patients with cardiac disease (58). Another meta-analysis of cohort studies and clinical 
trials reported that a combined intake of 250 mg of 20:5n-3 and 22:6n-3 per day lowered the risk 
of fatal coronary heart disease by 36%, with no further benefit from higher intakes (59). In contrast, 
some more recent studies have not reported beneficial effects of n-3 PUFA supplementation on 
CVD outcomes (60). For example, neither supplementation (for 40 months) with 18:3n-3 (2 g/day) 
or 20:5n-3 and 22:6n-3 (400 mg/day) reduced the rate of major cardiovascular events (fatal and 
non-fatal CVD and particular cardiac intervention), in a study of 4837 patients who had suffered a 
myocardial infarction (61). Another study of 12,513 patients with multiple CVD risk factors but not 
myocardial infarction found no effect of daily supplementation with 1 g/day n-3 PUFAs (providing 
at least 850 mg of 20:5n-3 and 22:6n-3) on cardiovascular mortality and morbidity over a 5 year 
period (62). A systematic review of the association between n-3 PUFAS and CVD risks factors or 
outcomes was published in 2016. The review included 61 randomized control trials and 37 
longitudinal observational studies. The authors concluded that there was high strength of evidence 
that high marine oil intake does not affect risk of major adverse cardiovascular events, all-cause 
death, sudden cardiac death, coronary revascularisation or blood pressure (63). Furthermore, a 
meta-analysis published in 2012, including 14 randomised, double-blind, placebo controlled trials 
involving 20,485 patients with a history of CVD, concluded that there was insufficient evidence that 
supplementation with n-3 PUFAs (20:5n-3 and 22:6n-3) reduced the risk of overall cardiovascular 
events (64). In summary, although earlier studies reported preventative effects of n-3 PUFA on CVD 
outcomes, the evidence remains inconclusive. Possible reasons for conflicting findings between 
earlier and more recent studies might include differences in supplementation periods and doses, 
sample sizes, dietary factors and improvements in drug treatments.  
In addition to effects on CVD, health benefits relating to n-3 PUFA consumption have been reported 
for a number of different conditions. The effect of n-3 PUFAs on the function of cell types involved 
in inflammation and the production of inflammatory mediators (see section 1.10) suggest they act 
in an anti-inflammatory and inflammation resolving manner (65). Accordingly, n-3 PUFAs have been 
reported to exert beneficial effects in inflammatory conditions such as rheumatoid arthritis, 
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inflammatory bowel disease and asthma (66-69). Furthermore, there is evidence that n-3 PUFAs 
are important for neurological development in infants and protecting against cognitive decline with 
ageing (57). Benefits have also been shown in mental health and behavioural conditions such as 
depression, attention deficit hyperactivity disorder (ADHD) and schizophrenia (57).  
There is less evidence for the protective effects of 18:3n-3. Nevertheless, the risk of fatal coronary 
heart disease was found to be 21% lower in subjects consuming high amounts of 18:3n-3 compared 
with low intakes in a meta-analysis of five prospective cohort studies (70). In such studies, it is 
difficult to isolate the activity of 18:3n-3 itself from the products formed by its conversion. However, 
the impact that 18:3n-3 deficiency has on neurological function strongly suggests that it has an 
important role as a precursor for the synthesis of longer chain n-3 PUFA, particularly 22:6n-3. 
Evidence has been obtained from studies on visual function in rhesus monkeys which have a similar 
retinal anatomy and visual capabilities to humans (71). In a study on infant rhesus monkeys fed an 
18:3n-3 deficient diet, 22:6n-3 in plasma phospholipids was progressively depleted and visual 
function was also shown to decline; visual acuity was half that of control infants at weeks 8 and 12 
of the diet (72). Low levels of 22:6n-3 were also found in the tissues of infant rhesus monkeys fed 
an 18:3n-3 deficient diet from birth and whose mothers had also been fed an 18:3n-3 deficient diet 
during pregnancy (73). The deficient animals showed impaired visual function for their age (73). 
Furthermore, in a human case study, a six year old child receiving parenteral nutrition that was 
deficient in 18:3n-3 experienced peripheral neuropathy and blurred vision. These neurological 
symptoms disappeared when the diet was enriched with 18:3n-3 (74). A study in rats showed that 
animals raised on n-3 deficient diets had 80% less 22:6n-3 in retinal rod outer segment (ROS) 
membranes and this correlated with reduced G-protein-coupled receptor (GPCR) signalling 
efficiency (75).  
1.5.3 Measuring n-3 PUFA status and synthesis 
Accurate assessment of n-3 PUFA status and endogenous synthesis is important for determining 
how these factors relate to health and disease. When measuring fatty acid synthesis it is important 
to consider the type of tissue and lipid fraction the fatty is being measured in and the measurement 
technique that is being used. Measurement of fatty acids status and synthesis in humans often 
requires biological samples that are easy to access and non-invasive, such as blood cells and plasma. 
The most commonly reported tissues for measuring fatty acids in the literature include 
subcutaneous adipose tissue from the buttock or abdomen, plasma, platelets and erythrocytes (76).  
The measurement of a fatty acid in a particular tissue reflects both the intake and the processes 
the fatty acids have been through in the body; for example, absorption, transport, uptake into 
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target tissues, metabolism from storage sites or excretion and also endogenous synthesis (77). 
Exchanges of fatty acids within and between lipid classes in tissues and blood ensures the 
widespread distribution of fatty acids throughout the body (76). Consequently, measurement of a 
fatty acid within a particular tissue represents a complex mixture of processes and will include fatty 
acids that have originated from the diet and from endogenous synthesis. 
1.5.3.1 Measurement of n-3 PUFA synthesis using stable isotope tracers 
Stable isotope tracer studies provide a powerful approach for measuring n-3 PUFA metabolism in 
humans, animal models and in vitro systems. The use of 18:3n-3 labelled with stable isotopes such 
as carbon 13 [13C] or deuterium [2H] has enabled detailed investigations into 18:3n-3 metabolism 
including its conversion to longer chain n-3 PUFA (by measuring labelled elongation products) and 
the extent of β-oxidation (by measuring labelled CO2 on breath or 2H in plasma water). The use of 
stable isotopes also overcomes the health hazards associated with using radioisotopes that were 
traditionally used to measure fatty acid metabolism.  
The introduction of gas chromatography (GC) in the 1950s and its subsequent development gave 
rise to the first convenient means of quantifying stable isotope tracers in complex biological 
mixtures. This approach relied on the development of sophisticated mass spectrometry (MS) 
technology techniques. More recently, GC coupled to a combustion furnace followed by isotope 
ratio mass spectrometry (GC-C-IRMS) has become a popular technique for high precision compound 
specific isotope analysis of fatty acids. This technique permits measurement of isotope ratios at 
precisions sufficient to detect differences due to natural processes in all compounds eluted in 
sufficient quantities from the GC (78). In this process GC separates the analyte from a mixture of 
compounds, the analyte is then oxidatively combusted and the analyte gases are subsequently 
ionised and detected allowing the stable isotope ratio to be measured relative to a standard of 
known isotopic enrichment. 
A disadvantage of IRMS is the fatty acid structure cannot be determined as this technique yields no 
molecular ion data. Furthermore, fatty acids labelled with stable isotopes can be expensive and 
coupled with the time and effort involved with using stable isotope tracer techniques they become 
less attractive for use in large-scale studies. Consequently many studies have small numbers of 
subjects, which raises the question of reliability particularly as individuals often have large natural 
variability (78). Furthermore, the [13C] content of different foods can vary which could lead to 
natural variations between individuals. In order to minimise the impact of this on results, the 
baseline [13C] enrichment must be subtracted. The average natural abundance of [13C] in food is 
about 1.1% but this varies depending on the food source (78). 
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1.5.3.2 Measuring n-3 PUFA synthesis using the product to precursor ratio 
Another technique that has been used to estimate n-3 fatty acid synthesis and therefore desaturase 
activity is the ratio of product, for example, 20:5n-3 or 22:6n-3 to precursor (18:3n-3). This ratio is 
also referred to as the desaturation index. The product to precursor ratio has been used in several 
studies (79-82) and is well established as a surrogate measure of desaturase activity. It is a 
particularly popular measurement in studies where it is used as a predictor of metabolic and CVD 
and mortality (83). 
The main advantage of using this technique to measure fatty acid synthesis is that fatty acid profiles 
and concentrations are relatively simple and cost-effective measurements compared with stable 
isotope tracer techniques. However, a major issue with this is that the fatty acid composition of the 
cell membrane is influenced by both dietary intake and metabolic pathways and therefore can only 
be a crude measure of synthesis. High dietary content of the fatty acid being measured can dilute 
the pool of endogenously synthesised product therefore causing inaccurate measurement. 
Furthermore, there is no evidence that this technique has been validated against direct 
measurements of synthesis using stable isotopes. Su and Brenna (1998), reported a non-tracer 
method for measuring desaturase activity using GC with flame ionisation detection (GC-FID) (84) . 
They simultaneously measured delta-6 and delta-9 desaturase activities in microsome preparations 
using a tracer and non-tracer method and found them to be consistent. However, their 
measurements were based on the rate of decrease in precursor (or increase in product) over time 
and were not merely a measure of the product to precursor ratio. A recent study reported a poor 
relationship between product to precursor ratios and delta-6 desaturase activity and concluded 
that coupled desaturation-elongation products more accurately reflected activity (22). 
1.6 Evidence for 18:3n-3 conversion in humans 
Findings from both stable isotope studies and studies where the amount of 18:3n-3 in the diet was 
increased have given complementary results about the metabolic fate of 18:3n-3. There has been 
consistent evidence from studies that increasing 18:3n-3 intake results in an increase in the 
proportion of 20:5n-3 in plasma and cell lipids. Burdge, 2006, plotted 18:3n-3 intake in g/day against 
the % change in 20:5n-3 and 22:6n-3 in plasma phospholipids using data from a number of different 
studies and found a significant positive correlation with 20:5n-3 (85). Increasing 18:3n-3 
consumption has also been shown to significantly increase the proportion of 22:5n-3 in plasma and 
cell lipids (86-90) but such studies have shown no significant increase in the proportion of 22:6n-3; 
in some studies 22:6n-3 has been shown to decrease significantly (89, 91). However, most of these 
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studies were done in men or mixtures of men and women and therefore do not give a clear 
indication of the ability of women to synthesise 22:6n-3. 
Evidence for the conversion of 18:3n-3 in humans has also come from stable isotope studies where 
participants consume 18:3n-3 labelled with stable isotope. Overall, data from these studies 
suggests that the conversion of 18:3n-3 to 20:5n-3 and 22:5n-3 is low, with estimates ranging from 
0.2% to 6% and 0.13% to 6%, respectively (85). The conversion of 18:3n-3 to 22:6n-3 has been 
shown to range from undetectable (92) up to 4% (93), although 4% appears to be an exception. The 
general consensus from stable isotope tracer studies is that conversion is actually 0.05% or less 
(85).  
1.7 Regulation of 18:3n-3 conversion 
1.7.1 Feedback inhibition and competition 
Stable isotope studies have shown that increasing consumption of 20:5n-3 and 22:6n-3, individually 
or combined, results in feedback inhibition of the pathway. In one study, supplementing the diet 
with 22:6n-3 (6.5 g/day) resulted in a 76% reduction in 20:5n-3 synthesis and an 86% reduction in 
22:6n-3 synthesis (94). Increased consumption of 20:5n-3 and 22:6n-3 has also been shown to 
decrease the synthesis of 22:6n-3 in women (95, 96) and of 20:5n-3 and 22:5n-3 in men (97). 
Another stable isotope study showed that high consumption of 18:3n-3 significantly reduced 
conversion to 20:5n-3; 22:5n-3 and 22:6n-3 synthesis also tended to be lower (98).This data 
suggests that increasing the consumption of n-3 PUFA down regulates their synthesis from 18:3n-3 
although how this happens is not fully understood. A suggested mechanism involves transcriptional 
regulation of FADS2 (6). It is also possible that high levels of 18:3n-3 intake may reduce 22:6n-3 
synthesis due to the role of delta-6 desaturase in two stages of the pathway, thereby increasing 
substrate competition. 
1.7.2 Gender differences in n-3 PUFA synthesis 
Evidence suggests that there are gender differences in 18:3n-3 metabolism. Two comparable stable 
isotope tracer studies, one in women approximately 28 years of age (99) and one in men 
approximately 36 years of age (100), found that 20:5n-3 synthesis was 2.5 times higher and 22:6n-
3 synthesis greater than 200 times higher in women compared with men. Further evidence comes 
from kinetic analysis by Pawlosky et al., (2003) who showed that conversion of 22:5n-3 to 22:6n-3 
had a rate constant coefficient that was approximately 4-fold higher in women compared with men 
who were both consuming a beef based diet (95, 96). Furthermore, the amount of 22:5n-3 used for 
22:6n-3 synthesis was nearly 3-fold greater in women compared with men. However, differences 
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between men and women were not seen when they were both consuming a fish based diet. A major 
limitation of both these studies were the small number of participants (six or less in each group) 
and the studies by Burdge and Wootton, 2002 were conducted at different times (99, 100). 
Findings from several studies suggest that the differences between men and women regarding the 
conversion 18:3n-3 could be explained by the effect of female hormones. It has been reported that 
22:6n-3 synthesis in young women using the oral contraceptive pill containing 17α-ethylnylestradiol 
(EE2) was almost 3-fold higher than in women that did not use it (99) . Another study found that 
oestrogen based hormone replacement therapy in post-menopausal women resulted in greater 
plasma dihomo-γ-linolenic (20:3n-6) and arachidonic acid (20:4n-6) concentrations (101). This 
supports the suggestion that oestrogen may increase the activity of the n-3 and n-6 pathway 
although only n-6 fatty PUFA were found to be increased. In a study by Giltay et al., (2004), the 
concentration of 22:6n-3 in the plasma CE fraction was reported to be significantly higher in women 
than in men who were both consuming diets with controlled 18:3n-3 and energy content (102). In 
this study 22:6n-3 status was also found to be higher in women taking oral contraceptives (0.58%) 
than those who were not (0.53%) but this was not found to be significant (P = 0.08). Furthermore, 
22:6n-3 in plasma CE in male to female transsexuals receiving EE2 was significantly increased (by 
42%) whereas in female to male transsexuals receiving testosterone 22:6n-3 was significantly 
decreased (by  20%). In another study, administration of raloxifene (an estrogen receptor 
modulator) or hormone replacement therapy (HRT) increased the proportion of 22:6n-3 in plasma 
CE by a mean of 22.1% and 14.9%, respectively, compared with the placebo group (103). These 
studies had the advantage of having a large number of participants; however, 22:6n-3 is a minor 
component of the CE pool and is much more abundant in phospholipids.   
The above studies suggested that oestrogen could be responsible for increasing 22:6n-3 synthesis. 
However, in a study investigating n-3 PUFA synthesis in the human hepatocarcinoma cell line 
(HepG2), progesterone, not EE2, significantly increased conversion of deuterated 18:3n-3 to 20:5n-
3, 22:5n-3 and 22:6n-3 and increased the expression of FADS2, FADS1, ELOVL2 and ELOVL5.  A 
limitation of this study is that these measurements were made in a cell line, which may be 
metabolically different to primary cells. However, progesterone also increased the expression of 
these genes in primary human hepatocytes and this was statistically significant for FADS2 (104). In 
another study, this time in rats, oestrogen and progesterone showed a significant positive 
correlation with hepatic Fads2 mRNA expression (105). Furthermore, the HRT administered in the 
study by Giltay et al., (2004) contained conjugated equine oestrogens (CEE) and also a synthetic 
form of progesterone – medroxyprogesterone acetate (MPA) (103). Collectively, the findings from 
these studies indicate gender differences in n-3 PUFA status and synthesis might involve the action 
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of sex hormones. However, it is less clear how the relative roles of oestrogen and progesterone 
influence the pathway and the mechanisms behind this.  
It has been suggested that greater 18:3n-3 conversion in women may be serving a biological role in 
meeting the demands of the developing foetus for 22:6n-3. In humans, the concentration of 22:6n-
3 in plasma PC has been shown to significantly increase between 16 weeks and 40 weeks gestation 
(106). In rats, 22:6n-3 has been shown to increase in plasma and also the liver during pregnancy 
(105). Rapid synthesis of brain tissue occurs during the last trimester of pregnancy and 
consequently the demand for 22:6n-3 is very high (107). Consequently, it has been suggested that 
the supply of 22:6n-3 to the developing foetus by the mother may be of particular importance (108). 
1.7.3 Gender differences in 18:3n-3 β-oxidation 
There is some evidence that the reported gender differences in 22:6n-3 status and 18:3n-3 
conversion could in part, be explained by β-oxidation; the process by which fatty acids are broken 
down for energy production, primarily in the mitochondria. In this process, fatty acids are activated 
by conversion to a fatty acyl CoA and cleavage of the chain generates acetyl CoA, which is used to 
yield energy by the tricarboxylic acid (TCA) cycle or is used in fatty acid synthesis de novo.  
Partitioning of [13C]18:3n-3 towards β-oxidation has been shown to be lower in young women 
compared with young men at 22% (99) and 33% (100) of the administered dose, respectively, over 
the same time period (24 h). Furthermore, in a study in older men, mean proportion of the 
administered dose of [13C]18:3n-3 recovered on breath as 13CO2 over 24 h was 33.8% (97). The 
higher level reported in men may be due to the differences between men and women in the mass 
of tissues such as skeletal and cardiac muscle, liver and kidney, where β-oxidation pathways are 
highly active (85). It could also be due to differences between men and women in the use of fat as 
an energy, which has been reported to be greater in men (109, 110). However, a major limitation 
of the studies reporting gender differences in 18:3n-3 β-oxidation is that there was no correction 
for loss of stable isotope label in the TCA cycle (111) and therefore the level of β-oxidation was 
probably underestimated. 
18:3n-3 has been shown to be the preferred substrate for β-oxidation compared with other fatty 
acids. One study in males demonstrated that, following ingestion of [13C] labelled fatty acids (16:0, 
18:0, 18:1n-9, 18:2n-6, 18:3n-3), recovery of 13CO2 on the breath over a period of 9 h was greater 
for 18:3n-3 than the other fatty acids (112). Preference for 18:3n-3 as a substrate for β-oxidation 
has also been demonstrated in rats (113) and more specifically, 18:3n-3 has been shown to be the 
preferred substrate for the rate limiting enzyme in mitochondrial fatty acid β-oxidation (114).  
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The carbon released by β-oxidation can also be recycled in de novo fatty acid synthesis. In animals, 
labelled 18:3n-3 has been shown to be recycled into brain SFA and MUFA (115). In humans, carbon 
recycling of labelled 18:3n-3 into SFA and MUFA measured in plasma lipids was reported to be 20% 
greater in men compared with women (116). Furthermore, the recycling of carbon from 18:3n-3 
into SFA and MUFA was greater than the conversion to longer chain n-3 PUFA in men, whereas in 
women it was the opposite. In summary, gender differences may be due in part, to differential 
partitioning towards β-oxidation in men and women therefore affecting the availability of 18:3n-3 
for conversion to longer chain n-3 PUFA. This may be made more pronounced by the fact that 18:3n-
3 is a preferred substrate for β-oxidation.  
1.7.4 n-3 PUFA synthesis and ageing 
Many of the health benefits relating to n-3 PUFA could be important for healthy ageing. The 
conversion of 18:3n-3 to longer chain n-3 PUFA and the extent of partitioning towards β-oxidation 
has been studied in older men (mean age 52 years) using the stable isotope tracer [U-13C]18:3n-3 
(97). The proportion of labelled 18:3n-3 recovered as 13CO2 in breath was calculated as being 
comparable to studies involving younger men; however, the proportion of 18:3n-3 converted to 
20:5n-3 and 22:5n-3 was between three and six times lower in the older men (97, 100, 117). The 
amount of 22:6n-3 synthesised did not differ between younger and older men but his may have 
been due to the very low synthesis of 22:6n-3 in men making any differences difficult to detect.  
Another study in humans found a decline in delta-6 desaturase activity with age and this was 
greater in women than in men (118). However, one study found no evidence that desaturase 
function decreased in ageing (post-menopausal) females (119). It should be noted that the last two 
studies mentioned measured the ratio of product to precursor as a way of estimating enzyme 
activity and not direct measures of synthesis using stable isotope tracers. Further evidence for how 
the activity of the n-3 pathway changes with age comes from studies in male rats that reported 
delta-6 desaturase activity in liver microsomes decreased with age (120, 121). Overall, less is known 
compared with gender differences about how ageing affects the conversion of 18:3n-3 to longer 
chain n-3 PUFA. Studies in humans and rats suggest it could decrease with age but more evidence 
is needed.  
1.7.5 Single nucleotide polymorphisms 
A number of studies have reported associations between single nucleotide polymorphisms (SNPs) 
and n-3 and n-6 PUFA levels. SNPs, a common type of genetic variation, are defined as a difference 
in a single nucleotide at a specific position in the genome. A study of 18 SNPs in 727 Caucasian 
adults reported strong associations between variants in the FADS2 and FADS1 genes and n-6 and 
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n-3 PUFA levels in serum phospholipids (122). Subjects carrying the minor alleles of 11 SNPs 
exhibited higher levels of 18:2n-6 and 18:3n-3 and decreased levels of their respective conversion 
products, 18:3n-6 and 20:4n-6 and 20:5n-3 and 22:5n-3 suggesting SNPs were altering desaturase 
activities. Interestingly, these SNPs were also associated with elevated levels of 20:2n-6, a product 
in the alternative delta-8 desaturation pathway, perhaps providing further evidence that delta-6 
desaturase catalyses delta-8 desaturation (see section 1.4.4). Another study, this time involving 
analysis of 13 SNPs in 658 adults with CVD, reported similar findings (123). Minor alleles of 
individual SNPs were associated with higher levels of 18:2n-6, 20:2n-6 and 18:3n-3 and lower levels 
of 20:4n-6 in serum phospholipids and erythrocyte membranes; the strongest association reported 
was with 20:4n-6. No significant association was found for the n-3 PUFAs 18:4n-3, 20:5n-3 or 22:6n-
3, which may have been due to no association with causative genetic factors or due to other factors 
such as diet (123). A study of 1,144 European adolescents, reported associations between SNPs in 
the FADS1 and FADS2 genes and delta-6 and delta-5 desaturase activities (124). The minor alleles 
of nine SNPs were associated with lower delta-5 desaturase activity, whereas the minor allele of 
one SNP was associated with higher delta-6 desaturase activity. However, ratios of n-6 PUFAs were 
used as proxy measures of desaturase activity in this study, which has questionable accuracy (see 
section 1.5.3.2).  
Since many of the SNPs analysed in the FADS1-FADS2 gene cluster are located in untranslated 
regions (UTRs), introns and intergenic regions, it has been suggested that a potential function of 
these SNPs is the regulation of transcription. This is supported by a functional study that showed 
variation in a specific SNP (rs968567) influenced promoter activity and binding of the transcription 
factor ELK1 (125). Promoter activity increased with the minor T allele (125) and in another study 
this minor allele of FADS2 was shown to be associated with higher levels of delta-6 desaturase 
activity (124).  
1.8 Peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) are defined as any peripheral blood cell having a round 
nucleus. These cells are a critical component of the immune system, collectively having important 
roles in innate (responses not specific to a particular pathogen) and adaptive (refers to the response 
to a specific antigen) immune responses (126, 127). PBMCs consist of lymphocytes (T-lymphocytes, 
B-lymphocytes and Natural Killer (NK) lymphocytes), monocytes and dendritic cells. In humans, the 
frequencies of these populations vary across individuals but PBMCs are typically composed of 70-
90% lymphocytes and 10-20% monocytes, while dendritic cells are rare, accounting for only 1-2%. 
The lymphocyte population consists of approximately 70-85% T-lymphocytes, 5-10% B-lymphocytes 
and 5-20% NK cells (128). B-lymphocytes mature in the bone marrow and are the cells responsible 
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for producing antibodies, also called immunoglobulins (Ig). The antibodies produced by B-
lymphocytes recognise individual antigens and function to neutralise and stimulate removal of 
pathogens. This type of immune protection is termed the humoral response, a component of the 
adaptive immune system (129). Monocytes also mature in the bone marrow and are the largest 
type of leukocyte. Monocytes can differentiate into macrophages, large phagocytic cells that play 
a critical role in innate immunity (126). Natural killer (NK) cells are large granular lymphocyte-like 
cells with important functions in innate immunity. They lack antigen-specific receptors but are 
capable of detecting and killing tumour and virus-infected cells. T-lymphocytes mature in the 
thymus and display a central role in cell-mediated immunity, a component of the adaptive immune 
system directed specifically at intracellular pathogens (127). T-lymphocytes recognise and respond 
to specific foreign antigens and can be further categorised into distinct sub-sets based on their 
effector function. The most defined of these sub-sets are helper T-lymphocytes (Th-lymphocytes) 
and cytotoxic T-lymphocytes (CTLs), characterised by the CD4 or CD8 molecules, respectively, on 
the cell surface. The activation of T-lymphocytes is discussed in more detail below. 
1.9 T-lymphocyte activation 
Resting (naïve) T-lymphocytes must be activated to proliferate and differentiate into effector cells 
before they can take part in an immune response. This response also generates memory cells that 
facilitate an accelerated response to subsequent challenge by the same antigen. The primary signal 
for T-lymphocyte activation involves recognition of specific antigens by a surface expressed, highly 
variable T cell receptor (TCR). The TCR cannot bind free antigen directly and instead recognises a 
foreign peptide bound to a major histocompatibility complex (MHC) protein on the surface of an 
antigen presenting cell (APC). There are two types of MHC: MHCI and MHCII. MHCI is expressed 
on virtually all somatic cells and presents endogenously generated peptides to CTLs (130). MHC II 
is found on macrophages, B-lymphocytes and dendritic cells and presents processed antigens 
derived primarily from exogenous sources to Th-lymphocytes (131). The TCR lacks the ability to 
signal independently and requires the CD3 co-receptor to transduce signals from the TCR into the 
lymphocyte. The presence of CD3 is a defining feature of T-lymphocytes and therefore is an 
effective marker used for their identification (132). The CD4 and CD8 co-receptors also play 
important roles in the signalling process acting to stabilise the interaction between the TCR and 
antigenic peptide-MHC complex (Figure 1.3). In addition, activation also requires a second signal 
involving binding of the co-stimulatory receptor CD28 on the T-lymphocyte with B7 molecules on 
the surface of the APC (133). The signals originating from the TCR trigger an intracellular signal 
transduction cascade, transmitting signals away from the membrane into the cytoplasm and 
nucleus resulting in initiation of distinct transcriptional programmes that allow T-lymphocytes to 
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execute their effector functions. One well defined model for signal transduction involves activation 
of phospholipase C (PLC) resulting in hydrolysis of membrane phospholipid phosphatidylinositol 
4,5 bisphosphate. This generates the secondary messengers inositol trisphosphate (IP3) and 
diacylglycerol (DAG), which increase intracellular calcium and activate protein kinase C (PKC), 
respectively (134). 
In response to stimulatory signals, T-lymphocytes secrete cytokines that function in promoting T-
lymphocyte proliferation and differentiation. For example, stimulated T-lymphocytes 
simultaneously synthesise interleukin-2 (IL-2) receptors and secrete IL-2. The binding of IL-2 to its 
receptors activates transcriptional pathways that promote T-lymphocytes to proliferate and 
differentiate into effector cells. Cytokines secreted by activated T-lymphocytes also activate other 
cell types including B-lymphocytes, NK cells and macrophages (135). 
 
 
Figure 1.3. Schematic representation of the TCR engagement with peptide-antigen MHC complex. 
APC, antigen presenting cell; MHC, major histocompatibility complex; TCR, T cell receptor. Adapted 
from Gascoigne, 2006 (136). 
 
1.9.1 T-lymphocyte activation and fatty acids 
T-lymphocyte activation is a highly complex process involving multiple events. De novo synthesis 
and turnover of membrane phospholipids are among the earliest events to occur following T-
lymphocyte activation (137-139). These events result in alterations to the fatty acid composition of 
membrane phospholipids. Early studies on calf and rabbit lymphocytes demonstrated a rapid 
enrichment (occurring within 4 h after stimulation) in polyunsaturated acyl moieties of membrane 
phospholipids (137). Furthermore, experiments in cultured human T-lymphocytes demonstrated 
that levels of 18:1n-9 and the n-3 PUFA 22:5n-3 and 22:6n-3 increased following stimulation where 
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the n-6 PUFA 18:2n-6 and 20:4n-6 decreased (40). These changes mainly affected major 
phospholipids (PC and PE) as opposed to neutral lipids (40). This study also showed that membrane 
fluidity increased following activation; an event documented in a number of earlier studies (140-
143). The authors suggested that the changes in fatty acid composition may contribute to the 
observed increase in membrane fluidity and could be important in the activation process (40).  
Exogenous fatty acids are essential for in vitro activation and continued proliferation of T-
lymphocytes (144, 145). In vitro experiments have demonstrated that activated T-lymphocytes 
increase the uptake of fatty acids, including the n-3 PUFAs 18:3n-3, 20:5n-3, 22:5n-3 and 22:6n-3, 
when available, from the culture medium (40, 49). A recent study in CD4+ T-lymphocytes 
demonstrated that both fatty acid uptake and de novo fatty acid biosynthesis pathways are 
required for robust proliferation after antigenic stimulation; inhibition of either results in 
insufficient proliferation and inhibition of both leads to apoptosis (146). Furthermore, an early 
study demonstrated that activation of n-3 PUFA synthesis from 18:3n-3 occurs in T-lymphocytes 
stimulated to proliferate whereas in resting T-lymphocytes synthesis was negligible (147). The 
findings from this study are discussed in more detail in section 3.1. Importantly, no other studies 
since have investigated the activity or regulation of PUFA synthesis in activated T-lymphocytes. 
Interestingly, a significant level of n-3 and n-6 PUFA biosynthesis has been previously reported in a 
spontaneously dividing leukaemic T-lymphocyte cell line (148), which is reminiscent of the well-
documented high level of de novo fatty acid synthesis observed in cancerous cells (149). De novo 
fatty acid synthesis occurs regardless of the level of exogenous fatty acids and serves important 
functions in membrane biosynthesis, energy storage and the production of signaling molecules in 
highly proliferating cancerous cells (149, 150). Less is known about the activity and importance of 
PUFA synthesis in cancerous cells, which is covered in more detail in section 6.1 in Chapter 6. 
1.9.2 Stimulating lymphocyte proliferation in culture 
Many studies have used cultured T-lymphocytes that have been stimulated to proliferate to 
investigate various T-lymphocyte responses. In vitro T-lymphocyte proliferation can be induced by 
various agents including monoclonal antibodies against certain surface antigens (e.g. CD3), 
chemicals such as calcium ionophore A23187 (increases cytosolic free Ca2+ concentration) and 
phorbol 12-myristate 13-acetate (PMA), which stimulates protein kinase C (135, 151), and 
mitogenic lectins such as concanavalin A (Con A) and phytohemagglutinin (PHA). Con A and PHA 
have been used extensively to study lymphocyte function in vitro. They exert their actions by 
binding and cross linking multiple cell surface glycoproteins, triggering intracellular events leading 
to mitosis (152).  
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Activated lymphocytes are known to express a number of molecules on their cell surface, which 
distinguish them from naïve T-lymphocytes. These molecules include receptor proteins, co-
stimulatory molecules, adhesion molecules, chemokine receptors, and MHC class II molecules 
(153). Examples of receptor proteins known to be upregulated in proliferating lymphocytes include: 
CD69 (the early activation antigen), CD25 (the interleukin-2 receptor), CD71 (the transferrin 
receptor), and CD95 (the Fas receptor). Such activation markers are easily measured using 
fluorochrome labelled monoclonal antibodies and flow cytometric analysis and therefore the 
response to stimulation can be determined (153).  
1.10 Effects of n-3 PUFAs on immune cell function 
n-3 PUFAs have many important effects on cell and tissue function. Specifically, this section focuses 
on the effect of n-3 PUFAs on the functional activities of the cells of the immune system. Evidence 
indicates that n-3 PUFAs have vast effects on diverse immunological processes including cytokine 
production, lymphocyte proliferation, surface molecule expression, phagocytosis and apoptosis 
and NK cell activity and leukocyte chemotaxis (154, 155). Their mechanisms of action can involve 
alterations in the physical properties of the cell membrane such as fluidity and architecture, gene 
expression changes and changes to the production of lipid mediators (156). The effects of n-3 PUFAs 
on some of the processes mentioned above are described in more detail below.  
1.10.1 Lymphocyte proliferation 
A number of studies have investigated the effect of n-3 PUFAs on lymphocyte proliferation 
(summarised in Table 1.1). A study in rats demonstrated that feeding diets containing high levels 
(20%) of fish oil (rich in 20:5n-3 and 22:6n-3) results in suppressed proliferation of mitogen 
stimulated lymphocytes compared with diets rich in other fats (157). Mice fed diets (for 10 days) 
containing purified 20:5n-3 or 22:6n-3 (1%) showed suppressed lymphocyte proliferation in Con A 
stimulated cultures (158). Studies have also reported that n-3 PUFAs suppress the proliferation of 
human lymphocytes. Dietary supplementation with capsules containing 2.4 g of n-3 PUFA per day 
over a 3 month period reduced the proliferation of PHA stimulated PBMCs in women aged 51-68 
years (159). However, this effect was not observed in young women in the same study. 
Furthermore, proliferation was only decreased in older women when lymphocytes were stimulated 
with PHA and not with Con A. Addition of 18 g per day of fish oil to the normal diet for 6 weeks 
suppressed PHA stimulated proliferation of PBMCs by 70% compared to pre-supplement level in 
men aged 21-39 years (160). However, proliferation was only significantly decreased when 
measured 10 weeks after cessation of supplementation and not at the end of the supplementation 
period at 6 weeks. Capsules containing a total of 1 g of 20:5n-3 and 22:6n-3 were shown to decrease 
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proliferation in Con A stimulated PBMCs from healthy older (aged 55-75 years) individuals (161). In 
a another study, supplementing the diet of human volunteers with flaxseed oil (providing 
approximately 15 g of 18:3n-3 per day) has also been shown to suppress the proliferation of PHA 
and Con A stimulated PBMCs (162). In addition to dietary studies, experiments in which n-3 PUFAs 
were added directly to the culture media have also shown they exert an inhibitory effect on 
lymphocyte proliferation. In Con A stimulated rat lymphocytes, 18:3n-3, 20:5n-3 and 22:6n-3 
supplementation of the culture medium decreased lymphocyte proliferation (163). The most 
potent inhibitor was shown to be 20:5n-3 and at concentrations above 50 µM the response was 
dose dependent (163). These findings were consistent with the results from a study in human 
PBMCs, where the proliferative response to Con A was inhibited following supplementation of the 
culture medium with 100 µM 18:3n-3, 20:5n-3 and 22:6n-3 (164).  
Overall, the results from these studies suggest that n-3 PUFAs have an inhibitory effect on 
lymphocyte proliferation. However, many of these studies used doses of n-3 PUFAs far greater (see 
Table 1.1 for details) than the recommended daily intake for the UK of 450 mg (46). Furthermore, 
some more recent studies have reported either unchanged (87, 91) or increased (165, 166) in 
human lymphocyte proliferation following dietary n-3 PUFA supplementation, which conflicts the 
findings of the earlier studies. In conclusion, the effect of n-3 PUFAs on lymphocyte proliferation 
remains controversial. This could be due to several factors including differences in doses, 
supplementation periods or cell culture conditions. For example, in some studies the cell culture 
medium was supplemented with FBS, typically at 10% (v/v), whereas others supplemented with 
autologous plasma. FBS contains several lipids that have the potential to be hydrolysed and 
incorporated into the lymphocyte membrane; possibly disrupting the balance of fatty acids in the 
membrane induced by dietary supplementation or, in the case of cell culture supplementation 
studies, these fatty acids may compete with exogenous fatty acids under study. Furthermore, the 
composition of FBS varies considerably between different lots and, together with variation in the 
type and/or amount of serum added, this might account for some of the inconsistencies between 
studies.  
 
 
 
 50 
Table 1.1. Studies investigating the effects of n-3 PUFAs on lymphocyte proliferation (continued on pages 51-53) 
Subjects/Study design Proliferation assay Results Ref 
Animal study 
Supplementation: dietary 
Female mice (n = 7) fed diets enriched 
in 1% 20:5n-3 or 1% 22:6n-3 for 10 
days (free access). 
Cells: Splenic lymphocytes 
Mitogen: Con A (5 µg/ml) 
Medium supplemented with 10% 
(v/v) FBS 
Culture period: 96 h, final 6 h in 
presence of [3H] thymidine 
Proliferation significantly suppressed by dietary 20:5n-3 (approximately 75%) and 22:6n-3 
(approximately 80%) relative to safflower oil control (3%). 
Summary: 20:5n-3 and 22:6n-3 supplementation decreased proliferation 
(158) 
Animal study 
Supplementation: dietary 
Male rats (n = 3-5) fed low fat (2.4% 
lipid) or high fat diets containing 20% 
of various test lipids (see results) for 
10 weeks (free access). 
Cells: Lymphocytes purified from 
spleen, thymus and mesenteric nodes 
Mitogen: Con A (5 µg/ml) 
Medium supplemented with 10% 
(v/v) FBS or 2.5% (v/v) autologous 
plasma 
Culture period: 48 h then further 18 h 
in presence of [3H] thymidine 
Spleen lymphocytes: 2.5% autologous plasma cultures - proliferation significantly lower in 
20% fish oil group compared to low fat group. 10% FBS cultures – proliferation significantly 
lower in 20% fish oil group than in 20% hydrogenated coconut oil (HCO) group. 
Mesenteric lymph node lymphocytes: 2.5% autologous plasma cultures - proliferation 
significantly lower in 20% fish oil group compared to low fat, 20% HCO or 20% safflower oil 
(SO) groups.  
Summary: fish oil supplementation decreased proliferation 
(157) 
Animal study 
Supplementation: culture medium 
Lymphocytes from male rats. BSA 
complexed 18:3n-3, 20:5n-3 and 
22:6n-3 added to culture medium at 
various concentrations (33-495 µM). 
Experiments performed at least twice 
with 3-8 replications. 
Cells: Cervical lymph node 
lymphocytes 
Mitogen: Con A (5 µg/ml) 
Medium supplemented with 10% 
(v/v) FBS or no serum. 
Culture period: 48 h then further 18 h 
in presence of [3H] thymidine 
All n-3 PUFAs inhibited proliferation at concentrations above 50 µM compared to albumin-
alone controls. Above 50 µM the inhibitory effect was dose dependent. At most 
concentrations the order of inhibition was: 20:5n-3>22:6n-3>18:3n-3. Time-course 
experiments with 100 µM n-3 PUFAs showed that 20:5n-3 and 18:3n-3 were inhibitory after 
42 h and 22:6n-3 after 54 h culture. In serum free conditions all n-3 PUFAs had an inhibitory 
effect compared with albumin-alone controls and was greater than observed in presence of 
serum.  
Summary: 18:3n-3, 20:5n-3 or 22:6n-3 supplementation decreased proliferation at higher 
concentrations 
(163) 
Human study 
Supplementation: dietary 
Healthy younger (aged 23-33 years) 
and older (age 51-68) women (n = 6 in 
each group). Diets supplemented with 
2.4 g n-3 PUFA (1.68 g 20:5n-3 and 
0.72 g 22:6n-3) per day for 3 months. 
Cells: PBMCs 
Mitogen: PHA (5 µg/ml) 
Medium supplemented with 10% 
(v/v) HI autologous plasma 
Culture period: 72 h then further 4 h 
in presence of [3H] thymidine 
Proliferation significantly reduced by n-3 PUFA in older women (36% reduction after 3 
months) but there was no significant change in younger women. 
Con A was also used as mitogen (concentration not known) but there was no significant 
change in proliferation. 
Summary: 20:5n-3 and 22:6n-3 supplementation decreased proliferation in older women 
(159) 
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Table 1.1. (continued from page 50) 
Subjects/Study design Proliferation assay Results Ref 
Human study 
Supplementation: dietary 
Healthy men, aged 21-39 years (n = 
9). Diets supplemented with 18 g 
fish oil (2.75 g 20:5n-3 and 1.85 g 
22:6n-3) per day for 6 weeks. 
Cells: PBMCs 
Mitogen: PHA (0.5, 1, 2,4, 8 µg/ml) 
Medium supplemented with 5 % (v/v) 
HI autologous serum 
Culture period: 48 h then pulsed with 
[3H] thymidine and cultured for further 
24 h 
10 weeks after ending supplementation proliferation levels induced by 1 µg/ml and 8 
µg/ml PHA were decreased by 78% and 70%, respectively, compared with pre-
supplementation levels. 
Summary: fish oil  supplementation decreased proliferation  
(160) 
Human study 
Supplementation: dietary 
Healthy men and women aged 56-74 
years. Diets supplemented daily with 
either 2 g 18:3n3, 720 mg 22:6n-3, 4 
g fish oil (720 mg 20:5n-3 and 280 
mg 22:6n-3) or placebo oil for 12 
weeks. 
Cells: PBMCs 
Mitogen: Con A (5, 15, 25, 50 µg/ml) 
Medium supplemented with 2.5% (v/v) 
autologous plasma 
Culture period: 48 h then further 18 h 
in presence of [3H] thymidine 
Fish oil treatment resulted in significant time-dependent decline in lymphocyte 
proliferation at all Con A concentrations. Mean decline after 12 weeks treatment was 
55%, 65%, 59% and 66% at 5, 15, 25 and 50 µg/ml Con A, respectively. Change in 
proliferation after 12 weeks of fish oil treatment was significantly different to change 
in placebo group. 
Lymphocyte proliferation was not significantly affected by 18:3n-3 or 22:6n-3 
treatments. 
Summary: fish oil supplementation but not 18:3n-3 or 22:6n-3 alone decreased 
proliferation 
(161) 
Human study 
Supplementation: dietary 
Healthy men aged 21-37 years. 14 
day stabilisation followed by 56 days 
on either basal diet (n = 5) or 
flaxseed diet (n = 5) then diets 
crossed over for further 56 days. 
Cells: PBMCs 
Mitogen: Con A (5 and 25 µg/ml) and 
PHA (2 and 10 µg/ml) 
Medium supplemented with 10% (v/v) 
FBS 
Culture period: 66 h then further 6 h in 
presence of [3H] thymidine 
18:3n-3 was 21-fold higher in flaxseed diet than basal diet. Lymphocyte proliferation 
significantly repressed by flaxseed diet in both Con A and PHA cultures. 
Summary: flaxseed supplementation decreased proliferation 
(162) 
Human study 
Supplementation: dietary 
Healthy men, aged 25-45 (n = 10). 
Diets supplemented with 3 g fish oil 
(0.78 g 20:5n-3 and 1.85 g 22:6n-3) 
per day for 2 months. 
Cells: PBMCs* 
Mitogen: Con A (5 µg/ml) 
Medium – no supplements detailed 
Culture period: 48 h then further 18 h 
in presence of [2-14C] thymidine 
Fish oil supplementation resulted in a 40% increase in lymphocyte proliferative capacity 
compared to pre-supplement levels. This response was reduced to normal levels after a 
2 month wash out period. 
Summary: fish oil  supplementation increased proliferation 
(166) 
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Table 1.1. (continued from pages 50-51) 
Subjects/Study design Proliferation assay Results Ref 
Human study 
Supplementation: dietary 
21 male a marathon runners aged 37 
± 2 years. Diets of 8 subjects 
supplemented daily with 3 g of fish 
oil containing 0.3 g 20:5n-3 or 1.5 g 
22:6n-3 for 60 days. 
Cells: PBMCs* 
Mitogen: Con A (50 µg/ml) 
Medium supplemented with 10%  (v/v) 
FBS 
Culture period: 48 h then further 18 h 
in presence of [2-14C] thymidine 
Fish oil supplementation resulted in an increase in lymphocyte proliferation in 
marathon runners relative to control group both before (90%) and after a race (49%). 
Summary: fish oil  supplementation increased proliferation 
(165) 
Human study 
Supplementation: dietary 
Healthy males (n = 8 per group) aged 
18-39 years. Diets supplemented 
daily with 3.5 g 18:3n-3 or 0.44, 0.94 
or 1.90 g of 20:5n-3 and 22:6n-3 for 
12 weeks. 
Cells: PBMCs 
Mitogen: Con A (25 µg/ml) 
Medium supplemented with 5%  (v/v) 
autologous plasma 
Culture period: 48 h then further 18 h 
in presence of [3H] thymidine 
Lymphocyte proliferation did not differ among treatment groups at baseline or at the 
end of supplementation. Proliferation did decrease with time in all groups so that it 
was significantly lower at 12 weeks than baseline but was also significant for the 
placebo group. 
Summary: supplementation with 18:3n-3 or 20:5n-3 and 22:6n-3 had no effect on 
proliferation 
(87) 
Human study 
Supplementation: dietary 
150 healthy males and females aged 
25-72. Randomly assigned to one of 
5 interventions: placebo (n = 30), 4.5 
g (n = 30) or 9.5 g (n = 31) 18:3n-
3/day or 0.77 g (n= 30) or 1.7 g (n = 
29) of 20:5n-3 and 22:6n-3 per day 
for 6 months. 
Cells: PBMCs 
Mitogen: Con A (5, 15, 25, 50 and 75 
µg/ml) 
Medium supplemented with 5%  (v/v) 
autologous plasma 
Culture period: 48 h then further 18 h 
in presence of [3H] thymidine 
There was no significant effect of time or treatment on lymphocyte proliferation for 
any concentration of Con A used. 
Summary: supplementation with 18:3n-3 or 20:5n-3 + 22:6n-3 had no effect on 
proliferation 
(91) 
Human study 
Supplementation: culture medium 
Lymphocytes isolated from 
peripheral blood collected from 
healthy women (aged 22-51). BSA 
complexed 18:3n-3, 20:5n-3 and 
22:6n-3 (100 µM) added to culture 
medium (n = 5 – 7). 
Cells: lymphocytes 
Mitogen: Con A (15 µg/ml) or PPD (10 
µg/ml 
Medium supplemented with 10% (v/v) 
FBS 
Culture period: 48 h then further 18 h 
in presence of [3H] thymidine 
In Con A stimulated cultures 20:5n-3 caused the greatest inhibition of lymphocyte 
proliferation (85%), followed by 22:6n-3 (57%) and then 18:3n-3 (33%). The 
proliferative response to PPD was lower than for Con A. In PPD stimulated cultures 
only 20:5n-3 (75%) and 22:6n-3 (51%) caused a significant decrease in lymphocyte 
proliferation. 
Summary: supplementation with 18:3n-3, 20:5n-3 or 22:6n-3 decreased proliferation 
(164) 
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Table 1.1. (continued from pages 50-52) 
Subjects/Study design Proliferation assay Results Ref 
Human study 
Supplementation: culture medium 
Lymphocytes isolated from healthy 
blood obtained from blood bank. 
20:5n-3 and 22:6n-3 in ethanol 
added to culture medium at 
increasing concentrations (12.5 - 400 
µM).  
Cells: PBMCs* 
Mitogen: Con A (5 µg/ml) 
Medium supplemented with 10% (v/v) 
FBS 
Culture period: 48 h then further 18 h 
in presence of [2-14C] thymidine 
Results were reported for 6 replicates from 4 different experiments. 20:5n-3 treatment 
at 25, 50, 75 and 100 µM or 22:6n-3 treatment at 50, 75 and 100 µM resulted in a dose 
dependent reduction in lymphocyte proliferation relative to control. 20:5n-3 and 
22:6n-3 promoted cell death at concentrations of 50 µM and 100 µM or above, 
respectively. 
Summary: supplementation with 20:5n-3 or 22:6n-3 decreased proliferation 
(167) 
*PBMCS maintained in RPMI medium for up to 2 h to allow adherence of monocytes to plates and separation from lymphocytes. FBS, fetal bovine serum; Con A, concanavalin A; 
PHA, phytohemagglutinin; PPD, purified protein derivative of Mycobacterium tuberculosis; HI, heat inactivated. 
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1.10.2 Eicosanoid production 
Eicosanoids are a family of oxygenated derivatives of the 20-carbon PUFAs arachidonic acid 
(20:4n-6), dihomo-γ-linolenic acid (20:3n-6) and 20:5n-3. They are bioactive signalling lipids that 
have well established roles in the regulation of inflammation and immunity. The PUFA precursor 
for eicosanoid synthesis is released from the cell membrane usually by the action of 
phospholipase A2 (PLA2). Eicosanoids include prostaglandins (PGs), thromboxanes (TXs), 
leukotrienes (LTs), lipoxins (LXs), hydroxyeicosatetraenoic acids (HETEs) and 
hydroperoxyeicosatetraenoic acids (HPETEs) and are produced by the action of cyclooxygenase 
(COX) or lipoxygenase (LOX) enzymes (Figure 1.4). The principle precursor for eicosanoid 
synthesis is 20:4n-6 due to its greater abundance in the membranes of most cells compared with 
20:3n-6 and 20:5n-3. Immune cells are both important sources and regulatory targets of 
eicosanoids (154). An early study reported lymphocytes to be poor producers of eicosanoids 
(168) although more recent evidence indicates that T-lymphocytes express COX and LOX 
enzymes and are a source of eicosanoids (169). Eicosanoids can have both pro- and anti-
inflammatory effects and therefore have a complex role in the regulation of immune and 
inflammatory responses. In general, eicosanoids derived from 20:4n-6 act in a pro-inflammatory 
manner, although this is an over-simplification since PGE2, for example, has both pro- and anti-
inflammatory effects, and LXA4 and LXB4 have anti-inflammatory effects (170, 171). The cells 
present, the nature of the activating signal, the timing of eicosanoid production and the 
sensitivity of target cells to the eicosanoid levels produced, all influence their overall effect 
(135).  
Increased dietary intake of 20:5n-3 and 22:6n-3 from fish oil results in increased proportions of 
these fatty acids in immune cell phospholipids (172, 173). This has been shown to be 
accompanied by a decrease in membrane 20:4n-6 content resulting in lower substrate 
availability for conversion to eicosanoids (172). Furthermore, 20:5n-3 and 22:6n-3 competitively 
inhibit the metabolism of 20:4n-6 to eicosanoids and 20:5n-3 itself is able to act as a substrate 
for both COX and 5-LOX enzymes. Macrophages isolated from mice fed a fish oil diet were 
demonstrated to produce less PGE2 and TXB2 following stimulation compared to mice fed on 
non-fish oil based diets (174) and dietary fish oil supplementation has been shown to result in 
increased in vitro generation of 5-LOX products of 20:5n-3 (5-series LTs) in human neutrophils 
(175). The metabolism of 20:5n-3 gives rise to structurally different mediators from those 
produced by 20:4n-6 (e.g. PGE3 instead of PGE2 and LTB5 instead of LTB4), which are considered 
to be less biologically potent than their analogues (65, 154). One reason for the lower biological 
potency of 20:5n-3-derived eicosanoids is their receptors typically have higher affinity for 20:4n-
6-derived mediators (176). 
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More recently, novel families of lipid mediators derived from 20:5n-3 and 22:6n-3 have been 
characterised. These include the E-series and D-series resolvins produced from 20:5n-3 and 
22:6n-3, respectively, and protectins and maresins produced from 22:6n-3 (Figure 1.4). 
Synthesis involves the COX and LOX pathways. E-series resolvins are derived from 20:5n-3 by a 
multistep process involving cytochrome (Cyt) P450 and 5-LOX where D-series resolvins are 
generated from 22:6n-3 by 15-LOX and 5-LOX. Alternative pathways for E- and D-series resolvin 
synthesis involve aspirin-acetylated COX-2.  
Resolvins, protectins and maresins have anti-inflammatory and inflammation resolving 
properties acting to control the magnitude and duration of inflammation (177). Consequently, 
these mediators are collectively termed specialised pro-resolving mediators (SPMs). 
Inflammation is part of a normal host response to infection and injury. Regulated inflammatory 
responses are essential to health but when uncontrolled they can lead to tissue damage and 
disease (65). n-3 PUFAs can exert important anti-inflammatory effects by a number of 
mechanisms in relation to lipid mediator synthesis: by decreasing membrane 20:4n-6 levels and 
capacity for 20:4n-6-derived eicosanoid synthesis, by increasing production of weakly 
inflammatory or anti-inflammatory eicosanoids derived from 20:5n-3 and by increasing the 
production of anti-inflammatory and inflammation resolving SPMs from 20:5n-3 and 22:6n-3 
(170). As mentioned in section 1.5.2, n-3 PUFAs have been reported to have beneficial effects in 
certain inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease and 
asthma (66-69). 
 
 
Figure 1.4. Overview of the synthesis of lipid mediators from 20:4n-6, 20:5n-3 and 22:6n-3. 
COX, cyclooxygenase; LOX, lipoxygenase; CytP450, cytochrome P450; PGs, prostaglandins; TXs, 
thromboxanes; LTs, leukotrienes; HETEs, hydroxyeicosatetraenoic acids. COX-2* indicates 
aspirin acetylated COX-2. Adapted from Buechler et al., 2017 (178) and Calder, 2010 (170). 
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1.10.3 Cytokine production 
Some studies have reported that supplementing the diet of healthy humans with fish oil, 
providing ≥2 g per day of 20:5n-3 and 22:6n-3, results in decreased production of certain 
cytokines including TNF, IL-1 and IL-6 (179-181). Furthermore, a significant negative correlation 
between mononuclear cell 20:5n-3 content and TNF-α and IL-1β production in response to 
stimulation has been demonstrated (182). However, there have been discrepancies in findings 
between studies with some studies administering lower amounts (< 2 g per day) of 20:5n-3 and 
22:6n-3 (87, 91), and also higher amounts (183, 184) reporting no effect on cytokine 
production. Feeding 13.7 g of 18:3n-3 per day for four weeks was shown to significantly 
decrease TNF-α and IL-1β production by 30% and 31%, respectively in stimulated human 
mononuculear cells (182). The same study showed that the effects of 18:3n-3 supplementation 
were more modest than the effects of 20:5n-3 and 22:6n-3; supplementation with 2.7 g per 
day of 20:5n-3 and 22:6n-3 decreased the production of TNF-α and IL-1β by 74% and 80%, 
respectively. In a different study, a diet high in 18:3n-3 (19.1 g per day for a 6 week period) was 
shown to inhibit the production of IL-6, IL-1β and TNF-α in PBMCs from human volunteers with 
moderate hypercholesterolemia (185). It is not known whether the inhibitory effects of 18:3n-
3 on cytokine production in these studies was due to 18:3n-3 itself or its conversion to longer 
chain n-3 PUFAs. In a different study, supplementing the diet with a lower dose of 18:3n-3 (3.5 
g per day over 12 weeks) did not alter the production of measured cytokines, including IL-6, IL-
1β and TNF-α in stimulated mononuclear cells (87). If the effects of 18:3n-3 on cytokine 
production are mediated by its conversion to longer chain n-3 PUFA, then it might be that lower 
doses of 18:3n-3 result in insufficient levels of conversion products required for inhibitory 
activity. In summary, the relationship between n-3 PUFA supplementation and cytokine 
production is not entirely clear since different studies (summarised in Table 1.2) have reported 
conflicting results. As already discussed for the effect of n-3 PUFAs on lymphocyte proliferation, 
the discrepancies in findings might be due to differences in study design, including the amount 
of n-3 PUFAs administered and the time-period over which supplementation and analysis took 
place, or experimental conditions including the cell culture conditions and cytokine 
measurement techniques.   
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Table 1.2. Studies investigating the effects of n-3 PUFAs on the production of cytokines (continued on pages 58-59) 
Subjects/Study design Cytokine analysis Results Ref 
Human study 
Supplementation: dietary 
Healthy males (n = 9) aged 27-39 
years. Diets supplemented with 4 g n-3 
PUFA (containing 2.04 g 20:5n-3 and 
1.40 g 22:6n-3) per day for 18 weeks. 
PBMCs cultured for 4 h in presence 
or absence of LPS (10 µg/ml). No 
serum concentration given. IL-6 
production measured in 
supernatants by ELISA. 
 
n-3 PUFA treatment  for 18 weeks significantly decreased basal (by 50%) and LPS-
stimulated (by 46%) IL-6 production compared to pre-supplementation levels. Decreased 
IL-6 production observed after n-3 PUFA supplementation seemed to depend mainly on 
IL-6 produced by monocytes, which represented approximately 19% of PBMC population. 
Summary: 20:5n-3 and 22:6n-3 supplementation decreased production of IL-6 
(180) 
Human study 
Supplementation: dietary 
Healthy males received a daily 
antioxidant preparation (n = 8, mean 
age 30.3) or placebo (n = 8, mean age 
30.6) for 12 weeks. Simultaneously, all 
subjects received a course of fish oil 
increasing in amount every 4 weeks, 
equivalent to a total 20:5n-3 and 
22:6n-3 intake of 0.3, 1.0 and then 2.0 
g/day. 
PBMCs cultured for 24 h in 
presence or absence of LPS (15 
µg/ml). Medium supplemented 
with 5% (v/v) autologous plasma. 
IL-6 and TNF-α production 
measured in supernatants by 
ELISA. 
 
Fish oil supplementation resulted in significant reductions in the production of both TNF- 
α and IL-6 by unstimulated and stimulated PBMC in both fish oil only and fish oil plus 
antioxidant groups. There were no significant differences between fish oil plus antioxidant 
and fish oil only groups so groups were combined (n = 16) for further analysis. TNF-α and 
IL-6 production by unstimulated and stimulated PBMC conformed to a negative but ‘U-
shaped’ dose response relationship with n-3 PUFA intake. Maximum inhibition was 
demonstrated at supplementary intake of 1 g/day. 20:5n-3 concentration in plasma and 
erythrocyte phospholipids were significantly negatively correlated with PBMC cytokine 
production. 
Summary: 20:5n-3 and 22:6n-3 supplementation decreased production of specific 
cytokines 
(181) 
Human study 
Supplementation: dietary 
Healthy males (n = 9) aged 21-39 
years. Diets supplemented with 2.76 g 
20:5n-3 and 1.86 g 22:6n-3 per day for 
6 weeks. 
PBMCs cultured for 24 h in 
presence of LPS (1 and 10 ng/ml) 
or PHA (3 µg/ml). Medium 
supplemented with 2% (v/v) 
autologous serum. IL-1α, IL-1β and 
TNF production in pooled cell 
lysates and supernatants 
determined by radio-
immunoassays. 
LPS (1 ng/ml): After 6 weeks supplementation there was a significant decrease in  IL-1β 
(by 43%) production compared to baseline. Decreases were also observed for IL-1α (32%) 
and TNF (22%) but were non-significant. 10 weeks following the end of supplementation 
significant decreases were measured for IL-1β (61%), IL-1α (39%) and TNF (40%) 
compared to baseline. All returned to pre-supplementation levels after 20 weeks. Similar 
results were observed for cells treated with 10 ng/ml LPS. 
PHA (3 µg/ml): After 6 weeks supplementation there was a significant decrease in  IL-1α 
(by 14%) production compared to baseline. 10 weeks following end of supplementation 
both  IL-1α and IL- β were significantly reduced, by 37% and 53%, respectively. 
Summary: 20:5n-3 and 22:6n-3 supplementation decreased production of specific 
cytokines 
(179) 
Human study 
Supplementation: dietary 
Healthy males (n = 8 per group) aged 
18-39 years. Diets supplemented daily 
with 3.5 g 18:3n-3 or 0.44, 0.94 or 1.90 
g of 20:5n-3 and 22:6n-3 for 12 weeks. 
PBMCs cultured for 24 h in 
medium supplemented with Con A 
(25 µg/ml) or LPS (15 µg/ml) and 
5% (v/v) autologous plasma. 
Supernatants were collected and 
cytokines measured by ELISA. 
 
Production of TNF-α and  IL-1β by PBMC stimulated with LPS and the production of IL-2, 
IL-4, IL-10 and IFN-γ by PBMC stimulated with Con A did not differ between treatment 
groups at baseline or at the end of supplementation and did not differ between time 
points within any treatment group. IL-6 production was significantly lower compared to 
baseline after 12 weeks supplementation with either 0.94 g/day (65% decrease) or 1.90 
g/day (40% decrease) 20:5n-3 and 22:6n-3 and significantly lower than observed in the 
placebo group. 
Summary: Higher doses of 20:5n-3 and 22:6n-3 decreased IL-6 production 
(87) 
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Table 1.2. (continued from page 57) 
Subjects/Study design Cytokine analysis Results Ref 
Human study 
Supplementation: dietary 
150 healthy males and females aged 
25-72. Randomly assigned to one of 5 
interventions: placebo (n = 30), 4.5 g (n 
= 30) or 9.5 g (n = 31) 18:3n-3/day or 
0.77 g (n= 30) or 1.7 g (n = 29) 20:5n-3 
or 22:6n-3 per day.  
PBMCs cultured for 24 h in 
medium supplemented with Con A 
(25 µg/ml) or LPS (15 µg/ml) and 
5% (v/v) autologous plasma. 
Supernatants were collected and 
cytokines measured by ELISA. 
 
Blood samples taken at 0, 3 and 6 months for analysis. PBMCs stimulated with LPS: 
production of TNF-α, IL-1β, IL-6 and IL-10 did not differ among the groups at baseline or at 
the end of the intervention. PBMCs stimulated with Con A:  production of IL-2, Il-4 and 
IFN-γ  did not differ among the groups at baseline or at the end of the intervention. 
Summary: No effect of n-3 PUFA supplementation on cytokine production 
(91) 
Human study 
Supplementation: dietary 
58 healthy monks aged 21-87 years. 
Diets supplemented with 0, 3, 6 or 9 g 
fish oil, providing 0, 1.06, 2.13 0r 3.19 
g/day n-3 PUFA for 1 year. 
Whole blood cytokine production 
measured in presence and absence 
of LPS (10 µg/ml). LPS added 
directly to blood and incubated for 
24 h at 25oC. Cytokines measured 
in plasma by radioimmunoassay 
except IL-6, which was measured 
by ELISA. 
Cytokine production was measured at baseline, 26 and 52 weeks after the start and at 4, 
8 and 26 weeks after cessation of supplementation. Circulating concentrations of IL-1β, 
TNF-α and IL-1Ra were not significantly different between the 0 and 9 g/day fish oil 
groups at any time point. In all groups, as well as the placebo group, LPS stimulated 
secretion of IL-1β and IL-1Ra was higher during supplementation than afterwards. LPS 
stimulated secretion of IL-1β, TNF-α and IL-1Ra was not significantly different between 
the placebo group and treatment groups at any time point.  
Summary: No effect of n-3 PUFA supplementation on cytokine production 
(183) 
Human study 
Supplementation: dietary 
42 healthy volunteers aged 23-65 
years. Diets supplemented with 
placebo, 4.7 g/day 20:5n-3 or 4.9 
g/day 22:6n-3 for 4 weeks. 
 
PBMCs cultured for 24 h in 
medium supplemented with 5% 
(v/v) autologous plasma and either 
Con A (25 µg/ml) or LPS (15 
µg/ml). Cytokines analysed in 
supernatant by flow cytometry 
with cytometric bead arrays. 
Cytokines measured immediately before or 4 weeks after supplementation. Cytokines 
measured for LPS stimulated cultures: TNF-α, IL-1β, IL-6, IL-8 and IL-10. Cytokines 
measured for Con A stimulated cultures: IL-2, IFN-γ, IL-10, IL-5, TNF-α and IL-4. There 
were no significant effects of time or treatment on the production of any of these 
cytokines. 
Summary: No effect of 20:5n-3 or 22:6n-3 supplementation on cytokine production 
(184) 
Human study 
Supplementation: dietary 
20 male (aged 36-39) and 3 female 
(aged 55-65), overweight or obese 
hypercholesterolemic volunteers 
assigned to a sequence of 3 
experimental diets: high 18:3n-3, high 
18:2n-6 and average American diet for 
6 weeks. 
Cytokines measured in serum and 
PBMC culture medium by ELISA. 
PBMCs cultured for 24 h in 
medium supplemented with TCH® 
serum replacement either with or 
without LPS (1 ng/ml and 10 
ng/ml). 
The high 18:3n-3 diet provided 19.1 g/day 18:3n-3 compared to 10.6 g/day and 2.3 g/day 
in the high 18:2n-6 and average American diets, respectively. Blood samples were 
collected and analysed at the end of each diet period. IL-6, IL-1β and TNF-α production by 
PBMCs were significantly lower with the 18:3n-3 diet compared to the 18:2n-6 or average 
American diets. PBMC production of TNF-α was inversely correlated with 18:3n-3 and 
with 20:5n-3 concentrations in PBMC lipids with the 18:3n-3 diet. 
Summary: 18:3n-3 supplementation decreased production of specific cytokines 
(185) 
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Table 1.2. (continued from pages 57-58) 
Subjects/Study design Cytokine analysis Results Ref 
Human study 
Supplementation: dietary 
Healthy males aged 24-44 years. Diet 
supplemented with flaxseed oil high in 
18:3n-3 (n = 15) or sunflower oil high 
in 18:2n-6 (n = 15) for 8 weeks. After 
first 4 weeks diets were supplemented 
with fish oil (1.62 g 20:5n-3 and 1.08 g 
22:6n-3 per day). 
PBMCs cultured for 24 h in 
medium supplemented with 5% 
(v/v) FBS and LPS (20 µg/ml). Cells 
were lysed, supernatants collected 
and cytokines measured by ELISA. 
Average 18:3n-3 consumption was 13.7 g/day in the flaxseed group and 1.1 g/day in 
sunflower group. After 4 weeks of dietary change TNF-α and IL-1β production decreased 
by 30% and 31%, respectively in the flaxseed group but did not change in the sunflower 
group. After fish oil supplementation (i.e. at 8 weeks) cytokine synthesis had decreased in 
both groups: in flaxseed group, TNF-α decreased by 77% and IL-1β decreased by 81%, 
whereas in the sunflower group TNF-α decreased by 70% and IL-1β decreased by 78%. 
The flaxseed diet increased 20:5n-3 content in PBMC phospholipids, whereas the 
sunflower diet did not. There was a significant inverse relationship between cellular 
20:5n-3 concentration and both TNF-α and IL-1β when results for both diets at 4 and 8 
weeks were combined. 
Summary: 18:3n-3 supplementation and 20:5n-3 and 22:6n-3 supplementation 
decreased production of specific cytokines 
(182) 
FBS, fetal bovine serum; Con A, concanavalin A; LPS, lipopolysaccharide; ELISA, enzyme-linked immunosorbent assay
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1.10.4 Gene expression 
Regulation of gene expression may be one mechanism through which n-3 PUFA affect immune cell 
function. PUFAs can affect gene expression by regulating the activity or abundance of transcription 
factors. These transcription factors include peroxisome proliferator-activated receptors (PPARs), 
sterol regulatory binding proteins (SREBPs) and nuclear factor kappa B (NF-κB). PPARs are a family 
of ligand-activated nuclear receptors that play an important role in cell differentiation and various 
metabolic processes, particularly lipid and glucose homeostasis (186, 187). There are three PPAR 
isoforms: PPARα, PPARβ/δ and PPARγ. PPARs are activated by a broad range of ligands including 
eicosanoids and n-3 PUFAs, such as 18:3n-3, 20:5n-3 and 22:6n-3 (53, 188-190). Therefore, 
through activation of PPAR, n-3 PUFAs are able to affect specific aspects of metabolism and cell 
function. In addition to the well-studied effects of PPARs on the metabolic system, several pieces 
of evidence suggest that PPARγ and in some cases PPARα, are important regulators of cells of the 
immune system including T-lymphocytes, monocytes and macrophages, displaying modulatory 
roles in inflammatory responses (191-193). A recent study showed that activated CD4+ T-
lymphocytes utilise exogenous fatty acids through MTORC1 (mechanistic target of rapamycin 
complex 1) mediated induction of PPARγ and its downstream fatty acid uptake target genes (146). 
Furthermore, the MTORC1-PPARγ pathway was demonstrated to be required for full activation 
and optimal proliferation (146).  
n-3 PUFAs also affect SREBP dependent gene expression. SREBPs have important roles in 
regulating genes of fatty acid and cholesterol metabolism. Three SREBPs are recognised: SREBP1a, 
SREBP1c and SREBP2. SREBPs are regulated post transcriptionally: the inactive precursor form is 
located in the ER and is activated following translocation to the Golgi and release of the 
transcriptionally active amino-terminal fragment of SREBP (n-SREBP) (194). n-3 PUFAs can 
significantly decrease transcriptionally active concentrations of n-SREBP (195). It is not entirely 
clear how this happens but appears to involve a combination of mechanisms including decreased 
SREBP transport out of the ER and interactions with different steps of sphingolipid metabolism 
(194). SREBPs have been reported to serve important functions in activated T-lymphocytes. For 
example, SREBPs were found to be required for full activation of CD8+ T-lymphocytes, displaying 
specific importance in the rapid synthesis of membranes required for cellular growth (196). 
Furthermore, SREBP-1 induced fatty acid biosynthesis programmes were shown to be required for 
optimal proliferation in both murine and human CD4+ T-lymphocytes (146). 
NF-κB is one of the key transcription factors involved in immune responses and plays an essential 
role in promoting T- and B-lymphocyte activation (197). In resting cells, NFκB is kept in an inactive 
form in the cytoplasm by inhibitor of NFκB (IκB) family members that prevent NFκB from moving 
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into the nucleus. Upon activation, IκB is phosphorylated by the IκB kinase (IKK) complex and 
subsequently degraded, which allows NFκB to move to the nucleus and activate target genes. 
Evidence indicates that n-3 PUFAs can downregulate the activity of NF-κB (198, 199). In human 
monocytic THP-1 cells stimulated with lipopolysaccharide (LPS), 20:5n-3 appeared to prevent NF-
κB activation by preventing the phosphorylation of IκB-α (199). 
1.10.5 Membrane properties 
As mentioned in section 1.9.1, T-lymphocyte activation has been shown to be accompanied by an 
increase in membrane fluidity. An early study demonstrated that T-lymphocyte activation was 
associated with an increase in the 22:5n-3 and 22:6n-3 content of major phospholipids (40). The 
authors suggested that these fatty acid compositional changes might contribute to the observed 
increase in membrane fluidity in activated T-lymphocytes. Furthermore, in rat lymphocytes 
supplementation of the culture medium with PUFA lead to increases in membrane fluidity above 
that caused by mitogen stimulation alone and it was proposed that this change in fluidity might be 
the mechanism through which PUFAs inhibit lymphocytes responses (49).  
PUFA acyl chains are highly disordered compared with saturated or monounsaturated acyl chains 
and therefore have unique structural effects on membranes (200). PUFAs can alter numerous 
properties of cell membranes, ultimately influencing protein function and signal transduction 
(201). One membrane property influenced by n-3 PUFAs is the organisation of membrane sub-
domains called lipid rafts. Lipid rafts are rich in sphingolipids and cholesterol and, relative to the 
surrounding membrane, are generally enriched in phospholipids containing saturated acyl chains 
(202). This allows close packing of lipids within rafts since the acyl chains of sphingolipids are also 
saturated and because saturated fatty acids are able to pack tightly with cholesterol (203). It is 
proposed that tight packing of lipids in lipid rafts is responsible for their resistance to extraction 
with non-ionic detergents; a signature property of lipid rafts (202). Many proteins important in 
signal transduction are predominately found in lipid rafts and consequently lipid rafts are thought 
to organise particular proteins to optimise their signalling capacity (202). Several important 
processes are reported to involve lipid rafts including T-lymphocyte activation and signal 
transduction (204-206). n-3 PUFAs have been reported to disrupt the composition and organisation 
of lipid rafts in T-lymphocytes and in turn suppress their activation (204, 207-209). Consequently, 
it has been suggested that a lipid raft mediated mechanism may contribute to the effects of n-3 
PUFA on immune cell function; in other words, the immunomodulatory effects of n-3 PUFAs have 
been linked to their ability to modify lipid rafts (209, 210). 
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1.10.6 Evidence from the delta-6 desaturase knock-out mouse 
A recent study used the delta-6 desaturase knock-out (D6KO) mouse model to study the 
immunomodulatory effects of individual n-3 and n-6 PUFA (211). The D6KO mouse lacks the Fads2 
gene that encodes the delta-6 desaturase protein, thereby blocking the rate-limiting step in n-3 
and n-6 PUFA metabolism. One of the most striking characteristics of this mouse model is sterility 
(212). Importantly, the D6KO mouse allows determination of the isolated effects of individual 
PUFAs on cell and tissue function, as it avoids the confounding effect of conversion to longer chain 
derivatives, and also provides a way to assess the importance of conversion of 18:2n-6 and 18:3n-
3 to longer chain n-6 and n-3 PUFAs, respectively. D6KO mice fed diets containing the n-6 LC PUFA 
precursor 18:2n-6 displayed a lower proportion of unchallenged splenic CD4+ T-lymphocytes 
compared to wild-type mice (211). Furthermore, again in mice fed 18:2n-6 enriched diets, IFN-γ 
production in LPS stimulated splenic mononuclear cells was 5-times lower in D6KO compared to 
wild-type mice. Both of these effects were rescued by dietary repletion with 20:4n-6, a 
downstream conversion product of 18:2n-6. These results suggests that these properties are 
dependent, to some extent on the conversion of 18:2n-6 to 20:4n-6, when dietary sources of 
20:4n-6 are lacking. 20:4n-6 was more potent than 18:2n-6 in promoting IFN-γ production and 
other pro-inflammatory cytokines (TNF-α and IL-6). There were no differences in IFN-γ production 
between mice fed 18:3n-3 or 20:5n-3/22:6n-3 based diets, which explains why there were no 
differences in IFN-γ production between D6KO and wild-type mice fed an 18:3n-3 enriched diet. 
Feeding 20:5n-3/22:6n-3 compared to 18:3n-3 significantly increased IL-10 production but there 
was no effect of genotype on production of this cytokine in mice fed 18:3n-3, indicating that 
functioning conversion was not able to emulate the effects of dietary supplementation. However, 
feeding 18:3n-3 did increase IL-10 production compared to 18:2n-6 and 20:4n-6 based diets, 
suggesting a possible independent effect of 18:3n-3. The amounts of n-6 and n-3 PUFAs fed to the 
mice in this study exceeded typical dietary intakes when translated to humans, a limitation 
highlighted by the authors. Furthermore, this study was limited by the number of immune 
functions assessed and did not analyse lymphocyte proliferation, arguably the most well-
characterised immunomodulatory effect exerted by n-3 PUFAs. The results from this paper suggest 
that newly synthesised PUFAs serve important immunomodulatory roles when exogenous sources 
of conversion products are lacking but a more extensive analysis is required. 
1.11 Epigenetic mechanisms 
Studies have linked the synthesis or status of n-3 and n-6 PUFA with the mRNA expression level of 
the genes encoding the desaturase and elongase enzymes that function in the conversion pathway 
(104, 105, 213). A possible mechanism emerging for the control of PUFA synthesis is epigenetic 
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regulation of these genes. Epigenetics is a term used to describe a number of different processes 
that can cause heritable changes in the expression of a gene without changes to the underlying 
DNA coding sequence. Epigenetic regulation occurs via three main mechanisms: DNA methylation, 
histone modifications and non-coding RNAs. Histone modifications and non-coding RNAs will be 
introduced first and then DNA methylation, which is perhaps the most well characterised form of 
epigenetic regulation, will be discussed last. 
1.11.1 Histone modifications 
Histones are basic proteins that package and organise DNA into nucleosomes. Nucleosomes form 
the basic repeating unit of eukaryotic chromatin and consist of a segment of DNA, approximately 
147 base pairs (bp), wound nearly twice around a histone octamer composed of two copies of each 
histone protein H2A, H2B, H3 and H4. Histone proteins contain two domains: a globular domain 
and an N-terminal tail domain. The N-terminal tails are exposed on the surface of the nucleosome 
and can therefore be subjected to modifications including acetylation, methylation, 
phosphorylation and ubiquitination (214). Histone modifications regulate gene expression by 
altering the accessibility of DNA resulting in regions of euchromatin, which is less condensed and 
transcriptionally active and heterochromatin, which is condensed and transcriptionally silent. 
Therefore, certain histone modifications promote transcriptional activation where others promote 
transcriptional repression. Histone acetylation, catalysed by histone acetyltransferases (HATs) is 
generally associated with increased gene expression (215). Histone acetylation involves addition of 
a negatively charged acetyl group to lysine residues of histone proteins, thereby reducing the 
affinity between histones and the negatively charged DNA. This results in a more open chromatin 
structure that is accessible for transcription. Histone acetylation can be reversed by the action of 
histone deacetylases (HDACs), resulting in a more condensed chromatin structure that is not 
accessible for transcription. Histone methyltransferases (HMTs) catalyse histone methylation. 
Histone methylation has varying effects on transcription depending on the specific lysine (K) or 
arginine (R) modified. Mono-, di- or tri-methylation of K9 on histone H3 (H3K9) or K20 on histone 
H4 (H4K20) are generally associated with transcriptional repression (216). In contrast, methylation 
of K4 on histone H3 (H3K4) and R3 on histone H4 (H4R3) are associated with active transcription 
(217, 218). Recent discoveries have demonstrated that histone methylation is reversible, which 
occurs by removal of methyl groups by histone demethylases (219). 
1.11.2 Non-coding RNAs 
Non-coding RNAs (ncRNAs) function as RNA molecules and are not translated into protein. They 
can act to regulate gene expression at the transcriptional and post-transcriptional level and 
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therefore can influence a large variety of biological functions. The ncRNAs involved in epigenetic 
processes can be categorised into two main groups according to the length of the transcript: short 
ncRNAs (<30 nucleotides) and the long ncRNAs (>200 nts). There are three major classes of short 
ncRNAs: microRNAs (miRNAs), short interfering RNAs (siRNAs) and piwi-interacting RNAs (piRNAs). 
MiRNAs and SiRNAs function in a similar way, causing gene silencing through complementary base 
pairing with target mRNAs, leading to degradation or translational repression (220). More recently, 
evidence indicates that siRNAs and miRNAs can guide chromatin remodelling in mammalian cells 
and therefore bring about transcriptional gene silencing (221, 222). siRNAs have been reported to 
guide transcriptional silencing complexes to specific chromosomal locations, promoting H3K9 
methylation and subsequent chromatin condensation (223, 224). The most thoroughly understood 
function of piRNAs is the repression of transposable elements through complementary base pairing 
and target slicing, particularly in germ line cells. A role for piRNAs in transcriptional gene silencing 
through heterochromatin formation is also emerging (225). Finally, long ncRNAs play an essential 
role in genomic imprinting and X-chromosome inactivation (226). The gene silencing effects of long 
ncRNAs appear to involve recruitment of histone modifying complexes such as the polycomb 
repressive complex 2 (PRC2), which induces H3K27 methylation (227, 228). 
1.11.3 DNA methylation 
DNA methylation is a stable epigenetic mark that can be transmitted through DNA replication and 
cell division (229). In mammals nearly all DNA methylation occurs on cytosine residues of CpG 
dinucleotides (230). CpG sites are regions of DNA where a cytosine nucleotide occurs adjacent to a 
guanine nucleotide and the ‘P’ stands for the intervening phosphate group. DNA methylation 
involves the transfer of a methyl group from S-adenosyl methionine (SAM) to the 5 position of 
cytosine to form 5-methyl cytosine and is catalysed by DNA methyltransferases (DNMTs). CpG 
dinucleotides are not randomly distributed throughout the genome but are clustered at the 5 prime 
(5’) ends of genes in regions known as CpG islands (231). CpG islands have been defined as a region 
greater than 200 base pairs with an observed ratio for the occurrence of CpGs of greater than 0.6 
(232). CpG islands are found in the promoters of approximately 60% of all mammalian genes (233). 
In general, high methylation of CpG islands is associated with transcription repression and low 
methylation is associated with activated gene expression (234). However, this is an 
oversimplification as there is increasing evidence to suggest that the binding of some transcription 
factors is enhanced by DNA methylation (235-237) and methylation can also act to block the binding 
of a repressive transcription factor (238) and therefore upregulate transcription.  
The chemical modification brought about by DNA methylation results in altered DNA-protein 
interactions, which can result in either direct or indirect blocking of transcription. Direct blocking 
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involves the methyl group physically preventing the binding of transcriptional machinery such as 
RNA polymerase II and transcription factors to their recognition sequence (239). DNA methylation 
can indirectly repress gene expression by the recruitment of proteins that bind to methylated 
cytosines, such as methyl cytosine binding protein 2 (MeCP2) (240, 241). Once, bound MeCP2 
recruits a corepressor complex containing histone deacetylases (HDACs) and histone 
methyltransferases (HMTs) (242, 243). Deacetylation and methylation of histone tails leads to a 
more condensed chromatin structure, making the transcription initiation site inaccessible to the 
transcription machinery (244, 245). MeCP2 therefore acts to link the epigenetic processes of DNA 
methylation and histone modifications (Figure 1.5).  
 
 
Figure 1.5. Schematic diagram of epigenetic silencing of transcription. 
Low DNA methylation is associated with increased gene transcription level through binding of 
transcription factors (TF) and RNA polymerase to the promoter region. Methylation of CpG sites 
represses gene transcription by preventing binding of TFs and RNA polymerase and via recruitment 
of MeCP2. MeCP2 recruits a corepressor complex containing histone deacetylases (HDACs) and 
histone methyltransferases (HMTs), which induces an inactive chromatin state. 
 
DNA methylation is critical for mammalian development. It is responsible for ensuring silencing of 
genes on the inactive X chromosome in females, maintenance of genomic imprinting where either 
the maternal or paternal allele is switched off and long term silencing of non-coding DNA (246). 
Genome wide demethylation occurs twice during mammalian development. Demethylation and de 
novo methylation occurs during gametogenesis and plays a critical role in the establishment of 
parental-specific methylation marks in imprinted genes (247). Extensive demethylation (except in 
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imprinted genes) also occurs between fertilisation and preimplantation development and is 
followed by de novo methylation of the embryo genome by DNMT3a and DNMT3b (248-250). DNA 
Methylation patterns are conserved after replication by the maintenance methyltransferase 
DNMT1. DNMT1 recognises hemi-methylated DNA and catalyses transfer of methyl groups to 
cytosine nucleotides on the unmethylated daughter strand thereby maintaining methylation 
patterns through cell division (250). DNA methylation and other epigenetic mechanisms are 
essential for cell differentiation during development. 
Genomic methylation patterns in somatic differentiated cells are generally stable and heritable. 
However, recent evidence indicates that plasticity in DNA methylation does not stop at birth and 
instead can change throughout the life course (251). For example, a progressive decrease in global 
DNA methylation has been reported with increasing age. In humans a progressive loss of 
methylation in genome wide repetitive elements was reported with increasing age in subjects aged 
between 55 and 92 years (252). In a different study, total genomic DNA methylation was found to 
be significantly lower in older (aged 65 to 80 years) than younger (aged 20 to 30 years) individuals 
(253). In contrast, increased methylation has been reported at specific gene promoters with 
increasing age (254, 255). These age-related methylation changes are similar to those seen in cancer 
cells. Cancer progression is characterised by a decrease in global methylation (256), which affects 
chromosomal stability (257). Cancer is also associated with hypermethylation of specific gene 
promoters, particularly of tumour suppressive genes (258).  
In addition to the effects of aging and disease, recent evidence indicates that epigenetic 
mechanisms can be modified by environmental factors, such as nutrition and environmental 
pollutants, both during development and later in the life course (251). Of particular relevance, 
dietary factors have been demonstrated to affect the methylation status of individual CpG 
dinucleotides in the FADS2 promoter, in studies in rodents (213, 259, 260) and human PBMCs (261). 
Furthermore, these studies reported that increased DNA methylation of individual CpG 
dinucleotides in the FADS2 promoter was associated with decreased FADS2 mRNA expression. The 
findings from the above-mentioned studies are discussed in more detail in section 5.1 in Chapter 5. 
Finally, regulation of gene expression by DNA methylation has been shown to play a central role in 
immune responses. Specifically, DNA methylation changes are important for the differentiation of 
Th-lymphocytes into distinct effector subsets, which is based on the types of cytokines produced 
(262). Certain histone modifications have also been reported to be associated with Th-lymphocyte 
differentiation (263, 264). Again, epigenetic regulation of Th-lymphocyte differentiation is 
discussed in more detail in section 5.1 in Chapter 5. 
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1.12 Rationale, aims and hypotheses 
Long chain n-3 PUFAs, particularly 20:5n-3 and 22:6n-3 are reported to have many beneficial effects 
on human health. In particular, findings from certain studies suggest they may have important 
effects on specific immune cell functions, although findings are not consistent in all studies. An early 
study demonstrated that PUFA synthesis is activated in human T-lymphocytes that have been 
stimulated to proliferate. However, this study was conducted in a small number of volunteers and 
there has since been no further investigation into the activity or regulation of PUFA synthesis in 
proliferating T-lymphocytes (see aim 1). Studies have demonstrated that the activity of the PUFA 
synthesis pathway is related to the mRNA expression levels of the genes encoding the desaturase 
and elongase enzymes that operate in the pathway (see aim 2). Furthermore, FADS2 transcription 
has been shown to be related to the DNA methylation status of specific CpG dinucleotides in its 
promoter region and DNA methylation is also known to be important for regulating the expression 
of specific genes involved in T-lymphocyte differentiation following activation (see aim 3). 
A high level of PUFA synthesis has been reported in a spontaneously dividing T-lymphocyte 
leukaemic cell line (Jurkat), resembling the wider dysregulation of de novo fatty acid synthesis seen 
in cancer cells. However, there has been no direct comparison of PUFA synthesis in Jurkat cells and 
primary T-lymphocytes. Furthermore, it is not known whether the high level of PUFA synthesis is 
mediated at the transcriptional level nor whether it is important for supporting cellular proliferation 
(see aims 4 to 7).  
Finally, a number of studies have reported gender differences in the conversion of 18:3n-3 to longer 
chain n-3 PUFAs in humans. However, this has not been investigated across the life course or 
specifically in immune cells. The effect of age on the activity of the PUFA synthesis pathway is less 
clear and requires further investigation (see aim 8).  
The general aims and hypotheses of this thesis, related to the activity and regulation of the PUFA 
biosynthesis in humans are given below with more specific versions given in the individual results 
chapters. 
Aims 
1. To compare the activity of the PUFA synthesis pathway in unstimulated and mitogen-stimulated 
PBMC populations. 
2. To compare the mRNA expression levels of the genes encoding the enzymes that function in 
the PUFA biosynthesis pathway in unstimulated and mitogen-stimulated PBMC populations. 
3. To determine whether any changes in mRNA expression in unstimulated and mitogen-
stimulated PBMC populations are associated with DNA methylation changes. 
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4. To compare the activity of the PUFA synthesis pathway in mitogen-stimulated PBMC 
populations and Jurkat cells. 
5. To compare the mRNA expression levels of the genes encoding the enzymes that function in 
the PUFA biosynthesis pathway in mitogen-stimulated PBMC populations and Jurkat cells. 
6. To determine whether any differences in mRNA expression between mitogen-stimulated PBMC 
populations and Jurkat cells are associated with DNA methylation changes. 
7. To investigate whether inhibition of the PUFA synthesis pathway affects the proliferation of 
mitogen-stimulated lymphocytes and Jurkat cells. 
8. To determine the effect of age and gender on the activity of the PUFA synthesis pathway and 
the mRNA expression levels of the genes encoding the enzymes that function in the pathway, 
in mitogen-stimulated PBMC populations. 
Hypotheses 
1. The activity of the PUFA synthesis pathway is higher in mitogen-stimulated compared to 
unstimulated PBMCs. 
2. The mRNA expression levels of the genes encoding the pathway enzymes are higher in mitogen-
stimulated compared to unstimulated PBMCs. 
3. DNA methylation levels in the promoter regions of the genes encoding the pathway enzymes 
are lower in mitogen-stimulated compared to unstimulated PBMCs. 
4. The activity of the PUFA synthesis pathway is higher in Jurkat cells compared to mitogen-
stimulated PBMCs. 
5. The mRNA expression levels of the genes encoding the pathway enzymes are higher in Jurkat 
cells compared to mitogen-stimulated PBMCs. 
6. DNA methylation levels in the promoter regions of the genes encoding the pathway enzymes 
are lower in Jurkat cells compared to mitogen-stimulated PBMCs. 
7. Inhibition of the PUFA synthesis pathway decreases proliferation of mitogen-stimulated 
lymphocytes and Jurkat cells. 
8. The activity of the PUFA synthesis pathway and mRNA expression levels of the pathway 
enzymes are higher in females compared to males and decrease with increasing age in mitogen-
stimulated PBMCs. 
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2.1 Reagents 
A list of reagents, chemicals, kits and suppliers can be found in Appendix A. All water used was 
generated using a Barnstead NANOpure Diamond™ (Thermo Scientific, UK) reagent grade water 
purification system unless otherwise stated. 
2.2 Human study protocol 
Healthy volunteers were recruited to take part in the ‘Epigenetic regulation of omega-3 
polyunsaturated fatty acid synthesis (EPUFA)’ research study conducted at the Centre for 
Endocrinology and Diabetic Research (CEDAR) at the Royal Surrey County Hospital (RSCH).  
2.2.1 Ethical approval 
Before the EPUFA study was undertaken approval was sought from two ethical review bodies: the 
NHS Research Ethics Service (NRES) and the University of Surrey ethics committee (UEC). For NRES 
review an application was prepared using the Integrated Research Application System (IRAS) and 
submitted to the NRES committee North West - Preston. The study was reviewed and given a 
favourable ethical opinion by both the NRES research ethics committee (REC) North West – Preston 
(REC reference 14/NW/1048) and the University of Surrey ethics committee (UEC reference 
EC/2014/112/FHMS). Clinical governance was provided by the RSCH NHS Foundation Trust 
Research and Development Office. 
2.2.2 Inclusion and exclusion criteria 
Healthy, White Caucasian, males and females aged between 18 and 71 with a BMI between 18.5 
kg/m2 and 30 kg/m2 were recruited to take part in the research study. The exclusion criteria are 
listed below. 
Exclusion criteria: 
 Aged <18 or >71 years 
 BMI <18.5 kg/m2 or >30 kg/m2 
 Pregnant women 
 Women receiving hormone based contraceptives 
 Women receiving hormone replacement therapy 
 Diagnosed type 1 or type 2 diabetes 
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 Use of any prescribed medication known to affect lipid metabolism (any medications listed by 
potential volunteers were passed on to the named clinician for the study to confirm 
acceptability) 
 Smokers 
 Male consuming more than 28 units of alcohol per week or females consuming more than 21 
units of alcohol per week 
 Consumption of more than one portion of oily fish per week 
 Consumption of fish oil capsules  
 Participation in another research study 
Participants were not asked whether they were taking any non-prescribed medications and 
therefore individuals taking anti-inflammatory agents such as aspirin were potentially included in 
the study. This represents a limitation since aspirin affects the conversion of n-3 PUFAs into 
downstream inflammatory mediators such as resolvins (See section 1.10.2 and Figure 1.4). 
2.2.3 Sample size calculations 
Preliminary power analysis showed that 10 males and 10 females would be sufficient to detect a 2-
fold difference in synthesis of [1-13C]20:5n-3 from [1-13C]18:3n-3 between males and females with 
80% power and P < 0.05, based on data from Burdge and Wootton, 2002 (99), and Burdge et al., 
2002 (100). Therefore, the study aimed to recruit 10 males and 10 females into each of the following 
age groups to ensure an even spread of ages: 18 to 37, 38 to 54 and 55 to 71 years. 
2.2.4 Recruitment 
Participants were recruited via posters and emails. Individuals interested in participating were 
emailed an information sheet (Appendix B.1) and were asked to complete a screening 
questionnaire (Appendix B.2). Potential participants that appeared to meet the inclusion criteria 
were invited to attend a study appointment at the CEDAR. A total of 89 volunteers attended the 
study appointment and of these volunteers three did not meet the inclusion criteria so a total of 86 
volunteers were included in the study. Samples from 18 volunteers were used to optimise the 
experimental techniques leaving 68 volunteers (31 males and 37 females) in the main study. 
2.2.5 Study appointment 
Participants were required to arrive fasted, having had nothing to eat or drink except water in the 
previous 10 h. Written informed consent was obtained (Appendix B.3) before the participants’ 
height, weight and percentage body fat were measured to confirm eligibility. Height was measured 
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using a stadiometer with shoes removed. Weight and body fat composition measurements were 
made using a TANITA bioelectrical impedance device.  
Two individual cotton swabs (Fisher Scientific) were used to collect buccal cells from each side of 
the mouth. Participants were asked to brush the inside of their cheeks with the swabs, which were 
then immersed in the collection tube containing 3 ml of water, sealed and placed on ice until 
processing within 2 h.  
Blood pressure was measured in triplicate by a research nurse who then collected blood samples 
with a winged blood collection needle and vacutainer tube (BD Biosciences).  Lithium heparin tubes 
were used to collect blood (42 ml) for peripheral blood mononuclear cell (PBMC) isolation, 
potassium ethylenediaminetetraacetic acid (K2-EDTA) tubes (4 ml) for total haemoglobin and 
plasma triglycerides (TG), total cholesterol and high density lipoprotein (HDL) cholesterol analysis 
and sodium fluoride/potassium oxalate tubes (2 ml) for plasma glucose analysis. Blood samples in 
K2-EDTA and sodium fluoride/potassium oxalate tubes were stored on ice until processing within 2 
h. The lithium heparin blood samples were stored in an air and watertight container, which was 
placed in a sample transport box cooled with two ice packs and transported to the University of 
Southampton where the blood samples were processed within 6 h from time of collection. An 
overview of the study day is given in Figure 2.2. 
2.3 Blood biochemistry analyses  
Total haemoglobin and plasma TG, total cholesterol, HDL cholesterol and glucose were measured 
in order to characterise the EPUFA study population. The results of the blood biochemistry analyses 
were sent to each participant’s general practitioner (GP) and a copy was sent to the volunteer.  
Total haemoglobin was measured using a GEM Oxygenation portable laboratory (OPL) portable 
analyser (Werfen, Spain) according to manufacturer’s instructions at the point of sampling. Blood 
for metabolites was centrifuged at 500 x g for 15 min at 4oC and the plasma was stored at -80 oC 
until analysis. Assays for measurement of plasma TG, HDL-cholesterol, total cholesterol and glucose 
were carried out on a COBAS MIRA auto-analyser (Roche Diagnostic, USA) using the following 
Horiba ABX Pentra kits: Triglycerides CP (kit A11A01668), HDL Direct CP (kit A11A01636), 
Cholesterol CP (A11A01634) and Glucose PAP CP (kit A11A01668). All assays were carried out 
according to manufacturer’s instructions and low and high quality controls (Horiba N and P controls) 
were included at the beginning, middle and end of each run in each run.  
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2.4 Isolation of PBMCs from heparinised blood samples 
PBMCs were isolated from 40 ml of the heparinised blood by density gradient centrifugation using 
an adaptation of the method described in Lomax et al., 2012 (265). A 10 ml volume of the density 
gradient solution Histopaque®-1077 (Sigma-Aldrich) was aliquoted into each of four sterile 50 ml 
centrifuge tubes and equilibrated to RT. An equal volume of blood was layered slowly over the 
Histopaque®-1077 ensuring two distinct layers were visible. Samples were centrifuged at 845 x g 
for 15 min at RT with no break applied. During centrifugation, differential migration of blood cells 
causes layers of different cell types to form (Figure 2.1). The bottom layer contains erythrocytes. 
Immediately above this in the Histopaque®-1077 layer there are mostly granulocytes. PBMCs are 
found at the interface between the Histopaque®-1077 layer and the plasma (top layer) in a region 
called the buffy coat. Platelets, also found in the buffy coat, are removed by subsequent washing 
and centrifugation steps. The samples were carefully removed from the centrifuge ensuring no 
disruption of layers.  
Plasma collection: 
The plasma layer was transferred into a new sterile 50 ml centrifuge tube. Next 200 µl of plasma 
was transferred to a screw capped glass tube and 600 µl 0.9% (w/v) NaCl was added ready for 
subsequent total lipid extraction (described in section 2.12.1). A further 2 ml of plasma was 
aliquoted into each of two 2 ml tubes and stored at -80 oC. The remaining plasma was kept at 4oC 
until required.  
PBMC collection and handling for downstream analyses: 
The layer containing the PBMCs was transferred into a sterile 50 ml sterile centrifuge tube and 
RPMI-1640 medium (Sigma-Aldrich) was added to a total volume of 40 ml in order to wash the cells 
before centrifuging at 300 x g, for 10 min at RT. After centrifugation the RPMI-1640 was decanted 
from the PBMC pellet and the cells were resuspended in 1 ml RPMI-1640. 10 µl of the cell 
suspension was removed and diluted with 90 µl RPMI-1640, which was then diluted a further 10 
times with 0.4 % trypan blue solution (Sigma-Aldrich) before counting using a haemocytometer. 
The concentration of cells was adjusted to 2 x 106/ml with RPMI-1640. A total of 10 x 106cells were 
transferred into a 15 ml centrifuge tube (these cells were designated for analysis of cell phenotypes 
using flow cytometry). A calculated volume of autologous plasma was then added to the remaining 
cells in the 50 ml centrifuge tube (these cells were designated for cell culture) to achieve a 
concentration of 2% autologous plasma in RPMI-1640. Both tubes were centrifuged at 300 x g, for 
10 min at RT.  
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Cells designated for analysis by flow cytometry: 
The cells designated for flow cytometry were washed with 10 ml phosphate buffered saline (PBS; 
Sigma-Aldrich) and centrifuged as before. The cell pellet was resuspended in 1 ml PBS before 
counting a using a 10-fold dilution in trypan blue and a haemocytometer. A total of 5 x 105 cells 
were transferred into each of four 5 ml round bottom tubes and stored at 4oC ready for analysis of 
cell phenotypes. Where there were surplus cells, 2 x 106 cells were transferred into 0.5 ml micro-
centrifuge tubes and pelleted by centrifugation at 300 x g, for 10 min at RT. The PBS wash was 
removed and the pellet was snap frozen on dry ice before being transferred to -80oC storage. These 
tubes were used for pre-culture mRNA expression and DNA methylation measurements.  
Cells designated for cell culture: 
The cells designated for cell culture were washed with 10 ml RPMI-1640 containing 2% autologous 
plasma and centrifuged as before. The supernatant was removed and the cells were resuspended 
in 1 ml PBMC medium (see Appendix A.2.1 for composition) containing 5% (v/v) autologous plasma 
before diluting a 10 µl aliquot 10-fold in trypan blue and counting cells using a haemocytometer. 
Cells were adjusted to a concentration of 1 x 106 cells/ml and cultured as described in section 2.6. 
Erythrocyte collection: 
The erythrocyte layer from the original gradient centrifugation was transferred into a sterile 50 ml 
centrifuge tube and washed three times with two volumes of 0.9 % NaCl to one volume of 
erythrocytes and centrifuged between washes at 200 x g for 10 min at RT to pellet the cells. After 
the final wash, 500 µl of erythrocytes were transferred to a screw capped glass tube and 500 µl of 
0.9% NaCl added ready for total lipid extraction (described in section 2.12.1). A further 1 ml of 
erythrocytes were added to each of two 2 ml tubes and stored at -80oC.  
 
 
Figure 2.1. Schematic of PBMC isolation procedure. 
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Figure 2.2. Overview of the EPUFA study day. 
The study day involved three locations: 1. Volunteers attended an appointment at the Centre for Endocrinology and Diabetic Research (CEDAR) at the Royal Surrey County 
Hospital (RSCH); 2. A portion of the blood samples were processed at the University of Surrey. 3. The remaining blood samples were transported to the University of 
Southampton where PBMCs were isolated and cultured.
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2.5 Analysis of PBMCs using flow cytometry 
The proportions of T-lymphocytes, B-lymphocytes and monocytes in the PBMC populations were 
determined by analysing the expression of the cell surface markers CD3, CD19 and CD14, 
respectively, using flow cytometry.   
Flow cytometry was performed using a Becton Dickinson FACS Calibur flow cytometer equipped 
with a 488 nm laser. In flow cytometry, the microfluidic system of the flow cytometer enables single 
cells to pass through a laser beam and the light scattered from the cells is detected. A detector in 
front of the laser beam measures the forward scatter (FSC) and detectors to the side of the laser 
beam measure the side scatter (SSC). FSC is proportional to cell size and SSC to cell granularity and 
therefore different cell populations can be distinguished based on their light scattering 
characteristics. Fluorescence detectors measure the fluorescence emitted from stained cells. Data 
was acquired using CellQuest Pro analysis software (BD Biosciences, USA) and then exported to 
FlowJo software version 7.6.5 (TreeStar, Inc, USA) for further analysis.  
2.5.1 Staining PBMCs with fluorescently conjugated antibodies 
Staining was performed according to manufacturer’s instructions for each fluorescently conjugated 
antibody. A total of 5 x 105 PBMCs were added to each of four individual 5 ml round bottom tubes 
in 100 µl PBS. They were then incubated for 30 min at 4oC in the dark with 10 µl of the following 
mouse anti-human fluorescently conjugated monoclonal antibodies (Bio-Rad): anti-CD3 FITC 
(fluorescein isothiocyanate), anti-CD19 FITC, anti-CD14 RPE (R. Phycoerythrin) and IgG1 (FITC) 
isotype control (BD Biosciences) or no antibody as a no stain (negative) control. Anti-CD3 FITC and 
anti-CD14 RPE were added to the same tube as a dual stain. Anti-CD3 FITC and CD19 FITC were 
diluted 1 in 10 with water immediately prior to being added to the cells. After incubation the cells 
were washed with 2 ml cell wash solution (BD Biosciences) and centrifuged at 211 x g for 5 min. The 
cells were resuspended in 200 µl cell fix solution (BD Biosciences) and kept at 4oC until analysis 
within 48 h.  
2.5.2 Optimisation of instrument settings for flow cytometry 
Before data were collected the instrument settings were optimised using CellQuest Pro analysis 
software. First the forward scatter (FSC) and side scatter (SSC) detectors were adjusted to obtain a 
clear population of PBMCs in an appropriate location on the plot. Next, the FSC threshold was 
adjusted to exclude most of the debris without excluding any of the population of interest. A gate 
was then drawn around the PBMC population (Figure 2.3) and the fluorescence channel 1 (FL-1) 
and fluorescence channel 2 (FL-2) were adjusted to appropriately position the negative population 
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and allow visualisation of the positive population in this region. Fluorochrome FITC was detected in 
FL-1 and RPE in FL-2. Finally, the fluorescence compensation was adjusted to correct for signal 
overspill between FL-1 and FL-2. The instrument settings (Appendix A.3) were then saved and used 
to analyse each sample. In all cases 104 total events were collected for analysis.  
2.5.3 Cell phenotyping data analysis 
A gate was drawn around the total PBMC population for freshly isolated (pre-culture) PBMCs 
(Figure 2.3; R1). Following culture (post-culture) a gate was drawn to capture total PBMCs including 
activated lymphocytes (Figure 2.3; R2). Figure 2.3 shows that the monocyte population largely 
disappeared following culture. The events within the PBMC gate (R1 or R2) were represented in a 
histogram showing fluorescence intensity on the x-axis and the number of events (cell count) on 
the y-axis Figure 2.4. The no stain control samples were used to set the position of a marker (M1) 
over positively staining events. The isotype control was used to verify that there was no non-specific 
binding. The percentage of events falling within the boundaries of M1 were reported as the 
percentage of events positive for the measured cell surface marker and therefore corresponding 
cell type within the PBMC population. 
 
Figure 2.3. Gating PBMC populations using flow cytometry. 
FSC and SSC settings were adjusted to obtain a clear population of PBMCs. The graphs show a PBMC 
population prior to culture (pre-culture), after 48 h culture without activation by Con A (No Con A) 
and after 48 h culture with activation by 5 µg/ml Con A. A gate (R1 for pre-culture and R2 for post-
culture) was drawn around the cells so only the PBMC population would be used for subsequent 
analysis.  
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Figure 2.4. Histograms showing expression of specific cell surface markers in PBMCs. 
(A) The cell surface marker CD3 is specific to T-lymphocytes, (B) CD19 to B-lymphocytes and (C) 
CD14 to monocytes. Red line shows the no stain control and the blue line shows the stained sample 
with the markers M1 and M2 set to include positively staining cells. 
 
2.6 Culture of PBMCs isolated from lithium heparin blood 
PBMCs isolated as described in section 2.4 were cultured in 52cm2 tissue culture dishes at 1 x 106 
cells/ml in PBMC medium (see Appendix A.2.1 for composition) supplemented with 5%  autologous 
plasma, 20 µM stable isotope labelled 18:3n-3 ([1-13C]18:3n-3) and 5 µg/ml concanavalin A (Con A). 
Details of the preparation of the stock solutions of [1-13C]18:3n-3 and Con A can be found in 
Appendix A.2.2. For 34 volunteers of the total 68 volunteers, parallel cultures were also prepared, 
without addition of Con A. Before adding to cells, a 0.8 ml aliquot of the supplemented medium 
was transferred to a screw cap glass tube ready for total lipid extraction (section 2.12.1). Cells were 
cultured for 48 h at 37oC under 5% CO2 in a humidified atmosphere. 
2.6.1 Harvesting PBMCs for downstream analyses 
After 48 h the PBMCs were collected from dishes using a cell scraper to remove any adhered cells 
and the cell suspensions were transferred to 15 ml centrifuge tubes and centrifuged at 300 x g for 
10 min. Each cell pellet was washed once with ice cold PBS, centrifuged as before and then 
resuspended in 1 ml ice cold PBS for cell counting. A 10 µl aliquot of cell suspension was diluted 10-
fold with PBS and then 2-fold with 0.4% trypan blue solution and counted using a haemocytometer.  
1 x 106 cells were transferred to each of four 1.5 ml microcentrifuge tubes and centrifuged at 300 x 
g for 10 min. The supernatants were removed and the cell pellets were snap frozen on dry ice prior 
to being transferred to storage at -80oC for subsequent RNA and DNA extraction (described in 
section 2.14). 5 x 105 cells were transferred to three individual 5 ml round bottom tubes in a final 
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volume of 100 µl PBS and stored at 4oC ready for measurement of cell activation by flow cytometry 
(described in section 2.7). The remaining cells were centrifuged at 300 x g and resuspended in 0.8 
ml 0.9% (w/v) NaCl. A 20 µl aliquot of the cell suspension was transferred to a 0.5 ml 
microcentrifuge tube and frozen on dry ice before storage at -80 oC for later total cell protein 
quantification (see section 2.13). Total lipid extracts and fatty acid methyl esters (FAMES) were 
prepared from the remaining cells as described in section 2.12.  
2.7 Measurement of T-lymphocyte activation by CD69 expression 
The proportion of activated T-lymphocytes was determined by measuring the cell surface 
expression of the activation marker CD69 on events in the PBMC region using flow cytometry. 
Following cell culture 5 x 105 PBMCs suspended in 100 µl PBS were incubated with 10 µl mouse 
anti-human CD69 FITC monoclonal antibody for 30 min at 4oC in the dark and processed for analysis 
by flow cytometry as described in section 2.5, using the same instrument settings. A gate (R2) was 
drawn around the PBMC population (Figure 2.3, post culture). The events within R2 were 
represented in a histogram and a marker (M1) was drawn over events staining positively for CD69 
FITC (Figure 2.5). The proportion of events falling within the boundaries of M1 were reported as 
percentage of cells expressing CD69. 
  
 
Figure 2.5.  Histograms showing CD69 expression in PBMCs. 
The red line shows the isotype control population and the blue line shows the CD69 (FITC) stained 
samples within the PBMC gate (R2 – see Figure 2.3) with the marker M1 set to include positively 
staining cells. The graphs show cells cultured for 48 h in the absence of Con A (no Con A) and cells 
cultured for 48 h in the presence of 5 µg/ml Con A (+ConA). 
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2.8 Revival and cell culture of purchased cryopreserved PBMCs 
Cryopreserved PBMCs purchased from StemCell Technologies (Canada) were used for additional 
cell culture experiments. Purchased PBMCs were used to determine the effect of 18:3n-3 
concentration on PBMC viability (section 2.9) and proliferation (section 2.10) as part of initial 
optimisation experiments before commencement of the EPUFA study. Purchased PBMCs were also 
used in experiments to determine the effect of the delta-6 desaturase inhibitor (SC-26196) on 
proliferation. Purchased PBMCs were used as these experiments were conducted after completion 
of the EPUFA study, in order to investigate hypotheses generated from the study findings.  
Purchased PBMCs were cultured in PBMC medium containing 10% (v/v) fetal bovine serum (FBS). 
The composition of the cell culture medium and details of cell culture treatment compounds are 
given in Appendix A.2. The PBMCS arrived frozen on dry ice and were transferred immediately to 
liquid nitrogen storage. When required, each vial of cryopreserved PBMCs was thawed in a 37oC 
water bath; being removed from the water bath when only a small frozen cell pellet remained. A 
20 µl aliquot of cells was set aside for counting using 0.4% trypan blue solution and a 
haemocytometer to confirm adequate cell number and viability. The remaining cell suspension was 
transferred to a 15 ml centrifuge tube. The vial was rinsed with 1 ml of PBMC medium containing 
10% FBS (equilibrated to 37oC) and added drop-wise to the cells whilst swirling the tube. A further 
10 ml medium was added on top and the cell suspension centrifuged at 300 x g for 10 min at RT. 
The supernatant was carefully removed and the cells resuspended in 1 ml PBMC medium containing 
10% FBS. Cells were counted and adjusted to a density of 1 x 106 cells/ml before culturing in 52cm2 
tissue culture dishes at 37oC under 5% CO2 in a humidified atmosphere. 
2.9 Cell viability assays 
The viability of purchased PBMCs, after exposure to specific cell culture treatments, was measured 
using two different viability assay kits: CellTiter-Glo Luminescent Cell Viability Assay (Promega) and 
LIVE/DEAD Fixable Red Dead Cell Stain Kit (Thermo Fisher Scientific). Both kits allowed rapid 
measurement of cell viability for large sample numbers.  
2.9.1 CellTiter-Glo Luminescent Cell Viability Assay 
This is a bioilluminescence assay based on quantitation of adenosine triphosphate (ATP) to 
determine cell viability since ATP is an indicator of metabolically active cells. The cells are lysed, 
releasing ATP and generating a luminescent signal that is proportional to the amount of ATP 
present.  
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In order to measure cell viability using this assay, 1 x 105 purchased PBMCs in 100 µl of PBMC 
medium containing 10% (v/v) FBS were plated in each well of opaque walled, flat bottom 96 well 
plates with six replicates for each treatment to be tested and vehicle control. Six replicate control 
wells, containing medium without cells, were also prepared in order to obtain a background 
luminescence value. The plate was then incubated at 37oC with 5% CO2 in a humidified atmosphere 
for the required amount of time depending on the specific experiment. Details of the treatments 
and incubation times for specific experiments are given in Chapter 3 (section 3.2.4). The plate was 
then equilibrated to room temperature for 30 min and processed according to manufacturer’s 
instructions. Luminescence was measured on a VarioSkan Flash luminometer (Thermo Fisher 
Scientific). Values were expressed relative to the vehicle control, which was set at 100%.  
2.9.2 LIVE/DEAD Fixable Red Dead Cell Stain Kit 
This kit differentially stains live and dead cells, based on their membrane integrity, for analysis using 
flow cytometry. The version of the kit containing the red fluorescent reactive dye (excitation max 
595 nm and emission max 615 nm) was chosen as it is suitable for dual measurement with CFSE 
(excitation max 490 nm and emission max 520 nm), where dual measurement was required for 
gating live cells for analysis of proliferation (see section 2.10). The fluorescent dye supplied with 
the kit reacts with cellular amines. For live cells, the dye cannot permeate the cell membrane and 
therefore only the cell surface amines are available to react with the dye. The membranes of 
necrotic cells become compromised allowing the dye to permeate and react with free amines inside 
the cell in addition to those on the cell surface. The result is much brighter staining for dead cells 
compared with live cells allowing clear discrimination. 
2.9.2.1 Staining PBMCs with LIVE/DEAD Fixable Red Dead Cell Stain 
A total of 2 x 105 PBMCs per well were plated in clear flat bottom 96 wells plates in 200 µl of PBMC 
medium containing 10% (v/v) FBS. There were six replicates for each test compound, vehicle control 
and blank (media). An additional six replicates treated with 1 mM 22:6n-3 were included as a cell 
death control. After the culture period (see Chapter 3, section 3.2.4 for details) the cells were 
transferred into 5 ml round bottom tubes, washed with 0.5 ml PBS and centrifuged at 300 x g for 
10 min. After centrifugation the PBS wash was removed and the PBMCs were resuspended in 200 
µl PBS containing 1 µl/ml red reactive dye. The cell suspension was incubated at 4oC for 30 min, 
protected from light. The cells were then washed with 0.5 ml of PBS containing 1% (w/v) bovine 
serum albumin (BSA) and centrifuged at 300 x g for 10 min. The supernatant was discarded and the 
cell pellet was resuspended in 200 µl PBS with 1% BSA. 
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2.9.2.2 Analysis of cell viability using flow cytometry 
The instruments settings used to acquire data are listed in Appendix A.3. A total of 104 events were 
recorded and the viability dye was measured in FL-2. A histogram showing FSC on the x-axis and 
number of events on the y-axis was drawn using FlowJo analysis software and a marker (M1, Figure 
2.6) was set to include dead and live cell populations but exclude debris. The events in M1 were 
used to draw another histogram with FL-2 fluorescence on the x-axis and number of events on the 
y-axis. The cell death control, which displayed two clear peaks of differing fluorescence intensity 
(Figure 2.6, graph C-bottom) was used to position a marker (M2) over the dead cell population. The 
percentage of events falling within the boundaries of M2 as a proportion of events in M1 were 
recorded as the percentage of non-viable cells. 
 
Figure 2.6. Measurement of PBMC viability using LIVE/DEAD Fixable Red Dead Cell Stain Kit. 
The top three histograms display FSC against count for all events with the marker M1 over total 
cells. The bottom three histograms display fluorescence in FL-2 against count for events in M1 with 
the marker M2 over the non-viable cells. (A) Negative control (unstained) PBMCs. (B) Stained 
PBMCs. (C) Positive control for cell death (PBMCs treated with 1 mM 22:6n-3). 
2.10 Analysis of PBMC proliferation using carboxyfluorescein succinimidyl ester (CFSE) 
CFSE is a dye that can be used for monitoring of cell divisions using a flow cytometer equipped with 
a blue 488 nm laser. CFSE passively diffuses across cell membranes where it is cleaved by 
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intracellular esterases making it highly fluorescent; nonviable cells cannot cleave the dye and 
remain non-fluorescent. The succinimidyl ester group enables CFSE to covalently bind to protein 
amine groups within cells and as they divide the dye is distributed equally between progeny cells 
resulting in a halving of the fluorescence of daughter cells. 
Cryopreserved PBMCs were thawed as described in section 2.8 and then a total of 4 x 107 viable 
PBMCs were suspended in 1 ml PBS containing 5% (v/v) FBS ready for staining with CFSE as detailed 
below. A further 2 x 106 PBMCs were adjusted to 1 x 106 cells per ml in PBMC medium containing 
10% (v/v) and were used as an unstained control.  
2.10.1 PBMC treatment with CFSE 
One vial containing 500 µg of lyophilised CFSE (Affymetrix eBioscience) was resuspended with 180 
µl dimethylsulfoxide (DMSO) to make a 5 mM stock solution. CFSE was diluted directly into the 1 
ml cell suspension containing approximately 4 x 107 viable PBMCs. After thorough mixing, the cells 
were incubated for 5 min at RT, protected from the light. CFSE staining was terminated by washing 
the cells with 10 ml PBS containing 5% (v/v) FBS and centrifuging at 300 x g for 5 min. The 
supernatant was discarded and the cell pellet was washed in the same manner twice more. After 
the final wash the cells were resuspended in 1 ml of PBMC medium containing 10% (v/v) FBS and 
counted using a haemocytometer. The concentration of viable cells was adjusted to 1 x 106/ml. 4 x 
106 cells were transferred to a fresh tube to be used as an unstimulated control. The remaining 
CFSE labelled cells and the unlabelled cells (set aside in section 2.10) were stimulated with Con A at 
a final concentration of 5 µg/ml. Stimulated CFSE labelled cells were then divided between three 
fresh tubes for treatment with SC-26196. Stock solutions containing 10 µM and 20 µM SC-26196 
were prepared as described in Appendix A.2.2. Cells were then treated with 100 nM or 200 nM SC-
26196 or just 0.02% (v/v) DMSO as a vehicle control. Cells were transferred to five individual 96 
well flat bottom culture plates with eight replicates per plate for each SC-26196 treatment and 
vehicle control, two replicates for the CFSE stained but unstimulated cells and two replicates for 
the unstained cells.  A further two replicates of CFSE stained stimulated cells treated with 1 mM 
22:6n-3 were added to one plate as a positive control for cell death. Cells were maintained in a 
humidified cell culture incubator at 37oC in a 5% CO2 atmosphere for up to 144 h.  
2.10.2 Preparation of CFSE labelled PBMCs for flow cytometry 
The first plate was removed after 48 h for analysis and then one plate was removed every 24 h until 
144 h. The remaining cells were transferred from the 96 well plates into 5 ml round bottom tubes, 
washed with 1 ml PBS and centrifuged at 300 x g for 10 min. The cell pellet was resuspended in 200 
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µl PBS containing 1 µl/ml of LIVE/DEAD red viability dye (see section 2.9.2 for details) and incubated 
at 4oC for 30 min, protected from light. Cells were washed with 1 ml PBS containing 1% (w/v) bovine 
serum albumin (BSA) and centrifuged for 5 min at 300 x g. The supernatant was discarded and the 
cells were resuspended in 200 µl 1% BSA (w/v) in PBS. 
2.10.3 Measuring CFSE fluorescence using flow cytometry  
CFSE fluorescence was measured in FL-1 and the LIVE/DEAD red viability dye fluorescence was 
detected in FL-2. The instruments settings were optimised for this analysis as described in section 
2.5.2 and are detailed in Appendix A.3. A total of 104 events were collected for all samples. The 
results were exported and analysed using FlowJo software version 7.6.5. The lymphocyte 
population was gated (R1) as shown Figure 2.7 (A) and non-viable cells were excluded from the 
analysis by combining R1 with a second gate (R2) around viable cells (Figure 2.7, B). The positive 
control for cell death was used to confirm the fluorescence intensity of the non-viable cells. The 
number of cell divisions for viable lymphocytes, shown as discrete peaks with decreasing CFSE 
fluorescence, were modelled and analysed using the FlowJo proliferation platform (Figure 2.7, C)., 
typically set with a coefficient of variation (CV) of 5-10 and a peak ratio of 0.5. A root mean squared 
(RMS) of <10 was required for inclusion in the analysis. The following measures of proliferation 
were recorded: 
 
 Percent divided – the percentage of cells from the original sample that divided. 
 Division Index – the average number of divisions that a cell from the original population has 
undergone; this is the average number of divisions for the entire population including the 
undivided peak. 
 Proliferation Index – the average number of cell divisions for the cells that entered cell division; 
this is the average number of division for the responding population. 
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Figure 2.7. Analysis of proliferating lymphocytes stained with CFSE by flow cytometry. 
(A) A gate was drawn around lymphocytes based on their light scatter characteristics (R1). (B) Dead 
cells in R1 were excluded by introduction of a sub-gate (R2). (C) Histogram showing multiple CFSE 
fluorescence peaks of proliferating lymphocytes. The proliferation model applied by the FlowJo 
software is shown in pink. The CFSE fluorescence peak of undivided cells (peak zero) is indicated by 
a red line. 
2.11 Cell line culture 
2.11.1 Revival and maintenance of HepG2 cells 
In house stocks of HepG2 cells (European Collection of Authenticated Cell Cultures [ECACC]), were 
removed from liquid nitrogen storage and thawed in a 37oC water bath until only a small frozen cell 
pellet remained. The cell suspension was transferred to a 15 ml centrifuge tube, washed with 10 ml 
HepG2 medium (see Appendix A.2.1 for composition), centrifuged at 200 x g and resuspended in 1 
ml HepG2 medium. Cells were counted using a haemocytometer before seeding in 75 cm2 tissue 
culture flasks at a density of 30 x 105 cells/cm2 in in 17 ml HepG2 medium. Once cultures reached 
approximately 80% confluency they were washed with 5 ml Hanks’ balanced salt solution (HBSS) 
before addition of 2 ml of 0.05% trypsin EDTA (Sigma-Aldrich). Cultures were then incubated at 
37oC to detach cells from the bottom of the flask. After 2-5 min the cultures were removed from 
the incubator and 10 ml HepG2 media was added to the flask to neutralise the trypsin. The cells 
were then split equally between four flasks and cultured as before. HepG2 cells were always left to 
adhere for 24 hrs before any experimental treatments. 
2.11.2 Revival and maintenance of Jurkat cells 
In-house stocks of Jurkat cells (ECACC), were removed from liquid nitrogen storage and thawed and 
washed as described for HepG2 cells but with Jurkat medium (see Appendix A.2.1 for composition) 
and with centrifuging at 300 x g. Cells were seeded in 25 cm2 culture flasks at a density of 300 x 105 
cells/ml in 15 ml Jurkat medium. Cells were split between new flasks when density reached 
approximately 1 x 106 cells/ml. 
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2.12 Fatty acid analysis 
2.12.1 Total lipid extraction 
Following cell culture, PBMC and Jurkat cells were pelleted by centrifugation and resuspended in 
0.8 ml of 0.9 % (w/v) NaCl whereas HepG2 were scraped from the surface of the culture plate in 0.8 
ml of 0.9 % (w/v) NaCl and transferred to a glass screw capped tube ready for downstream total 
lipid extraction. Plasma and erythrocytes were prepared for total lipid extraction as described in 
section 2.4. Total lipids were extracted using an adaptation of the method described by Folch (266). 
A quality control (QC) sample (100 µg of L-α-phosphatidylcholine [Sigma-Aldrich]) and a blank were 
processed at the same time as the samples. The QC contained known proportions of 16:0 (33%), 
18:0 (13%), 18:1n-9 (31%), and 18:2n-6 (15%), which were monitored for each run. 
Diheptadecanoyl-sn-glycero-3-phosphocholine (17:0 PC [Sigma-Aldrich]) was added to each sample 
and to the QC and blank as an internal standard for quantitative analysis. The amount added 
depended on the sample being processed (5 µg for PBMCs and 25 µg for Jurkat cells, HepG2 cells, 
plasma and erythrocytes). Next, 5 ml of 2:1 (v:v) chloroform to methanol containing 50 mg/l 
butylated hydroxytoluene (BHT) was added followed by 1 ml of 1 M NaCl. Samples were vortexed 
and centrifuged at 850 x g for 10 min at RT. The lower phase containing the total lipid extract was 
collected by aspiration and dried under nitrogen at 40oC. 
2.12.2 Separation of the phosphatidylcholine (PC) lipid class from plasma samples by solid 
phase extraction (SPE) 
The PC lipid class was only isolated from total lipid extracted from plasma samples, using the 
method described by Burdge et al., 2000 (267). For all other sample types the total lipid extract was 
used directly for the preparation of fatty acid methyl esters (FAMEs) described in section 2.12.3. 
Aminopropylsilica cartridges (Agilent, USA) were placed on an SPE tank connected to a vacuum 
pump and 2 ml of chloroform was added to each cartridge and allowed to drip through under 
gravity into a collection tube. The total lipid extract was dissolved in 1 ml of chloroform, added to 
the cartridge and allowed to drip through under gravity. After no more drips fell, the remaining 
liquid was drawn through the cartridge under vacuum. The cartridge was washed with 2 ml 
chloroform under vacuum and the solution collected was discarded. A new collection tube was 
placed in the SPE tank and 2 ml chloroform:methanol (60:40, v:v) was passed through the cartridges 
under vacuum, eluting the PC fraction, which was dried under nitrogen at 40oC. 
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2.12.3 Preparation of fatty acid methyl esters (FAMES) 
Total lipid extracts and purified PC fractions were dissolved in 500 µl of toluene and vortex mixed. 
1 ml of methylation reagent (methanol containing 2 % (v/v) H2SO4.) was added and mixed gently. 
Tubes were heated at 50oC for 2 h. After cooling, 1 ml of neutralising solution (0.5 M KHCO3 and 
0.25 M K2CO3) was added followed by 1 ml of hexane. Samples were vortexed and centrifuged at 
200 x g for 2 min at RT. The upper solvent phase containing the FAMES was removed and dried 
under nitrogen at 40oC. Each dried sample was reconstituted in 150 µl of hexane and transferred 
to a glass GC auto-sampler vial. 
2.12.4 FAME analysis using gas chromatography (GC) 
FAMES were separated using an Agilent J&W CP-Sil 88 capillary column (100 m length, 0.25 mm 
diameter and 0.2 µm film thickness) on an Agilent 6890 gas chromatograph (Agilent, UK) equipped 
with a flame ionisation detector (FID). The injector and detector temperatures were set at 255oC. 
The oven temperature was set to start at 70oC, ramped at 8oC/min to 110oC, ramped at 5oC/min to 
170oC and held for 10 min, ramped at 4oC/min to 240oC and held for 16.5 min and then ramped at 
60oC/min to 250oC and held for 10 min. Helium was used as the carrier gas. FAMES were analysed 
using Chemstation software (Agilent) and were identified by comparison of their retention times 
with that of standards containing known mixtures of FAMES: 37 FAMES, Menhaden oil and an n-3 
preparation made by mixing 18:3n-3, 18:4n-3 and 20:3n-3 and an n-6 mix containing 22:4n-6 and 
22:5n-6 (all purchased from Sigma-Aldrich). FAMES were quantified using the area of the internal 
standard. 
2.12.5 Measuring stable isotope enrichment using GC-C-IRMS 
FAMES were separated on a gas chromatograph (Thermo trace GC ultra, Bremen, Germany) 
equipped with an Agilent J&W DB-wax capillary column (30 m length, 0.25 mm diameter and 0.25 
µm film thickness). The injector was set at 250oC. The initial oven temperature was set at 120oC for 
1 min, then ramped at 25oC/min to 180oC and held for 32.5 min and then ramped at 25oC/min to 
240oC and held for 13.7 min. Effluent of the GC was carried by helium carrier gas into a high 
temperature (940oC) combustion furnace where FAMES were oxidatively combusted to CO2 
molecules, which were then ionised and detected using a Thermo Finnigan DeltaPlus XP IRMS. 
Faraday cups are positioned to simultaneously measure ion currents at mass to charge ratios (m/z) 
of 44, 45 and 46, representative of 12C16O2, 13C16O2 + 12C17O16O and 12C18O16O, respectively. The m/z 
46 signal is used to correct the m/z 45 signal for the minor contribution of the 17O isotope, using a 
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correction algorithm based on the assumed relationship between 17O and 18O isotopic abundance, 
so as to recover the true 13C/12C ratio.  
The 13C/12C ratios for identified fatty acids were measured relative to a laboratory reference gas 
standard calibrated to a reference FAME standard (Indiana University Standardised Methyl Ester)   
that had itself been standardised against the international standard Pee Dee Belemnite (PDB). 
Before the start of each run a zero enrichment test was performed in order to measure the 
reproducibility of the 13C/12C ratio of the CO2 reference gas by introducing ten pulses of reference 
gas and monitoring the standard deviation of the delta (δ) values relative to a specified pulse; a 
mean standard deviation of <0.06 was accepted according to the manufacturer’s specifications. The 
background level of Argon (m/z 40) was also monitored before the start of each run to ensure there 
were no leaks in the system; a stable value of <100 mV was accepted. Peaks were identified by their 
retention times relative to the same standards described for GC-FID (section 2.12.4). The δ values 
of enriched ([1-13C]18:3n-3 diluted 100 times with unlabelled 18:3n-3) and unenriched 18:3n-3 
were also recorded for each run to monitor variability. Since PBMC numbers were limited, fatty 
acids extracted from erythrocytes (total lipid) and plasma (PC fraction) were converted to FAMEs 
and run on the GC-C-IRMS in order to obtain surrogate background δ values for each fatty acid 
being analysed.  
2.12.5.1 GC-C-IRMS calculations 
GC-C-IRMS data, expressed as delta (δ) values were converted to 13C/12C ratios using the equations 
detailed below (268). The standard δ notation describes the relative deviation of the 13C/12C ratio 
in parts per thousand (‰) from PDB.  
 
RSPL = 13C/12C ratio in the sample 
RPDB = 13C/12C ratio in the PDB international standard (0.0112372)              
RSPL is obtained by rearrangement of the equation: RSPL = (δ13CPDB/1000 + 1) x 0.0112372 
The percentage13C abundance in each fatty acid is described using the atom percent (AP) and atom 
percent excess (APE). AP is calculated from the ratio using the following equation: 
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The AP corrected for background enrichment is called APE. The absolute amount of a specific 
labelled fatty acid is calculated by multiplying the APE by the total amount of that fatty acid 
(determined by GC-FID) per unit sample, which is most commonly mg of protein. A factor must be 
applied to correct for the presence of unlabelled carbons in the precursor and the addition of 
unlabelled carbons during fatty acid elongation and derivatisation to FAMES. For example, 
conversion of the tracer [1-13C]18:3n-3 to 20:5n-3 would result in one labelled carbon (from the 
precursor [1-13C]18:3n-3) out of the 21 total carbons (20 carbons in the fatty acid chain plus one 
carbon added during derivatization) being labelled with 13C. Therefore a correction factor of 21/1 
would need to be applied to achieve the moles of labelled 20:5n-3. All data was normalised to the 
concentration of [1-13C]18:3n-3 in the PBMC growth medium (measured by GC-C-IRMS) to account 
for any slight differences that may have occurred when pipetting the stable isotope labelled 18:3n-
3 into the PBMC growth medium. 
2.12.5.2 GC-C-IRMS Standard Curve 
A standard curve was prepared to test the GC-C-IRMS over a range of 13C/12C ratios. The standards 
were made using [U-13C]18:2n-6 due to the high cost and limited availability of [1-13C]18:3n-3. 
Individual stock solutions of [U-13C]18:2n-6 (16.68 µg/ml) and unlabelled 18:2n-6 (289.95 µg/ml) 
were prepared in chloroform. A series of defined amounts of [U-13C]18:2n-6 were pipetted into 
tubes followed by 300 µl (86.985 µg) of unlabelled 18:2n-6. The standards were dried under 
nitrogen at 40oC and methylated as described in section 2.12.4. The FAMEs were measured using 
GC-C-IRMS. The µmoles of [U-13C]18:2n-6 and unlabelled 18:2n-6 in each standard were calculated 
and multiplied by 18 to achieve the µmoles of 13C and 12C, respectively. The µmoles of 13C was 
divided by the µmoles of 12C and multiplied by a correction factor of 18/19 (to account for the 
carbon added to each fatty acid molecule during the methylation step) in order to calculate the 
expected 13C/12C ratio. The expected 13C/12C ratios were plotted against the 13C/12C ratios measured 
on the GC-C-IRMS (Figure 2.8). Perfect agreement would have a slope of 1x and for this standard 
curve a slope of 1.002x was achieved. The relationship was linear for delta values ranging from -28 
to 2115. 
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Figure 2.8. Standard curve of expected versus observed 13C/12C ratio measured by GC-C-IRMS. 
Equation of the line y = 1.002x-0.001342, R2 = 0.9994. 
 
2.12.5.3 Determination of dilution factor for labelled fatty acids with unlabelled fatty 
acids 
A dilution experiment was carried out in order to find an appropriate ratio of labelled to unlabelled 
18:2n-6 to add to cells for accurate measurement of 13C/12C ratios in cellular fatty acids using GC-C-
IRMS. 1 mM stock solutions of [U-13C]18:2n-6 and unlabelled 18:2n-6 were prepared as described 
in Appendix A.2.2. [U-13C]18:2n-6 was then diluted with unlabelled 18:2n-6 at the following ratios: 
1/10, 1/30, 1/60, 1/100. These dilutions were then added in triplicate to the media of Jurkat and 
HepG2 cell cultures to achieve a final concentration of 10 µM total 18:2n-6 (labelled and unlabelled) 
and incubated for 72 h. Additional replicates were treated with 10 µM of unlabelled 18:2n-6 as a 
background control.  
Table 2.1 shows that the δ13C PDB (‰) measurements for 18:2n-6, 20:3n-6, 20:4n-6 and 22:4n-6 
increased as the dose of [U-13C]18:2n-6 was increased (except for the 1/100 dilution where δ13C PDB 
(‰) for 18:2n-6 was slightly elevated in HepG2 cells relative to the 1/60 dilution). In HepG2 cells, 
the peak area for 22:4n-6 was below the detection limit.  
GC-C-IRMS instruments are optimised to determine precise isotope ratios near natural abundance 
(δ13C equal to -35 to -5 ‰). As isotope ratios increase precision decreases but an arbitrary limit of 
δ13C less than 1500 ‰ can be set for measuring compounds enriched with stable isotopes without 
severely compromising precision (268, 269). For HepG2 cells all dilutions achieved delta values 
below 1500 ‰ for all labelled fatty acids measured (Table 2.1). In Jurkat cells this was only achieved 
using the 1/30, 1/60 and 1/100 dilutions, however, the 1/30 dilution was close to the detection 
limit for 18:2n-6. It was concluded from this experiment that [U-13C]18:2n-6 will need to be diluted 
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by a factor of at least 1/60 with unlabelled 18:2n-6 before addition to cell culture experiments. The 
labelled 18:3n-3 used in future experiments has only one of the 18 carbons labelled with 13C and 
therefore it was calculated that the dilution factor should be approximately 18 times less (e.g. 1/3 
instead of 1/60). However, when this was tested the delta values were higher than the arbitrary 
limit of 1500 ‰ and a dilution factor of 1/10 was sufficient for accurate measurement. 
 
Table 2.1. Determination of optimal dilution of [U-13C]18:2n-6 with unlabelled 18:2n-6 for precise 
measurement of delta values using GC-C-IRMS.  
 Ratio of [U-13C]18:2n-6 to unlabelled 18:2n-6 
Fatty acids HepG2 Jurkat 
δ13C PDB(‰) 1/10 1/30 1/60 1/100 1/10 1/30 1/60 1/100 
18:2n-6 980.12 451.01 278.72 448.31 5044.82 1479.33 601.33 363.82 
20:3n-6 1395.36 759.49 283.77 210.08 2897.26 896.40 375.01 246.64 
20:4n-6 633.99 240.83 69.63 60.56 2534.85 768.03 312.62 215.77 
22:4n-6 ND ND ND ND 2182.84 643.85 264.40 181.14 
Values are the mean of three replicates from individual cell culture flasks. ND = not detectable. 
 
2.13 Measurement of total cell protein 
Total cell protein was extracted from a 20 µl aliquot of cells in 0.9 % NaCl, which were harvested 
as described in section 2.6.1. An equal volume of radioimmunoprecipitation assay (RIPA) buffer 
(Table 2.2) containing 10 µl/ml of Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo 
Fisher Scientific) was added to the cell suspension and incubated on ice for 20 min. The cell 
suspension was then centrifuged at 16,000 x g for 10 min and the supernatant transferred to a 
clean 0.5 ml microcentrifuge tube. The protein concentration of samples was determined using a 
Pierce Protein Assay kit (Thermo Fisher Scientific) according manufacturer’s instructions for the 
microplate procedure. BSA standards were prepared at the following concentrations using RIPA 
buffer as the diluent: 2000, 1500, 1000, 750, 500, 250, 125, 25 and 0 (blank) μg/ml. 10 μl of each 
sample and standard were added in duplicate to a flat bottom 96 well plate and 200 μl of the 
working buffer provided with the kit was added. The plate was covered and incubated at 37oC for 
30 min. Absorbance at 562 nm was measured using a spectrophotometer (thermolabsystems 
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multiskan Ex). A standard curve was prepared (Figure 2.9) by plotting the mean blank corrected 
562 nm measurement for each BSA standard against its concentration in μg/ml. The standard 
curve was best fit with a quadratic equation as specified by the kit manufacturer. The 
concentration of protein in each sample was then determined using the standard curve. 
 
                                  Table 2.2. Composition of RIPA buffer 
Reagent Final Concentration 
NaCl 150 mM 
Triton X-100 1 % 
Sodium deoxycholate 0.5 % 
Sodium dodecyl sulphate 0.1 % 
Tris pH 8.0 50 mM 
 
 
 
Figure 2.9. Typical BSA standard curve. 
A BSA standard curve was used to determine protein concentration for samples measured using a 
Pierce Protein Assay kit. The curve was best fit with the quadratic equation Y = -1 x 10x2 + 0.0007x 
+ 0.005. R2 = 0.9991. 
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2.14 Nucleic acid extraction 
2.14.1 Preparation of cultured cells for nucleic acid extraction 
PBMC pellets were collected as described in section 2.6.1. For Jurkat cells the growth medium 
containing cells in suspension was collected and centrifuged at 300 x g for 5 min and the 
supernatant removed. The cell pellet was washed with 1 ml ice cold PBS and centrifuged again at 
300 x g for 5 min. The PBS wash was repeated once more before the resulting cell pellet was stored 
at -80oC until required for RNA extraction.  
2.14.2 RNA extraction 
RNA was extracted from cell pellets using the Qiagen RNeasy® Mini kit (Qiagen) according to 
manufacturer’s instructions. An optional on column DNase digestion was carried out using the 
RNase-free DNase set (Qiagen) to eliminate genomic DNA contamination. RNA was eluted in 30 μl 
RNase-free water and its concentration was measured using a nanodrop1000 spectrophotometer 
(Labtech, UK) by measuring absorbance at 260 nm. RNA purity was assessed using the 260/280 and 
260/230 ratios. The integrity of the RNA was checked using agarose gel electrophoresis described 
in section 2.14.4. The ribosomal RNAs (rRNA) 28S and 18S should appear as sharp bands (indicative 
of intact RNA). 28S rRNA and 18S rRNA are approximately 5 kb and 2 kb in size respectively. The 
apparent ratio of 28S rRNA to 18S rRNA should be approximately 2:1. This integrity check relies on 
assumption that the rRNA quality reflects that of the mRNA which is in too low abundance to 
visualise. An example of extracted RNA (300 ng) analysed by agarose gel electrophoresis is given in 
Figure 2.10. 
 
 
Figure 2.10. RNA quality inspected by agarose gel electrophoresis. 
300 ng of RNA was analysed on a 1% agarose gel and ran at 120 volts. The 28S and 18S rRNA bands 
are indicative of intact RNA. Far left lane is 1 kb ladder followed by RNA from eight PBMC samples. 
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2.14.3 DNA extraction 
DNA was extracted from cell pellets using the Qiagen DNeasy® blood and tissue kit according to the 
manufacturer’s instructions. The DNA was eluted in 30 μl RNase and DNase-free water and 
quantified using a nanodrop1000 spectrophotometer by measuring absorbance at 260 nm. DNA 
purity was assessed using the 260/280 and 260/230 ratios. DNA integrity was visually inspected by 
running 250 ng on an Agarose gel as described in section 2.14.4; degradation of DNA would result 
in a DNA ladder appearance. An example of extracted DNA (250 ng) analysed by agarose gel 
electrophoresis is given in Figure 2.11. 
 
 
Figure 2.11. DNA quality inspected by agarose gel electrophoresis. 
250 ng of DNA was analysed on a 0.8% agarose gel and ran at 120 volts. Far left lane is 1 kb ladder 
followed by DNA from eight PBMC samples. 
 
2.14.4 Agaraose gel electrophoresis  
Agarose gel electrophoresis was used to assess DNA and RNA quality and also the size and quality 
of PCR product. To make the gel, agarose (Sigma-Aldrich) was dissolved in 1 X Tris-acetate-EDTA 
(TAE) buffer (Fisher Scientific) by heating in a microwave. The following percentage (w/v) gels were 
used for running genomic DNA, RNA and PCR product, respectively:  0.8%, 1% and 2%. 7 μl of the 
nucleic acid stain GelRed (Cambridge Bioscience) was added prior to pouring the gel into a mould 
containing combs for casting wells and then the gel was left to set for approximately 15 min. The 
set gel was inserted into a gel tank containing TAE as a running buffer. Samples were mixed with 
BlueJuice™ (Thermo Fisher Scientific) gel loading buffer (10X) to achieve a 1X concentration and 
loaded into the gel. 5 μl of either a 1 kb or 100 bp ladder (Appendix A.5) was loaded depending on 
the size of the material being analysed. The gels were run at 120 volts and stopped when the loading 
dye had migrated a suitable distance for each application.  
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2.15 Real-time RT-PCR 
The protocol detailed below for the analysis of relative gene expression by real-time RT-PCR was 
based on the method described in Hoile et al., 2014 (261). 
2.15.1 Complementary DNA (cDNA) Synthesis 
Complementary DNA (cDNA) was synthesised by reverse transcription. 1 μl of a dNTPs mix 
(Promega), containing equimolar amounts of each dNTP (10 mM) and 1 μl of random nonamers 
(Sigma-Aldrich) at 50 μM were added to 500 ng of RNA in a total volume of 10 μl and incubated for 
10 min at 70oC. Samples were then placed on wet ice for at least 1 min. A master mix containing 4 
μl 5 X M-MLV reaction buffer, 1 μl M-MLV Reverse Transcriptase (200 units/μl) and 5 μl RNase-free 
water was prepared and added to each sample (10 μl). Samples were transferred to a Veriti Thermal 
Cycler (Applied Biosciences, USA) where they were incubated at 15oC for 10 min, followed by 60 
min at 37oC and then 10 min at 90 oC to denature the reverse transcriptase. The newly synthesised 
cDNA was diluted with RNase free water to a total volume of 100 μl and stored at -20oC. 
2.15.2 Real-time RT-PCR primers 
Qiagen Quantitect primer assays, which contain a mix of forward and reverse primers for a 
specific gene were used to measure each gene of interest by real-time RT-PCR ( 
 
Table 2.3). Upon arrival the Quantitect primers were reconstituted in 1.1 ml tris-EDTA (TE) buffer 
(Promega) to obtain a 10X assay solution. Qiagen does not disclose the primer sequences, 
however, bioinformatic information was available and all Quantitect primer assays used were 
designed to cross exon/exon boundaries and therefore should not amplify genomic DNA. Primers 
for the reference genes were obtained from Primer design again as ready-made mixes of forward 
and reverse primers. Reference genes are used to normalise data to constitutively expressed 
genes that are not affected by the experimental conditions. The reference genes were selected 
using geNorm analysis (see section 2.15.3.2). 
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Table 2.3. Human primer assays used for real-time RT-PCR. 
Primer target Primer Assay 
FADS1 Qiagen Hs_FADS1_2_SG Quantitect Primer Assay (QT02322621) 
FADS2 Qiagen Hs_FADS2_1_SG Quantitect Primer Assay (QT00077175) 
ELOVL2 Qiagen Hs_ELOVL2_1_SG Quantitect Primer Assay (QT00059017) 
ELOVL4 Qiagen Hs_ELOVL4_1_SG Quantitect Primer Assay (QT00017283) 
ELOVL5 Qiagen Hs_ELOVL5_1_SG Quantitect Primer Assay (QT00096334) 
DNMT1 Qiagen Hs_DNMT1_1_SG Quantitect Primer Assay (QT00034335) 
DNMT3a Qiagen Hs_DNMT3A_1_SG Quantitect Primer Assay (QT00090832) 
DNMT3b Qiagen Hs_DNMT3B_1_SG Quantitect Primer Assay (QT00032067) 
EIF4A2 Primerdesign reference gene assay (HK-SY-hu) 
RPL13A Primerdesign reference gene assay (HK-SY-hu) 
SDHA Primerdesign reference gene assay (HK-SY-hu) 
18S rRNA Primerdesign reference gene assay (HK-SY-hu) 
 
2.15.3 Real-time RT-PCR 
cDNA was diluted to a final concentration of 5 ng/µl in RNase and DNase free water, assuming 100% 
conversion of RNA to cDNA. A series of six cDNA standards were made by serial dilutions of cDNA 
prepared from HepG2 cells representing input RNA of 15 ng, 7.5 ng, 3 ng, 1.5 ng, 0.15 ng, 0.075 ng 
and 0.015 ng. A master-mix for each primer set was made containing 5 µl of Quantifast SYBR green 
(Qiagen), 0.5 µl of each primer set and 1.5 µl of RNase and DNase free water. This was added to 3 
µl of sample and standard cDNA, in duplicate, in a white 384 well plate to give a final volume of 10 
µl. Each plate included two no template controls (ntcs) where the sample cDNA was replaced with 
3 µl of RNase and DNase free water. Standards were always measured for all primer sets on a plate. 
Plates were analysed using a LightCycler® 480 system (Roche Diagnostics, Switzerland) with the 
following cycling conditions: 95oC for 15 min, followed by 45 cycles of 95oC for 10 s, 60oC for 30 s 
and 72oC for 30 s. A melt curve step followed comprising 95oC for 15 s, 60oC for 1 min and a gradual 
increase up to 95 oC. 
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The melt curve analysis was performed to verify amplification of a single PCR product and absence 
of primer dimers on the basis that different size fragments of DNA differ in their melting points. The 
melting curve graphically displays the change in fluorescence when double stranded DNA 
dissociates into single stranded DNA when its melting point (Tm) is reached. This results in a sudden 
decrease in fluorescence due to the release of SYBR green. An example of a melt curve is given in 
Figure 2.12. 
2.15.3.1 Quantification of mRNA expression levels 
Expression levels of the target genes were quantified using the relative standard curve method 
(270) as described below. 
Standard curves were constructed for both the target and reference genes. The relative amount of 
each target and reference gene for each sample was then determined by interpolating from the 
standard curve. The value for the target gene was divided by the geometric mean of the reference 
genes in order to normalise the data for differences in input. An example standard curve is given in 
Figure 2.12. 
 
 
Figure 2.12. Standard curve and melt curve for FADS2. 
(A) FADS2 standard curve: slope = -3.409. R2 = 0.991. (B) FADS2 melting curve showing amplification 
of one specific product for all samples and no primer dimer. Samples are represented by red lines 
and ntcs are represented by blue lines.  
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2.15.3.2 GeNorm analysis for selection of most suitable reference genes 
A GeNorm kit (Primerdesign) was used to determine the best candidate reference genes for 
normalisation in real-time RT-PCR experiments. Real-time RT-PCR was carried out for a panel of six 
reference genes (Figure 2.13) on cDNA from a representative set of samples (six replicates) for each 
comparative analysis of mRNA expression. The reference genes were ranked in order of expression 
stability using qbase+ (Biogazelle, Belgium) real-time RT-PCR data analysis software. The software 
generated two graphs, the first (Figure 2.13, A) shows the average expression stability value 
(geNorm M) for each reference gene, starting with least stable on the left and the most stable on 
the right. The second graph (Figure 2.13, B) was used to determine the optimum number of 
reference genes to include; the graph shows sequential inclusion of each reference gene, the 
optimum number being when the geNorm V value drops below 0.15. The optimal number of 
reference targets was given as four (geNorm V < 0.15). The three reference genes with the lowest 
geNorm M (RPL13A, SDHA, EIF4A2) were selected. For the fourth reference gene 18S was selected 
instead of B2M since 18S rRNA level has been shown to remain unchanged in stimulated compared 
with unstimulated T-lymphocytes (271). 
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Figure 2.13. Graphs generated by geNorm analysis software (qbase+). 
(A) Graph of average expression stability value (geNorm M) for each reference gene. (B) Graph 
showing the optimum number of reference genes; found when geNorm V is less than 0.15 (green 
line). 
2.16 Pyrosequencing 
Sodium bisulphite pyrosequencing was used to measure the DNA methylation status of 52 and 26 
CpG dinucleotides in the regions adjacent to the human FADS2 and FADS1 transcription start sites 
(TSS), respectively, using the method described in Hoile et al., 2014 (261). The location of the FADS2 
TSS was obtained from a publication (272) and the location of the FADS1 TSS was identified from 
the published sequence in the Ensembl genome browser (Ensembl transcript ID: 
ENST00000350997.11). The CpG dinucleotides measured were in a region between -18 and –1661 
from the TSS for FADS2 (Figure 2.15) and +64 and –713 bp from the TSS for FADS1 (Figure 2.16). 
DNA methylation levels of nine CpG dinucleotides were also measured in a putative enhancer 
region (273) located in the intergenic region 7397 bp and 3202 bp from FADS2 and FADS1, 
respectively (Figure 2.17).  
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2.16.1 Sodium bisulphite conversion of DNA 
Sodium bisulphite conversion of genomic DNA was used to differentiate unmethylated versus 
methylated cytosines. Bisulphite conversion of DNA (500 ng) was carried out using the Zymo 
Research EZ-96 DNA Methylation-Gold™ Kit (Cambridge Bioscience, UK) according to the 
manufacturer’s instructions. Bisulphite converted DNA was eluted in 30 μl RNase and DNase free 
water and stored at -20oC for subsequent PCR amplification. 
2.16.2 PCR of bisulphite converted DNA 
Prior to pyrosequencing, the genomic regions of interest were amplified using PCR. 
2.16.2.1 Primer design and optimisation 
Primer sequences were designed using PSQ Assay design software (Biotage, Sweden) and were 
ordered from Eurofins (Luxembourg), supplied at a stock concentration of 100 μM. Upon arrival, 
primers were stored at -20oC upon and were diluted to a working concentration of 10 μM prior to 
use. Primers sequences can be found in Table 2.4. The positions of the CpG dinucleotides measured 
are given relative to the reported transcription start sites of FADS2 and FADS1. For analysis of the 
intergenic region between FADS2 and FADS1, genomic coordinates (assembly GRCh38 from the 
Genome Reference Consortium) for the CpG dinucleotides are given. One of each primer pair was 
labelled with biotin at the 5’ end, depending on the assay design. This biotin labelled primer is 
incorporated into the PCR fragment while the amplification takes place and the biotinylated strand 
then serves as the template in the downstream pyrosequencing reaction. An annealing 
temperature gradient was run for each primer pair to determine which temperature gave the 
strongest single band of the correct size when the PCR products were analysed using gel 
electrophoresis.  
2.16.2.2 PCR amplification of pyrosequencing template 
PCR was carried out on bisulphite converted DNA using the primers listed in Table 2.4. For each PCR 
a reaction mix was set up containing 12.5 μl of 2 X Kapa2G Robust HotStart ReadyMix (Kapa 
Biosystems), 0.5 μl of each 10 μM forward and reverse primers (0.4 μM final concentration) and 
10.5 μl of RNase and DNase free water. The reaction mix (24 μl) was added to 1 μl of bisulphite 
converted DNA in a 96 well plate giving a final volume of 25 μl. Two ntcs were also prepared for 
each primer pair where the master mix was added to 1 μl of RNase and DNase free water instead 
of DNA. Cycling conditions were as follows: 95oC for 3 min (initial denaturation) then 45 cycles of 
95oC for 15 s (denaturation), amplicon specific annealing temperature (Table 2.5) for 15 s, 72oC for 
15 sec (extension) followed by a final extension step of 72oC for 1 min. The PCR products were run 
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on a 2% agarose gel to assess the size and quality of the amplified product (example given in Figure 
2.14). 
 
 
Figure 2.14. Example agarose gel electrophoresis of pyrosequencing PCR product. 
The gel shows four PBMC samples followed by two ntcs and 1 kb DNA ladder. 
 
2.16.1 Primers for pyrosequencing 
All sequencing primers were designed using PSQ Assay Design software and were ordered from 
Eurofins, supplied at a concentration of 100 μM and stored at -20oC upon arrival. The primers were 
diluted to a 10 μM working concentration prior to use. Details of all sequencing primers are given 
in Table 2.5. Each sequencing primer was initially optimised in pyrosequencing reactions containing 
either 5 μl or 10 μl of PCR product and the volume chosen is given in Table 2.5. The FADS2 and 
FADS1 assays were based on previously published sequences (261). 
2.16.2 Immobilisation of PCR Product to Streptavidin Beads 
The optimised volume of PCR product was added to a 96 well plate and made up to a volume of 40 
μl with high purity water. A master mix containing 2 μl of streptavidin-coated sepharose beads (GE 
healthcare) and 38 μl of binding buffer (Qiagen), was prepared and 40 μl dispensed into each well. 
The plate was sealed and shaken on a plate shaker for 5 min at RT to allow capture of the 
biotinylated PCR product on streptavidin coated beads. 
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2.16.3 Preparation of single stranded pyrosequencing template DNA  
For each sequencing primer a master mix containing 0.5 μl sequencing primer and 11.5 μl annealing 
buffer (Qiagen) was made and 12 μl was dispensed into the appropriate well of a PSQ HS 96 well 
plate (Qiagen). The plate was then inserted into the holding bay of the Pyromark Q96 Vacuum Prep 
Workstation (Biotage). Vacuum pressure was applied and the beads with immobilised PCR product 
were picked up from the 96 well pate by the vacuum prep tool. The vacuum prep tool with the 
attached beads was then washed by aspirating 70% ethanol through the filter probes. The vacuum 
prep tool was then immersed in denaturation solution (0.2 M NaOH) to separate the double 
stranded DNA into single strands. During this step the 5’ biotinylated strand remains immobilised 
on the beads while the released single strand is filtered out. The vacuum prep tool was next placed 
in wash solution (Qiagen) and the beads were washed by aspiration of the solution. The vacuum 
prep tool was then aligned with the PSQ plate before switching off the vacuum pressure and 
lowering into the PSQ plate. The beads with attached single stranded templates were released into 
the plate by gentle shaking. 
2.16.4 Primer annealing and pyrosequencing 
The PSQ plate was heated at 80oC for 2 min and allowed to cool for at least 5 min in order to allow 
the sequencing primers to anneal to the single stranded template DNA. For each pyrosequencing 
assay, the volume of nucleotides, enzyme and substrate (Qiagen PyroMark Gold Q96 reagents) 
required for each run was calculated by the software. The required amount was added to the 
appropriate PyroMark HS capillary dispensing tip (Qiagen) ensuring no bubbles were present. The 
tips were then inserted into dispensing tip holder, which was then placed in the pyrosequencer 
(Biotage PyroMark MD, Sweden). A tip test was carried out to ensure all tips were dispensing 
accurately. Finally, the PSQ plate was inserted into the pyrosequencer and the pyrosequencing run 
was started. Percent DNA methylation was analysed using Pyro Q CpG software. For each 
pyrosequencing assay a 0% and 100% methylated (Millipore) control DNA sample was processed 
alongside the samples and run each time. At least one bisulphite conversion control was included 
in each assay run file. This is a cytosine not followed by a guanine and should have been converted 
to a thymine (100% thymine) during bisulphite treatment and consequently can be used as a control 
for complete bisulphite conversion. 
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Figure 2.15. Location of CpG dinucleotides analysed by pyrosequencing relative to FADS2 TSS. 
The TSS (blue), translation start codon (orange) and CpG dinucleotides (yellow) are highlighted with 
measured CpG dinucleotides in bold font and their position (bp) relative to the FADS2 TSS is written 
above. The underlined region is a CpG island. 
 
                                                                                      -1661 
TTATCTATATGGTATGTTAATCCATTTCTGAGAAAATAATTTTCTTGGTTCCATTTCCGT 
          -1655 
CAACGTTTGACAGTCCTCAAGGCCACCATACTCTCTGGAGGTCTTGCTTCATCCTCTTAT 
 
TTTGTACAGAAGGCTTTTGTTTGGGATGTCTGCTCACACTCAAAGACAGAGAGGCCTTAC 
 
TGTCTTTATGTCTGCAGTCTGTGGAGTGAATGAAGGATGCTCAGGGCTGACACCAGCATG 
 
AAATGTGATGGGAGAGGTTGGGGACTGTGTGAATGTGAGGAAAGGGAGCCCATCTGCCCC 
 
CCCAAGTACAACCCCACCAGTTGGGCAGAGTGATCCCCCCACCACCCCTGCATTGCTGTG 
                                      -1337 
AAATTTAGATTGGGCAGGGCCCGTTTGACCATCTCTCTCAATCTCAGGCTCTCCATTTTC 
                                     -1278 
AAGTGAGATGTAATAATATGCGTCCTGTTTACCTCTCAGCCTGTGATGAGAATCTAATGA 
 
TTAGGGTGTGCTAGCACACAGGCACCTGTAAATCCCATTGAAATCTGAGGGCCCTATAAC 
                                 -1156                                                  -1119 
TCCTCTAGTGATTCCCAAGCCTCGTGCACCCCACCCTCTCTGTTCATCCTTACTTCCCAC 
               -1112            -1101                                         -1071 -1067 
GTGTCCCGTTAGCCCTCCGGATGCAGTCAGGCCCATTTCCCCCAGGACGCCCGGCACTAA 
         -1056                                                             -1013 
GCCGCCCCATCCAGCTGGGGTCTGAGGGGCCTGTCTCTTGCCCCACGCCTAAAAGACCTA 
                                  -980    -975 
ACCCTCCTCCTATCCCTTCGATACGGCAGTCTTTATTTGCTGGAGTCTGCACAACATCAC 
                                           -914 
TGCCCAATGATGTGTCTGCTTCCACGATTCCCAAAGAGACTGAGCTTACTGAGACCAGGG 
                 -871-869                -855 
CAAGGACCGCGCCAGTTCCTCATCGCCCCCTTCCTCTGCCTTCCCCTCCCTTCCCCCTCA 
        -817            -806                                            -775 
CCGCAGCCATGGCGCCCAGACCAAGAAAGCAGAGCAGAGGTTCCGCAATTCTTTTCTAAG 
                                  -718 
ATTGTCTGACTAGAGGGTTCAAAGCCCTCTAATCCAAGGCCGGCTTGTGTCTCTAGGGAG 
                        -686                      -669-667 
GTTGCAGAAAGGCGCCAGAATGTGGATGGCGCGGACAATGTGGGATACTGGAGTCTCGAC 
 
TGCCGCGCGCCAAGGAAGGGCGTCACCTAGCCAAGCCGGCCCTGGAGTTGAGTGCCCCGC 
 
AGCCCGCCGGTCCACCCGCCCGGCCGCTTGCTGGCACCCTGGTGGCCGCGCCGGCTTTGT 
 
GTCGGCATCAGGTGCAAACCCCCAGAGCGCCGGGCGTGCGCGCACGCGCCCCGGAGCGCG 
 
CGGAGCCCATTCGTTGCCCCCACCGGGATCTCCTCTAGGATCTCCTCCGGCGCCCGGGGC 
                              -374     -368              -356               -344 
CGGAGAGTGGGGGAGGGAGGAGGTCGGACACGTAGCCTGCCTCGCAGCAGGGCTCGACTC 
         -336-334 
CACGCGGGAGGGCGGGGGAGCCGGGGACCCGCCGCTCCAGCCCGCTGGCCTTCGAAAGAT 
               -258   -253 -250-248 -244                  -230 
CCTCCTGGGCCAATGGCAGGCGGGGCGACGCGACCGGATTGGTGCAGGCGCTCTGCTGAT 
       -218               -205  -201 -198      -191-189                      -172    -167 
CGCTGTGGAAACTCGGGCGGCGGGGAACGCGGGAGGATGTGGAACCCGAGGCGGGGGGAG 
       -157      -149             -133                     -117 
CCGGAGGGGCGGGCAGAGGAGGTGTCGAGGCCCTGAGCTCCCGGGGAGTTTTTACTGGAG 
                                    -64                   -50                                       
GCAAAAGTCCATAGCGGGAGGGCTGAGGGAGGGGCGGAGGAAGGGGACCGCTTGGGGGCA 
                                      -18 
CTGGGAAGCCAGGGATCCTCCGCCAGGAAGGCAGGGACACTCCCGAGCGCAGGCGAGAAG 
 
GCTGGGGGAGGGGGCGCGGTGGGAGGAGTAGGAGAAGACAAAAGCCGAAAGCGAAGAGGG 
 
CCCGGGCTGCACACACCGGCTGGGAGGCAGCCGTCTGTGCAGCGAGCAGCCGGCGCGGGG 
 
AGGCCGCAGTGCACGGGGCGTCACAGTCGGCAGGCAGCATGGGGAAGGGAGGGAACCAGG 
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Figure 2.16. Location of CpG dinucleotides analysed by pyrosequencing relative to FADS1 TSS. 
The TSS (blue), translation start codon (orange) and CpG dinucleotides (yellow) are highlighted with 
measured CpG dinucleotides in bold font and their position (bp) relative to the FADS1 TSS is written 
above. The underlined region is a CpG island. 
 
 
 
 
 
 
 
 
 
 
 
                                          -713 
CATAGGGTTGTTAGGAGAATTAAATGAGTTAAGGTTTGCAAAACGCTAAGAACAGTGCCT 
 
GGCACACAGTAAGTGCTTTATAAAGTGTTTGTTGAATAAATAAAATTTTGGACCTAAACT 
                                                                                -581 
CTGGGTCTCTTCAGGACTGCAACAGCTTTGTAACTGGCAACCCCACTTTTAGGTGCGTTC 
 
CCACTCCTCTAAAACCCAGAGATCTAAATGCCAAATCTCTCTGCTTAAAAAGTCTCCCAG 
                     -506 
GGCTCCTAGGCGCCTCCAGGCTAGAACAGAAATGCCTCAGCTTGAAGACCCAGGCTTTTC 
                              -430 
AGGTGAAACACCTAAGGGTCAGGAGACGCTAGGATCATCACTCAAGGATCCCAGTGAATT 
 
TTTCCAAAATACAATAAAAATAAAAACAAAAAGAGGCAAACAGGGTTATAAAAATTGTGG 
 
GGCATTTTAAATGTTTCATTGAACAAATTAAAGCATTAACAGCCCTCCCCCAACCACCAC 
                            -262 
CAAGCCCAAGAGACCGTAAATATGCTGTTCACAAGATAACTGCAACTTTCAAGGGCTCTC 
                         -204                    -188    -183 -180 
AGGCTGCTACTTCGGGCAGCACAATTGGCGGCACGACGTGGCAAGCAGGCAGTAGTTTCC 
                               -140                -127 
AACCCTGGAGGGTCAGCGTCTGGAGACCCCGGCCAAGGCATCCACAGCCTAAAGATGATG 
          -94-92   -88   -84             -74      -68                       -51      -45 
TCCGCGACCGCCCGGGCAGCCTCGTGCACGGAAAAACCTCAACCCCGGCCCCGCCCACCC 
         -30       -21                                  +15+17     +23 
TTCCTGCGGCCACCCCGCAGCCCTGGCCCCTCAGTCCATTCACTCCTGCAGCGCGGCCCC 
                                          +47               +59 +61 +64 
GCACCCAGGGCCTGCACTAGAACCGCTGTTCCTACCGCGGCGCCCCCTGGGAGCCAACGC 
 
CGCGATGCCCGCCTGACGTCAGGAAGTCGAATCCGGCGGCGACGCCTTTAGGGAGCCCGC 
 
GAGGGGGCGCGTGTTGGCAGCCCAGCTGTGAGTTGCCCAAGACCCACCGGGGGACGGGAT 
 
CTCGCTCCCCGCGCCACGAGGCTCGGCCAATGGGAACGCGCGCTGCGAGGCCCGCCGGTC 
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Figure 2.17. Location of CpG dinucleotides in the FADS2/FADS1 intergenic region analysed by 
pyrosequencing. 
Measured CpG dinucleotides are highlighted yellow, in bold font and with the chromosomal 
coordinate (assembly GRCh38) written above.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GTGCTGGGAATACAAAGTTCAGTACTATATGGGTCATGCCTAGTCATGTCTACTGGAGGA 
                              61820364 
GAGAGACAAGTGAGTCACGGATTATAGGTCAGTAGGATAGATGCAAATTAAATTCATCTT 
 
ACTCAGGATTTAAACAGCTTATATGACATGACTTTGCATTCATGTTTCTTTGCTTTTCAT 
                                     61820508 
GTGTTCTTAGGTCAGTGTCATGTATTTTGCTACCTCCCTAACGAGCTTATAATCCAGGAT 
 
AGGGCTGTGGATTCTGTTTATACTACCAATACATATTCAGAGCACCTTGGTTTGGAGTTC 
                      61820621 61820625                      
TAGGTGGAATCCCACATAAATTTGCTGAATTGGCCGGGCGTGGCAGCTCATGCCTGTAAT 
                                              61820674 
CCCTGCACTTTGGGAGGGTGAGGAGGGCGGATCACCTGAGGTCAGGAGCTCCAGACCCAC 
61820717                                                  61820755 
TTGGCCAACACGGTGAAACCCTGTCTCTACTAAAATACAAAAATTAGCCGGGTGTGGTGG 
                                                       61820814 
GGGGTGCCTGTAATCCCAGCTACTTTGTGGGGGTGAGGCAGGAGAATCGCTTGAACCCAG 
                                     61820848 
GAGGCAAAGGTTGCAGTGAGCCGAGATTGCACCACTGCACTCCAGCCTGGGTGACAGAGC 
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Table 2.4. Pyrosequencing PCR primers.  
CpGs Covered 
Forward Primer 
(5’-3’) 
Reverse Primer 
(5’-3’) 
Amplicon Size 
(bp) 
Annealing Temperature 
(oC) 
FADS2     
-1661 to -1655   GTATGGTGGTTTTGAGGATTGTT *AAAATACTCCCTAATTCTACCTTTCAACTA 
168 54 
-1337 to -1156   TTGTTGTGAAATTTAGATTGGGTAGG *CCTAAAAAAAATAAACCTAACTACAT 290 54 
-1119 to -1056 *ATTTGAGGGTTTTATAATTTTTTTAGTGAT   ACCCTAATCTCAATAAACTCAATCT 319 56 
-1013 to -975   GGGTAGTGATGTTGTGTAGATT *TACACCCCACCCTCTCTAT 221 58 
-914 to -855   GGTAGTTTTTATTTGTTGGAGTTTGTAT *AAACCTCTACTCTACTTTCTTAATCT 199 56 
-817 to -775 *ATTGAGTTTATTGAGATTAGGGTAAGG   ACTTTAAACCCTCTAATCAAACAATCTT 167 56 
-718 to -667   ATTGTTTGATTAGAGGGTTTAAAGTT *AAACTCCAATATCCCACATTAT 116 54 
-374 to -334   GGATAATGTGGGATATTGGAGTT *CCTACCATTAACCCAAAAAAATCTTTC 408 60 
-258 to -84   AAGATTTTTTTGGGTTAATGGT *AAATCCCTAACTTCCCAATAC 263 56 
-230 to -133   GAAAGATTTTTTTGGGTTAATGGTAG *ATCCCTAACTTCCCAATACC 263 60 
-64 to -50 *GGGGAGTTTTTATTGGAGGTAA   AATCCCTAACTTCCCAATACC 95 52 
-18   TGGGGGTATTGGGAAGTTAG *CCCTCCCCCAACCTTCTC 80 58 
FADS1     
-713   TAGGGTTGTTAGGAGAATTAAATGAG *AAAACACTTACTATATACCAAACACTATT 77 50 
-581   AAGAATAGTGTTTGGTATATAGTAAGTG *TCTCCTAACCCTTAAATATTTCACCT 279 50 
-506 *AAGAATAGTGTTTGGTATATAGTAAGTG   AACCTCTCCTAACCCTTAAATATTTCACCT 283 52 
-430   AGGGTTTTTAGGAGTTTTTAGGTTAGAA *ACAATTTTTATAACCCTATTTACCTCTTT 180 52 
-262 to -188   AGAGGTAAATAGGGTTATAAAAATTGTG *CCTCCAAAATTAAAAACTACTACCTACTTA 220 52 
-94 to -21   AGTGAATGGATTGAGGGGTTAG *ACCCCCACCAAAACATCCACA 139 58 
+17 to +64   GGAGGGTTAGAGTTTGGAGATT *CCCCCCATAAATCTTAAACAACTCACAA 347 52 
FADS2/FADS1 intergenic region    
61820364 to 61820508   ATGGGTTATGTTTAGTTATGTTTATTGG *AAACAAAATCCACAACCCTATCC 231 60 
61820621 to 61820755   GGTTTGGAGTTTTAGGTGGAATTTTA *TACCTCACCCCCACAAAATAAC 232 60 
61820814 to 61820848   GTTTGGAGTTTTAGGTGGAATTTTATA *CACCCAAACTAAAATACAATAATACAAT 304 60 
The location of the biotin tag is indicated by *. 
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Table 2.5. Pyrosequencing sequencing primers. 
CpGs Measured 
Sequencing primer 
(5’-3’) 
Volume of PCR product 
added (µl) 
FADS2   
-1661, -1655 TGGTTTTGAGGATTGTTAA  10 
-1337 AGATTGGGTAGGGTT 10 
-1278 GGTTTTTTATTTTTAAGTGAGATG 10 
-1156 GGGTTTTATAATTTTTTTAGTGAT 10 
-1119, -1112, -1101 AAAATAAACCTAACTACATCC 10 
-1071, -1067, -1056 CCTCAAACCCCAACT 5 
-1013,  ATAGGAGGAGGGTTAG 10 
-980, -975 GTAGATTTTAGTAAATAAAGATTGT 10 
-914 ATTATTGTTTAATGATGTGTTTG 5 
-871, -869, -855 TGAGATTAGGGTAAGGA 10 
-817, -806 ACCTCTACTCTACTTTCTT 
 
10 
-775 CCTCTAATCAAACAATCTTAAAA 5 
-718 AGAGGGTTTAAAGTTTTTTAAT 5 
-686 AGGGAGGTTGTAGAAA 
 
10 
-669, -667 GTTAGAATGTGGATGG 10 
-374, -368, -356, -344, -336, -334 GAGGGAGGAGGT 10 
-258, -253, -250, -248, -244, GATTTTTTTGGGTTAATGGTA 10 
-230, -218, -205, -201, -198, -191, -189 GGATTGGTGTAGG 10 
-172, -167, -157, -149 GAAAGATTTTTTTGGGTTAATGGTAG 10 
-133 GGGTAGAGGAGGTGT 5 
-117 GAGGTTTTGAGTTTT 
 
10 
 -84 ATTGGAGGTAAAAGTTTATAG 10 
-64, -50 CCCAATACCCCCAAA 10 
-18 GGGAAGTTAGGGATT 10 
FADS1   
-713 GGAGAATTAAATGAGTTAAGG 10 
-581 AGTTTTGTAATTGGTAATTTTA 10 
-506 CTAAAACATTTCTATTCTAACCT 5 
-430 AATATTTAAGGGTTAGGAG 10 
-262 AGTTTTTTTTTAATTATTATTAAGT 10 
-204 AGGGTTTTTAGGTTGT 5 
-188, -183, -180 TTGTTATTTAGGGTAGTATAATTGG 10 
-94, -92, -88, -84, -74, -68 GGTAGGGGTTGAGGTTT 10 
-51, -45, -30, -21 GATTGAGGGGTTAGG 5 
+17, +15, +23 AGTTTTGGTTTTTTAGTTTATTTA 10 
+47, +59, +61, +64 ATTTAGGGTTTGTATTAGAAT 10 
FADS2/FADS1 intergenic region   
61820364 GGAGAGAGATAAGTGAG 
 
10 
61820508 GGTTAGTGTTATGTATTTTGTTAT 
 
10 
61820621, 61820625 ATATAAATTTGTTGAATTGG 
 
10 
61820674 GGGAGGGTGAGGAGG 
 
10 
61820717 AGGAGTTTTAGATTTATTTGG  
 
10 
61820755 GAAATTTTGTTTTTATTAAAATATA 
 
10 
61820814 GGGTGAGGTAGGAGA 
 
10 
61820848 AAAGGTTGTAGTGAGT 
 
10 
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2.17 5’ Rapid Amplification of cDNA Ends (5’ RACE) 
5’ RACE enables amplification of nucleic acid sequences at the 5’-end of mRNA templates and 
therefore permits identification of the TSS. Duplicate PBMC cultures were prepared from purchased 
PBMCs; one stimulated with 5 μg/ml Con A the other without as described in section 2.6. 5’ RACE 
was also performed for Jurkat cells cultured as described in section  2.11.2. Cultures were harvested 
after 48 h and RNA was extracted as detailed in section 2.14.2. Two different 5’ RACE procedures 
were used: Ambion 5’ RNA ligase mediated RACE (5’ RLM RACE) and SMARTer® 5’ RACE (Clontech 
Laboratories).  
2.17.1 5’ RLM RACE 
5’ RLM RACE was carried out for 10 μg of input RNA according to manufacturer’s instructions. An 
overview of this process is given in Figure 2.18. 
 
 
Figure 2.18. Overview of RLM 5’ RACE procedure. 
Calf intestine alkaline phosphatase (CIP); Tobacco acid pyrophosphatase (TAP). Adapted from the 
Ambion 5’ RLM RACE handbook. 
 
2.17.1.1 Nested PCR for 5’ RLM RACE 
The 5’ end of the FADS2 transcript was amplified by nested PCR. Two nested primer sequences 
corresponding to the 5’ RACE adapter sequence were provided with the 5’ RLM RACE kit. Two 
nested antisense primers (Gene Specific Inner and Outer primers) specific to the FADS2 transcript 
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were designed using Primer-BLAST software (NCBI, USA) ensuring they were as close to the 5’ end 
of the known transcript as possible in order to avoid an overly large amplification product. In 
addition, a forward FADS2 specific primer (Gene Specific 5’ Control primer) was designed to verify 
presence of the target. The positions of the gene specific primers are given in Figure 2.20. All 
primers (Table 2.6) were supplied by Eurofins at a concentration of 100 µM and were stored at -
20oC upon arrival. 1 µl of 5’ RLM RACE cDNA was amplified in an outer PCR using 1.25 U Go Taq 
Hot Start DNA polymerase (Promega), 10 µl 5X Go Taq Flexi Buffer, 1.5 mM MgCl2, forward and 
reverse primers at a final concentration of 0.4 µM and dNTPs at a final concentration of 200 µM 
each in a total volume of 50 µl with RNase and DNase free water. An annealing temperature 
gradient of 55oC, 60oC and 65oC was run for each primer set. PCR was carried out using a Veriti 
Thermal Cycler with the following cycling conditions: 94oC for 2 min (initial denaturation), 
followed by 35 cycles of 94oC for 30 s (denaturation), 60oC  for 30 s (annealing) and 72oC for 1 min 
(extension) followed by a final extension at 72oC for 5 min. 1 µl of the outer PCR was used as a 
template for the inner PCR with the same reaction components and conditions.  
2.17.2 SMARTer® 5’ RACE 
SMARTer® 5’ RACE was carried out for 1 μg of input RNA according to manufacturer’s instructions. 
An overview of this process is given in Figure 2.19. 
 
 
Figure 2.19. Overview of SMARTer® 5’ RACE procedure. 
Reverse transcriptase (RT). Adapted from the Clontech Laboratories SMARTer® RACE 5’/3’ Kit User 
Manual. 
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2.17.2.1 SMARTer® 5’ RACE PCR 
A universal primer mix designed to bind to the incorporated SMARTer II A Oligonucleotide 
sequence was provided with the SMARTer® 5’ RACE kit. An antisense primer ( 
Table 2.6) specific to the FADS2 transcript (Gene Specific primer) was designed using Primer-
BLAST software. The gene specific primer was designed to have a Tm > 70 oC to enable the use of 
touchdown PCR. The following sequence was added to the 5’ –end of the gene specific primer for 
downstream In-Fusion cloning: GATTACGCCAAGCTT. SMARTer® 5’ RACE does not generally 
require nested PCR and therefore only one gene specific primer was designed. Presence of the 
target was verified using the same forward FADS2 specific primer (Gene Specific 5’ Control 
Primer) and Inner Gene Specific Primer designed for 5’ RLM RACE (section 2.17.1). 2.5 µl of RACE-
ready cDNA was amplified using 1.25 U SeqAmp DNA polymerase, 25 µl 2X SeqAmp buffer, 5 µl 
10X UPM, 1 µl Gene Specific Primer (final concentration of 0.2 µM) and 15.5 µl of nuclease free 
water to give a total volume of 50 µl. PCR was carried out using a Veriti Thermal Cycler with the 
cycling conditions below.  
 
 5 cycles: 
94oC 30 s 
72oC 3 min 
 5 cycles: 
94oC 30 s 
70oC 30 s 
72oC 3 min 
 25 cycles: 
94oC 30 s 
68oC 30 s 
72oC 3 min 
2.17.3 Purification of amplified RACE products by gel extraction 
PCR products were analysed using agarose gel electrophoresis and extracted from the gel using 
using a Zymoclean gel DNA recovery kit (Zymo Research), according to manufacturer’s instructions. 
Gel purified products were quantified using a nanodrop spectrophotometer and 300 ng was 
analysed using agarose gel electrophoresis to check purity. 
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Table 2.6. Gene specific primer sequences for FADS2 5’ RACE 
Primer Sequence (5’–3’) 
Gene specific 5’ Control ACAAAAGCCGAAAGCGAAGAG 
5’ RLM RACE Gene Specific Outer TTGCATCTTCTCCAGCGTAGT 
5’ RLM RACE Gene Specific Inner GGTGCGCAGGTTATGCTTCT 
SMARTer® 5’ RACE Gene Specific GATTACGCCAAGCTTGGGCTGCCATTCGCCCAGAACAAACACG 
The 15 bp sequence required for In-Fusion cloning is shown in bold. 
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Exon 1 CCATAGCGGGAGGGCTGAGGGAGGGGCGGAGGAAGGGGACCGCTTGGGGGCACTGGGAAG 
CCAGGGATCCTCCGCCAGGAAGGCAGGGACACTCCCGAGCGCAGGCGAGAAGGCTGGGGG                              
 AGGGGGCGCGGTGGGAGGAGTAGGAGAAGACAAAAGCCGAAAGCGAAGAGGGCCCGGGCT                        
 GCACACACCGGCTGGGAGGCAGCCGTCTGTGCAGCGAGCAGCCGGCGCGGGGAGGCCGCA                        
 GTGCACGGGGCGTCACAGTCGGCAGGCAGCATGGGGAAGGGAGGGAACCAGGGCGAGGGG                                          
 GCCGCCGAGCGCGAGGTGTCGGTGCCCACCTTCAGCTGGGAGGAGATTCAGAAGCATAAC 
 CTGCGCACCGACAGGTGGCTGGTCATTGACCGCAAGGTTTACAACATCACCAAATGGTCC                                     
Exon 2 ATCCAGCACCCGGGGGGCCAGCGGGTCATCGGGCACTACGCTGGAGAAGATGCAACGGAT   
 GCCTTCCGCGCCTTCCACCCTGACCTGGAATTCGTGGGCAAGTTCTTGAAACCCCTGCTG   
Exon 3 ATTGGTGAACTGGCCCCGGAGGAGCCCAGCCAGGACCACGGCAAGAACTCAAAGATCACT   
 GAGGACTTCCGGGCCCTGAGGAAGACGGCTGAGGACATGAACCTGTTCAAGACCAACCAC   
 GTGTTCTTCCTCCTCCTCCTGGCCCACATCATCGCCCTGGAGAGCATTGCATGGTTCACT 
GTCTTTTACTTTGGCAATGGCTGGATTCCTACCCTCATCACGGCCTTTGTCCTTGCTACC   
Exon 4 TCTCAGGCCCAAGCTGGATGGCTGCAACATGATTATGGCCACCTGTCTGTCTACAGAAAA   
Exon 5 CCCAAGTGGAACCACCTTGTCCACAAATTCGTCATTGGCCACTTAAAGGGTGCCTCTGCC   
AACTGGTGGAATCATCGCCACTTCCAGCACCACGCCAAGCCTAACATCTTCCACAAGGAT   
CCCGATGTGAACATGCTGCACGTGTTTGTTCTGGGCGAATGGCAGCCCATCGAGTACGGC   
Figure 2.20. Locations of FADS2 5’ RLM RACE primers. 
(A) Schematic of primer positions for 5’ RLM RACE showing size of control amplicons. (B) Schematic of 
primer positions for SMARTer® 5’ RACE. Note the gene specific inner primer from 5’ RLM RACE is used 
as the control primer to verify presence of FADS2 transcript. (C) Exons 1 to 5 (alternating black and 
red) of FADS2 mRNA transcript (Ensembl transcript ID: ENST00000278840.8). Only part of the 5’UTR 
(underlined) in exon 1 is shown. The positions of the forward 5’ gene specific control primer (green), 
reverse 5’ RLM RACE gene specific inner and outer primers in exon 1 and reverse SMARTer® 5’ RACE 
gene specific primer in exon 5 (all yellow) and the published TSS for FADS2 (blue) are highlighted.  
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2.17.4 Cloning 5’ RACE products for DNA sequencing 
2.17.4.1 Bacterial cell culture media 
Antibiotics: 
An ampicillin stock solution was made at a concentration of 100 mg/ml, filter sterilised by passing 
through a 0.2 µm filter and then aliquoted into 1.5 ml tubes and stored at -20oC. 
LB media: 
20 g Luria broth (LB) powder was mixed with one litre of water and autoclaved (3 bar, 121oC, 15 
min) to sterilise. 
LB Agar plates: 
20 g LB powder plus 15 g agar powder per litre of water were autoclaved to sterilise. The solution 
was allowed to cool to approximately 30oC before supplementing with 100 µg/ml ampicillin. 25 ml 
was poured into 90 mm petri dishes and allowed to cool. Plates were sealed and stored inverted 
(to prevent condensation forming on the agar) at 4oC until use. 
2.17.4.2 Insertion of 5’ RLM RACE products into plasmid vector using TA Cloning® 
5’ RLM RACE PCR products were cloned using the TOPO® TA Cloning® Kit for Sequencing (Thermo 
Fisher). The plasmid vector pCR™4-TOPO® (Figure 2.21) provided with the kit is supplied linearised 
with single overhanging 3’ deoxythymidine (T) residues. PCR products produced by Taq DNA 
polymerase have a single deoxyadenosine (A) added to the 3’ ends due to its terminal transferase 
activity. This allows PCR products to ligate efficiently with the pCR™4-TOPO® plasmid vector by a 
method called TA Cloning®. The cloning reaction was carried out using 1 µl PCR product, 1 µl salt 
solution (provided with kit), 3 µl nucease free water and 1 µl pCR™4-TOPO® plasmid vector giving 
a final volume of 6 µl. The reaction components were mixed gently and incubated for 5 min at RT 
and then placed on ice. 
2.17.4.3 Transformation of pCR™4-TOPO® construct into chemically competent E. coli 
After performing the cloning reaction the pCR™4-TOPO® construct was transformed into One Shot® 
TOP10 chemically competent E. coli. 2 µl of the TOPO cloning reaction was added to one vial of One 
Shot® TOP10 chemically competent E. coli, mixed gently and then incubated on ice for 5 min. The 
cells were heat shocked at 42oC for 30 s then transferred to ice immediately. 250 µl of RT SOC 
medium (provided with kit) was added and cultures were shaken horizontally at 37oC, 200 rpm for 
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1 h. 50 µl of suspended cells from each transformation was spread onto a pre-warmed ampicillin 
agar plate and incubated at 37oC overnight. The plasmid vector contains the ampicillin resistance 
gene allowing transformants to be distinguished from non-transformants by their ability to survive 
on the ampicillin containing agar. Four single colonies were picked and grown in 5 ml LB media 
supplemented with 100 µg/ml ampicillin in a shaking incubator at 37oC overnight. 
2.17.4.4 Insertion of SMARTer 5’ RACE  products into plasmid vector using In-Fusion 
Cloning 
SMARTer® 5’ RACE products were cloned using the In-Fusion cloning kit, which was provided as part 
of the SMARTer® 5’/3’ RACE kit. In-Fusion cloning is a ligation-independent cloning method based 
on the annealing of complementary ends of a cloning insert and linearised cloning vector. The 
plasmid vector pRACE (Figure 2.22) provided with the kit is supplied linearised and contains 15 bp 
extensions complementary to the PCR product ends. Single stranded 15 nucleotide overhangs at 
the termini of the cloning insert and linearised cloning vector are generated by the In-Fusion 
enzyme mix and these overhangs are annealed at the sites of complementarity. The cloning 
reaction was carried out using 1 µl (50 ng) pRACE vector, 7 µl (150 ng) gel-purified RACE product 
and 2 µl In-Fusion HD Master Mix. The reaction components were mixed gently and incubated for 
15 min at 50 oC and then placed on ice. 
2.17.4.5 Transformation of pRACE construct into Stellar Competent Cells 
After performing the cloning reaction the pRACE construct was transformed into Stellar Competent 
Cells. 2.5 µl of the In-Fusion cloning reaction was added to 50 µl of Stellar Competent Cells, mixed 
gently and then incubated on ice for 30 min. The cells were heat shocked at 42oC for 45 s then 
transferred to ice immediately. Pre-warmed SOC medium (37 oC) was added to bring the final 
volume to 500 µl and cultures were shaken horizontally at 37oC, 200 rpm for 1 h. 50 µl of each 
transformation reaction was spread onto a pre-warmed ampicillin agar plate and incubated at 37oC 
overnight. Eleven single colonies were picked and grown in 5 ml LB media supplemented with 100 
µg/ml ampicillin in a shaking incubator (200 rpm) at 37oC overnight. 
2.17.4.6 Plasmid preparations and restriction enzyme digest 
1.5 ml of bacterial cultures from sections 2.17.4.3 and 2.17.4.5 were pelleted by centrifugation at 
7000 x g for 3 min. Plasmid DNA was then purified using a QIAprep Spin Miniprep Kit (Qiagen) 
according to manufacturer’s instructions. Plasmid DNA was eluted in 50 µl RNase and DNase free 
water and quantity and purity was measured using a NanoDrop spectrophotometer. To confirm 
presence of the 5’ RACE PCR product insert in the plasmid vector a restriction endonuclease digest 
was performed. 500 ng of the pCR™4-TOPO® construct was digested with 1 µl of EcoRI, and 300 ng 
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of the pRACE construct was digested with 0.5 µl EcoRI and 0.5 µl HindIII (FastDigest Restriction 
Enzymes, Thermo Fisher Scientific). Digests were performed in 1 µl 10 X FastDigest buffer and RNase 
and DNase free water (to achieve a total reaction volume of 10 µl) and incubated at 37 oC for 30 
min. The digested plasmid DNA was analysed by agarose gel electrophoresis to check the 
appropriate sized insert had been cut out of the digested vector. 
2.17.4.7 Sequencing RACE products 
Between 600 ng and 2000 ng of each 5’ RACE clone was sent to GATC Biotech (Germany) for 
sequencing. The T3 and T7 sequencing primers (Figure 2.21) were selected for forward and reverse 
sequencing reads of pCR™4-TOPO® constructs. The M13 forward and M13 reverse sequencing 
primers were selected for sequencing of pRACE constructs (Figure 2.22). 
 
 
Figure 2.21. Map of pCR™4-TOPO® plasmid and sequence surrounding the TOPO®cloning site. 
(A) Circular map showing the features of the pCR™4-TOPO® vector including the ampicillin 
resistance coding region used for selection of transformants and the TOPO® cloning site. (B) 
Detailed view of the sequence surrounding the TOPO® cloning site including 3’ T overhangs, T3 and 
T7 priming sites and EcoRI restriction sites. Taken from the TOPO® TA Cloning® Kit for Sequencing 
product manual (Thermo Fisher Scientific). 
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Figure 2.22. pRACE vector map and In-Fusion cloning site. 
Circular map showing the features of the pRACE vector including the ampicillin resistance coding 
region used for selection of transformants and the In-Fusion cloning site. A view of the sequence 
surrounding the In-Fusion cloning site is given below showing the EcoRI and HindIII restriction sites 
and the regions of homology to the universal primer mix (UPM) and gene specific primer (GSP). 
Taken from the pRACE vector map document produced by Clontech Laboratories. 
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2.18 Statistical analysis 
Statistical analysis was carried out using IBM SPSS statistics 22.0 (IBM, USA) and GraphPad Prism 6 
(GraphPad software, USA). All data are expressed as mean ± standard error of the mean (SEM) or 
median ± interquartile range (IQR). Statistical significance was set at P < 0.05. Normality of data was 
assessed both numerically using Kolmogorov-Smirnov and Schapiro-Wilk tests and graphically by 
inspecting histograms and normal Q-Q plots. Data that were not normally distributed were analysed 
with the appropriate non-parametric statistical test. Details of individual statistical tests are given 
in Figure legends. Comparisons between unstimulated and Con A stimulated PBMCs were analysed 
as paired data as the PBMCs were derived from the same individual and cultured in media 
supplemented with autologous plasma. Paired data are displayed in graphs with connecting lines 
and also in graphs displaying difference scores. 
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Chapter 3: Does activation of PBMCs increase the 
activity of the PUFA biosynthesis pathway? 
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3.1 Introduction 
In mammals, conversion of 18:3n-3 to longer chain n-3 PUFAs involves the sequential action of 
desaturase (delta-6 desaturase and delta-5 desaturase) and fatty acid elongase (elongase-5 and 
elongase-2) enzymes followed by one cycle of fatty acid β-oxidation to form 22:6n-3 (the details of 
this pathway are given in section 1.4.1 and Figure 1.1). The conventional pathway begins with delta-
6 desaturation of 18:3n-3 to yield 18:4n-3. However, as detailed in section 1.4.4 and Figure 1.2, an 
alternative pathway, consisting of elongation of 18:3n-3 to yield 20:3n-3 followed by desaturation 
at the delta-8 position to form 20:4n-3 (a product in the conventional pathway), has been reported 
(19, 33).  
Activation of T-lymphocytes is a complex process involving marked changes to the morphology, 
biochemistry and function of the cells resulting in mature blast cells that can divide to generate 
effector T-lymphocytes (section 1.9). In this process T-lymphocytes switch their metabolic 
programme from β-oxidation and catabolic metabolism to aerobic glycolysis and anabolic 
metabolism (274). As discussed in section 1.9.2, T-lymphocyte proliferation can be activated in vitro 
by a number of different agents including non-specific mitogens such as the plant lectins Con A and 
PHA. Con A binds to α-mannose and α-glucose containing glycoprotein or glycolipid receptors on 
the cell surface, inducing activation of T-lymphocytes and acts as an in vitro model for activation of 
lymphocytes by specific antigens (152).  
T-lymphocyte activation involves rapid changes in the phospholipid metabolism of plasma 
membranes including de novo synthesis and changes in the fatty acid moieties of membrane 
phospholipids (137-139) and phospholipid hydrolysis to generate lipid second messengers (134). 
Exogenous fatty acids are essential for in vitro activation and continued proliferation of T-
lymphocytes (144, 145). In vitro experiments have demonstrated that fatty acid uptake is increased 
in activated T-lymphocytes and this has been shown to include the n-3 PUFAs 18:3n-3, 20:5n-3, 
22:5n-3 and 22:6n-3, when available in the culture medium (40, 49). However, at high doses the 
fatty acids, particularly n-3 PUFAs, begin to exert inhibitory effects on lymphocyte proliferation in 
vitro (163, 164, 275).  
A recent study in CD4+ T-lymphocytes demonstrated that both fatty acid uptake and de novo 
biosynthesis pathways are required for robust proliferation after antigenic stimulation; whereas 
inhibition of either results in insufficient proliferation and inhibition of both leads to apoptosis 
(146). As discussed in section 1.10, n-3 PUFAs have important effects on lymphocyte function (135) 
but the ability of mitogen stimulated lymphocytes to synthesise these fatty acids has only been 
investigated in a single study (147). The researchers measured n-3 PUFA synthesis in PBMCs from 
healthy individuals using the radiolabelled precursor [1-14C]18:3n-3. Treatment of PBMCs with the 
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T-lymphocyte mitogen PHA progressively increased delta-6 and delta-5 desaturase activity (147). 
Radioactivity recovered in tetraene fraction (18:4n-3 and 20:4n-3 combined) after 72 h was low for 
both unstimulated and PHA stimulated cells, at 1.5% and 1.4%, respectively. Activity of both delta-
5 and delta-6 desaturases increased in activated cells, estimated from the radioactivity recovered 
in the pentaene fraction (20:5n-3 and 22:5n-3 combined), which was 5.4% for non-activated and 
14.4% for activated cells. No radioactivity was observed in the hexaene fraction indicating no 
synthesis of 22:6n-3. The study also showed that supplementation with 30 µM unlabelled 18:3n-3 
significantly raised the proportion of its elongation product 20:3n-3 in activated cells and the n-6 
PUFA pathway equivalent to 20:3n-3 (20:2n-6) also increased after supplementation with 30 µM 
unlabelled 18:2n-6. There were no significant changes in the proportions of other n-3 PUFA derived 
from 18:3n-3 but their total amount increased, indicating the existence of desaturase activities in 
activated cells (147). The authors of this study concluded that the importance of n-3 PUFA synthesis 
relative to fatty acid uptake in the lipid compositional changes that occur in activated lymphocytes 
is small, merely representing a fine-tuning of the final fatty acid composition of cell phospholipids 
for synthesis of new cell membranes. However, this study was limited by a small sample number 
and did not report findings for individual radiolabeled fatty acids, only combined fractions. 
Aims 
The aims of this chapter are to determine whether the previous observation of increased n-3 PUFA 
synthesis in activated human PBMCs is repeatable and whether inhibition of n-3 PUFA synthesis 
affects proliferation.  
Hypotheses 
 CD69 expression in PBMCs is higher in response to activation. 
 Synthesis of individual n-3 PUFAs in PBMCs is higher in response to activation. 
 Inhibition of the n-3/n-6 PUFA biosynthesis pathway decreases the proliferation of 
lymphocytes. 
To address these hypotheses, the expression of the activation marker CD69 and the levels of 
individual n-3 PUFAs synthesised from stable isotope labelled 18:3n-3 were measured in PBMCs 
cultured in the presence and absence of Con A. For clarity, figures show combined male and female 
data. The results of statistical analysis of individual male and female groups are given in the text. 
Since measurement of n-3 PUFA synthesis required addition of 18:3n-3 to the culture medium, the 
effect of 18:3n-3 supplementation on PBMC proliferation and viability was examined first. Finally, 
Con A stimulated PBMCs were treated with the delta-6 desaturase inhibitor SC-26196 to determine 
how pathway inhibition affects proliferation.  
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3.2 Methods 
3.2.1 Sample collection, PBMC Isolation and measurement of cell specific surface markers  
Volunteers were recruited as part of the EPUFA study as described in section 2.2. Anthropometric 
measurements were taken (section 2.2.5) and plasma TG, total cholesterol, HDL cholesterol and 
glucose concentration and blood total haemoglobin concentration were measured as detailed in 
section 2.3. PBMCs were isolated from lithium heparin blood (section 2.4) and the proportions of 
T-lymphocytes, B-lymphocytes and monocytes within the PBMC population were determined by 
measuring the expression of the cell surface markers CD3, CD19 and CD14, respectively, using flow 
cytometry as described in section 2.5. These markers were also analysed following cell culture. 
3.2.2 PBMC culture and measurement of CD69 expression 
PBMCs cultures treated with 20 µM stable isotope labelled 18:3n-3 ([1-13C]18:3n-3) diluted 1/10 
with unlabelled 18:3n-3 and either no Con A or 5 µg/ml Con A, were maintained for 48 h as detailed 
in Figure 3.1. PBMCs were harvested as described in section 2.6.1. Activation was confirmed by 
measurement of CD69 positive events by flow cytometry (section 2.7).  
 
Figure 3.1. Experimental design for comparison of Con A stimulated and unstimulated PBMCs. 
 
3.2.3 Measurement of n-3 PUFA synthesis 
PBMCs were harvested as described in section 2.6.1 and erythrocytes and plasma collected as 
described in section 2.4. Total lipid was extracted (section 2.12.1) and the PC lipid class was purified 
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from plasma total lipid extract using SPE (section 2.12.2). [13C]-label incorporation into specific n-3 
PUFAs in PBMCs was measured by a combination of GC and GC-C-IRMS as detailed in section 
2.12.5with normalisation to total cell protein (section 2.13). The average 13C/12C ratio of erythrocyte 
total lipid and plasma PC fatty acids was utilised for background correction. Zero values represent 
either where the 13C/12C ratio was the same as background or where no fatty acid peak was 
detected.  
3.2.4 Viability and proliferation measurements 
These experiments were carried out on purchased PBMCs that were revived and cultured as 
described in section 2.8. 
To determine the effect of 18:3n-3 supplementation on PBMC viability, cultures were prepared 
either with or without 5 µg/ml Con A treatment and six replicate cultures of each were treated with 
10 µM, 20 µM or 50 µM 18:3n-3 or 0.02 % (v/v) ethanol vehicle control for 48 h. Viability was 
measured using the LIVE/DEAD Red Dead Cell Stain Kit and flow cytometry as described in section 
2.9.2. The same experimental design was used to measure the number of viable cells using the 
CellTiter-Glo Luminescent Cell Viability Assay as described in section 2.9.1. Proliferation analysis of 
PBMCs treated with 0 µM or 20 µM 18:3n-3 for 120 h, in the presence of 5 µg/ml Con A, was carried 
out using CFSE staining and flow cytometry as described in section 2.10.  
The viability of Con A treated (5 µg/ml Con A) PBMCs, after 144 h of exposure to 100 nM and 200 
nM SC-26196 compared to a 0.02 % (v/v) DMSO vehicle control was measured using the LIVE/DEAD 
Red Dead Cell Stain Kit and flow cytometry (section 2.9.2.), with six replicate cultures for each 
treatment. Proliferation analysis of Con A treated (5 µg/ml) PBMCs incubated with 0 nM (0.02 % 
(v/v) DMSO vehicle control), 100 nM and 200 nM SC-26196 for 48 h, 72 h, 96 h, 120 h and 144 h 
was carried out using CFSE staining and flow cytometry as described in section 2.10. Six replicate 
cultures were performed for each SC-26196 concentration and time point. Cultures were also 
prepared without Con A treatment as a non-proliferating control. 
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3.3 Results 
3.3.1 Study population characteristics 
Table 3.1 shows the characteristics of males and females in the volunteer population used for 
comparison of n-3 PUFA synthesis in unstimulated and Con A stimulated PBMC cultures; this 
population was also used for comparisons of gene expression and DNA methylation in stimulated 
and unstimulated PBMCs, given in later chapters. A smaller population of volunteers was used for 
these comparisons since this aspect of the analysis required duplicate cultures, which was not 
feasible for the total EPUFA study population. Furthermore, a more homogeneous age range was 
chosen as the effect of age on the activity of the pathway was not known at this stage. All 
participants were considered healthy based on the measurements in Table 3.1 and information 
given in screening questionnaires. Males and females did not significantly differ by age, BMI, plasma 
total cholesterol concentration or plasma glucose concentration. Females had significantly higher 
Plasma HDL concentration (P < 0.0001). As expected mean weight and total haemoglobin were 
significantly lower in females (P < 0.001) and body fat percentage significantly higher than in men 
(P < 0.001). The proportions of T-lymphocytes (CD3+), B-lymphocytes (CD19+) and monocytes 
(CD14+) within the PBMC population are shown for freshly isolated (pre-culture) and cultured (post-
culture) PBMCs with and without Con A stimulation, in Table 3.2. There was a significant increase 
in the proportion of T-lymphocytes (P < 0.01) and a significant decrease in the proportion of 
monocytes (P < 0.0001) following both unstimulated and stimulated culture compared with freshly 
isolated cells. The proportion of B-lymphocytes also significantly decreased following culture under 
stimulating conditions (P < 0.01), compared with freshly isolated cells.  
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Table 3.1. Characteristics of population used for unstimulated and stimulated PBMC comparisons 
Characteristic Male Female P value 
Age (years)* 30 [18-38] 34 [20-47] NS 
Body weight (kg) 78.8 ± 2.3 66.9 ± 2.8 <0.001 
BMI (kg/m2) 24.3 ± 0.6 23.7 ± 0.7 NS 
Body fat (%) 19.3 ± 1.2 30.8 ± 1.8 <0.001 
Plasma TG (mmol/l) 1.2 ± 0.09 0.9 ± 0.07 NS 
Plasma total cholesterol (mmol/l) 4.5 ± 0.3 4.6 ± 0.2 NS 
Plasma HDL cholesterol (mmol/l) 1.1 ± 0.1 1.7 ± 0.1 <0.0001 
Plasma glucose (mmol/l) 4.9 ± 0.1 4.5 ± 0.1 NS 
Total haemoglobin (g/l) 146 ± 3.0 122 ± 3.0 <0.001 
Data are mean ± SEM; * data are mean [range]; Male n = 16, Female n = 18. P values are for differences 
between females and males determined using an independent samples t-test. 
 
 
Table 3.2. PBMC phenotypes 
Cell phenotype 
(% of PBMCs) 
Pre-culture Post-culture 
0 µg/ml Con A 
Post-culture 
5 µg/ml Con A 
CD3+ 62.7 ± 1.6a 69.8 ± 1.7b 70.5 ± 1.8b 
CD19+ 7.5 ± 0.5a  5.8 ± 0.5ab   5.6 ± 0.4b 
CD14+ 11.4 ± 0.9a  3.2 ± 0.3b  1.6 ± 0.3b 
Data are mean ± SEM; n = 34. Results are for positive events within the PBMC gate, measured by flow 
cytometry. Statistical comparisons were by one-way ANOVA with Tukey’s post hoc test. For each cell 
phenotype, means that were significantly different between groups are indicated by different superscripts (P 
< 0.01). 
 
 
3.3.2 The effect of 18:3n-3 treatment on viability and proliferation 
Since measurement of n-3 PUFA synthesis requires addition of stable isotope labelled 18:3n-3 to 
the culture medium, the effect of 18:3n-3 supplementation on PBMC viability and proliferation was 
determined using purchased PBMCs. The proportion of live cells in unstimulated PBMC cultures 
was not affected by treatment with any concentration of 18:3n-3 tested (Figure 3.2) but was 
significantly decreased in Con A stimulated cells treated with 50 µM 18:3n-3 (P < 0.0001). The 
number of viable PBMCs assessed by cellular ATP content (Figure 3.3) was not affected by any 
18:3n-3 concentration tested in unstimulated cultures but was significantly decreased by all three 
concentrations of 18:3n-3 (P < 0.0001) in Con A stimulated cultures. Treatment of Con A stimulated 
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PBMC cultures with 20 µM 18:3n-3 significantly decreased all CFSE proliferative measures (Figure 
3.4): % divided (P < 0.01), division index (P < 0.001) and proliferation index (P < 0.0001). 
 
 
Figure 3.2. The effect of 18:3n-3 treatment on PBMC viability. 
The proportion of live cells was determined for total cell events using the LIVE/DEAD viability dye 
and flow cytometry. Values are mean ± SEM (n = 6 replicates per treatment group) for unstimulated 
(no Con A) and stimulated (+ Con A) cultures. 18:3n-3 (µM) indicates final concentration in culture 
medium. Statistical analysis was by One-Way ANOVA with Dunnett’s post hoc test. ****P < 0.0001 
compared to the control group (0 µM 18:3n-3). 
 
 
Figure 3.3. The effect of 18:3n-3 treatment on relative ATP content of PBMCs. 
Relative ATP content of PBMCs was determined using the CellTiter-Glo Luminescent cell viability 
assay.  18:3n-3 (µM) indicates final concentration in culture medium. Values are mean ± SEM (n = 
6 replicates per treatment group) for unstimulated (no Con A) and stimulated (+ Con A) cultures. 
Statistical analysis was by One-Way ANOVA with Dunnett’s post hoc test. ****P < 0.0001 compared 
to the control group (0 µM 18:3n-3). 
 
 127 
 
Figure 3.4. The effect of 18:3n-3 on proliferation in stimulated PBMCs. 
Graphs A (% Divided), B (Division Index) and C (Proliferation Index) show results for gated events 
with the light scatter characteristics of viable lymphocytes following CFSE staining. 18:3n-3 (µM) 
indicates final concentration in culture medium.  Values are mean ± SEM (n = 6 replicates per 
treatment group) Statistical analysis was by independent-samples t-test. ****P < 0.0001, ***P < 
0.001, **P < 0.01. 
 
3.3.3 The effect of PBMC activation on CD69 expression 
For unstimulated versus stimulated comparisons, first activation by Con A was confirmed by 
measuring CD69 expression on the cell surface (Figure 3.5). Treatment of PBMCs with 5 µg/ml Con 
A increased the proportion of CD69 positive events in all samples, compared with untreated cells 
and the mean increase was statistically significant (P < 0.0001). Statistical analysis of separate male 
and female groups, by paired-samples t-test (data not shown), revealed that Con A treatment 
significantly increased CD69 expression in both males and females (P < 0.0001).  
 
Figure 3.5. The effect of PBMC activation on CD69 expression. 
Graphs show results for gated events with the light scattering characteristics of PBMCs (n = 34). 
Left: % CD69+ events for unstimulated (0 µg/ml Con A) and Con A stimulated (5 µg/ml Con A) 
PBMCs. Right: Difference in % CD69+ events (stimulated minus unstimulated) showing mean ± SEM. 
Statistical analysis was by paired-samples t-test (P value is shown on the right hand graph). 
A B C 
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3.3.4 The effect of PBMC activation on n-3 PUFA synthesis 
Stable isotope enrichment in [1-13C]18:3n-3 conversion products confirmed de novo synthesis of 
individual n-3 PUFAs in PBMCs, except for 22:6n-3 where there was no enrichment and 18:4n-3 
where there was no detectable fatty acid peak. Increased activity of the PUFA synthesis pathway 
was detected in Con A stimulated cells. The level of [1-13C]18:3n-3 was significantly higher in 
stimulated cells (P < 0.0001) and the levels of its stable isotope labelled conversion products 20:3n-
3 (P < 0.0001), 20:4n-3 (P < 0.0001), 20:5n-3 (P < 0.001)  and 22:5n-3 (P < 0.0001) were also 
significantly higher (Figure 3.6). Analysis of male and female groups separately (data not shown), 
revealed significant increases in 18:3n-3, 20:3n-3, 20:4n-3, 22:5n-3 (P < 0.001 for all) and 20:5n-3 
(P < 0.05) in Con A treated PBMCs in both males and females.  
3.3.5 Relationship between CD69 expression and n-3 PUFA synthesis 
The relationships between the amounts of labelled n-3 PUFAs and CD69 positive events within the 
PBMC gate were analysed by Spearman’s rank-order correlation (Figure 3.7). This analysis was 
carried out on the total EPUFA study population (characteristics are given in Table 7.1, Chapter 7). 
The sum of the 18:3n-3 conversion products 20:3n-3, 20:4n-3, 20:5n-3 and 22:5n-3 was calculated 
to determine the relationship between total n-3 PUFA synthesis and CD69 expression. Uptake of 
18:3n-3 showed a significant positive correlation with CD69 expression (Rs = 0.257, P < 0.05). CD69 
expression was also correlated positively with the amount of [13C]20:3n-3 (Rs = 0.483, P < 0.001), 
[13C]20:4n-3 (Rs = 0.392, P < 0.01), [13C]20:5n-3 (Rs = 0.531, P < 0.0001), [13C]22:5n-3 (Rs = 0.555, P < 
0.0001) and total synthesised [13C]n-3 PUFA (Rs = 0.534, P < 0.0001). The strongest relationships 
existed for 22:5n-3 and total synthesised n-3 PUFA. 
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Figure 3.6. The effect of PBMC activation on n-3 PUFA synthesis. 
Left: [13C]-labelled n-3 PUFAs in  unstimulated (0 µg/ml Con A) and Con A stimulated (5 µg/ml Con 
A) PBMCs. Right: Difference in [13C] labelled n-3 PUFAs (stimulated minus unstimulated) showing 
median ± IQR (n = 32). Statistical analysis was by Wilcoxon signed-rank test (P value is shown on the 
right hand graph). 
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Figure 3.7. Relationship between n-3 PUFA synthesis and CD69 expression. 
The relationships between uptake of 18:3n-3 and synthesis of individual n-3 PUFAs and total 
synthesised n-3 PUFAs and CD69 expression were assessed by Spearman’s rank-order correlation, 
where rs is the Spearman’s Correlation coefficient. 
 
3.3.6 The effect of delta-6 desaturase inhibition on T-lymphocyte proliferation 
The effect of SC-26196 treatment on proliferation was measured using the intracellular stain CFSE 
at five time points. Proliferation was measured for events with the light scattering characteristics 
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of viable lymphocytes and since Con A is a T-lymphocyte mitogen it is assumed that the analysis is 
representative of this cell type. 
The effect of treatment with 50 nM, 100 nM and 200 nM SC-26196 on the viability of PBMCs 
cultured with 5 µg/ml ConA was determined using the LIVE/DEAD red viability dye (Figure 3.8). 
Viability for the vehicle control group was 79.8 %. Viability was significantly reduced to 77.9 % (P < 
0.01) 76.9 % (P < 0.001) and 77.4 % (P < 0.01) for the 50 nM, 100 nM and 200 nM SC-26196 groups, 
respectively. Inhibition of delta-6 desaturase activity by SC-26196 was confirmed by measuring 
conversion of [1-13C]18:3n-3 in a T-lymphocyte cell line (section 6.3.4, Chapter 6).  
Con A treated cells showed multiple CFSE fluorescence peaks over time indicating multiple 
generations of proliferating cells, where unstimulated cells showed a single bright fluorescence 
peak indicating no activation (Figure 3.9).  Three measures of proliferation were recorded: % 
divided, division index and proliferation index (Figure 3.10). Briefly, % divided represents the 
percentage of the original cell population that entered cell division, the division index represents 
the average number of divisions for the entire population and the proliferation index is a measure 
of the average number of divisions for the responding population (see section 2.10.3 for more 
details). Statistical analysis by two-way repeated measures ANOVA reported a significant 
interaction between time and SC-26196 concentration for each measure: proliferation index (P < 
0.01, partial η2 = 0.42 ), division index (P < 0.0001, partial η2 = 0.56) and % divided (P < 0.01, partial 
η2 = 0.40). Since there were significant interactions, simple main effects were analysed. Treatment 
with 200 nM SC-26196 significantly decreased the percentage of cells that had entered division (% 
divided) after 72 h (P < 0.01) and 96 h (P < 0.05), compared to the control group. The division index 
was significantly decreased by treatment with 200 nM SC-26196 after 72 h, 96 h and 144 h culture 
(P < 0.01 for all) and by treatment with 100 nM SC26196 after 144 h culture (P < 0.01), compared 
to the control group. After 144 h culture the proliferation index was significantly decreased by 
treatment with 100 nM and 200 nM SC-26196 compared to the control group (P < 0.01 for both). 
There was no effect of SC-26196 treatment on the proliferation index, division or percentage of 
dividing cells after 120 h culture. 
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Figure 3.8. The effect of SC-26196 treatment on PBMC viability. 
The proportion of live cells was determined for total cell events using the LIVE/DEAD red viability 
dye and flow cytometry. Values are mean ± SEM (n = 6 for each treatment group). Statistical analysis 
was by one-Way ANOVA with Dunnett’s post hoc test for comparison of each SC-26196 
concentration to the vehicle control (0 nM SC-26196). ***P < 0.001, **P < 0.01. 
 
 
Figure 3.9. Histograms showing proliferation of CFSE stained T-lymphocytes over time. 
The graphs show results for gated events with the light scatter characteristics of viable 
lymphocytes. The red line shows undivided cells (cells cultured in the absence of Con A) and the 
blue line shows cells cultured in the presence of 5 µg/ml Con A. 
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Figure 3.10. The effect of SC-26196 on proliferation of T-lymphocytes activated by Con A. 
Graphs A (% Divided), B (Division Index) and C (Proliferation Index) show results for gated events 
with the light scatter characteristics of viable lymphocytes following CFSE staining. Values are mean 
± SEM. Statistical analysis was by two-way repeated measures ANOVA with time and SC-26196 
concentration as fixed factors. Simple main effects were analysed to compare treatment with 100 
nM SC-26196 (green stars) and 200 nM SC-26196 (blue stars) to the 0 nM SC-26196 control at each 
time-point, **P < 0.001, *P < 0.05. 
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3.4 Discussion 
Overall, the findings from these experiments confirmed that activation is required to stimulate n-3 
PUFA synthesis in PBMCs. 
Characterisation of cell phenotypes using flow cytometry confirmed successful extraction of PBMCs 
from participants’ blood samples. In humans, the frequencies of these populations vary across 
individuals, however, the proportions of CD3+ T-lymphocytes, CD19+ B-lymphocytes and CD14+ 
monocytes in PBMCs (Table 3.2) were consistent with previously reported proportions in healthy 
individuals (276). The culture environment significantly increased the proportion of T-lymphocytes 
in the PBMC population compared to freshly isolated cells. However, there was no significant 
difference in the proportion of T-lymphocytes between stimulated and unstimulated cultures, 
which is surprising since Con A stimulates T-lymphocytes to proliferate. A possible explanation 
could be down modulation of the TCR-CD3 complex, which has been reported to occur following 
activation (277-279). Previous findings indicate that activation causes down modulation by 
preventing recycling rather than inducing internalisation of the TCR-CD3 complex (280, 281). A 
consequence of this possible down-modulation would be underestimation of T-lymphocytes. Co-
staining with antibodies for CD3 and other markers for T-lymphocyte sub-populations such as CD4 
and CD8 would be necessary to overcome this limitation and give greater confidence in accurately 
identifying cells. There was a small yet significant reduction in the proportion of B-lymphocytes 
following culture with Con A (5.6%) compared to freshly isolated PBMCs (7.5%). A larger decrease 
was observed for monocytes, which decreased from 11.4% in freshly isolated cells to 3.2% and 1.6% 
after culture in the presence and absence of Con A, respectively. This decrease was probably due 
to the adherent nature of monocytes and consequently the challenge in recovering them. 
Differential staining of live and dead cells showed that treatment of Con A stimulated PBMCs with 
10 µM or 20 µM 18:3n-3 did not decrease the proportion of viable cells in the population, however 
there was a significant reduction in cell viability with 50 µM 18:3n-3 treatment as shown in Figure 
3.2. In contrast, the viability of unstimulated PBMCs was not affected by any of the 18:3n-3 
concentrations tested. Viability was also assessed using an assay that determined the number of 
viable cells in culture based on quantitation of ATP and therefore the result reflected the ability of 
the cells to proliferate, not merely their survival. In unstimulated PBMCs, 18:3n-3 treatment did not 
affect ATP content relative to the vehicle control. Since unstimulated PBMCs do not proliferate in 
culture this result was interpreted as 18:3n-3 having no effect on cell survival, supporting the results 
of the viability staining. However, in cells stimulated to proliferate, the number of viable cells 
relative to the control was significantly lower at all 18:3n-3 concentrations tested indicating that 
18:3n-3 treatments affects the ability of cells to proliferate in culture. This was confirmed by CFSE 
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staining in cells cultured for a longer period (120 h) where all measured proliferative indices were 
significantly lower in PBMCs cultured in the presence of 20 µM 18:3n-3. This demonstrates that the 
system is behaving as previously shown, where the proliferative response to Con A treatment was 
inhibited by 18:3n-3 (164). Supplementation of culture medium with a concentration of 20 µM 
stable isotope labelled 18:3n-3 was chosen for subsequent measurement of n-3 PUFA synthesis as 
it did not reduce cell survival and although this concentration had a small inhibitory effect on 
proliferation it was required for detection of fatty acid peaks for isotopic analysis. 
Con A treatment caused a marked increase in the proportion of cells expressing the activation 
marker CD69. CD69+ events increased from a mean of 1.4% in unstimulated cells to 51.2% in 
stimulated cells, confirming cell activation. This level is 10% lower than reported in a study by other 
researchers where lymphocytes were treated with 5 µg/ml Con A (265). However, they measured 
CD69 expression in CD3+CD4+ T-lymphocytes after 24 h culture compared to the total PBMC 
population after 48 h in the present study. Since Con A is an activator of T-lymphocytes, 
measurement of CD69 positive cells within the T-lymphocyte population would explain the higher 
proportion observed. CD69 is an early activation marker and expression peaks by 24 h and then 
declines (282). A decrease in CD69 expression in CD3+ T-lymphocytes by approximately 10% 
between 15 and 48 h of culture, dramatically dropping by 50% between 15 and 96 h has been 
reported in PHA stimulated lymphocytes (283). Therefore, measurement of CD69 after 48 h in this 
study allowed confirmation of cell activation but may have not been within the optimal time-period 
for measurement. However, in other studies it was found that the maximum number of CD3+ cells 
expressing CD69 occurred by 24 h stimulation with Con A and remained stable for a 72 h culture 
period (284) or reduced slightly (285).  
The level of stable isotope labelled 18:3n-3 was significantly higher in Con A treated PBMCs (Figure 
3.6) indicating that activation increases the uptake of 18:3n-3 from the culture medium, which is 
consistent with other studies that have shown that media supplementation with 18:3n-3 increases 
its proportion in stimulated cells (49, 147). The levels of labelled 18:3n-3 conversion products were 
also significantly higher in activated cells, except for 22:6n-3 where there was no evidence for 
synthesis. These results are in agreement with the single previous study that showed activation of 
the n-3 PUFA conversion pathway in stimulated cells (147). However, the previous study did not 
distinguish individual n-3 PUFAs and instead reported results for groups of n-3 PUFAs based on the 
number of double bonds in the carbon chain. Therefore, this is the first time that significant 
increases in the synthesis of individual fatty acids in the n-3 PUFA pathway, up to 22:5n-3, have 
been shown in stimulated compared with unstimulated PBMCs.  
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The major metabolite of 18:3n-3 after 48 h was 20:3n-3, which is a product in the alternative 
delta-8 desaturation pathway. However, the data for 20:3n-3 synthesis contained an outlier with 
a [1-13C]20:3n-3 value of 2.91 pmol/µg protein compared to 1.31 pmol/µg protein for the next 
highest value. Removal of this outlier would make 20:3n-3 synthesis appear more comparable 
with 20:4n-3 synthesis. However, these data were analysed by Wilcoxon signed-rank test, a non-
parametric test, which tested the null hypothesis that the median difference in n-3 PUFA 
synthesis between unstimulated and Con A stimulated PBMCs is equal to zero. Since data are 
ranked, the outlier would simply be recognised as a case that is ranked one above the case below 
and therefore this test is resistant to outliers. Nevertheless, whether this outlier is a true result is 
an important question and would need to be assessed by repeating the experiment, which was 
not possible due to limited sample.   
Measurement of 20:3n-3 synthesis in activated PBMCs in the present study, supports the findings 
from a previous study on n-3 PUFA synthesis in PHA stimulated PBMCs, where media 
supplementation with unlabelled 18:3n-3 significantly increased the proportion of 20:3n-3 but did 
not significantly increase the proportions of any other n-3 PUFAs (147). It is important to highlight 
that this previous study did not measure stable isotope labelled 20:3n-3 and therefore the findings 
from this chapter provide the first direct evidence for synthesis of 20:3n-3 in mitogen treated 
human PBMCs.  
The first product in the classical pathway (18:4n-3) could not be detected indicating that activated 
PBMCs may be using the alternative pathway as the major route for n-3 PUFA synthesis. A delta-8 
desaturation step would be required to feed 20:3n-3 back into the main pathway. The occurrence 
and importance of delta-8 desaturation in mammalian tissues has been a debateable issue. 
Previous studies have provided evidence for delta-8 desaturation in rat testes (38), human testes 
(39) and also in mouse rat and human cultured cell lines (41, 42). Contradictory to these findings, 
some experiments in mice liver and rat liver and testes have reported delta-8 desaturation as either 
not occurring or as a questionable route for the biosynthesis of PUFAs (33, 36, 37). Furthermore, 
there is no molecular evidence for a specific gene that encodes delta-8 desaturase activity. A study 
in yeast transformed with mammalian FADS2 demonstrated that the delta-6 desaturase enzyme 
encoded by FADS2 had the ability to catalyse delta-8 desaturation of 20:3n-3 and 20:2n-6 to yield 
20:4n-3 and 20:3n-6, respectively (19). However, delta-8 desaturation appeared to be a minor route 
for n-3 PUFA synthesis, since delta-6 desaturase activity was shown to be favoured 23-fold over 
delta-8 desaturase activity. The biological importance of this alternative pathway is not known. 
Possible explanations could include providing a route for n-3 and n-6 PUFA biosynthesis if the 
classical pathway is inhibited. However, if the delta-8 desaturation step is catalysed by the product 
of FADS2, inhibition of ‘delta-6 desaturase’ would also inhibit conversion of 20:3n-3 to 20:4n-3, 
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unless there is another desaturase that is capable of catalysing this step. It has been suggested that 
the alternative pathway could be important in tissues with a high demand for eicosanoid synthesis, 
since delta-8 desaturation of 20:2n-6 (the n-6 equivalent to 20:3n-3 in the alternative delta-8 
desaturation pathway) directly yields 20:3n-6, which is an immediate precursor of prostaglandin E1 
(PGE1) (19). This may not be relevant in lymphocytes as a review of studies investigating eicosanoid 
synthesis concluded lymphocytes have poor capacity for synthesis of eicosanoids (168). 
Nonetheless, monocytes present in PBMC populations do possess the capacity for eicosanoid 
synthesis and an earlier study demonstrated PUFA synthesised by lymphocytes can be utilised by 
monocytes for eicosanoid synthesis (286). At present, there is no evidence that 20:3n-3 and 20:2n-
6, or their delta-5 desaturation conversion products 20:4(5,11,14,17) and 20:3(5,11,14), 
respectively, are metabolised directly to lipid signalling molecules. However, 20:2n-6 has been 
shown to modulate the production of inflammatory mediators, including increasing prostaglandin 
E2 (PGE2) and tumour necrosis factor-α (TNF- α) production, in murine macrophages (287). 
Furthermore, in another study, 20:2n-6 was found to be a potent inhibitor of leukotriene B4 (LTB4) 
binding to pig neutrophil LTB4 receptors (288). Therefore, given the level of 20:3n-3 synthesis 
measured in the present work, it would be interesting to investigate the effect of this fatty acid on 
inflammatory mediators in future experiments. A limitation of the EPUFA study design was that 
participants potentially taking anti-inflammatory agents such as aspirin were not excluded from the 
study. Aspirin can trigger the synthesis of 20:5n-3 and 22:6n-3 derived inflammatory mediators 
called resolvins; several epimeric isoforms are generated as a result of the effects of aspirin on the 
activity of COX-2. Consequently, consumption of aspirin may have influenced the levels of 20:5n-3 
and 22:6n-3 measured in PBMCs.  
There were significant positive correlations between all the newly synthesised n-3 PUFAs that were 
measured and the cell surface expression of CD69 in PBMCs (Figure 3.7). This further supports the 
finding that n-3 PUFA synthesis is increased in stimulated PBMCs and suggests the level of synthesis 
relates to the number of activated cells. The strongest correlations were for 22:5n-3 and the sum 
of all synthesised n-3 PUFA. The sum was calculated to give a measurement of overall synthesis 
since the amount of individual fatty acids does not only reflect their synthesis but also their 
conversion. Whether n-3 PUFA synthesis precedes or succeeds CD69 expression or whether there 
is causal relationship between them is unknown. The signals necessary for appropriate CD69 
regulation appear to be within a 700 bp region of the start of transcription of the gene (289). The 
regulation of many genes involved in T-lymphocyte activation occurs largely at the transcriptional 
level (290). Since n-3 PUFAs are known regulators of gene transcription it would be interesting to 
investigate whether they play a role in the signal transduction events leading to induction of CD69 
expression. 
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Analysis of cell proliferation using the intracellular dye CFSE enabled characterisation of the 
response of Con A stimulated T-lymphocytes within a PBMC population to treatment with the delta-
6 desaturase inhibitor SC-26196. Proliferation analysis was performed for events within the 
lymphocyte gate but since Con A is a T-lymphocyte mitogen it was assumed that the analysis was 
representative of this lymphocyte sub-set. Con A treatment induced multiple CFSE fluorescence 
peaks that increased over time indicating multiple generations of proliferating T-lymphocytes 
(Figure 3.9). Unstimulated cells showed a single bright fluorescence peak confirming no 
proliferation. Inhibition of delta-6 desaturase activity decreased both the proportion of cells that 
entered into cell division and the number of cell divisions in the total and responding (cells that 
entered division) cell populations after 144 h culture. These indices of proliferation were also 
significantly lower at earlier time points when cells were treated with the higher (200 nM) 
concentration of SC-26196. However, there were no differences after 120 h culture. Despite the 
statistically significant differences, the effects were small and therefore biological significance is 
questionable. Furthermore, treatment with all SC-26196 concentrations was associated with a 
small (< 3%) but significant decrease in PBMC viability relative to the vehicle control. This study 
showed that there was considerable variability in capacity for n-3 PUFA synthesis between different 
individuals (Figure 3.6). Therefore, the results from this inhibitor experiment might be explained by 
the fact that delta-6 desaturase activity in PBMCs from this individual was negligible. This is a 
limitation when using purchased PBMCs from a single individual and repeating the experiment with 
cells from individuals with a range of synthesis capacities would provide more insight into how the 
pathway activity relates to proliferation. Furthermore, the concentrations of SC-26196 used in this 
experiment did not completely restrict PUFA synthesis and it could be that enough PUFA synthesis 
was sustained for proliferation. Nonetheless, these results suggest that inhibition of the pathway 
may be having a small effect on the proliferative process. This supports the proposed requirement 
of n-3 PUFA synthesis in fine-tuning membrane fatty acid composition needed to support 
membrane synthesis in proliferating lymphocytes (147).  
The suggestion that n-3 PUFA synthesis is required for proliferation conflicts the evidence that they 
inhibit proliferation. However, this could be explained by the concentration of fatty acids used as 
lower concentrations of some unsaturated fatty acids have been shown to increase lymphocyte 
proliferation (167). Alternatively, it could be that n-3 PUFA synthesis functions in modulating the 
proliferative response. The action of n-3 PUFAs are complex and as discussed in section 1.10, they 
are reported to have numerous and diverse immunomodulatory effects. For example, by 
influencing the function of membrane associated proteins and signaling pathways through their 
effect on membrane fluidity, by modulating gene expression including the mRNA expression of 
 139 
cytokine genes and through modifying the production and activity of inflammatory mediators such 
as eicosanoids and resolvins.  
In summary, treatment of PBMCs with the T-lymphocyte mitogen Con A significantly increased the 
expression of the activation marker CD69, the uptake of 18:3n-3 and synthesis of its conversion 
products 20:3n-3, 20:4n-3, 20:5n-3 and 22:5n-3 compared with untreated PBMCs, where synthesis 
was negligible. The most highly synthesised n-3 PUFA was 20:3n-3, a product in the alternative 
delta-8 desaturation pathway, which increased 10-fold in activated cells. Up-regulation of the 
pathway in stimulated cells suggests PUFA synthesis may have an important role in the activation 
and/or function of proliferating lymphocytes. However, reducing PUFA synthesis using a delta-6 
desaturase inhibitor only had a small effect on the proliferative response. Consequently, whether 
PUFA synthesis is needed for lymphocyte activation and proliferation is questionable and a 
complete knockdown of PUFA synthesis in future experiments would be required to answer this 
question. 
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Chapter 4: Does activation of PBMCs change   
transcriptional regulation of the genes encoding the 
desaturase and elongase enzymes involved in the 
PUFA biosynthesis pathway? 
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4.1 Introduction 
Activation of T-lymphocytes results in an elaborate transcriptional response involving increased 
expression of a multitude of genes that function in cell proliferation and immune function (290, 
291). This transcriptional response has been shown to include increased expression of genes 
involved in fatty acid uptake and biosynthesis in activated CD4+ T-lymphocytes (146).  
The findings reported in Chapter 3 showed that n-3 PUFA synthesis significantly increased in Con A 
activated PBMCs compared with untreated cells. This confirmed previous findings where n-3 PUFA 
synthesis increased in PBMCs stimulated with PHA (147). Previous studies in rat liver and the HepG2 
liver cancer cell line have shown associations between n-3 and n-6 PUFA synthesis levels and the 
transcriptional activity of the genes encoding the pathway enzymes (104, 105, 213). However, it is 
not known whether increased activity of the pathway in activated PBMCs is associated with higher 
mRNA expression of the genes encoding the enzymes involved in the main PUFA biosynthesis 
pathway: delta-6 desaturase (FADS2), delta-5 desaturase (FADS1), elongase-5 (ELOVL5) and 
elongase-2 (ELOVL2). The identities of the enzymes that operate in the alternative delta-8 
desaturation pathway, shown to be active in PBMCs, are not clear. Experiments involving 
heterologous expression of ELOVL5 and FADS2 in S. cerevisiae have provided evidence that the 
ELOVL5 gene product is capable of elongating 18:3n-3 to 20:3n-3 (26) and the FADS2 gene product 
is capable of desaturating 20:3n-3 at the delta-8 position to yield 20:4n-3 (19). However, it is not 
known if these processes occur in humans. 
Aim 
To investigate the effect of PBMC activation on the mRNA expression of the desaturase and 
elongase enzymes involved in the PUFA synthesis pathway. 
Hypotheses 
 FADS2, FADS1, ELOVL5 and ELOVL2 mRNA expression levels are higher in response to PBMC 
activation. 
 FADS2, FADS1, ELOVL5 and ELOVL2 mRNA expression levels in activated PBMCs are positively 
correlated with the proportion of activated cells. 
To address these hypotheses, the relative mRNA expression of FADS2, FADS1, ELOVL5 and ELOVL2 
were compared between PBMCs cultured with and without the T-lymphocyte mitogen Con A and 
the relationships between the expression of these genes and the proportion of Con A treated 
PBMCs expressing CD69 were analysed. 
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4.2 Methods 
All PBMC samples were obtained from volunteers participating in the EPUFA study described in 
section 2.2. PBMCs were isolated and cultured in the presence or absence of Con A using the 
experimental design described in section 3.2 and summarised in Figure 3.1 (Chapter 3). The subject 
characteristics and PBMC phenotypes are given in Table 3.1 and Table 3.2, respectively.  
4.2.1 Measurement of mRNA expression 
The overall procedure for measuring mRNA expression by real-time RT-PCR is given in section 2.15. 
Briefly, total RNA was extracted from PBMC pellets and converted to cDNA. cDNA was amplified by 
real-time RT-PCR using commercially prepared primer pairs for FADS2, FADS1, ELOVL5 and ELOVL2. 
Quantitation of mRNA expression levels was carried out using the relative standard curve method 
described in section  2.15.3.1 with normalisation to four reference genes (EIF4A2, RPL13A, SDHA 
and 18S rRNA). Reference genes were selected based on expression stability determined by 
GeNorm analysis (2.15.3.2). The amplification efficienciy of each real-time RT-PCR assay was 
calculated from the slope of the standard curve using the equation below. 
Amplification efficiency = [10(-1/slope)]-1 
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4.3 Results 
PCR efficiency, evaluated from the slope of each standard curve, was 96% for FADS2, 94% for FADS1 
and 98% for both ELOVL5 and ELOVL2 assays. Standard curves for all primer sets had an R2 value > 
0.99 (Figure 4.1). ELOVL2 was below the lower limit of quantification for all unstimulated samples 
and was quantifiable in 12 out 34 Con A stimulated samples. Furthermore, for 21 unstimulated 
PBMC samples and 6 stimulated PBMC samples, no amplification above background fluorescence 
was detected. Consequently, relative ELOVL2 mRNA expression between unstimulated and 
stimulated samples could not be analysed. Con A treatment significantly increased the mRNA 
expression of FADS2 (P < 0.0001), FADS1 (P < 0.01) and ELOVL5 (P < 0.01) compared with untreated 
cells (Figure 4.2). The differences between mRNA expression levels in Con A stimulated and 
unstimulated PBMCs are shown in Figure 4.2 (right), where positive values represent an increase in 
mRNA expression, negative values a decrease and zero represents no expression change. The 
median difference in FADS2, FADS1 and ELOVL5 relative mRNA expression between Con A 
stimulated and unstimulated PBMCs was 0.26, 0.04 and 0.51, respectively. Statistical analysis by 
Wilcoxon signed-rank test of separate male and female groups (data not shown) revealed that Con 
A treatment significantly increased FADS2 mRNA expression in both males (P < 0.0001) and females 
(P < 0.01) compared with untreated cells, whereas FADS1 (P < 0.05) and ELOVL5 (P < 0.05) were 
also significantly increased in males.  
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Figure 4.1. Real-time RT-PCR standard curves for FADS2, FADS1, ELOVL5 and ELOVL2 assays. 
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Figure 4.2. The effect of PBMC activation on FADS2, FADS1 and ELOVL5 mRNA expression. 
Left: mRNA expression normalised to EIF4A2, 18S, SDHA and RPL13A for unstimulated (0 µg/ml Con 
A) and stimulated (5 µg/ml Con A) PBMCs. Right: Difference scores in mRNA expression (Con A 
stimulated minus unstimulated) showing median and IQR. Statistical analysis was by Wilcoxon 
signed-rank test (P value is shown on the right hand graph) for FADS2 (n = 32), FADS1 (n = 31) and 
ELOVL5 (n = 28). 
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4.3.1 Relationship between CD69 expression and mRNA expression 
The relationship between the proportion of CD69 positive events measured in the PBMC gate by 
flow cytometry and relative mRNA expression were analysed by Spearman’s rank-order correlation 
for the total EPUFA population (Figure 4.3). There were significant positive correlations between 
CD69 expression and the mRNA expression of FADS2 (rs = 0.354, P < 0.01), FADS1 (rs = 0.470, P = < 
0.0001) and ELOVL5 (rs = 0.348, P < 0.01). 
 
 
Figure 4.3. Relationship between CD69 expression and FADS2, FADS1 and ELOVL5 mRNA 
expression. 
The relationships between the proportion of CD69 positive events (% CD69+) measured within a 
PBMC gate and the relative mRNA expression of FADS2 (n = 67), FADS1 (n = 66) and ELOVL5 (n = 66) 
were assessed by Spearman’s rank-order correlation, where rs is the Spearman’s Correlation 
coefficient. 
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4.4 Discussion 
Activation of PBMCs by Con A significantly increased the mRNA expression of three genes (FADS2, 
FADS1 and ELOVL5) encoding enzymes involved in conversion of 18:3n-3 to longer chain 
metabolites, compared with untreated PBMCs. In Chapter 3, it was shown that the synthesis of 
20:3n-3, 20:4n-3, 20:5n-3 and 22:5n-3 was also significantly increased in Con A activated cells. 
These findings suggest that changes in the mRNA expression of these genes affects the capacity of 
cells for n-3 PUFA synthesis. This is in agreement with other studies that have shown that increased 
activity of this PUFA biosynthesis pathway is associated with increased mRNA expression of the 
genes encoding the enzymes that operate in the pathway (105, 213). Analysis of the proportion of 
cells within the PBMC gate expressing the cell surface activation marker CD69 revealed significant 
positive correlations between CD69 expression and the mRNA expression of FADS2, FADS1, and 
ELOVL5. This suggests that the level of transcription relates to the level of cell activation and 
complements the positive relationships observed between the proportion of cells expressing CD69 
and the levels of synthesised n-3 PUFAs. Taken together, the present findings suggest that the 
effects of Con A activation on n-3 PUFA synthesis are mediated at the transcriptional level.  
Consistent with the current findings, upregulation of FADS2 mRNA expression in activated 
lymphocytes has been demonstrated previously. Antibody induced activation of cultured CD4+ T-
cells increased FADS2 mRNA expression compared with naïve CD4+ T-cells, which was shown to be 
controlled by direct binding of the transcription factor SREBP1 activated through TCR stimulation 
and MTOR-mediated signalling (146). However, in contrast to the present study, Angela et al., 2016 
found no increase in ELOVL5 mRNA expression. It is presumed that the present analysis should be 
most representative of T-lymphocyte activation since the majority of PBMCs are T-lymphocytes and 
Con A primarily activates this lymphocyte subset. However, the difference in findings could be 
explained by ELOVL5 mRNA expression changing in a different cell type or lymphocyte sub-
population present in PBMCs. PBMCs are a heterogeneous population of cells and therefore 
measured gene expression profiles are not resolved to an individual cell population; a limitation 
when interpreting gene expression results as it is not known which cell types are the source of 
detected differences.  
Chapter 3 reported no measurable fatty acid peak for 18:4n-3, the delta-6 desaturase conversion 
product of 18:3n-3 and the most highly synthesised n-3 PUFA was 20:3n-3, which is the immediate 
elongation product of 18:3n-3. Together, this suggests that PBMCs may use the alternative delta-8 
desaturation pathway as the primary route to longer chain n-3 PUFA synthesis. However, FADS2 
mRNA was expressed in PBMCs and increased in activated cells. This suggests conversion of 18:3n-
3 to 18:4n-3 could have been operating but the presence of FADS2 protein would need to be 
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verified by Western blotting. Inspection of raw Ct values suggested that ELOVL5 (mean Ct 23.53), 
was more highly expressed than FADS2 (mean Ct 26.86); based on the principle that the lower the 
RT-PCR template amount, the more amplification cycles are needed to reach the threshold 
fluorescence. However, this should be interpreted with caution as the amplification efficiency was 
not identical for the FADS2 (96%) and ELOVL5 (98%).  In a previous study, expression of human 
ELOVL5 in S. cervisiae revealed that it is capable of elongating 18:3n-3 to 20:3n-3 (26). Therefore, 
since in the present study both ELOVL5 expression and 20:3n-3 synthesis were elevated, it is 
speculated that elongation of 18:3n-3 to 20:3n-3 in PBMCs is catalysed by elongase-5. Furthermore, 
potential competition between elongase-5 and delta-6 desaturase for the substrate 18:3n-3 may 
explain the predominance of the alternative delta-8 desaturation pathway. However, the 
involvement of elongase-5 in 20:3n-3 synthesis in PBMCs would need confirming, which would be 
possible by using siRNA to knock down ELOVL5 expression. 
ELOVL2 mRNA expression was below the quantitation limit of the assay for all the unstimulated 
samples and was only quantifiable in four of the 34 stimulated samples. Furthermore, no 
amplification of ELOVL2 could be detected in 21 of the unstimulated compared with six of the Con 
A stimulated PBMC samples. This indicates that the mRNA expression of ELOVL2 is either absent or 
very low in both unstimulated and stimulated PBMCs. The observation that amplification of ELOVL2 
was detectable in a greater number of stimulated compared with unstimulated samples suggests 
some upregulation of ELOVL2 in stimulated cells may occur. However, the biological importance of 
very low copy numbers of ELOVL2 mRNA is not known. Elongase-2 has been shown to be involved 
in the conversion of 22:5n-3 to 22:6n-3 by elongation of 22:5n-3 to the 24 carbon intermediate 
24:5n-3 (27). Consequently, the minimal expression of ELOVL2 mRNA could explain the lack of 
22:6n-3 synthesis observed in PBMCs. However, conversion of 22:5n-3 to 22:6n-3 involves multiple 
steps including desaturation at the delta-6 position, translocation to peroxisomes and one cycle of 
β-oxidation, after which 22:6n-3 may be further degraded or moved back to the endoplasmic 
reticulum for membrane biosynthesis (4). Therefore, there are additional steps that could act as 
control points in the synthesis of 22:6n-3 and incubation of PBMCs with the pathway intermediates 
downstream of elongation (24:5n-3) and desaturation (24:6n-3) could help to verify the mechanism 
responsible. Finally, it has been shown that conversion of 20:5n-3 to 22:5n-3 can be catalysed by 
both elongase-2 and elongase-5 enzymes (29) but the minimal expression of ELOVL2 mRNA 
suggests that ELOVL5 may be more important for the conversion of 20:5n-3 to 22:5n-3 in activated 
PBMCs. 
In summary, Con A mediated activation of PBMCs significantly increased the mRNA expression of 
FADS2, FADS1 and ELOVL5 compared with untreated cells. ELOVL2 expression was below the 
detection limit and may explain the lack of 22:6n-3 synthesis observed in PBMCs. In combination 
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with the data in Chapter 3, the findings from this chapter suggest that Con A mediated upregulation 
of n-3 PUFA synthesis is controlled at the transcriptional level. Elucidation of the molecular 
mechanisms controlling the transcription of these genes would be important for understanding the 
regulation of n-3 PUFA synthesis in activated PBMCs. 
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Chapter 5: Do changes in FADS2 and FADS1 gene 
expression levels involve a change in the DNA 
methylation status of their promoter regions? 
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5.1 Introduction 
In the previous chapters, it was shown that activation of PBMCs by Con A resulted in significantly 
higher synthesis of n-3 PUFAs derived from 18:3n-3 and this was accompanied by significant 
increases in the mRNA expression levels of FADS2, FADS1 and ELOVL5. This suggested 
transcriptional control of n-3 PUFA synthesis in PBMCs. As discussed in section 1.11, epigenetic 
modifications have been shown to be related to changes in the mRNA expression of specific genes. 
In particular, DNA methylation of cytosines in CpG dinucleotides is an important mechanism by 
which gene expression can be regulated. DNA methyltransferase (DNMT) enzymes are responsible 
for establishment and maintenance of DNA methylation; DNMT3a and DNMT3b induce DNA 
methylation marks, which are maintained through cell division by DNMT1. In general, low 
methylation of promoter regions is associated with actively transcribed genes, whereas a high 
methylation is associated with transcriptional silencing (292, 293). DNA methylation can repress 
transcription directly by interfering with transcription factor binding and indirectly through 
recruitment of methyl-CpG binding proteins that, in turn, recruit corepressors that modify 
chromatin (242, 294). Although DNA methylation patterns are primarily established during 
development and persist throughout the life course, some DNA methylation marks appear to 
display plasticity in response to environmental changes (251). 
Several studies in rodents have shown that increased DNA methylation of the Fads2 promoter, in 
response to dietary factors, is accompanied by decreased mRNA expression. In a study in mice, 
postnatal 18:3n-3 supplementation increased average Fads2 methylation in maternal and offspring 
livers and for maternal livers the level of promoter methylation correlated negatively with Fads2 
mRNA expression (259). In rats, changes to the amount and type of dietary fat fed in pregnancy 
increased methylation at specific CpG loci in the Fads2 promoter and decreased mRNA expression 
in the liver of adult offspring (213). This was accompanied by lower proportions of 22:6n-3 and 
20:4n-6 in membrane phospholipids and the study also showed that hepatic Fads2 mRNA 
expression correlated negatively with methylation of four CpG dinucleotides in the Fads2 promoter 
(213). In another study in rats, feeding dams increased dietary fat resulted in increased methylation 
of specific CpG loci in the Fads2 promoter, which was accompanied by a decrease in mRNA 
expression in aortae of adult offspring (260). Mutation of a specific CpG dinucleotide that was 
hypermethylated confirmed its role in regulating Fads2 transcription. This CpG dinucleotide was 
located in a putative oestrogen receptor response element and oestrogen treatment induced a 
significant dose-related increase in activity of the wild type FADS2 promoter but had no effect on 
the mutated promoter (260). Hypermethylation of the Fads2 promoter and lower mRNA expression 
and delta-6 desaturase activity have also been observed in livers of mice with 
hyperhomocysteinmia (HHcy) compared with wild type mice (295). Together these studies provide 
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evidence that regulation of FADS2 transcription by DNA methylation may contribute to the 
regulation of PUFA synthesis in rodents. 
Plasticity in the methylation status of CpG dinucleotides in the FADS2 proximal promoter has also 
been demonstrated in human PBMCs isolated from patients with renal disease (261). The 
methylation status of specific CpG dinucleotides located in a region extending approximately 1000 
bp from the FADS2 transcription start site (TSS) were altered in response to dietary 
supplementation with n-3 PUFAs or olive oil when compared to baseline. Furthermore, the 
methylation levels of four CpG dinucleotides were associated negatively with the level of their 
transcripts. This suggests that the level of methylation in the region directly upstream of the FADS2 
could be important in transcriptional regulation in human PBMCs.  
The close proximity of FADS2 and FADS1 and their divergent transcription configuration suggests 
their transcription may be coordinated by regulatory factors in the genomic region between the 
genes. The DNA methylation status of a specific CpG dinucleotide (cg27386326) situated in this 
intergenic region has been shown to be associated with delta-6 and delta-5 desaturase activities in 
human liver samples (273). Bioinformatics analysis revealed that this CpG dinucleotide is positioned 
in a putative enhancer (273). Enhancers are distinct genomic regions that generally act from a 
distance to upregulate the transcription of a target gene from its TSS. Active enhancers are bound 
by activating transcription factors and are brought into proximity of their respective target 
promoters by looping (296). Therefore, CpG dinucleotides in the putative enhancer region located 
between FADS1 and FADS2 could be important in regulating their transcription in addition to loci in 
the region directly upstream of the TSS.  
DNA methylation changes are known to be important in regulating the expression of genes involved 
in T-lymphocyte activation. For example, when naïve CD4+ T-lymphocytes are stimulated by antigen 
they differentiate into one of several lineages of Th-lymphocytes including Th1- and Th2-
lymphocytes, which are defined by their pattern of cytokine production (135). This involves 
reciprocal activation and silencing of specific cytokine genes, which is fundamental to the 
differentiation process. Several studies have indicated the importance of promoter DNA 
methylation in regulating transcription of cytokine genes. For example, during Th1 lineage 
commitment the promoter region of the IFN-γ gene undergoes progressive demethylation and 
activation while the IL-4 gene remains hypermethylated and silenced. Conversely, Th2 lineage 
commitment involves progressive hypomethylation and activation of IL-4 where IFN-γ gene remains 
hypermethylated and silenced (297-301). However, it has been shown that demethylation is not 
required for primary transcription of the IL-4 gene but instead is strongly associated with high level 
IL-4 transcription (301). Demethylation is believed to be a passive process whereby during cell 
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division the newly replicated DNA strand does not become methylated (229). However, 
demethylation and enhanced transcription of another cytokine (IL-2) gene following activation 
occurs before commencement of cell division suggesting an active mechanism for demethylation 
(302, 303). The DNA methylation changes discussed are stable and heritable providing a cellular 
memory enabling reiteration of cytokine gene expression upon re-encounter with antigen in a 
manner that is independent of the cell cycle, facilitating rapid cytokine production in a secondary 
immune response (302). Finally, in addition to DNA methylation changes, H3 and H4 histone 
acetylation has been shown to increase in the IFN-γ and IL-4 loci following TH1 and TH2 
differentiation, respectively, providing accessibility for transcription (263, 264). 
In summary, DNA methylation is known to be important in the regulation of gene expression in 
activated T-lymphocytes and in studies in rodents and human PBMCs, FADS2 transcription has been 
shown to be related to the DNA methylation status of its promoter region. However, it is not known 
whether the increase in FADS2, FADS1 and ELOVL5 mRNA expression measured in activated PBMCs 
involves altered DNA methylation.  
Aims 
To investigate whether in vitro activation of PBMCs induces altered DNA methylation of specific 
CpG dinucleotides located in the FADS2 and FADS1 proximal promotors and intergenic region and 
to characterise the effect of cell culture on the methylation status of these CpG dinucleotides. This 
chapter also aims to investigate whether DNMT mRNA expression is altered in response to Con A 
activation. 
Hypotheses 
 The methylation levels of specific CpGs measured in the FADS2 and FADS1 promoter regions 
and intergenic region are significantly lower in response to activation. 
 The mRNA expression levels of DNMT1, DNMT3a and DNMT3b are significantly lower in 
response to activation. 
To address these aims and hypothesis, percentage DNA methylation was compared in PBMCs 
cultured in the presence and absence of the T-lymphocyte mitogen Con A, using pyrosequencing 
assays designed to measure CpG dinucleotides located in the FADS2 and FADS1 promoters and 
intergenic region. The DNA methylation levels of these CpG dinucleotides were also measured in 
freshly isolated PBMCs in order to characterise the effect of cell culture on methylation status. 
Secondly, DNMT1, DNMT3a and DNMT3b mRNA expression was compared in unstimulated and 
Con A stimulated PBMCs. Finally, to follow on from the findings from the DNA methylation 
comparisons, a technique called 5’RACE was carried out to characterise the FADS2 TSS and in silico 
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analysis was performed to predict transcription factor binding sites in the regions measured in the 
pyrosequencing assays. 
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5.2 Methods 
5.2.1 Experimental Design 
All PBMC samples were obtained from volunteers participating in the EPUFA study described in 
section 2.2. PBMCs were isolated and cultured in the presence and absence of Con A using the 
experimental design described in Section 3.2 and summarised in Figure 3.1, Chapter 3. The subject 
characteristics and PBMC phenotypes are given in Table 3.1 and Table 3.2, respectively. Following 
culture, PBMC pellets were collected and frozen (section 2.6.1) ready for subsequent DNA 
extraction. In addition, PBMC pellets from 10 of the volunteers (8 male and 2 female) were also 
collected and frozen immediately after isolation without undergoing cell culture (section 2.4).  
5.2.2 DNA extraction and pyrosequencing analysis 
DNA was extracted from PBMC pellets (section 2.14.3) and sodium bisulphite pyrosequencing 
(section 2.16) was used to measure the DNA methylation status of CpG dinucleotides in the regions 
adjacent to the human FADS2 and FADS1 transcription start sites. The CpG dinucleotides measured 
were in a region between -18 and –1661 from the TSS for FADS2 (Figure 2.15) and +64 and –713 bp 
from the TSS for FADS1 (Figure 2.16). DNA methylation levels of nine CpG dinucleotides, located in 
the intergenic region 7397 bp and 3202 bp from FADS2 and FADS1, respectively were also measured 
(Figure 2.17).  
5.2.3 DNMT1, DNMT3a and DNMT3b mRNA expression 
DNMT mRNA expression analysis was carried out by real-time RT-PCR using the procedure 
described in section 2.15.  
5.2.4 5’ RACE 
5’ RACE (section 2.17) was carried out to determine the sequence at the 5’ end of the FADS2 
transcript and therefore characterise the TSS in cultured PBMCs treated with and without Con A. 
Purchased cryopreserved PBMCs were revived and cultured (section 2.8) using the experimental 
design and conditions described in section 3.2. Two different RACE procedures were performed on 
RNA extracted (section 2.14.2) from PBMC pellets: RNA ligase mediated (RLM) 5’ RACE, which only 
amplifies cDNA from full length capped mRNA (section 2.17.1) and SMARTer® 5’ RACE (section 
2.17.2). Cloned 5’RLM-RACE (2.17.4.2) and SMARTer® 5’ RACE products (2.17.4.4) were sent for 
sequencing as described in section 2.17.4.7. 
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5.3 Results 
5.3.1 FADS2 promoter methylation status 
Overall, the level of FADS2 methylation increased with increasing distance from the TSS (Figure 5.1, 
graph A). The region displayed a relatively highly methylated domain located distal to the TSS 
followed by a sharp decrease by approximately a third at -1119. There was a transitionary region 
with generally increasing methylation between -1112 and -975, an intermediate region between -
914 and -667 and then a very lowly methylated region approaching the TSS. Mean differences in 
methylation levels between untreated (unstimulated) and Con A treated (stimulated) PBMCs are 
displayed in Figure 5.1, graph B. Con A stimulation significantly increased the methylation status of 
12 CpG dinucleotides located at -1278, -1156, -1112, -1101, -1071, -1067, -1013, -980, -975, -871, -
686 and -667 ranging between a difference of 1.1 to 11.4 percentage points (P < 0.001 for all). When 
male and female groups were analysed separately (data not shown) the methylation status of CpG 
-1112 was significantly increased in both males and females. Females also showed a significant 
increase in methylation at -975, and -871 and males at -1156, -1101 and -1067 (P < 0.001 for all).  
The methylation profile of PBMCs that had not undergone cell culture (pre-culture) was similar to 
the profile of unstimulated cultured PBMCs (post-culture) as shown in Figure 5.2 (graph, A). Mean 
differences in methylation levels between pre-culture and unstimulated PBMCs are displayed in 
Figure 5.2, graph B). For most of the CpG dinucleotides measured, methylation was increased in 
cultured compared with pre-culture PBMCs, however, this was only statistically significant for -1661 
(P < 0.001).  
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Figure 5.1. The effect of PBMC activation on the methylation of individual CpG loci in the FADS2 promoter. 
Values are mean ± SEM, n = 25 to 33. Locations of CpG dinucleotides are relative to the TSS. (A) Mean methylation in unstimulated (0 µg/ml Con A) and 
Con A stimulated (5 µg/ml Con A) PBMCs. (B) Mean difference in methylation (stimulated minus unstimulated). A positive value represents an increase in 
methylation in Con A stimulated PBMCs and a negative value represents a decrease. *Statistically significant mean difference in methylation determined 
by paired-samples t-test. The P-value for significance was adjusted to P < 0.001 by the Holm-Sidak correction for multiple tests.
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Figure 5.2. The effect of PBMC culture on the methylation of individual CpG loci in the FADS2 promoter. 
Values are mean ± SEM, n = 7 to 10. Locations of CpG dinucleotides are relative to the TSS. (A) Mean methylation in uncultured (pre-culture) and 
unstimulated cultured PBMCs (post-culture). (B) Mean difference in methylation (post-culture minus pre-culture). A positive value represents an increase 
in methylation in cultured PBMCs and a negative value represents a decrease. *Statistically significant mean difference in methylation determined by 
paired-samples t-test. The P-value for significance was adjusted to P < 0.001 by the Holm-Sidak correction for multiple tests.
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5.4 FADS1 promoter methylation status 
The level of methylation of FADS1 tended to be inversely related to the distance from the TSS but 
the transition from low to high methylation was sharper than for FADS2 (Figure 5.3, graph A). There 
was a highly methylated region (> 60%) distal to the TTS, which then halved to approximately 30% 
at CpG -262, followed by a downstream region of consistently low methylation (< 5%). Mean 
differences in methylation levels between unstimulated and stimulated PBMCs (stimulated minus 
unstimulated) are displayed in Figure 5.3 (graph, B). Con A stimulation significantly increased the 
methylation status of one CpG dinucleotide located at -262 bp from the TSS (P < 0.001). When male 
and female groups were analysed separately (data not shown) the methylation status of -430, -262, 
-94 and -88 were significantly increased in females but no CpG dinucleotides reached the adjusted 
level for statistical significance (P < 0.001) in males.  
The pattern of methylation in pre-culture PBMCs was consistent with that measured in post-culture 
samples (Figure 5.4, graph A). Methylation increased at all CpG dinucleotides measured in post-
culture compared with pre-culture samples (Figure 5.4, graph B) but did not reach the adjusted 
level for statistical significance. 
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Figure 5.3. The effect of PBMC activation on the methylation of individual CpG loci in the FADS1 
promoter. 
Values are mean ± SEM, n = 28 to 33. Locations of CpG dinucleotides are relative to the TSS. (A) 
Mean methylation in unstimulated (0 µg/ml Con A) and Con A stimulated (5 µg/ml Con A) PBMCs. 
(B) Mean difference in methylation (stimulated minus unstimulated). A positive value represents 
an increase in methylation in Con A stimulated PBMCs and a negative value represents a 
decrease.*Statistically significant mean difference in methylation determined by paired-samples t-
test. The P-value for significance was adjusted to P < 0.001 by the Holm-Sidak correction for multiple 
tests. 
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Figure 5.4. The effect of PBMC culture on the methylation of individual CpG loci in the FADS1 
promoter. 
Values are mean ± SEM, n = 8 to 10. Locations of CpG dinucleotides are relative to the TSS. (A) Mean 
methylation in uncultured (pre-culture) and unstimulated cultured PBMCs (post-culture). (B) Mean 
difference in methylation (post-culture minus pre-culture). A positive value represents an increase 
in methylation in cultured PBMCs and a negative value represents a decrease. Mean differences in 
methylation were analysed by paired-samples t-test. The P-value for significance was adjusted to P 
< 0.001 by the Holm-Sidak correction for multiple tests. 
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5.4.1 FADS2/FADS1 intergenic region methylation status 
All CpG dinucleotides measured in the putative enhancer in the FADS2/FADS1 intergenic region 
were highly (> 75%) methylated (Figure 5.5, graph A). Mean differences in methylation levels 
between unstimulated and stimulated PBMCs are displayed in Figure 5.5 (graph, B). Stimulation of 
PBMCs with Con A significantly decreased the level of methylation compared to untreated cells at 
CpG loci 0 and +113 (P < 0.001), although the differences were small at 3.5 and 2.1 percentage 
points, respectively. There were no significant differences when male and female were analysed 
separately (data not shown).  
The methylation profile of uncultured PBMCs was similar to that of cultured samples (Figure 5.6, 
graph A). There were no significant differences in methylation status between pre-culture and post-
culture PBMC samples (Figure 5.6, graph B). 
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Figure 5.5. The effect of PBMC activation on the methylation of individual CpG loci in the 
FADS2/FADS1 intergenic region.  
Values are mean ± SEM, n = 28 to 32. Locations of CpG dinucleotides are relative to cg27386326. 
(A) Mean methylation in unstimulated (0 µg/ml Con A) and Con A stimulated (5 µg/ml Con A) 
PBMCs. (B) Mean difference in methylation (stimulated minus unstimulated). A positive value 
represents an increase in methylation in Con A stimulated PBMCs and a negative value represents 
a decrease. *Statistically significant mean difference in methylation determined by paired-samples 
t-test. The P-value for significance was adjusted to P < 0.001 by the Holm-Sidak correction for 
multiple tests. 
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Figure 5.6. The effect of PBMC culture on the methylation of individual CpG loci in the 
FADS2/FADS1 intergenic region. 
Values are mean ± SEM, n = 10. Locations of CpG dinucleotides are relative to cg27386326. (A) 
Mean methylation in uncultured (pre-culture) and unstimulated cultured PBMCs (post-culture). (B) 
Mean difference in methylation (post-culture minus pre-culture). A positive value represents an 
increase in methylation in cultured PBMCs and a negative value represents a decrease. Mean 
differences in methylation were analysed by paired-samples t-test. The P-value for significance was 
adjusted to P < 0.001 by the Holm-Sidak correction for multiple tests. 
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5.4.2 DNMT1, DNMT3a and DNMT3b mRNA expression 
Due to limited sample amount, preliminary analysis of DNMT expression was performed for seven 
paired PBMC samples. There were significant increases in DNMT1 and DNMT3a expression (P < 
0.05) in Con A stimulated compared with unstimulated PBMCs (Figure 5.7). DNMT3b expression 
also increased but did not reach statistical significance. 
 
Figure 5.7. mRNA expression of DNMT1, DNMT3a and DNMT3b. 
Left: mRNA expression normalised to EIF4A2, 18S, SDHA and RPL13A for unstimulated (0 µg/ml Con 
A) and stimulated (5 µg/ml Con A) PBMCs. Right: Difference scores (stimulated minus unstimulated) 
for mRNA expression showing median and IQR. A positive value represents an increase in mRNA 
expression in Con A stimulated PBMCs and a negative value represents a decrease. Statistical 
analysis was by Wilcoxon signed-rank test for DNMT1 (n = 7), DNMT3a (n = 7) and DNMT3b (n = 6). 
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5.4.3 Characterisation of the FADS2 TSS in unstimulated and stimulated PBMCs by 5’ RACE 
Pyrosequencing analysis suggested that there might be an alternative start site for FADS2 
transcription in stimulated cells compared to unstimulated cells given the wide region of increased 
methylation observed. Therefore, a technique called 5’RACE was carried out to characterise the 
FADS2 TSS and to determine if there are different transcripts in unstimulated and Con A stimulated 
PBMCs. 
5.4.3.1 5’ RLM-RACE cDNA control PCR 
First, 5’ RACE was carried out using the 5’RLM-RACE kit. In 5’RLM-RACE, ligation of an adapter 
sequence to the 5’ end of mature mRNA molecules followed by cDNA conversion enables 
amplification of the 5’ end of the transcript by PCR. To verify the presence of the FADS2 transcript 
following the 5’ RLM-RACE cDNA conversion step, a control PCR was carried out using the Gene 
Specific 5’ Control Primer and the Gene Specific Inner Primer (Table 2.6). These primers were 
designed to bind within the FADS2 transcript so the RT and PCR reactions could be evaluated 
independently of the CIP, TAP and ligation reactions. This was also carried out for a positive control 
sample prepared from mouse thymus RNA using primers for the Cxcr4 gene provided with the 5’ 
RLM-RACE kit. The amplified products were of the expected size for the positive control sample for 
both the 5’ RACE outer and inner primers (Figure 5.8, B). The FADS2 primers also amplified the 
expected size product in Con A stimulated samples (Figure 5.8, A), but no PCR product could be 
amplified in unstimulated samples, perhaps because the level of this transcript was too low. It was 
decided to proceed with 5’ RACE nested PCR just in stimulated samples to determine whether the 
TSS matched the published TSS (273). 
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Figure 5.8. 5’RLM RACE control PCR to verify presence of FADS2 transcript. 
Agarose gel showing PCR products for Con A stimulated (+C) and unstimulated (-C) PBMCs and a 
mouse thymus positive control (+Ctrl) sample including minus TAP (-TAP) control samples for each 
and a no template control (NTC). (A) FADS2 (expected product size = 220 bp). (B) Cxcr4 positive 
control (expected product size, outer = 259 bp and inner = 217 bp).  
 
5.4.3.2 Nested PCR for 5’ RLM-RACE 
Nested PCR was performed to amplify the 5’ end of the FADS2 and positive control (Cxcr4) 
transcripts. The products obtained after the inner PCR are shown in Figure 5.9. The positive control 
produced a band of the expected size (301 bp) indicating that the 5’ RLM RACE and PCR had been 
successful and the minus TAP control indicated that the product was specific to de-capped, full 
length mRNA. A smear of non-specific product was visible in the minus TAP control but the 5’ RLM 
RACE handbook states that this is not a concern. A larger second band was visible in the positive 
control, which according to the 5’RLM RACE handbook happens when the PCR has a very high yield. 
The FADS2 inner PCR produced a product of approximately 500 bp. The minus TAP control, which 
should have no visible PCR product, produced a product of approximately 300 bp suggesting that 
the FADS2 5’RACE was not specific to full length mRNA. However, since the positive control was 
successful and for FADS2 the minus TAP control produced a 200 bp smaller product than the TAP 
treated sample, it was decided to sequence both FADS2 products. 
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Figure 5.9. FADS2 5’ RLM RACE nested PCR. 
Agarose gel showing inner products from nested PCR on Con A stimulated PBMC (+C) and also 
mouse thymus positive control (+Ctrl) 5’ RACE samples including minus TAP (-TAP) control samples 
for each and a no template control (NTC).  
 
5.4.3.3 Cloning and sequence analysis of FADS2 5’ RLM-RACE products 
To identify the sequence of the FADS2 5’ RLM RACE transcripts, PCR products were inserted into 
the pCR™4-TOPO® plasmid vector and cloned. Restriction digest confirmed the presence of the 
expected sized inserts (approximately 500 bp for the TAP treated and 300 bp for the minus TAP 
control RACE products) in the plasmid vector (Figure 5.10) before three clones for each product 
were sequenced in both directions. The Basic Local Alignment Search Tool (BLAST) confirmed the 
products matched the FADS2 sequence. Sequenced RACE products contained the expected 36 bp 
sequence of the 5’ RACE adapter enabling orientation of the 5’ end of the detected FADS2 
transcript. Both sequenced RACE products began at exactly the same location, corresponding to 
the fourth exon of FADS2 variant 1 (RefSeq: NM_004265.3; Ensembl transcript ID: 
ENST00000278840.8) but in the reverse complement orientation with the sequence proceeding to 
the middle of the third exon of FADS2 variant 1 (Figure 5.11). In the TAP treated RACE product the 
sequence then joined the sequence corresponding to the 5’UTR in the first exon of FADS2 variant 1 
(this time in the same orientation as the published sequence), only 2 bp (or 6 bp since AGGG 
corresponds to both exon 1 and the reverse complement of exon 3) upstream of the reported TSS. 
For the minus TAP control RACE product the junction was 204 bp (or 208 bp as interestingly again 
AGGG could have come from either exon) downstream therefore explaining the 200 bp smaller PCR 
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product obtained. Both sequences were than analysed up to exon 1, which contained the gene 
specific inner 5’RACE PCR primer. The complex nature of this arrangement (for it to be real it would 
have been transcribed from both DNA strands and joined into a single mRNA) and the failed minus 
TAP control (no PCR product should have been obtained) suggested that the sequence was probably 
a 5’RACE artefact. Furthermore, the product could not be verified by PCR amplification when tested 
on control PBMC cDNA (data not shown). However, it could be argued that the level of the 
transcript, if it were real, was too low to amplify. Interestingly, a FADS2 product starting with the 
reverse complement of exon 4 (at exactly same nucleotide) had been previously detected in the 
laboratory by another researcher (Dr Rebecca Clarke-Harris) when 5’ RLM RACE had been 
performed on RNA from HepG2 cells but the sequence downstream of the reverse complement of 
exon 4 differed to the sequence obtained in PBMCs. This suggests that the FADS2 5’RACE product 
detected is a consistent artefact associated with the 5’RLM-RACE kit and therefore it was decided 
to repeat FADS2 5’RACE using a different kit. 
 
 
Figure 5.10. Digests of 5’ RLM RACE PCR – pCR4-TOPO clones with EcoRI and NotI. 
Three Con A treated PBMC (+C) and minus TAP control (+C-TAP) FADS2 RACE product pCR4-TOPO 
clones (C1-C3) were digested with EcoRI to confirm presence of appropriate sized inserts in the 
plasmid vector (+C ~500 bp and +C-TAP ~300 bp) or NotI to linearise the plasmid. An undigested 
(uncut) control of one clone is also shown.  
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Figure 5.11. Sequences of FADS2 5’ RLM RACE products. 
Sequence corresponding to the reverse complement of exon 4 (blue), the reverse complement of 
exon 3 (red) and exon 1 (black) of FADS2 variant 1 are shown in differing colours with sequence 
corresponding to the 5’UTR underlined. Dotted underline indicates sequence corresponding to 
both exon 4 and exon 1 of the main FADS2 variant. The reported FADS2 TSS is highlighted blue and 
the inner gene specific RACE primer is highlighted yellow. (A) FADS2 5’ RLM-RACE product (B) FADS2 
–TAP control 5’ RLM-RACE product. 
 
5.4.3.4 5’ SMARTer RACE cDNA control PCR 
FADS2 5’ RACE was repeated using a SMARTer® RACE kit. This kit does not require adaptor ligation 
and uses suppression and step-out PCR techniques to increase specificity. This time, FADS2 5’ 
RACE was also carried out on RNA extracted from the Jurkat T-lymphocyte leukaemic cell line, in 
addition to unstimulated and stimulated PBMCs since FADS2 mRNA expression and DNA 
methylation status was also analysed in Jurkat cells (see Chapter 6). To verify the presence of the 
FADS2 transcript following the SMARTer® 5’RACE cDNA conversion step, a control PCR was carried 
out using the same Gene Specific 5’ Control Primer and the Gene Specific Inner Primer (Table 2.6) 
used to verify the presence of FADS2 transcript in the 5’ RLM-RACE procedure. These primers 
were designed to bind within the FADS2 transcript and amplified the expected size product (220 
bp) for unstimulated and Con A stimulated PBMCs samples and Jurkat cells (Figure 5.12). The 
   A 
   TTTGTGGACAAGGTGGTTCCACTTGGGTTTTCTGTAGACAGACAGGTGGCCATAATCATG 
   TTGCAGCCATCCAGCTTGGGCCTGAGAGGTAGCAAGGACAAAGGCCGTGATGAGGGTAGG 
   AATCCAGCCATTGCCAAAGTAAAAGACAGTGAACCATGCAATGCTCTCCAGGGACACTCC 
   CGAGCGCAGGCGAGAAGGCTGGGGGAGGGGGCGCGGTGGGAGGAGTAGGAGAAGACAAAA 
   GCCGAAAGCGAAGAGGGCCCGGGCTGCACACACCGGCTGGGAGGCAGCCGTCTGTGCAGC 
   GAGCAGCCGGCGCGGGGAGGCCGCAGTGCACGGGGCGTCACAGTCGGCAGGCAGCATGGG 
   GAAGGGAGGGAACCAGGGCGAGGGGGCCGCCGAGCGCGAGGTGTCGGTGCCCACCTTCAG 
   CTGGGAGGAGATTCAGAAGCATAACCTGCGCACC 
   B 
   TTTGTGGACAAGGTGGTTCCACTTGGGTTTTCTGTAGACAGACAGGTGGCCATAATCATG 
   TTGCAGCCATCCAGCTTGGGCCTGAGAGGTAGCAAGGACAAAGGCCGTGATGAGGGTAGG 
   AATCCAGCCATTGCCAAAGTAAAAGACAGTGAACCATGCAATGCTCTCCAGGGCGAGGGG  
   GCCGCCGAGCGCGAGGTGTCGGTGCCCACCTTCAGCTGGGAGGAGATTCAGAAGCATAAC 
   CTGCGCACC 
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intensity of the bands reflects the relative abundance of transcripts measured using real-time RT-
PCR in Chapter 3 (Con A stimulated PBMC > unstimulated PBMC). 
 
 
Figure 5.12. SMARTer® 5’ RACE control PCR to verify presence of FADS2 transcript. 
Agarose gel showing duplicate FADS2 PCR products (expected size 220 bp) for Con A stimulated 
(+C) and unstimulated (-C) PBMC and Jurkat (JK) samples and no template control (ntc) reactions. 
 
 
5.4.3.5 SMARTer® 5’ RACE PCR reactions 
Touchdown PCR was performed in order to amplify the 5’ end of the FADS2 transcripts using the 
gene specific primer designed for the SMARTer® 5’RACE protocol. RACE ready cDNA was also 
prepared from mouse total heart RNA provided with the kit and a control PCR was carried out using 
the supplied control 5’RACE primer specific for the mouse transferrin receptor gene. The PCR 
products obtained are shown in Figure 5.13. The positive control produced a band of the expected 
size (2100 bp) indicating that the cDNA conversion and PCR had been successful. The FADS2 gene 
specific primer generated a main PCR product of approximately 1000 bp for unstimulated and Con 
A stimulated PBMC and Jurkat samples.  
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Figure 5.13. FADS2 SMARTer® 5’RACE PCR. 
Agarose gel showing FADS2 5’RACE PCR products for unstimulated PBMC (-C), Con A stimulated 
PBMC (+C) and Jurkat (JK) samples amplified using the FADS2 gene specific primer (GSP) and a 
positive control (+Ctrl) sample. No template control (ntc) reactions were ran for the FADS2 GSP and 
positive control. 
 
5.4.3.6 Cloning and sequence analysis of FADS2 SMARTer® 5’RACE products 
To identify the sequence of the FADS2 SMARTer® 5’RACE transcripts, PCR products were inserted 
into the pRACE plasmid vector provided with the kit and cloned. Restriction digest with EcoRI and 
HindIII was carried out to confirm the presence of the expected sized inserts (Figure 5.14). Products 
amplified with the Gene Specific Primer contained an EcoRI recognition site within the insert and 
consequently digestion produced two bands of approximately 400 bp and 600 bp (the sum of which 
matched the expected size of the insert). Thirteen clones for each product were sequenced (except 
for Jurkat samples where eleven clones were sequenced) in both directions. Nucleotide BLAST 
analysis confirmed the products matched the sequence for FADS2 variant 1 (RefSeq: NM_004265.3; 
Ensembl transcript ID: ENST00000278840.8). The 5’ ends of the RACE products obtained from 
unstimulated and Con A stimulated PBMCs and Jurkat samples are shown in Figure 5.15. All 
sequences proceeded to the location of the GSP in exon 5. Some variation in the start sites of 5’ 
RACE products from unstimulated and Con A stimulated PBMC samples and Jurkat cells was 
evident. However, there was also variation between individual clones for each of these samples. 
Overall, the results indicate that there is no distinct difference in the TSS between unstimulated 
and Con A stimulated PBMC samples and Jurkat cells. 
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Figure 5.14. Digests of SMARTer® 5’RACE PCR – pRACE clones with EcoRI and HindIII. 
Gel shows example digest for three Con A stimulated PBMC (PBMC +Con A) FADS2 RACE product 
pRACE clones (C1 to C3). Plasmids were digested with EcoRI and HindIII to confirm presence of the 
appropriate sized insert of ~1000 bp (image shows bands of ~400 bp and ~600 bp due to presence 
of an EcoRI recognition site within the insert) in the plasmid vector. Linearised (lin) and undigested 
(uncut) plasmids are also shown. 
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Figure 5.15. 5’ sequence of FADS2 SMARTer® 5’RACE products. 
The first nucleotide of each sequenced RACE insert clone is highlighted grey with the number above 
indicating the number of clones corresponding to that particular start site for unstimulated PBMC 
(highlighted yellow), Con A stimulated PBMC (highlighted green) and Jurkat cells (highlighted pink). 
Sequence corresponding to exon 1 of FADS2 variant 1 is shown in black with the 5’UTR underlined 
and sequence corresponding to exon 2 is displayed in red. All sequences proceeded to the position 
of the Gene Specific Primer (GSP) located in exon 5 (sequence not shown). The reported FADS2 TSS 
is highlighted in blue and the translation start codon in orange. 
 
 
5.4.3.7 Analysis of putative transcription factor binding sites 
To determine which transcription factors may be binding in the regions that were found to be 
differentially methylated between unstimulated and Con A stimulated PBMCs, sequences were 
analysed for putative transcription factor binding consensus sequences using MatInspector 
software (http://www.genomatix.de/cgi-bin//matinspector). A number of transcription factors 
were predicted to bind in the differentially methylated regions in the FADS2 and FADS1 promoters 
and FADS2/FADS1 putative enhancer (Table 5.1). 
 
 
  
 GCCAATGGCAGGCGGGGCGACGCGACCGGATTGGTGCAGGCGCTCTGCTGATCGCTGTGG 
                                 2        1     1 
 AAACTCGGGCGGCGGGGAACGCGGGAGGATGTGGAACCCGAGGCGGGGGGAGCCGGAGGG 
   3                           1                     2 
 GCGGGCAGAGGAGGTGTCGAGGCCCTGAGCTCCCGGGGAGTTTTTACTGGAGGCAAAAGT 
                           1/1                1     1  1 
 CCATAGCGGGAGGGCTGAGGGAGGGGCGGAGGAAGGGGACCGCTTGGGGGCACTGGGAAG 
   1/1     2              1 
 CCAGGGATCCTCCGCCAGGAAGGCAGGGACACTCCCGAGCGCAGGCGAGAAGGCTGGGGG 
                       1                                3 
 AGGGGGCGCGGTGGGAGGAGTAGGAGAAGACAAAAGCCGAAAGCGAAGAGGGCCCGGGCT 
 3/1/6 
 GCACACACCGGCTGGGAGGCAGCCGTCTGTGCAGCGAGCAGCCGGCGCGGGGAGGCCGCA 
 
 GTGCACGGGGCGTCACAGTCGGCAGGCAGCATGGGGGGAAGAGGGAACCAGGGCGAGGGG 
       1 
 GCCGCCGAGCGCGAGGTGTCGGTGCCCACCTTCAGCTGGGAGGAGATTCAGAAGCATAAC 
            1 
 CTGCGCACCGACAGGTGGCTGGTCATTGACCGCAAGGTTTACAACATCACCAAATGGTCC 
                                                         1 
 ATCCAGCACCCGGGGGGCCAGCGGGTCATCGGGCACTACGCTGGAGAAGATGCAACGGAT 
     
 GCCTTCCGCGCCTTCCACCCTGACCTGGAATTCGTGGGCAAGTT. . . . GSP   
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Table 5.1. Putative transcription factor binding sites in the differentially methylated regions of FADS2, FADS1 and the FADS2/FADS1 intergenic region 
(continued on page 177) 
TF    CpG Sequence Strand Core 
sim. 
Matrix 
sim. 
Reported expression and function in lymphocytes Refs 
FADS2         
ELK1  -1661 acgttgacGGAAatggaacca 
 
- 1.00 0.91 B-lymphocyte receptor signalling (304, 305) 
CMYC  -1156 caagcctCGTGcacccc + 1.00 0.95 T-lymphocyte development and proliferation (306, 307) 
VMYB  -1337                     
-1112  
gagatggtcaAACGggccctg 
ccggagggctAACGggacacg  
 
-                              
- 
1.00                 
1.00 
0.95                 
0.97 
Regulation of proliferation, differentiation and 
tumorigenesis 
(308) 
WHN  -1278                      
-1071/-1067    
aggACGCatat 
aggACGCccgg   
 
-                             
+ 
1.00                 
1.00 
0.96                 
0.96 
Unknown but important in thymic epithelial cell 
differentiation that regulate T-lymphocyte precursors 
(309) 
NMYC  -1119/                 
-1112 
cttcccaCGTGtcccgt + 1.00 1.00 T-lymphocyte development and proliferation (307) 
DEC2  -1112 ttcccaCGTGtcccg + 1.00 0.97 Facilitates Th2 differentiation (310-312) 
MNT  -1112 cgggaCACGtgggaagt - 1.00 0.99 Upregulated in proliferating lymphocytes. Protects 
lymphocytes from apoptosis 
(313) 
SP4  -1013                     
-855 
cttttaGGCGtggggca 
gaagggGGCGatgagga 
 
-                              
- 
1.00                 
1.00 
0.90                 
0.94 
Regulation of IL-17 expression (309) 
DMP1  -1101 cctccGGATgcagtc + 1.00 0.98 Involved in tumour suppression (leukaemia) (314) 
CETS1(P54)  -1101 agccctCCGGatgcagtcagg + 1.00 0.95 Regulation of B-and T-lymphocyte functions (315-317) 
GATA1  -980/-975 cttcGATAcggca 
 
+ 1.00 0.98 Expression detected in CD4+ T-lymohocytes (318) 
BRE  -871/-869            
-669/-667 
ccgCGCC                                          
ccgCGCC 
 
+                             
- 
1.00       
1.00 
1.00                 
1.00 
Anti-apoptotic protein. Expression detected in Jurkat 
cells 
(319) 
AML1  -817 ggctGCGGtgagggg 
 
- 0.91 0.94 Suggested to function in T-lymphocyte differentiation (320) 
SREBP1  -817 cccTCACcgcagcca 
 
+ 1.00 0.92 Metabolic programming of activated T-lymphocytes (196) 
E2F3  -806                      
-686 
ccatgGCGCccagacca 
gaaagGCGCcagaatgt 
 
+              
+ 
1.00        
1.00 
0.91           
0.94 
Cell cycle progression (321) 
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Table 5.1. (continued from page 176) 
TF    CpG Sequence Strand 
Core 
sim. 
Matrix 
sim. 
Reported expression and function in lymphocytes Refs 
FADS1         
CEBPE  -713 agcgttttGCAAacc 
 
- 1.00 0.99 Proliferation and differentiation (322) 
IK1  -581 gagtGGGAacgca 
 
- 1.00 0.93 Potential regulator of lymphocyte differentiation (323) 
RBPJK  -581 ggagTGGGaacgc 
 
- 1.00 0.96 Repressor (324) 
E2F3  -506 cctagGCGCctccaggc 
 
+ 1.00 0.90 Cell cycle progression (321) 
AP2  -506 ctaGCCTggaggcgc 
 
- 1.00 0.94 Expression detected in T-lymphocytes (325, 326) 
WHN 
 
 -430                   
-140 
gagACGCtagg 
cagACGCtgac 
 
+           
- 
1.00      
1.00 
0.98      
0.96 
Unknown but important in thymic epithelial cells 
 
(309) 
HOXB9  262 agagaccgTAAAtatgc + 1 Upregulated in Hodgkin lymphoma (327) 
THAP1  -204 acttcgGGCAg 
 
+ 1.00 0.91 Apoptosis in T-cell acute lymphoblastic leukaemia (328) 
AHRR  -188/-183/      
-180 
tggcggcacgaCGTGgcaagcaggc 
 
+ 1.00 0.93 Lymphoid cell development. (329) 
MAX  -188/-183/     
-180 
cttgcCACGtcgtgccg 
 
- 1.00 0.91 Proliferation, differentiation and apoptosis (330) 
HIF-1  -188/-183/     
-180 
cggcacgaCGTGgcaag 
 
+ 1.00 0.92 Cytolytic activity in CD8+ T-lymphocytes (331) 
CREB  -183/-180 gcggcacgACGTggcaagcag 
 
+ 1.00 0.90 Proliferation and survival of mature B-lymphocytes (332) 
FADS2/FADS1 intergenic region       
VMYB  0 ctacctccctAACGagcttat + 1.00 0.90 Proliferation, differentiation and tumorigenesis (308) 
HIF-1  +113/+117 tgcCACGcccg 
 
- 0.91 0.94 Cytolytic activity in CD8+ T-lymphocytes (331) 
KLF7  +113/+117 
+166 
tggccgGGCGtggcagctc 
gaggagGGCGgatcacctg 
 
+              
+ 
1.00      
1.00 
0.91      
0.94 
Suggested role in T-lymphocyte development (333) 
ZKSCAN3  +247 gcaccCCCCaccacacccggcta 
 
- 1.00 1.00 Highly expressed in chronic lymphocytic leukaemia  (334) 
SREBP1*  +166 (c)ggaTCACctgaggtc 
 
+ 1.00 0.94 Metabolic programming of activated T-lymphocytes (196) 
Potential binding sites for transcription factors identified using MatInspector core/vertebrate transcription factor database. The sequence containing and surrounding the 
differentially methylated CpG dinucleotides was analysed. Core sim. (core similarities) refers to base pair matching for the core consensus sequence (capitalised) while Matrix 
sim. (matrix similarities) refers to overall matching (both are scored out of 1.00). Results are for sequences covering CpGs and with Core sim. and Matrix. Sim ≥ 0.9. *The CpG 
is outside of the SREBP1 binding sequence by 1 bp (shown in brackets) but was included in results since SREBP1 has been reported to regulate FADS2.  
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5.5 Discussion 
The findings presented in this chapter showed that activation of PBMCs with Con A induced altered 
methylation of specific CpG dinucleotides in the 5’ regulatory regions and in an intergenic region of 
two genes (FADS2 and FADS1) that encode the key desaturase enzymes in the PUFA biosynthesis 
pathway. 
The promoter region of FADS2 was characterised by a decline in the level of methylation of 
individual CpG loci towards the TSS. The methylation profile for uncultured and cultured PBMCs 
(with and without Con A stimulation) was in agreement with a previously published profile of FADS2 
methylation in uncultured PBMCs from patients with renal disease (261). FADS1 promoter 
methylation also decreased towards the TSS but the transition was sharper than observed in FADS2 
with the methylation level stepping down from over 90% to approximately 20% at CpG locus -262. 
Again, FADS1 methylation was consistent with the previously published profile with the drop in 
methylation occurring at the same CpG locus reported by Hoile et al., 2014 (261). The methylation 
level of the majority of CpG dinucleotides measured in FADS2 increased in cultured (unstimulated) 
compared with freshly isolated PBMCs, by a maximum of 8 percentage points. However, the 
difference only reached statistical significance for the CpG dinucleotide located furthest from the 
TSS. Cell culture increased methylation in all of the CpG loci measured in FADS1 but none were 
significantly different and the greatest difference was only 2 percentage points. The sample size 
was lower (n = 10) than used in the unstimulated versus stimulated PBMC comparisons (n = 33) and 
therefore the results may be underpowered. However, overall these results suggest that cultured 
PBMCs retain the DNA methylation characteristics of freshly isolated cells, making them a suitable 
model for analysing DNA methylation changes. 
Con A treatment significantly increased FADS2 promoter methylation at 12 CpG dinucleotides in a 
region between -1278 bp and -667 bp from the TSS with the difference in methylation ranging from 
1% to 11%. This finding is contradictory to the general view that DNA methylation is a repressive 
epigenetic mark, since in Chapter 4 FADS2 mRNA expression was shown to increase in stimulated 
PBMCs. In FADS1, methylation also increased after stimulation but only at one specific CpG 
dinucelotide from a level of 25% to 30%. However, fewer CpG dinucleotides were measured in 
FADS1 compared with FADS2 and for both genes there is the possibility that there were methylation 
changes in CpG dinucleotides not covered by the assays.  
One explanation for the increased methylation coinciding with increased gene expression could be 
the DNA methylation preventing the binding of an inhibiting factor such as a transcriptional 
repressor. Transcriptional repressor proteins associate with their target genes either directly 
through a DNA binding domain or indirectly by interacting with other DNA bound proteins. DNA 
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methylation interfering with repressor binding has not been widely reported but has been 
implicated as the mechanism explaining methylation at the promoter region of the FOXA2 gene and 
elevated expression during endoderm development (238). In silico analysis, using MatInspector 
software, predicted that a number of transcription factors may bind across the region that was 
differentially methylated in FADS2 (Table 5.1). Many of these transcription factors are reported to 
function in lymphocyte differentiation and proliferation (references given in Table 5.1). 
Interestingly, DEC2 and MNT, predicted to bind across CpG -1112, are well characterised repressors 
of transcription (310, 335). However, DEC2 has also been shown to directly activate genes in T-
lymphocytes (311). Many transcription factors can act as both activators and repressors depending 
on their co-factors. It is important to note that the sequences in Table 5.1 are only putative binding 
sites for the transcription factors listed and actual binding and the effect of DNA methylation on 
binding would need to be validated experimentally, for example using an electrophoretic mobility 
shift assay (EMSA). Interestingly, two transcription factors (ELK1 and SREBP1) known to regulate 
the transcription of FADS2 (125, 146) were predicted to bind within the region. The predicted 
binding site for ELK1 was highly methylated in PBMCS (85%) and the predicted site for SREBP1 
showed an intermediate level of methylation (20%) but neither were significantly altered by 
activation. In FADS1, the transcription factor HOXB9 was predicted to bind over CpG -262 (Table 
5.1), which was significantly increased in stimulated cells. HOXB9 is a member of the HOX family of 
transcription factors, which are major regulators of animal developmental programmes and 
function as both transcriptional activators and repressors (336). 
In some cases, CpG methylation has been demonstrated to be required for binding of transcription 
factors. For example, methylation of the CpG in the cAMP response element (CRE) sequence 
(TGACGTCA) has been shown to enhance the binding of C/EBPα, which activates specific genes 
critical in activation of differentiation in various cell types (237). Furthermore, the binding of the 
SP1 transcription factor to DNA and activation of transcription has been shown to occur even when 
the CpG dinucleotide within its binding site is methylated (337). Furthermore, in another study SP1 
was shown to bind with higher affinity to methylated residues (235). Therefore, the relationship 
between DNA methylation and gene expression is complex but preference of transcriptional 
activators for methylated cytosines could provide another potential explanation for the increase in 
methylation and gene expression observed for FADS2 and FADS1.  
So far, the possible explanations for the concurrence of increased methylation and higher gene 
expression have not addressed why methylation increased over a wide area in FADS2. The extent 
of increased methylation in FADS2 following Con A treatment could suggest the use of an 
alternative promoter for transcription in activated cells. Alternative promoters provide an 
important mechanism by which gene expression can be regulated, influencing both transcript 
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diversity and gene expression levels. The use of more than one transcription initiation site can 
permit gene expression under different cellular conditions and individual promoters can provide 
tissue specific expression (338). A considerable fraction of genes with methylated proximal 
promoters display elevated expression and in many such cases transcription is initiated at a distal 
CpG island that functions as an alternative promoter (339). There are alternative transcription 
initation sites for different protein coding splice variants of the FADS2 gene. The NCBI Reference 
Sequence database (RefSeq) lists three protein coding FADS2 transcripts. The TSS for the FADS2 
variants 2 (RefSeq: NM_001281501.1) and 3 (RefSeq: NM_001281502.1) are situated over 11 kb 
upstream of the classical FADS2 variant 1 (RefSeq: NM_004265.3). However, these variants would 
not have been detected in the gene expression analysis as the amplified exons were unique to 
FADS2 variant 1; therefore the increased expression measured in stimulated compared with 
unstimulated PBMCs related to the classical variant.  
5’RACE was carried out in order to determine whether the FADS2 TSS differed in Con A stimulated 
and unstimulated PBMCs. Initially, 5’RACE was conducted using 5’RLM-RACE, which has the 
advantage of being specific to mature capped mRNA molecules. No transcript could be detected 
for unstimulated PBMCs in control experiments possibly because the level of the transcript was too 
low to detect after the RACE specific cDNA conversion. A FADS2 5’RACE product was obtained for 
stimulated PBMCs but a product was also obtained for the minus TAP control indicating the result 
was not specific to mature mRNAs. However, the minus TAP product was 200 bp smaller, which is 
difficult to explain. The RACE product obtained for stimulated PBMCs exhibited a non-collinear 
arrangement, which would have required transcription from both DNA strands and subsequent 
fusion into a single mRNA, if it were real. Considering the minus TAP control product and complex 
exon arrangement, it was concluded that the observed product was most likely an artefact of the 
nested PCR. Analysis of the arrangement suggested that it was a PCR-generated chimera, which 
occurs as the result of recombination between similar sequences during amplification (340, 341). 
The experiment was repeated using a different 5’RACE procedure in order to avoid problems 
inherent to the 5’ RLM RACE kit components, since a strikingly similar arrangement had been 
observed in HepG2 cells as detailed in the results. RACE was repeated using the SMARTer 5’RACE 
kit and this time the procedure was also carried out for a T-lymphocyte cell line (Jurkat) in addition 
to PBMCs. This confirmed the product obtained in 5’ RLM RACE to be an artefact. Visualisation of 
RACE products on an agarose gel revealed a main transcript that did not differ in size between 
samples. Sequencing of RACE products confirmed the products corresponded to the 5’ end of 
FADS2 variant 1. Although there was a small degree of variation in the start sites of 5’ RACE products 
from unstimulated and Con A stimulated PBMC samples and Jurkat cells, there was also variation 
between individual clones from the same sample and no distinct overall pattern. Therefore, it was 
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concluded that there is no distinct difference in the TSS for FADS2 expressed in unstimulated and 
Con A stimulated PBMC samples and Jurkat cells. The observed differences could represent true 
variation in the FADS2 TSS, in other words the TSS is not well defined. Many genes have multiple 
transcription initiation sites and do not conform to the TATA box model, named for its conserved 
DNA sequence, where transcription is initiated from a defined nucleotide (342, 343). These are 
termed TATA-less promoters and represent more than 80% of mammalian protein-coding genes 
(344). Analysis of the FADS2 sequence revealed no TATA box close to the TSS, which commonly 
located 25-35 bp upstream. A limitation of the SMARTer 5’RACE procedure was that, unlike 5’ RLM 
RACE, it does not guarantee specificity for mature capped mRNA molecules. Therefore, the shorter 
products may have represented partially degraded mRNAs. To minimise the impact of this a large 
number of clones were sequence maximise the amount of 5’ sequence obtained.  
It has been demonstrated that the inhibition of gene expression by low density promoter 
methylation can be overcome by an enhancer (345). Furthermore, it has been reported that T-
lymphocyte differentiation and lineage commitment is associated with changes in DNA methylation 
in enhancer regions (346). In this study, there was consistently high methylation (> 77%) of CpG 
dinucleotides measured in a putative enhancer region between FADS1 and FADS2 in both pre-
culture and post-culture PBMCs, which is characteristic of CpG residues outside of CpG islands. The 
methylation levels of two CpG dinucleotides were significantly lower in Con A stimulated compared 
with unstimulated PBMCs. This included the CpG (cg27386326) for which the methylation level was 
shown previously to correlate negatively with delta-6 and delta-5 desaturase activity (273) and an 
adjacent CpG dinucleotide (113 bp downstream). However, it is not known whether the decrease 
in methylation of 3.5 and 2.1 percentage points would be sufficient to explain the change in 
magnitude of gene expression. In silico analysis predicted binding sites for transcription factors in 
this region (Table 5.1) including SREBP1 (known to activate FADS2 transcription) therefore further 
supporting this region as a possible enhancer for FADS gene expression. However, again 
transcription factor binding and the influence methylation on binding would need experimental 
verification.  
As discussed earlier, increases in CpG dinucleotide methylation were also observed in cultured 
PBMCs compared with PBMCs prior to culture. These increases, were similar in terms of the CpG 
loci altered in unstimulated compared to stimulated cultured cells but the magnitude of the 
changes were smaller. This suggests that the culture system may be having a stimulatory effect. 
Alternatively, it could be merely an effect of the PBMCs being in an alien environment. Another 
explanation could be that the increased methylation was due to the presence of 18:3n-3 in the 
culture medium, since, in rodents, 18:3n-3 supplementation has been shown to induce FADS2 
promoter methylation (259). However, unstimulated and stimulated cultures both had 18:3n-3 
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present in the media and methylation was greater in stimulated cells. It could be that capacity for 
de novo methylation was greater in stimulated cells, which is supported by results from preliminary 
experiments shown in Figure 5.11 that suggested the expression of the DNMTs was higher in Con 
A treated PBMCs. It is thought that de novo methylation in somatic cells is mainly restricted to 
methylated genomic regions where it is proposed that DNMT3a and DNMT3b have a role in 
restoring methylation at CpG sites missed by DNMT1 (347). However, a previous study has shown 
active DNMT3b recruitment to the IL-4 locus in developing T-lymphocytes, indicating that it may be 
responsible for de novo methylation of this locus (348). Activation of naïve CD4+ T-lymphocytes has 
been shown to increase FADS2 expression through mTOR (mechanistic target of rapamycin) 
mediated activation of transcription factor SREBP1 (146). Therefore, one theory could be that FADS 
gene expression increased due to activation of specific transcription factors under stimulating 
conditions and the presence of 18:3n-3 may have attenuated the increased gene expression by 
inducing methylation. The effect of 18:3n-3 on methylation status and gene expression could be 
determined by repeating the experiments with and without 18:3n-3 in the culture medium. 
Finally, the heterogeneous cell population could also explain the simultaneous increase in 
methylation and gene expression in stimulated PBMCs. For example, it may be that the methylation 
change occurred in a different cell type to the gene expression change. This represents the main 
limitation when working with a mixed cell population due to inability to resolve the source of the 
change. Furthermore, a change in the proportion of particular cell types during culture could change 
the level of methylation without an active mechanism. In order to answer these questions 
experiments would need replicating on purified individual populations.  
In summary, stimulation of PBMC cultures with Con A induced increased methylation of CpG 
dinucleotides in the FADS2 and FADS1 promoter regions but it is not clear how these changes relate 
to the regulation of gene expression. In FADS2, DNA methylation increased over a number of CpG 
dinucleotides whereas for FADS1 methylation only significantly increased at one CpG dinucleotide. 
These findings contradict the increased expression measured in activated cells. Possible 
explanations were discussed, including decreased repressor binding, preferential binding of 
transcription factors to methylated CpGs, the heterogeneity of the PBMC population, the presence 
of 18:3n-3 in the culture medium and alternative promoter usage in activated cells. The latter was 
investigated using 5’RACE and it was concluded that there was no distinct difference in the FADS2 
TSS between unstimulated and Con A stimulated PBMCs. 
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Chapter 6: Is PUFA synthesis dysregulated in a 
spontaneously dividing leukaemic T-lymphocyte cell 
line? 
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6.1 Introduction 
The findings from the previous chapters showed that activation of n-3 PUFA synthesis occurs in 
PBMCs activated by the T-lymphocyte mitogen Con A and this was associated with upregulation of 
the genes encoding three key enzymes that operate in the pathway. Furthermore, PBMC activation 
was associated with DNA methylation changes in the FADS2 and FADS1 regulatory regions.  
Jurkat cells, a leukaemic cell line of human T-lymphocytes, are able to proliferate in culture without 
need for activation. Consistent with their effects on proliferating primary T-lymphocytes, high 
concentrations of n-3 PUFAs are known to reduce Jurkat proliferation when added to the culture 
medium (349, 350). 22:6n-3 has been demonstrated to be the most potent inhibitor, where 100 
µM decreased proliferation by 96% compared with 59% for 20:5n-3 (350). Studies have shown that 
Jurkat cells take up 18:3n-3 and 18:2n-6 from the culture medium and convert them to longer chain 
n-3 and n-6 PUFAs, respectively, determined by increased proportions of conversion products after 
supplementation (148, 351). Furthermore, direct measurement of synthesis using stable isotope 
tracers demonstrated that Jurkat cells are able to synthesise significant amounts of n-3 and n-6 
PUFAs (148). Interestingly, no PUFA synthesis was detected in another leukaemic T-lymphocyte cell 
line (CEM) and was virtually absent in the B-lymphocyte cell lines tested (148). The reported high 
activity of the PUFA desaturation and elongation pathway suggests PUFA synthesis may be 
dysregulated in Jurkat cells.  
It is well understood that de novo fatty acid biogenesis from two carbon precursors is dysregulated 
in cancer cells (352). While most human cells show a preference for exogenous sources of fatty 
acids, cancerous cells display a shift towards de novo fatty acid biosynthesis regardless of the levels 
of extracellular lipids (149). Cellular proliferation is common to all cancers and requires a constant 
supply of fatty acids for synthesis of membranes and signalling molecules (353, 354). Studies have 
indicated that cancer cells synthesise fatty acids predominately for membrane phospholipids (355, 
356). An in vivo study using [14C]glucose demonstrated that 93% of labelled esterified fatty acids in 
the Ehrlich ascites tumour (EAT) model were derived from de novo synthesis by tumour cells, while 
newly synthesied fatty acids transported from liver and adipose tissue represented less than 7% of 
radioactivity measured in the EAT (357). Furthermore, studies investigating the effect of inhibition 
of fatty acid synthase (FAS) on cancer cell proliferation and survival have demonstrated the 
dependence of various types of cancer cells on endogenous fatty acid synthesis (356, 358, 359). 
Although the main products of de novo fatty acid synthesis are saturated fatty acids, increased 
desaturase activity has also been shown in some cancers. Studies have reported elevated stearoyl-
CoA desaturase 1 (SCD1) expression and activity and increased MUFA content in cancerous cells 
(360, 361). Additionally, loss of SREBP activity has been shown to attenuate cancer cell proliferation 
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through disruption of SCD1-mediated desaturation of newly synthesised saturated fatty acids, 
resulting in an imbalance between saturated and monounsaturated fatty acids (362). Upregulation 
of delta-6 desaturase has also been demonstrated in various cancerous tissues (363, 364). High 
levels of 18:2n-6 conversion products (18:3n-6, 20:3n-6 and 20:4n-6) have been reported in breast 
cancer compared with non-cancerous tissue and product to precursor ratios indicated delta-6 
desaturase activity was increased in cancerous tissue (363). The study also reported elevated PGE2 
concentration in cancer tissue, which is a metabolite of 20:4n-6 and is generally considered to 
promote tumour growth by, for example, supporting processes such as inflammation and 
angiogenesis (365). 
In summary, increased de novo fatty acid synthesis is crucial for cancer cell proliferation and there 
is evidence that desaturase activity is also elevated in cancerous tissues. High levels of PUFA 
synthesis previously detected in the leukaemic T-lymphocyte Jurkat cell line suggests dysregulation 
of pathway activity. However, there has been no direct comparison of PUFA synthesis in Jurkat cells 
and primary T-lymphocytes. Furthermore, transcriptional control of PUFA synthesis in Jurkat cells 
has not been investigated.  
Aims 
The aims of this chapter are to determine whether PUFA synthesis is dysregulated in Jurkat cells 
and to determine whether PUFA synthesis is important for Jurkat cell proliferation. 
Hypotheses 
 n-3 PUFA synthesis is higher in Jurkat cells relative to activated PBMCs. 
 The mRNA expression levels of the genes encoding the enzymes that function in the PUFA 
synthesis pathway are higher in Jurkat cells relative to activated PBMCs. 
 DNA methylation levels in the FADS2 and FADS1 promoters and putative enhancer region are 
lower in Jurkat cells relative to activated PBMCs. 
 Inhibition of delta-6 desaturase reduces the proliferation of Jurkat cells. 
To address these hypotheses the levels of individual n-3 PUFAs synthesised from [1-13C]18:3n-3 and 
the mRNA expression of FADS2, FADS1, ELOVL5 and ELOVL2 were compared in Jurkat cells and Con 
A stimulated PBMCs. These measures were also compared with the HepG2 liver cancer cell line. 
HepG2 cells are a relevant model system for investigating PUFA synthesis as studies using 
radiolabelled 18:3n-3 and 18:2n-6 have demonstrated full pathway activity (366, 367). 
Furthermore, HepG2 cells have been shown to express the genes encoding both desaturase (FADS2 
and FADS1) and elongase enzymes (ELOVL5 and ELOVL2) (104). The DNA methylation status of 
individual CpG dinucleotides in the FADS2 and FADS1 promoters and intergenic region were 
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measured to determine if any gene expression differences were associated with DNA methylation 
changes. Finally, Jurkat cells were treated with the delta-6 desaturase inhibitor SC-26196 to 
determine how pathway inhibition affects proliferation. 
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6.2 Methods 
6.2.1 Cell culture 
All PBMC samples were obtained from volunteers participating in the EPUFA study described in 
Section 2.2. The subject characteristics and PBMC phenotypes are given in Table 3.1 and Table 3.2, 
respectively, in Chapter 3. PBMCs were isolated (section 2.4) and cultured for 48 h in the presence 
of 5 µg/ml Con A and 20 µM [1-13C]18:3n-3 diluted 1/10 with unlabelled 18:3n-3 as described in 
section 2.6. PBMC activation was confirmed by measurement of CD69 positive events by flow 
cytometry (section 2.7). Jurkat and HepG2 cells were cultured using the conditions described in 
sections 2.11.2 and 2.11.1, respectively. For the analyses described below Jurkat and HepG2 cells 
were cultured for 48 h in the presence of 20 µM [1-13C]18:3n-3 diluted 1/10 with unlabelled 18:3n-
3. For comparison of n-3 PUFA synthesis in Jurkat and HepG2 cells cultured with 10 µM or 20 µM 
of [1-13C]18:3n-3 diluted 1/10 with unlabelled 18:3n-3, cells were incubated for 72 h.  
6.2.2 Measurement of n-3 PUFA synthesis 
[13C]-label incorporation into specific n-3 PUFAs was measured by a combination of GC and GC-C-
IRMS as detailed in section 2.12 with normalisation to total cell protein (section 2.13). 
6.2.3 Measurement of mRNA expression 
Total RNA was extracted from PBMC, Jurkat and HepG2 cell pellets as described in section 2.14.2. 
The mRNA expression of FADS2, FADS1, ELOVL5 and ELOVL2 was measured by real-time RT-PCR as 
detailed in section 2.15.  
6.2.4 DNA extraction and pyrosequencing analysis 
DNA was extracted from PBMC and Jurkat cell pellets (section 2.14.3) and sodium bisulphite 
pyrosequencing (section 2.16) was used to measure the DNA methylation status of CpG 
dinucleotides in the regions adjacent to the human FADS2 (Figure 2.15) and FADS1 (Figure 2.16) TSS 
and in an intergenic region between FADS2 and FADS1 (Figure 2.17).  
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6.2.5 The effect of SC-26196 treatment on PUFA synthesis and proliferation in Jurkat cells 
Jurkat cells were incubated with 0 nM (0.02 % (v/v) DMSO vehicle control), 50 nM, 100 nM or 200 
nM SC26196 and 20 µM [1-13C]18:3n-3 or 20 µM [U-13C]18:2n-6 diluted 1/10 and 1/60 with 
unlabelled 18:3n-3 and 18:2n-6, respectively, for 48 h. Six replicate cultures were prepared for each 
treatment. [13C] label incorporation into specific n-3 and n-6 PUFAs was measured by a combination 
of GC and GC-C-IRMS with normalisation to total cell protein. Analysis of the effect of SC-26196 
treatment on Jurkat cell proliferation was kindly carried out by Eduardo Perez-Mojica. Jurkat cells 
were seeded at 100,000 cells/ml in 50 ml medium and incubated with 0 nM or 200 nM SC-26196 
for 144 h. Cells were harvested every 24 h and viable cells were counted using a haemocytometer 
after staining with 0.4% trypan blue to distinguish dead cells. Ten replicate cultures were prepared 
for each treatment and time point. 
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6.3 Results 
6.3.1 n-3 PUFA biosynthesis 
The levels of [13C]-labelled n-3 PUFAs were measured in stimulated PBMCs and in Jurkat and HepG2 
cells in order to compare the activity of the PUFA biosynthesis pathway (Figure 6.1). Jurkat cells 
displayed stable isotope enrichment throughout the pathway. An enriched peak was also detected 
for 18:4n-3, but was close to the detection limit and was consequently only quantifiable in five of 
the ten replicates (data not shown); for these replicates mean [13C]18:4n-3 normalised to total cell 
protein was 0.35 pmol/µg cell protein. In HepG2 cells and PBMCs, there was no detectable 18:4n-3 
peak, and in PBMCs no enrichment was detected in 22:6n-3. Incorporation of 18:3n-3 was 
significantly higher in PBMCs compared with Jurkat (P < 0.0001) and HepG2 cells (P < 0.01).  
[13C]20:3n-3 was 2.5 and 2.2 times higher in PBMCs and Jurkat cells, respectively, compared with 
HepG2 cells, but was not significantly different. Jurkat cells synthesised higher amounts of 20:4n-3, 
20:5n-3 and 22:5n-3 than the other cell types (P < 0.0001). In HepG2 cells, the amount of [13C]20:5n-
3 was significantly higher (17-fold) than in PBMCs (P < 0.0001). The amount of [13C]22:5n-3 
measured in Jurkat cells was 27-fold and 142-fold higher than in HepG2 cells and PBMCs, 
respectively (P < 0.0001). Stable isotope enrichment was detected in 22:6n-3 in Jurkat cells but the 
amount of [13C]22:6n-3 measured was negligible compared with the amounts of [1-13C]20:4n-3, [1-
13C]20:5n-3 and [1-13C]22:5n-3, which were 62-, 138- and 236-fold higher than [1-13C]22:6n-3, 
respectively. Synthesis of [1-13C]22:6n-3 was also detected in HepG2 cells, but again there was 
considerably higher synthesis of [1-13C]20:4n-3 (7.5-fold), [1-13C]20:5n-3 (28-fold) and [1-13C]22:5n-
3 (5-fold). 
Since low amounts of [1-13C]22:6n-3 were detected in both Jurkat and HepG2 cells, additional 
analysis of n-3 PUFA synthesis in Jurkat and HepG2 cells was carried out. Cells were treated with 10 
µM or 20 µM [1-13C]18:3n-3 diluted 1/10 with unlabelled 18:3n-3 to determine whether increasing 
the amount of 18:3n-3 increased 22:6n-3 synthesis. In both cells the amount of [1-13C]18:3n-3 and 
[1-13C]20:5n-3 and [1-13C]22:5n-3 increased significantly with increasing [1-13C]18:3n-3 
concentration (Figure 6.2). The amount of [1-13C]22:6n-3 also increased in HepG2 cells but did not 
change in Jurkat cells. This suggests that 22:6n-3 is not synthesised in Jurkat cells and it is possible 
that the [13C]-enrichment detected could have been be due to incomplete resolution of 22:6n-3 
from the large enriched 22:5n-3 peak (Figure 6.3). 
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Figure 6.1. Comparison of n-3 PUFA synthesis in PBMC, Jurkat and HepG2 cells. 
Values are mean ± SEM for Con A stimulated PBMCs (n = 32), Jurkat cells (n = 9 replicates) and 
HepG2 cells (n = 6 replicates). Statistical analysis was by one-way ANOVA with Tukey’s post hoc test. 
Significant differences are indicated by different letters (P < 0.01 for all). 
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Figure 6.2. The effect of 18:3n-3 concentration on n-3 PUFA synthesis in Jurkat and HepG2 cells. 
Cells were treated with 10 µM or 20 µM of [1-13C]18:3n-3 diluted 1/10 with unlabelled 18:3n-3. 
Values are mean ± SEM (n = 6 replicates). Statistical analysis was by independent-samples t-test for 
each n-3 PUFA. ****P < 0.0001, ***P < 0.001, **P < 0.01. 
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Figure 6.3. GC-C-IRMS Chromatograms showing n-3 PUFAs. 
The chromatograms were obtained from GC-C-IRMS analysis of fatty acid methyl esters from PBMC, 
Jurkat and HepG2 cultures incubated with [1-13C]18:3n-3. The peaks corresponding to 18:3n-3, 
20:3n-3, 20:4n-3, 20:5n-3, 22:5n-3 and 22:6n-3 are labelled. 
 
6.3.2 FADS2, FADS1, ELOVL5 and ELOVL2 mRNA expression 
The mRNA expression levels of the genes encoding the PUFA pathway enzymes were compared 
between activated PBMCs, Jurkat and HepG2 cells to determine whether their expression reflects 
the activity of the pathway. The mRNA expression levels of FADS2, FADS1, and ELOVL5 were 
significantly higher in Jurkat cells relative to PBMCs and HepG2 cells (Figure 6.4). FADS2 showed the 
greatest fold difference in expression (30-fold) in Jurkat cells compared with PBMCs followed by 
FADS1 and ELOVL5 that were 25-fold and 9-fold, respectively (P < 0.0001 for all). Expression levels 
of FADS2, FADS1 and ELOVL5 in Jurkat cells were 8-, 2- and 9-fold that in HepG2 cells (P < 0.0001 
for all), respectively. There were no significant differences in FADS2 and ELOVL5 expression 
between PBMCs and HepG2 cells but FADS1 was significantly higher (13-fold) in HepG2 cells (P < 
0.0001). For ELOVL2, only 12 out of 34 PBMC samples had quantifiable levels of expression. ELOVL2 
expression was measurable in Jurkat cells but was close to the detection limit, whereas ELOVL2 
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expression in HepG2 cells was approximately 150- and 900-fold that in Jurkat cells and PBMCs, 
respectively. 
 
 
Figure 6.4. Comparison of FADS2, FADS1, ELOVL5 and ELOVL2 mRNA expression in PBMCs, Jurkat 
and HepG2cells. 
Values are mean ± SEM for Con A stimulated PBMCs (n = 32, 31, 28 and 12, for FADS2, FADS1, 
ELOVL5 and ELOVL2, respectively) and Jurkat and HepG2 cells (n = 10 replicates for all genes). 
Statistical analysis was by one-way ANOVA with Tukey’s post hoc test. Significant differences are 
indicated by different letters (P < 0.0001 for all). 
 
6.3.3 DNA methylation in the FADS2 and FADS1 promoter and intergenic regions 
The DNA methylation status of individual CpG loci in the FADS2 and FADS1 promoters and intergenic 
region were compared between PBMCs and Jurkat cells in order to determine whether the 
measured gene expression differences were associated with differences in DNA methylation. Jurkat 
cells showed the same overall pattern of increasing methylation with increasing distance from the 
FADS2 TSS as seen in PBMCs (Figure 6.5). However, there were significant differences in the 
methylation levels of individual CpG dinucleotides over a 994 bp region. The methylation level of 
the most distal CpG locus measured was significantly higher, by 8 percentage points, in Jurkat cells 
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compared with PBMCs (P < 0.0001). All CpG dinucleotides between -1655 and -667 bp had 
significantly lower methylation in Jurkat cells with the difference in methylation ranging from 7 to 
49 percentage points. For 17 out of 24 CpG loci in this region, the level of methylation was over 
50% lower in Jurkat cells compared to PBMCs. 
FADS1 displayed a highly methylated region distal to the TSS, followed by sharp drop in methylation 
at CpG locus -262 and then a lowly methylated region proximal to the TSS in both PBMCs and Jurkat 
cells (Figure 6.6). Again, the methylation level of the most distal (relative to the TSS) CpG locus (-
713) measured was significantly higher, by 8 percentage points, in Jurkat cells compared with 
PBMCs (P < 0.0001). The methylation levels of two CpG dinucleotides, -430 and -262, were 
significantly lower in Jurkat cells by 6 and 10 percentage points, respectively (both P < 0.0001). 
There was a significantly (P < 0.0001) lower level of methylation at CpG dinucleotides -204 and -88 
in Jurkat cells, however, the methylation levels of these CpG dinucleotides were less than 5%, which 
has been previously been shown to be the detection limit for pyrosequencing (368). 
CpG loci surrounding cg27386326, a CpG locus situated in a putative FADS2/FADS1 enhancer that 
has shown previously to be associated with delta-6 desaturase activity (273) were analysed to 
determine if there were differences between PBMCs and Jurkat cells. The methylation level of the 
CpG locus -144 was significantly higher by 5 percentage points in Jurkat cells compared to PBMCs, 
where the methylation level of the CpG locus +209 was 20 percentage points lower in Jurkat cells 
(Figure 6.7).   
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Figure 6.5. Methylation of individual CpG loci in the FADS2 promoter in PBMC and Jurkat cells. 
Values are mean ± SEM for Con A stimulated PBMCs (n = 25 to 33) and Jurkat cells (n = 8 to 10). Locations of CpG dinucleotides are relative to the TSS. 
*Means that were significantly different determined by independent-samples t-test. The P-value for significance was adjusted to P < 0.001 by the Holm-
Sidak correction for multiple tests. 
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Figure 6.6. Methylation of individual CpG loci in the FADS1 promoter in PBMC and Jurkat cells. 
Values are mean ± SEM for Con A stimulated PBMCs (n = 28 to 33) and Jurkat cells (n = 9 to 10). 
Locations of CpG dinucleotides are relative to the TSS. *Means that were significantly different 
determined by independent-samples t-test. The P-value for significance was adjusted to P < 0.001 
by the Holm-Sidak correction for multiple tests. 
 
 
Figure 6.7. Methylation of individual CpG loci in the FADS2/FADS1 intergenic region in PBMC and 
Jurkat cells. 
Values are mean ± SEM for Con A stimulated PBMCs (n = 28 to 33) and Jurkat cells (n = 9 to 10). 
Locations of CpG dinucleotides are relative to cg27386326. *Means that were significantly different 
determined by independent-samples t-test. The P-value for significance was adjusted to P < 0.001 
by the Holm-Sidak correction for multiple tests. 
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6.3.4 The effect of delta-6 desaturase inhibition on Jurkat cell proliferation 
Inhibition of delta-6 desaturase activity by SC-26196 was confirmed by measurement of n-3 and n-
6 PUFA biosynthesis in Jurkat cells. Since delta-6 desaturase acts on both n-3 and n-6 PUFAs, 
analysis of both pathways enabled thorough analysis of the effect of SC-26196 on delta-6 
desaturase activity. A concentration of 200 nM SC-26196 was recommended by the supplier. SC-
26196 has an IC50 of 200 nM and at this concentration has been shown to be a selective and long 
lasting delta-6 desaturase inhibitor (369, 370). Initial experiments where Jurkat cells were 
incubated with 0, 50, 100 and 200 nM SC-26196 in the presence of [U-13C]18:2n-6 or [1-13C]18:3n-
3 demonstrated a dose response in inhibition of delta-6 desaturase activity and (Figure 6.8). Using 
n-6 PUFAs, this was determined by measuring the amount of stable isotope labelled substrate ([U-
13C]18:2n-6) and its immediate delta-6 desaturase conversion product [U-13C]18:3n-6 at increasing 
SC-26196 concentrations. For n-3 PUFAs, [1-13C]18:4n-3, the immediate delta-6 desaturase 
conversion product of [1-13C]18:3n-3 was not detectable so the [1-13C]18:4n-3 elongation product 
[1-13C]20:4n-3 was measured instead (Figure 6.8). Figure 6.9 shows the effect of 200 nM SC-26196 
treatment on all measured PUFAs in the conversion pathway. SC-26196 caused a significant 
increase in the levels of labelled 18:3n-3 and 18:2n-6 and decreases in the downstream conversion 
products 20:4n-3, 20:5n-3, 22:5n-3 and 18:3n-6, 20:3n-6, 20:4n-6 and 22:4n-6, respectively. The 
amounts of labelled 20:3n-3, 20:2n-6 and 22:2n-6 (an elongation product of 20:2n-6), which are 
synthesised in the alternative delta-8 desaturation pathway, also increased in the presence of SC-
26196. The levels of 18:4n-3 and 22:5n-6 were below the detection limit so could not be quantified. 
Next, it was determined whether treatment with 200 nM SC-26196 affects the viability and 
proliferation of Jurkat cells. There was a significant main effect of time on Jurkat cell viability (P < 
0.0001) such that the viability of Jurkat cells decreased from 96% to 89% after 144 h of culture in 
both treated and untreated cells (Figure 6.10, graph A), but there was no significant effect of SC-
26196 treatment on viability. There was a statistically significant interaction between SC-26196 
treatment and time on Jurkat cell number (P < 0.0001, partial η2 = 0.451). Therefore, simple main 
effects were analysed. SC-26196 treatment significantly increased the number of Jurkat cells by 
approximately 1.5 x 107  cells  after 24 h (P < 0.0001) and significantly decreased the number of cells 
by approximately 2.5 x 107 cells after 144 h (P = 0.451) culture (Figure 6.10, graph B). 
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Figure 6.8. The effect of SC-26196 concentration on 20:4n-3 and 18:3n-6 synthesis in Jurkat cells. 
Values are mean ± SEM (n = 6 replicates) for Jurkat cells cultured with increasing concentrations of 
the delta-6 desaturase inhibitor SC-26196. Statistical analysis was by one-way ANOVA with 
Dunnett’s post hoc test ***P < 0.001; **P < 0.01; *P < 0.05. 
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Figure 6.9. The effect of SC-26196 treatment on n-3 and n-6 PUFA synthesis. 
(A) n-3 PUFAs synthesised from [1-13C]18:3n-3. (B) n-6 PUFAs synthesised from [U-13C]18:2n-6. 
Values are mean ± SEM (n = 6 replicates) for Jurkat cells cultured with and without 200 nM of the 
delta-6 desaturase inhibitor SC-26196. Statistical analysis was by independent-samples t-test. ***P 
< 0.001; **P < 0.01; *P < 0.05. 
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Figure 6.10. The effect of SC-26196 treatment on Jurkat cell proliferation. 
Jurkat cell viability (A) and number (B) were determined by counting using trypan blue staining and 
a haemocytometer. Values are mean ± SEM (n = 10 replicates). Statistical analysis was by two-way 
repeated measures ANOVA. ***P < 0.001; *P < 0.05. 
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6.4 Discussion 
The data presented in this chapter showed that n-3 PUFA synthesis is constitutively active in Jurkat 
cells. Conversion of 18:3n-3 to 20:4n-3, 20:5n-3 and 22:5n-3 was substantially higher in Jurkat cells 
compared with PBMCs activated with the T-lymphocyte mitogen Con A. Synthesis was also 
significantly higher in Jurkat cells compared with the HepG2 cell line, in which full pathway activity 
has been previously characterised (104, 366, 367). This is in agreement with previous findings that 
showed the activity of the PUFA synthesis pathway was significantly higher in Jurkat cells relative 
to other cell lines (148). As discussed in Chapter 3, synthesis of 20:3n-3, a product in the alternative 
delta-8 desaturation pathway, was prominent in PBMCs. Synthesis of 20:3n-3 was also detected in 
Jurkat and HepG2 cells indicating that this pathway is also operating in these cells types. However, 
it is not known whether 20:3n-3 was converted to 20:4n-3 and therefore fed back into the main 
pathway. The findings from this Chapter demonstrate that n-3 PUFA synthesis is elevated in a 
leukaemic cell line, which is consistent with reports of increased delta-6 desaturase activity in 
cancerous cells (363, 364). Possible explanations for increased activity of the PUFA synthesis 
pathway in Jurkat cells are discussed later in this section. 
Stable isotope enrichment in 22:6n-3 indicated synthesis of this fatty acid was active in Jurkat and 
HepG2 cells. The amounts of synthesised 22:6n-3 were comparable between these two cell types, 
however, in Jurkat cells synthesis was considerably lower than upstream 18:3n-3 conversion 
products. The previous publication on n-3 PUFA synthesis in Jurkat cells also reported lower 22:6n-
3 synthesis compared with 20:5n-3 and 22:5n-3, measured as 10%, 60% and 20% of total cell 
radioactivity, respectively (148). In the present study, increasing the concentration of [1-13C]18:3n-
3 in the culture medium, as expected, increased the amounts of conversion products [1-13C]20:5n-
3 and [1-13C]22:5n-3 in Jurkat and HepG2 cells. The amount of [1-13C]22:6n-3 also increased in 
HepG2 cells at the higher concentration of precursor but interestingly, remained unchanged in 
Jurkat cells. One interpretation could be that 22:6n-3 is not synthesised in Jurkat cells and the 
enrichment detected was due to carryover from the elevated 22:5n-3 synthesis, which produced a 
large enriched peak beside the 22:6n-3 peak in GC-C-IRMS analysis. This has been previously 
reported as a limitation of GC-C-IRMS, where isotope measurements for compounds eluting 
immediately after enriched compounds were significantly affected due to carryover effects (371). 
A possible solution to this issue would be to run the samples on a different column that reverses 
the order in which the fatty acids are eluted, for example, by using a low polarity phase, 5% 
diphenyl/95% dimethyl polysiloxane capillary column (Rtx®-5, Thames Restek). As stated earlier, 
enrichment in 22:6n-3 has been reported previously in Jurkat cells cultured with radiolabelled 
18:3n-3. However, culture supplementation with unlabelled 18:3n-3, in the same study, increased 
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the proportions of the conversion products 20:4n-3, 20:5n-3 and 22:5n-3 but decreased 22:6n-3 
(148). This raises further doubt over the ability of Jurkat cells to synthesise 22:6n-3. 
The mRNA expression of FADS2, FADS1 and ELOVL5 were substantially higher in Jurkat cells 
compared with activated PBMCs and HepG2 cells. This suggests that the high level of n-3 PUFA 
synthesis observed in Jurkat cells is controlled at the transcriptional level and is in agreement with 
previous studies that have shown that increased mRNA expression is associated with increased 
pathway activity (104, 105, 213). ELOVL2 mRNA expression was significantly higher in HepG2 cells 
relative to both PBMCs (900-fold) and Jurkats (150-fold). ELOVL2 mRNA expression was minimal in 
PBMCs and Jurkat cells and as discussed in Chapter 4, this may explain the restricted 22:6n-3 
synthesis in these cells. This is further supported by the observation that HepG2 cells both 
synthesised 22:6n-3 and expressed ELOVL2 mRNA, which is consistent with previous reports (104, 
366, 367). 
Comparison of DNA methylation in activated PBMCs and Jurkat cells revealed substantially lower 
methylation over a large number of CpG dinucleotides, between 667 bp and 1655 bp upstream of 
the reported FADS2 TSS, in Jurkat cells. However, for one CpG dinucleotide (-1661) methylation was 
higher in Jurkat cells. This same region also displayed methylation differences between 
unstimulated and stimulated PBMCs in this study (Chapter 5) and in response to dietary oil 
supplementation in another study in PBMCs (261). As shown in Table 5.1 in Chapter 5, this 
differentially methylated region contains putative binding sites for a number of transcription factors 
including SREBP1, a known activator of FADS2 transcription (146). As discussed in section 1.11.3, a 
high level of gene expression is often associated with low promoter methylation (372, 373). 
Therefore, the findings in this chapter suggest that the lower level of DNA methylation in the FADS2 
promoter region might explain the high level of FADS2 transcription observed in Jurkat cells. 
Consistent with the present findings, previous studies in rat liver and aortae demonstrated that 
reduced methylation in the Fads2 promoter region was associated with increased Fads2 
transcription (213, 260). Furthermore, methylation differences between activated PBMCs and 
Jurkat cells were also observed in the FADS1 promoter region. The most distal CpG dinucleotide 
measured relative to the FADS1 TSS displayed significantly higher methylation in Jurkat cells where 
methylation of four downstream CpG dinucleotides decreased. However, two of these CpG 
dinucelotides were in a region of very low methylation (<5%). Nonetheless, the methylation 
changes measured in FADS1 may explain the elevated mRNA expression levels in Jurkat cells. 
Finally, altered methylation in Jurkat cells relative to activated PBMCs was also measured in a 
putative enhancer region (273) located in the intergenic region between FADS2 and FADS1. For one 
CpG dinucleotide, methylation was 5 percentage points higher in Jurkat cells whereas lower 
methylation by 20 percentage points was measured for a CpG dinucleotide located 37 bp 
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downstream (relative to the FADS2 TSS) of a predicted SREBP1 binding site (Table 5.1). These 
findings suggest that methylation in this predicted enhancer region could be important for the 
elevated FADS2 and FADS1 transcription observed in Jurkat cells relative to activated PBMCs. This 
complements the findings from a previous study in which methylation of another CpG in this region 
(cg27386326) was reported to be negatively correlated with delta-6 and delta-5 desaturase activity 
(273). 
The findings from this chapter suggest that n-3 PUFA synthesis is dysregulated in Jurkat cells and 
reduced methylation could be the mechanism responsible for elevated transcription of the FADS2 
and FADS1 genes. Aberrant DNA methylation is a common feature of cancerous cells (374). Global 
loss of DNA methylation, particularly in regions that are normally inactivated, occurs in a wide 
variety of cancers (256). Hypermethylation in the promoter regions of tumour suppressor genes is 
one of the most prevalent characteristics of cancer genomes (374). However, promoter 
hypomethylation and increased gene expression have been reported for specific genes in various 
cancers including the BCL2 and HOXII genes in leukaemia (375, 376). Therefore, the findings in this 
chapter are consistent with changes that have been shown for other genes in leukaemic cells.  
Since Jurkat cells divide spontaneously in culture without need for activation it was hypothesised 
that the high level of PUFA synthesis measured in Jurkat cells is important for providing fatty acids 
to support membrane synthesis in a highly proliferating cell population. However, inhibition of the 
pathway using the delta-6 desaturase inhibitor SC-26196 only caused a small significant decrease 
(6%) in the number of cells after 144 h with no significant differences at earlier time points, except 
after 24 h where the number of cells increased by 16%. Why delta-6 desaturase inhibition caused 
an increase in cell number after 24 h is not clear. The small decrease in cell number at 144 h might 
have occurred because exogenous fatty acids in the media were becoming depleted and 
consequently endogenous PUFA synthesis became important in supporting growth. Repeating the 
experiment using fatty acid depleted media could answer this question. The measured differences 
in cell number were small and could represent type I statistical errors. Furthermore, measurement 
of n-3 and n-6 PUFA synthesis demonstrated that 200 nM SC-26196 did not inhibit PUFA synthesis 
completely and therefore enough synthesis may have been sustained in the presence of the 
inhibitor to support cell growth. The results from this experiment are consistent with the results 
obtained from proliferation analysis in activated PBMCs treated with SC-26196, where only a small 
reduction in proliferation was observed. Given the high level of PUFA synthesis in Jurkat cells, it is 
postulated that it serves additional functions to merely supporting cell growth. For example, as 
discussed in section 1.10.2, n-6 and n-3 PUFAs are precursors to eicosanoids and n-3 PUFAs can also 
be converted to resolvins. There have been conflicting reports on eicosanoid production in Jurkat 
cells; some early studies reported that Jurkat cells do not synthesise eicosanoids (168, 377), while 
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another demonstrated that Jurkat cells are able to convert 20:4n-6 to prostaglandins and 
thromboxanes (378). More recently, 5-lipoxygenase (5-LOX) activity and leukotriene synthesis have 
been detected in activated Jurkat cells (379, 380). Furthermore, in a previous study, Jurkat cells 
incubated with radiolabelled 18:3n-3 and 18:2n-6 released radiolabelled n-3 and to a larger extent, 
n-6 PUFAs into the culture medium, respectively (148). The main n-3 PUFA released was 20:5n-3 
and the main n-6 PUFA was 20:4n-6. The authors highlighted that this reflects the release of 20:4n-
6 in normal T-lymphocytes stimulated with PHA, which was shown to be utilised by monocytes for 
eicosanoid synthesis (286).  
Finally, inhibition of delta-6 desaturase activity as expected increased the levels of [1-13C]18:3n-3 
and [1-13C]18:2n-6 and decreased [13C]-labelled conversion products in the classical n-3 and n-6 
PUFA pathways, respectively. The levels of [13C]20:3n-3 and [13C]20:2n-6, products in the alternative 
delta-8 desaturation pathway, significantly increased. Furthermore, [13C]22:2n-6, an elongation 
product of 20:2n-6 was also detected and was significantly increased by SC-26196 treatment. The 
levels of these products may have risen due to there being more 18:3n-3 and 18:2n-6 available, 
since conversion to 18:4n-3 and 18:3n-6, respectively, was restricted. This supports the theory that 
the delta-8 pathway is in competition with the classical pathway and prevails when elongase activity 
on 18:3n-3 and 18:2n-6 is greater than delta-6 desaturase activity. Therefore, the alternative delta-
8 desaturation pathway could provide an important route for PUFA synthesis when delta-6 
desaturase activity is restricted. Another explanation could be that delta-6 desaturase catalyses the 
delta-8 desaturation of 20:3n-3 and 20:2n-6 to form 20:4n-3 and 20:3n-6, respectively. The FADS2 
gene product has been shown to be able to delta-8 desaturate 20:3n-3 and 20:2n-6 to 20:4n-3 and 
20:3n-6, respectively, in S. cerevisiae transformed with mammalian FADS2 (19). Therefore, if this 
same activity were present in Jurkat cells inhibition of the delta-6 desaturase enzyme would explain 
the accumulation of 20:3n-3 and 20:2n-6 due to decreased conversion. Synthesis of 18:4n-3 was 
not detectable in Jurkat cells, however the n-6 pathway equivalent (18:3n-6) was detected and was 
significantly decreased by inhibition of delta-6 desaturase confirming that the classical PUFA 
pathway was operating in Jurkat cells. Synthesis of 20:3n-3 was also detected in PBMCs and HepG2 
cells but no 18:4n-3 peak could be detected in either of these cells. A previous study was able to 
measure 18:4n-3 (1.6% of total radioactivity) and 20:3n-3 (6.8% of total radioactivity) synthesised 
from radiolabelled 18:3n-3 in HepG2 cells (367). The greater detection of 20:3n-3 in this study does 
not necessarily mean the delta-8 desaturation pathway is favoured, it could be that conversion of 
18:3n-3 to 20:4n-3 happens at much greater rate than conversion of 20:3n-3 and therefore 18:4n-
3 does not accumulate so quickly. This is supported by findings from a different study, in a human 
MCF7 cell system stably transformed with FADS2, where increasing the concentration of 18:3n-3 
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resulted in greater accumulation of 20:4n-3 compared to 18:4n-3, indicating rapid or coupled 
elongation of 18:4n-3 (22). 
In summary, the findings from this chapter showed substantially higher levels of n-3 PUFA synthesis 
and FADS2, FADS1 and ELOVL5 mRNA expression in Jurkat cells relative to activated PBMCs. DNA 
methylation was significantly lower over a large number of CpG dinucleotides in the FADS2 
promoter region and lower methylation levels of individual CpG dinucleotides were also detected 
in the FADS1 promoter and a putative FADS2/FADS1 enhancer region. These findings suggest that 
PUFA synthesis is dysregulated in Jurkat cells at the level of transcription and lower DNA 
methylation may be a mechanism through which gene expression is elevated. Partial inhibition of 
PUFA synthesis only had a minor effect on Jurkat proliferation suggesting that support of new cell 
membrane synthesis may not be the primary role of PUFA synthesis in Jurkat cells. Nonetheless, 
the high level of PUFA synthesis measured in Jurkat cells suggest that the activity of the pathway is 
important for Jurkat cell function. Similar to activated PBMCs, expression of ELOVL2 and synthesis 
of 22:6n-3 appeared to be restricted in Jurkat cells where both were functioning in HepG2 cells; this 
suggests that ELOVL2 expression acts as control point for 22:6n-3 synthesis.  
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Chapter 7: Is the activity of the PUFA biosynthesis 
pathway influenced by age and gender in activated 
PBMCs? 
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7.1 Introduction 
As discussed in section 1.7.2 evidence suggests that there are gender differences in the activity of 
the PUFA biosynthesis pathway. Both 22:6n-3 status and synthesis have been shown to be higher 
in women compared to men (95, 96, 99, 100, 381, 382). Furthermore, 22:6n-3 status was found to 
be higher in women taking the oral contraceptive pill and in women receiving hormone 
replacement therapy (102, 103), which suggests that sex hormones play a role in the regulation of 
PUFA synthesis. In pregnant rats, positive correlations between Fads2 hepatic mRNA expression 
and plasma oestradiol and progesterone concentrations have been reported (105). A study in 
cultured human (HepG2) cells demonstrated that progesterone treatment increased n-3 PUFA 
synthesis from stable isotope labelled 18:3n-3 and FADS2, FADS1, ELOVL5 and ELOVL2 mRNA 
expression (104). Furthermore, in the same study progesterone induced increased expression of 
FADS2 in primary hepatocytes. These findings indicate that gender differences in PUFA synthesis 
may be mediated through the effects of female hormones on the transcription of genes that encode 
the enzymes that function in the pathway. In addition to sex hormones, gender differences might 
also be explained by lower partitioning of 18:3n-3 to β-oxidation in women compared with men 
therefore affecting the availability of 18:3n-3 for conversion to longer chain n-3 PUFAs (99, 100). 
Rapid catabolism of 18:3n-3 has been shown to restrict the rate of PUFA synthesis (95, 383). 
The effect of aging on n-3 PUFA synthesis is less clear due to fewer studies and conflicting evidence. 
As detailed in section 1.7.4 comparison of studies in younger and older men indicated that synthesis 
of 20:5n-3 and 22:5n-3 was lower in older men but there was no difference in 22:6n-3 synthesis 
(97, 100, 117). Furthermore, studies have reported a decline in delta-6 desaturase activity in rats 
(120, 121) and humans (118) with age, where another study in humans found no evidence for this 
(119). Progesterone and oestradiol concentrations decrease following the menopause (384) yet in 
a previous study no differences in delta-6 desaturation function in pre- and post-menopausal 
women were found (119). However, the study used the ratio of product to precursor to indirectly 
estimate desaturation function, which has limited accuracy due to the influence of dietary factors. 
In agreement with an earlier study, the findings presented in Chapter 3 demonstrated that 
activation of n-3 PUFA synthesis occurs upon treatment of PBMCs with a T-lymphocyte mitogen 
(147). However, no studies have assessed the capacity for PUFA synthesis in males and females 
across the life course and specifically in immune cells.  
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Aim 
The aim of this chapter is determine whether the activity of the PUFA synthesis pathway, including 
the expression of the genes that operate in the pathway differs with age, gender and menopausal 
status in activated PBMCs.  
Hypotheses 
 The activity of the PUFA biosynthesis pathway in activated PBMCs is higher in females 
compared with males. 
  The activity of the PUFA biosynthesis pathway in activated PBMCs is higher in pre- compared 
with post-menopausal females. 
 The activity of the PUFA biosynthesis pathway in activated PBMCs decreases with increasing 
age. 
To address these hypotheses the levels of individual n-3 PUFAs synthesised from [1-13C]18:3n-3 and 
the mRNA expression of FADS2, FADS1 and ELOVL5 were compared in Con A stimulated PBMCs 
from males and females of differing ages. Activation of PBMCs by Con A was confirmed by 
measuring the cell surface expression of the activation marker CD69. Analysis of ELOVL2 mRNA 
expression was not carried out as its expression was shown to be negligible to absent in activated 
PBMCs (Chapter 4).  
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7.2 Methods 
7.2.1 PBMC isolation and measurement of cell specific surface markers 
Volunteers were recruited as part of the EPUFA study as described in section 2.2. Recruitment 
aimed to ensure an even spread of ages for males and females across the life course. 
Anthropometric measurements were taken (section 2.2.5) and plasma TG, total cholesterol, HDL 
cholesterol and glucose concentration and blood total haemoglobin concentration were measured 
as detailed in section 2.3. PBMCs were isolated from lithium heparin blood (section 2.4) and the 
proportions of T-lymphocytes, B-lymphocytes and monocytes within the PBMC population were 
determined by measuring the expression of the cell surface markers CD3, CD19 and CD14, 
respectively, using flow cytometry (section 2.5). These markers were also analysed following cell 
culture. 
7.2.2 PBMC culture and measurement of CD69 expression 
Isolated PBMCs were cultured for 48 h in the presence of 5 µg/ml Con A and 20 µM [1-13C]18:3n-
3 diluted 1/10 with unlabelled 18:3n-3 as described in section 2.6. PBMC activation was confirmed 
by measurement of CD69+ events by flow cytometry (section 2.7). 
7.2.3 Measurement of n-3 PUFA synthesis 
[13C]-label incorporation into specific n-3 PUFAs was measured by a combination of GC and GC-C-
IRMS as detailed in section 2.12 with normalisation to total cell protein (section 2.13). 
7.2.4 Measurement of mRNA expression 
Total RNA was extracted from PBMC pellets as described in section 2.14.2. The mRNA expression 
levels of FADS2, FADS1 and ELOVL5 were measured by real-time RT-PCR as detailed in section 2.15. 
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7.3 Results 
7.3.1 Study population characteristics 
Table 7.1 shows the characteristics of the volunteer population (total EPUFA population) included 
in the experiments detailed in this Chapter. All participants were considered healthy based on these 
measurements and information given in screening questionnaires. Males and females did not 
significantly differ by age, BMI, plasma total cholesterol concentration or plasma glucose 
concentration. Females had significantly lower plasma TG and higher plasma HDL concentrations 
(both P < 0.0001). As expected mean body weight and total haemoglobin were significantly lower 
in females (P < 0.0001) and body fat percentage significantly higher than in men (P < 0.0001). The 
proportions of T-lymphocytes (CD3+), B-lymphocytes (CD19+) and monocytes (CD14+) within the 
PBMC population are shown for freshly isolated (pre-culture) and PBMCs cultured in the presence 
of Con A (post-culture + 5 µg/ml Con A), in Table 7.2. The proportion of T-lymphocytes was 
significantly higher in cultured PBMCs compared with freshly isolated cells in both males and 
females (P < 0.01). The proportion of B-lymphocytes decreased following culture but only reached 
statistical significance in females (P < 0.01) where monocytes were significantly lower in both males 
and females (P < 0.001). 
 
Table 7.1. Characteristics of total EPUFA study population 
Characteristic Male Female P value 
Age (years)* 39 [18-71] 43 [20-70] NS 
Body weight (kg) 79.1 ± 1.8 65.9 ± 1.7 <0.0001 
BMI (kg/m2) 24.7 ± 0.5 23.6 ± 0.5 NS 
Body fat (%) 20.6 ± 1.8 31.2 ± 1.1 <0.0001 
Plasma TG (mmol/l) 1.4 ± 0.1 0.9 ± 0.0 <0.0001 
Plasma total cholesterol (mmol/l) 4.8 ± 0.2 4.8 ± 0.2 NS 
Plasma HDL cholesterol (mmol/l) 1.1 ± 0.0 1.7 ± 0.0 <0.0001 
Plasma glucose (mmol/l) 5.0 ± 0.1 4.7 ± 0.1 NS 
Total haemoglobin (g/l) 144 ± 3.0 122 ± 2.0 <0.0001 
Data are mean ± SEM; *data are mean [range]; Male n = 31, Female n = 37. P values are for differences 
between females and males determined using an independent-samples t-test. 
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Table 7.2. PBMC phenotypes 
Cell phenotype 
(% of PBMCs) 
Pre-culture Post-culture + 5 µg/ml Con A 
Male Female Male Female 
CD3+ 59.6 ± 2.0 62.9 ± 1.4 67.8 ± 1.9* 71.6 ± 1.5* 
CD19+ 7.6 ± 0.5 7.2 ± 0.5 6.4 ± 0.5 4.8 ± 0.5* 
CD14+ 12.7 ± 0.9 11.0 ± 0.7 1.8 ± 0.2* 1.6 ± 0.2* 
Data are mean ± SEM; Male n = 31, Female n = 37. Results are for positive events within the PBMC gate, 
measured by flow cytometry. Statistical comparisons were by one-way ANOVA with Tukey’s post hoc test. 
There were no significant difference between males and females when measured pre- or post-culture. Blue 
and red asterisks indicate means that were significantly from pre-culture measurements in separate male and 
female groups, respectively, for each cell phenotype (P < 0.01).  
 
7.3.2 The effect of PBMC activation on CD69 expression 
Activation of cultured PBMCs by Con A was confirmed by measuring the expression of CD69 on the 
cell surface. The mean proportion of PBMCs expressing CD69 was significantly higher in male 
(49.83%) compared with female (41.28%) volunteers (Figure 7.1). 
 
 
Figure 7.1. The effect of PBMC activation on CD69 expression. 
Graph of % CD69+ events within a PBMC gate for males (n = 31 ) and females (n = 37) showing 
mean ± SEM. Statistical analysis was by independent-samples t-test. 
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7.3.3 The relationship between age and n-3 PUFA synthesis 
Multiple linear regression analysis was conducted to estimate the association between age and the 
amounts of individual synthesised n-3 PUFAs and also the sum of these measured n-3 PUFAs in 
males and females (    Table 7.3). PBMCs are a heterogeneous mix of blood cell populations and 
different profiles of distinct cell types may lead to false discoveries. Multiple linear regression 
analysis provides a way of accounting for such potentially confounding variables that have been 
included in the model. Model 1 held the proportions of CD3+, CD19+ and CD14+ constant where 
Model 2 also held the proportion of activated cells (CD69+) constant. No significant associations 
were found in males or females in either model except for 20:3n-3 where model 2 predicted that 
an increase in age of one year is associated with an increase in [1-13C]20:3n-3 by 0.012 pmol/µg 
protein with 95% confidence that this value is between 0.000152 and 0.023. This would represent 
a difference in the amount of [1-13C]20:3n-3 between the youngest (20 years) and oldest (70 years) 
female volunteers of 0.6 pmol/µg protein, with the range of plausible values being between 0.008 
and 1.15 pmol/µg protein. 
7.3.4 The relationship between FADS2, FADS1 and ELOVL5 mRNA expression and age 
The same multiple linear regression models described in section 7.3.3 estimated the association 
between age and the mRNA expression levels of FADS2, FADS1 and ELOVL5 (    Table 7.4). Model 2 
predicted that an increase in age of one year is associated with an increase in relative FADS2 mRNA 
expression by 0.012 for males, with 95% confidence that this value is between 0.003 and 0.022. 
This would represent a difference between the youngest (18 years) and oldest (71 years) male 
volunteer of 0.636 with the range of plausible values being between 0.159 and 1.166. There were 
no significant associations between age and FADS1 or ELOVL5 mRNA expression levels in males or 
females.
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    Table 7.3.  Multiple regression analysis of the relationship between n-3 PUFA synthesis and age 
n-3 
PUFA 
Model 1  Model 2 
Male Female  Male Female 
β (95% Cl) P β (95% CI) P  β (95% CI) P β (95% CI) P 
18:3n-3 -0.018 (-0.055, 0.019) 0.324  0.008 (-0.040, 0.055) 0.748  -0.007 (-0.046, 0.031) 0.703  0.014 (-0.032, 0.061) 0.540 
20:3n-3 -0.012 (-0.028, 0.003) 0.119  0.009 (-0.004, 0.022) 0.157  -0.008 (-0.024, 0.009) 0.344 0.012 (0.000, 0.023)   0.047* 
20:4n-3 -0.006 (-0.018, 0.006) 0.343  0.008 (-0.005, 0.022) 0.225  -0.002 (-0.015, 0.010) 0.710  0.011 (-0.002, 0.024) 0.101 
20:5n-3 -0.002 (-0.007, 0.003) 0.534 -0.002 (-0.006, 0.002) 0.386  -0.000 (-0.005,0.005) 0.126 -0.001 (-0.005, 0.003) 0.601 
22:5n-3 -0.001 (-0.005, 0.003) 0.683 -0.001 (-0.003, 0.002) 0.520   0.001 (-0.003, 0.004) 0.718  0.000 (-0.002, 0.002) 0.838 
Total -0.039 (-0.097, 0.020) 0.184 0.022 (-0.041, 0.086) 0.479  -0.017 (-0.075, 0.042) 0.561  0.035 (-0.023, 0.094) 0.223 
‘β’ denotes the parameter estimate (estimated change in [1-13C]n-3 PUFA amount (pmol/µg protein) per increase in age of one year). ‘Total’ sum of all measured       
[1-13C]n-3 PUFAs. Model 1 was adjusted for the proportions of CD3+, CD19+ and CD14+ cells and Model 2 included CD69+ cells as an additional covariate. *P < 0.05. 
 
    Table 7.4. Multiple regression analysis of the relationship between FADS2, FADS1 and ELOVL5 mRNA expression and age 
Gene 
Model 1  Model 2 
Male Female  Male Female 
β (95% CI) P β (95% CI) P  β (95% CI) P β (95% CI) P 
FADS2  0.009 (-0.001, 0.018) 0.073 -0.004 (-0.017, 0.009) 0.549   0.012 (0.003, 0.022) 0.013* -0.002 (-0.015, 0.010) 0.700 
FADS1  0.001 (-0.001, 0.003) 0.357 -0.001 (-0.005, 0.002) 0.377   0.002 (0.001, 0.005) 0.039 -0.001 (-0.004, 0.002) 0.577 
ELOVL5 -0.014 (-0.043, 0.014) 0.311 -0.005 (-0.037, 0.027) 0.781  -0.011 (-0.21, 0.043) 0.502 -0.001 (-0.033, 0.030) 0.943 
‘β’ denotes the parameter estimate (estimated change in relative mRNA expression level per increase in age of one year). Model 1 was adjusted for the proportions of        
CD3+, CD19+ and CD14+ cells and Model 2 included CD69+ cells as an additional covariate.*P < 0.05. 
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7.3.5 The effect of gender on n-3 PUFA synthesis 
The amounts of individual [1-13C] labelled n-3 PUFAs were compared in Con A treated PBMCs from 
male and female volunteers (Figure 7.2). Statistical analysis by one-way ANCOVA with the 
proportions of CD3+, CD19+ and CD14+ cells and age as covariates indicated there were no 
significant differences between males and females. Inclusion of the proportion of activated cells 
(CD69+) as an additional covariate also returned no significant results. Adjusted means are not 
shown as there were no significant differences. Furthermore, there were no significant differences 
between males and females when the sum of individual [1-13C]18:3n-3 conversion products were 
analysed by ANCOVA with the covariates described above (data not shown). 
 
 
Figure 7.2. Comparison of n-3 PUFA synthesis in males and females. 
The amounts of individual [1-13C] labelled n-3 PUFAs in male (n = 30) and female (n = 36) volunteers. 
Data were analysed by two different one-way ANCOVA models, one with the proportions of CD3+, 
CD19+ and CD14+ cells and age as covariates and another with CD69+ cells as an additional 
covariate. Graphs show mean ± SEM (unadjusted).  
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7.3.6 The effect of gender on FADS2, FADS1 and ELOVL5 mRNA expression 
The mRNA expression levels of FADS2, FADS1 and ELOVL5 were compared in Con A treated PBMCs 
from male and female volunteers (Figure 7.3). Statistical analysis by one-way ANCOVA with the 
same covariates detailed in section 7.3.5 indicated there were no significant differences between 
males and females.  
 
Figure 7.3. Comparison of FADS2, FADS1, and ELOVL5 mRNA expression in males and females. 
Relative mRNA expression normalised to EIF4A2, 18S, SDHA and RPL13A in male (n = 31) and female 
(n = 36 for FADS2 and 35 for FADS1 and ELOVL5) volunteers. Data were analysed by two different 
one-way ANCOVA models, one with the proportions of CD3+, CD19+ and CD14+ cells and age as 
covariates and another with CD69+ cells as an additional covariate. Graphs show mean ± SEM 
(unadjusted). 
 
7.3.7 The effect of menopausal status on n-3 PUFA synthesis 
Since female hormones have been shown to upregulate n-3 PUFA synthesis, the amounts of 
individual [1-13C]n-3 PUFAs were compared in Con A treated PBMCs from pre- and post-menopausal 
females (Figure 7.4). Mean differences assessed by one-way ANCOVA adjusted for the proportion 
of CD3+, CD19+ and CD14+ cells returned no significant differences. Inclusion of CD69+ cells as an 
additional covariate also returned no significant results. Furthermore, there were no significant 
differences between pre- and post-menopausal females when the sum of individual [1-13C]18:3n-3 
conversion products were analysed by ANCOVA with the covariates described above (data not 
shown). 
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Figure 7.4. Comparison of n-3 PUFA synthesis in pre- and post-menopausal females. 
The amounts of individual [1-13C] labelled n-3 PUFAs in pre-menopausal (n = 25) and post-
menopausal (n = 9) volunteers are shown. Data were analysed by two different one-way ANCOVA 
models, one with the proportions of CD3+, CD19+ and CD14+ cells as covariates and another with 
CD69+ cells as an additional covariate. Graphs show mean ± SEM (unadjusted).   
 
 
7.3.8 The effect of menopausal status on FADS2, FADS1 and ELOVL5 mRNA expression 
Differences in the mRNA expression levels of FADS2, FADS1 and ELOVL5 were compared in Con A 
treated PBMCs from pre- and post-menopausal female volunteers (Figure 7.5). Analysis by one-way 
ANCOVA including the covariates described in section 7.3.7 returned no significant differences 
between females that were pre- or post-menopause. 
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Figure 7.5. Comparison of FADS2, FADS1, ELOVL5 and ELOVL2 mRNA expression in pre- and post- 
menopausal females. 
Relative mRNA expression normalised to EIF4A2, 18S, SDHA and RPL13A in pre-menopausal (n = 25 
for FADS2 and 24 for FADS1 and ELOVL5) and post-menopausal (n = 9) volunteers. Data were 
analysed by two different one-way ANCOVA models, one with the proportions of CD3+, CD19+ and 
CD14+ cells as covariates and another with CD69+ cells as an additional covariate. Graphs show 
mean ± SEM (unadjusted).   
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7.4 Discussion 
The findings from this chapter suggest that age, gender and menopausal status do not affect the 
level of n-3 PUFA synthesis or the mRNA expression of three key enzymes that function in the PUFA 
biosynthesis pathway in activated PBMCs. 
There were no significant differences in the proportions of CD3+, CD19+ and CD14+ between male 
and female volunteers. Activation of PBMC cultures was confirmed by measuring expression of 
the activation marker CD69. The proportion of cells expressing CD69 was significantly higher in 
males compared with females. Differences in immune functions between males and females have 
been observed previously. For example, both humoral and cell mediated immunity have been 
reported to be more active in females than in males (385, 386). Furthermore, in a previous study 
using PHA stimulated human cells, the percentage of CD69+ T lymphocytes was reported to be 
significantly higher in female samples compared with males (387). Possible reasons for the 
conflicting findings could include the use of a different T-lymphocyte mitogen, the younger age 
range of volunteers (18-38), or the smaller number of volunteers (6 males and females) compared 
to the present study. Leave out differences in immune functions.  
There were no differences in the amounts of n-3 PUFAs synthesised from [1-13C]18:3n-3 or FADS2, 
FADS1 or ELOVL5 mRNA expression levels between males and females. Furthermore, these 
measures did not differ between pre- and post-menopausal women. These findings disagree with 
earlier reports of greater activity of the PUFA synthesis pathway in females compared to males (95, 
96, 99, 100) and in response to female hormones (102-104). However, there are several differences 
between the present study and the earlier studies reporting gender differences in n-3 PUFA 
synthesis. The previous studies measured plasma concentrations of labelled n-3 PUFAs following 
ingestion of stable isotope labelled 18:3n-3, where the present study used a culture system, which 
may explain the inconsistent findings. Plasma concentrations represent an indirect measure of 
18:3n-3 conversion and therefore have limited precision, as they do not account for those 
synthesised PUFAs not released into the bloodstream or taken up by target tissues. The artificial 
environment provided by the present culture method is also a limitation and labelled n-3 PUFAs 
that may have been released into the culture media were not examined. Furthermore, neither 
procedure accounted for further metabolism of synthesised n-3 PUFAs into lipid signalling 
molecules. The previous studies measured the levels of stable isotope labelled n-3 PUFAs at regular 
intervals and over longer time-periods than the present study. In the studies by Burdge and 
Wootton, analysis was based on area under the curve of the time course plot of the plasma [13C] 
labelled fatty acids over 21 days (99, 100). Pawlosky et al., used a physiological compartmental 
model to determine the rate constant coefficients for the conversion of individual fatty acids from 
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plasma concentration time curves of deuterated n-3 PUFAs over 168 h (95). Therefore, the single 
measurement of [13C] labelled n-3 PUFAs after 48 h performed in the present study may not have 
been sufficient to detect gender differences. However, in a previous study 48 h provided an 
adequate culture period for measuring the effects of progesterone treatment on n-3 PUFA 
synthesis in HepG2 cells and FADS2 expression in HepG2 cells and primary hepatocytes (104). In 
addition to different study designs and analysis procedures the previous studies had substantially 
fewer participants, six and five males and females, in the studies by Burdge and Wootton, 2002 (99, 
100) and Pawlosky et al., 2003 (95, 96), respectively compared to 31 males and 37 females in this 
study.  
The gender differences reported in previous studies were largely explained by synthesis of 22:6n-
3. The studies in young men and women reported 200-fold greater synthesis of 22:6n-3 in women 
compared to men yet only 2.5 fold greater synthesis of 20:5n-3 and no differences in 22:5n-3 (99, 
100). Pawlosky et al., 2003 only found a significant gender difference in synthesis of 22:6n-3 from 
22:5n-3, where the rate constant coefficient was 4-fold greater in women compared with men (95, 
96). Interestingly, activated PBMCs did not synthesise 22:6n-3, which may provide another 
explanation for the discrepancy in findings. Another explanation for the different findings could be 
that regulation of n-3 PUFA synthesis in activated PBMCs may differ to other tissues. Furthermore, 
activated PBMCs showed the highest level of conversion to 20:3n-3 after 48 h, a product of the 
delta-8 desaturation pathway, which was not measured in the earlier studies.  
Some outlying data points were observed in the gene expression data in Figure 7.3. The gene 
expression data for FADS2 males contained an outlier that had a relative expression value of 1.87; 
the next data point below had a value of 1.18. For ELOVL5 females, the observed outlier had a value 
of 6.75 whereas the next data point below was 3.29. The elevated mRNA expression measured in 
these individuals did not correspond to higher amounts of stable isotope labelled n-3 PUFAs and 
therefore could not explain higher synthesis in these individuals. However, higher mRNA expression 
does not necessarily translate to higher levels of corresponding proteins, the latter of which could 
be measured using the Western blot technique. There is a chance that these outliers may have been 
a product of experimental error and the experiment would ultimately need repeating in order to 
verify that they are true results.  
Previous reports on the effect of age on the activity of the PUFA synthesis pathway have been 
conflicting with some reporting decreases where others no change (97, 100, 117-119). In this study, 
there was no significant effect of age on the amounts of synthesised n-3 PUFA except for 20:3n-3, 
which was predicted to increase with increasing age in females when the proportion of activated 
cells was kept constant. However, the model only predicted and increase of 0.012 pmol/µg protein 
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per year, which represents a difference of 0.6 pmol/µg protein between the youngest and oldest 
female volunteer. Similarly, there were no significant relationships between mRNA expression 
levels and age except for FADS2, which was predicted to be 0.012 units higher with each year of 
age in males when adjusted for the proportion of activated cells. This would be mean a difference 
of 0.636 units between the youngest and oldest male volunteers. However, whether these values 
are biologically relevant is not known. As mentioned earlier there were no differences in the 
amounts of [1-13C] labelled conversion products or the mRNA expression levels of FADS2, FADS1 or 
ELOVL5 between pre- and post-menopausal women. This complements an earlier study that 
reported no differences in desaturase function between pre- and post-menopause groups 
measured indirectly using ratios of substrates and products (119). 
In summary, no differences in the activity of the PUFA synthesis pathway were found between 
males and females in activated PBMCs. Furthermore, menopausal status did not affect PUFA 
synthesis activity. Together this data suggests that female hormones are not important for the 
regulation of n-3 PUFA synthesis in activated PBMCs, which is contradictory to some findings in 
other tissues. However, the difference in results may also be explained by variations in study design 
or the lack of 22:6n-3 synthesis in activated PBMCs. Finally, there was no clear effect of age on 
capacity for 18:3n-3 conversion. 
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8.1 Activation of PBMCs induces upregulation of the PUFA synthesis pathway 
The findings from this study showed that n-3 PUFA synthesis is activated in PBMCs stimulated with 
the T-lymphocyte mitogen Con A. This finding is consistent with an early study that demonstrated 
activation of the pathway in PBMCs treated with a different T-lymphocyte mitogen, PHA (147). In 
the present study, activation of PBMCs by Con A also significantly increased the mRNA expression 
of three genes (FADS2, FADS1 and ELOVL5) encoding enzymes involved in conversion of 18:3n-3 to 
longer chain metabolites, compared with untreated PBMCs. This complements previous findings in 
other tissues where increased activity of the PUFA synthesis pathway was associated with increased 
expression of the genes encoding the pathway enzymes (105, 213). Taken together, these findings 
suggest that Con A mediated upregulation of n-3 PUFA synthesis is controlled at the transcriptional 
level.  
The most highly synthesised n-3 PUFA after 48 h culture was 20:3n-3, a product in the alternative 
delta-8 desaturation pathway. This provides the first direct evidence for synthesis of 20:3n-3 in 
mitogen stimulated PBMCs. The inability to detect 18:4n-3, the delta-6 desaturase conversion 
product of 18:3n-3, suggested that activated PBMCs might be using the alternative pathway as the 
main route for longer chain n-3 PUFA synthesis. However, a recent study in a human MCF7 cell 
system stably transformed with FADS2, showed that increasing the availability of 18:3n-3 resulted 
in accumulation of 20:4n-3 in preference to 18:4n-3, indicating rapid or coupled elongation of 
18:4n-3 (22). Therefore, in the present study 18:4n-3 may have been synthesised but did not 
accumulate to the level where it could be detected. A delta-8 desaturation step would be required 
to feed 20:3n-3 back into the main pathway; whether this step was occurring in PBMCs was not 
experimentally determined. There is no molecular evidence for a specific gene that encodes delta-
8 desaturase activity, but the Fads2 gene product has been shown to be able to delta-8 desaturate 
20:3n-3 to 20:4n-3 in S. cerevisiae transformed with mammalian Fads2 (19). However, there has 
been no investigation into the ability of delta-6 desaturase to catalyse delta-8 desaturation in 
mammalian cells. There is conflicting evidence over the functioning and importance of delta-8 
desaturation in mammalian tissues (36, 38, 39, 41, 42). A study in mice showed that metabolism of 
20:3n-3 by elongation and delta-5 desaturation to 20:4(5,11,14,17) was much greater than delta-8 
desaturation (33). Delta-5 desaturation of 20:3n-3 but not delta-8 desaturation has also been 
reported as an alternative route for n-3 PUFA synthesis in the K562 leukemic cell line, which lacks 
delta-6 desaturase activity (44).   
Findings from the present study suggested that ELOVL5 was more highly expressed than FADS2 in 
activated PBMCs. In a previous study, heterologous expression of human ELOVL5 in S. cerevisiae 
revealed that it is capable of elongating 18:3n-3 to 20:3n-3 (26). Therefore, since in the present 
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study both ELOVL5 expression and 20:3n-3 synthesis were elevated, it is speculated that elongation 
of 18:3n-3 to 20:3n-3 in PBMCs is catalysed by elongase-5. Furthermore, potential competition 
between elongase-5 and delta-6 desaturase for the substrate 18:3n-3 may explain the prevalence 
of 20:3n-3 in activated PBMCs.  These results indicate that conversion to 20:3n-3 could be important 
as an alternative route for n-3 PUFAs in situations where delta-6 desaturase is limited. However, if 
delta-8 desaturation is catalysed by delta-6 desaturase, conversion of 20:3n-3 to 20:4n-3 and 
downstream n-3 PUFAs in the main pathway would also be restricted, as demonstrated in K562 
leukaemic cells that lack delta-6 desaturase activity (44). 
There was no evidence for synthesis of 22:6n-3 in resting or activated PBMCs. Real-time RT-PCR 
analysis revealed the expression of ELOVL2 to be absent to negligible in activated PBMCs. This is 
consistent with limited expression of ELOVL2 in most human tissues including an apparent lack of 
expression in human leukocytes (388). Elongase-2 has been shown to be involved in the conversion 
of 22:5n-3 to 22:6n-3 by catalysing the elongation of 22:5n-3 to the 24 carbon intermediate 24:5n-
3 (27). Therefore, the questionable expression of ELOVL2 mRNA may explain the lack of 22:6n-3 
synthesis observed in PBMCs. Both elongase-2 and elongase-5 are capable of catalysing the 
elongation of 20:5n-3 to 22:5n-3 (389). However, the results from this study indicate that elongase-
5 (the product of the ELOVL5 gene) is the main if not sole elongase enzyme responsible for PUFA 
elongation in activated PBMCs. The findings from this study have provided important mechanistic 
insights into the activity of the PUFA synthesis pathway in activated PBMCs, which are summarised 
in Figure 8.1.  
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Figure 8.1. Schematic diagram showing activity of PUFA synthesis pathway measured in PBMCs. 
Green arrows indicate components that increased in Con A stimulated compared to unstimulated 
PBMCs. Components that were not detected (ND), present at low levels (low) or not synthesised 
(indicated by a cross) are shown in red. Genes speculated to function at the corresponding step are 
shown in blue with a question mark. The pathway intermediates 24:5n-3 and 24:6n-3 were not 
measured. 
 
8.2 DNA methylation changes in activated PBMCs 
The findings discussed so far suggest that upregulation of n-3 PUFA synthesis in activated PBMCs is 
controlled at the transcriptional level. DNA methylation changes are important in regulating the 
expression of specific cytokine genes involved in T-lymphocyte activation (297-301). In general, low 
methylation of promoter regions is associated with actively transcribed genes, whereas high 
methylation is associated with transcriptional silencing (292, 293). However, in the present study, 
analysis of DNA methylation in the FADS2 promoter, covering a region that previously displayed 
plasticity in PBMCs (261), revealed extensive increases in methylation in activated PBMCs. The DNA 
methylation status of one CpG dinucleotide in the FADS1 promoter region was also significantly 
increased. These findings are contradictory to the general view that DNA methylation is a repressive 
epigenetic mark (292, 293). 
The relationship between DNA methylation and gene expression is complex and there are several 
hypotheses that might explain the increased levels of both measured in this study. The finding could 
be attributable to the heterogeneous cell population if the methylation change occurred in a 
different cell type or subset to the source of the gene expression change, or if changes to the 
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proportion of different cell types passively altered the methylation status. Another explanation 
could be that the DNA methylation prevents the binding of an inhibiting factor such as a 
transcriptional repressor. In silico analysis, using MatInspector software, predicted that a number 
of transcription factors, previously reported to be involved in lymphocyte function, might bind 
across the differentially methylated in FADS2. Two of these transcription factors, DEC2 and MNT, 
are known transcriptional repressors (310, 335), although DEC2 has also been shown to activate 
genes in T-lymphocytes (311). Alternatively, DNA methylation of CpG dinucleotides may act to 
enhance binding of transcription factors as shown for C/EBPα and SP1 (235, 237). Finally, the 
increased methylation might be due to the presence of 18:3n-3 in the culture medium. In rodents, 
18:3n-3 supplementation has been shown to induce FADS2 promoter methylation (259). Therefore, 
one theory is that increased DNA methylation, induced by 18:3n-3, attenuated the increase in 
FADS2 gene expression brought about by upregulation of a FADS2 transcriptional activator in 
stimulated PBMCs. This theory assumes that active methylation was increased under stimulating 
conditions as 18:3n-3 was added to both unstimulated and stimulated cultures. 
A considerable fraction of genes with methylated proximal promoters display elevated expression 
and in many such cases transcription is initiated at a distal CpG island that functions as an 
alternative promoter (339). Given the extent of increased FADS2 methylation in PBMCs following 
Con A treatment, the use of an alternative transcription initiation site for FADS2 transcription in 
activated PBMCs was hypothesised. This hypothesis was tested using 5’RACE, which enabled 
amplification and subsequent sequencing of the 5’ ends of FADS2 mRNAs. The results indicated that 
there was no distinct difference in the FADS2 TSS between unstimulated and Con A stimulated 
PBMCs. 
In addition to their promoter regions, the methylation status of specific CpG dinucleotides located 
in the intergenic region between the FADS1 and FADS2 genes were measured. The region analysed 
has been previously reported to display the histone modification signature of a putative enhancer 
(273). Furthermore, in the same previous study, the methylation status of a specific CpG 
dinucleotide (cg27386326) located in this putative FADS enhancer region was shown to correlate 
negatively with delta-6 and delta-5 desaturase activities albeit being measured using the surrogate 
product to precursor ratio (273). In the present study, the methylation levels of two CpG 
dinucleotides including cg27386326 and an adjacent CpG dinucleotide (113 bp downstream) were 
significantly lower in Con A stimulated compared with unstimulated PBMCs but only by 3.5 and 2.1 
percentage points, respectively. It is questionable whether a change this small could explain the 
magnitude of change in FADS1 and FADS2 gene expression. Nevertheless, predicted binding sites 
for transcription factors, including SREBP1, provided further support for this region as a possible 
enhancer, although actual binding would need proving experimentally.  
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In summary, activation of PBMCs by Con A induced DNA methylation changes in the FADS2 and 
FADS1 promoter regions and a putative enhancer region situated between these genes, but it is not 
clear how these changes relate to the transcriptional regulation of PUFA synthesis. 
8.3 Discussion of possible functions of PUFA synthesis in activated PBMCs 
The activation of PUFA synthesis in PBMCs following Con A stimulation raises the question of its 
biological function. Activation of lymphocytes induces proliferation, which is accompanied by both 
phospholipid synthesis and remodelling of existing phospholipids in order to support new 
membrane formation (137-139). A recent study in CD4+ T-lymphocytes demonstrated that both 
fatty acid uptake and de novo fatty acid synthesis from glucose are required for robust proliferation 
after antigenic stimulation (146). Considering this, it was postulated that PUFA synthesis might 
serve a role in supporting lymphocyte proliferation. The intracellular dye, CFSE was used to trace 
the proliferation of lymphocytes in PBMC cultures treated with or without the delta-6 desaturase 
inhibitor SC-26196. Results suggested that inhibition of the PUFA pathway causes a small decrease 
in proliferation. This reflects a previously proposed function of n-3 PUFA synthesis in supporting 
membrane synthesis through fine-tuning membrane fatty acid composition (147). However, a 
limitation of the present study was that PUFA synthesis was only reduced by the inhibitor, not 
completely restricted and therefore enough synthesis may have been maintained to support 
proliferation. Furthermore, it is possible that PUFA synthesis is of greater importance when 
exogenous long chain PUFAs are limited. Consequently, the importance of PUFA synthesis in 
supporting lymphocyte proliferation remains unclear. 
The suggestion that PUFA synthesis is required for proliferation conflicts with the evidence that 
both n-6 and n-3 PUFA inhibit lymphocyte proliferation (163, 164, 390, 391). This might be 
explained by concentration and time factors where a finely controlled timing and level of synthesis 
may serve to aid proliferation. This suggestion is supported by a study that showed lower 
concentrations of the n-6 PUFA 18:2n-6 stimulated lymphocyte proliferation where higher 
concentrations inhibited it (167). An alternative theory is that PUFA synthesis might be involved in 
modulating lymphocyte responses and therefore serves an immuno-regulatory function. The 
possible immune-regulatory role aligns with the widely reported anti-inflammatory effects of n-3 
PUFAs. However, since 18:2n-6 is much more prevalent in the diet, the metabolism of n-6 PUFA 
may be more relevant. Modulation of lymphocyte responses by newly synthesised PUFAs might be 
mediated via their conversion to lipid signalling molecules such as eicosanoids and, in the case of 
n-3 PUFAs, resolvins. Eicosanoids, such as prostaglandin E2, are known to have anti-proliferative 
effects. However, evidence suggests that inhibition of lymphocyte proliferation by PUFAs is 
independent of eicosanoids (392). Furthermore, lymphocytes have been reported to be poor 
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producers of eicosanoids (168) although an earlier study demonstrated PUFA synthesised by 
lymphocytes can be utilised by monocytes for eicosanoid synthesis (286).  
Another way newly synthesised PUFAs may act to modulate lymphocyte proliferation is through 
their effects on plasma membrane organisation and fluidity. An increase in membrane fluidity is a 
characteristic part of lymphocyte activation and is associated with a change in membrane 
phospholipid fatty acid composition. Incorporation of PUFA from the culture media in stimulated 
lymphocytes has been shown to further increase membrane fluidity (40, 49) and it has been 
proposed that that this change in fluidity might be the mechanism through which these fatty acids 
inhibit lymphocytes responses (40, 49). Enrichment of PUFA in the plasma membrane also alters 
the lateral organisation of membrane signalling assemblies called lipid rafts. Several important 
processes involve lipid rafts including T-lymphocyte activation and signal transduction (204). n-3 
PUFAs have been reported to disrupt efficient functioning of lipid rafts in T-lymphocytes and in turn 
suppress their activation (207). 
In this study, both the amounts of synthesised n-3 PUFAs and the mRNA expression of FADS2, 
FADS1 and ELOVL5 positively correlated with the proportion of PBMCs expressing the activation 
marker CD69. This further confirmed that the PUFA synthesis pathway is upregulated in activated 
cells. Interestingly, recent evidence suggests that CD69 could be involved in down regulating 
immune responses, which contradicts early in vitro data that suggested CD69 exerts a 
proinflammatory function (393, 394). For example, CD69 has been demonstrated to modulate 
immune allergic responses through negative regulation of allergen induced T-cell effector 
responses (395). The biological functions of both CD69 and PUFA are pleiotropic and complex but 
a possible link between CD69 expression and PUFA synthesis may be a potentially productive 
research area to explore. 
Finally, 20:3n-3, a product in the alternative delta-8 desaturation pathway, was the main n-3 PUFA 
synthesised in activated PBMCs. It is not known whether the delta-8 desaturation pathway 
functions as an alternative route for longer chain n-3 PUFA synthesis or whether the products of 
this pathway have their own distinct biological activities. At present, there is no evidence that 
20:3n-3 and 20:2n-6, or their delta-5 desaturation conversion products 20:4(5,11,14,17) and 
20:3(5,11,14), respectively, are metabolised directly to lipid signalling molecules. However, 20:2n-
6 has been shown to modulate the production of inflammatory mediators, including increasing 
prostaglandin E2 (PGE2) and tumour necrosis factor-α (TNF- α) production, in murine macrophages 
(287). Furthermore, in another study, 20:2n-6 was found to be a potent inhibitor of leukotriene B4 
(LTB4) binding to pig neutrophil LTB4 receptors (288). Considering this, PUFAs synthesised in the 
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alternative delta-8 desaturation pathway, previously thought to be dead end products, may in fact 
have important functions in immune cells. 
To summarise, newly synthesised PUFAs may serve many functions in activated lymphocytes, 
including supporting synthesis of new cell membranes to support proliferation, modifying the 
production and activity of inflammatory mediators, influencing the function of membrane 
associated proteins and signaling pathways by effecting membrane architecture and fluidity and by 
modulating gene expression. Furthermore, these targets are interconnected and therefore 
influence the activity of one another. T-lymphocytes are crucial regulators of the immune response 
and greater understanding of the role of PUFA synthesis in activated T-lymphocytes could 
ultimately lead to the discovery of potential targets for treatment of immune-cell mediated 
disorders. Figure 8.2 attempts to give an overview of the regulation and possible functions of PUFA 
synthesis is activated PBMCs. 
 
Figure 8.2. Schematic summary of the regulation and possible functions of PUFA synthesis in 
PBMCs. 
The top half of the diagram (lighter blue) summarises the findings from the analysis of PUFA 
synthesis in Con A stimulated relative to unstimulated PBMCs in this study. The bottom half of the 
diagram (darker blue) depicts the speculated functions of newly synthesised PUFAs. 
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8.4 PUFA synthesis is dysregulated in a spontaneously dividing T-lymphocyte leukaemic cell 
line 
The findings from this study revealed that n-3 PUFA synthesis was elevated in the spontaneously 
dividing Jurkat T-lymphocyte leukaemic cell line. Conversion of 18:3n-3 to 20:4n-3, 20:5n-3 and 
22:5n-3 was substantially higher in Jurkat cells relative to stimulated PBMCs and the HepG2 liver 
carcinoma cell line, corroborating previous reports of elevated PUFA synthesis in Jurkat cells 
compared with other cell types (148). However, the present study showed for the first time that 
FADS2, FADS1 and ELOVL5 mRNA expression levels are also elevated in Jurkat cells compared with 
activated PBMCs and HepG2 cells. Together these findings suggest transcriptional dysregulation of 
PUFA synthesis in Jurkat cells. Furthermore, analysis of DNA methylation in the FADS2 promoter 
region revealed substantially lower methylation over a large number of CpG dinucleotides, between 
667 bp and 1655 bp upstream of the reported FADS2 TSS, in Jurkat cells compared with activated 
PBMCs. Lower methylation was also measured for two CpGs dinucleotides in the FADS1 promoter 
region. Since high levels of gene expression are generally associated with low levels of promoter 
methylation, the present findings imply that transcriptional dysregulation of PUFA synthesis in 
Jurkat cells involves altered DNA methylation. Aberrant DNA methylation is a common feature of 
cancerous cells (374). Promoter hypomethylation and increased gene expression have been 
reported for specific genes in various cancers including the BCL2 and HOXII genes in leukaemia (375, 
376). In the present study, lower DNA methylation was also measured for a CpG dinucleotide 
located in the putative FADS enhancer region (273) in Jurkat cells compared to stimulated PBMCs, 
further supporting a possible role of this region as an enhancer of FADS transcription. 
Detection of enriched peaks corresponding to 18:4n-3 and 18:2n-6 in GC-C-IRMS analysis confirmed 
the classical pathway was functioning in Jurkat cells. Enrichment in 20:3n-3 and 20:2n-6 was also 
detected in Jurkat cells, indicating that as in stimulated PBMCs, at least part of the delta-8 
desaturation pathway was also operating. Inhibition of the delta-6 desaturase enzyme increased 
the synthesis of these PUFAs. This may be due to there being more 13:3n-3 and 18:2n-6 available 
for conversion, supporting the hypothesis that the alternative delta-8 desaturation and classical 
pathways are in competition. Alternatively, as demonstrated in yeast transformed with mammalian 
Fads2, delta-8 desaturation might be catalysed by the delta-6 desaturase enzyme. Therefore, if this 
same activity were present in Jurkat cells, inhibition of the delta-6 desaturase enzyme would explain 
the accumulation of 20:3n-3 and 20:2n-6 as a result of decreased conversion to 20:3n-6 and 20:4n-
3, respectively. There was a low level of 22:6n-3 synthesis in Jurkat cells. However, the occurrence 
of this became questionable when an experiment showed that increasing the concentration of 
18:3n-3 in the culture medium increased the levels of n-3 PUFAs upstream of 22:6n-3 but not 22:6n-
3 itself. The enrichment measured in 22:6n-3 might be explained by carryover from the large 
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enriched 22:5n-3 peak beside the 22:6n-3 peak in GC-C-IRMS analysis. Questionable 22:6n-3 
synthesis in Jurkat cells and also minimal ELOVL2 mRNA expression aligns with data from PBMCs 
and suggests possible truncation of the pathway at 22:5n-3 in T-lymphocytes.  
Since Jurkat cells are a highly proliferating cell population, it was hypothesised that PUFA synthesis 
might be important for supporting the formation of new membranes in dividing cells. However, 
inhibition of the pathway using the delta-6 desaturase inhibitor SC-26196 had a minimal effect, 
decreasing cell number by 6%. This may have been because the concentration of inhibitor did not 
completely inhibit PUFA synthesis and sufficient levels were maintained to support growth. 
Alternatively, as discussed for PBMCs, the pathway may be serving additional functions to merely 
supporting cell growth. However, given the magnitude of PUFA synthesis in Jurkat cells and the high 
level of proliferation, the theory that PUFA synthesis might be involved in modulating the 
proliferative response becomes doubtful. However, the actions of newly synthesised PUFA in 
cancerous cells may not be comparable to normal cells. The high activity of the PUFA synthesis 
pathway in Jurkat cells reflects the dysregulated de novo fatty acid biogenesis from two carbon 
precursors in cancer cells in general (352). Elucidation of the functional significance of PUFA 
synthesis in Jurkat could be important for understanding how the activity of this pathway relates to 
the perpetuation of cancer cells. 
8.5 The effect of age and gender on PUFA synthesis in activated PBMCs 
In this study, the activity of the PUFA synthesis pathway in Con A stimulated PBMCs was compared 
between males and females across the life course. The activation of the pathway following 
stimulation clearly indicates its importance in the immune response but no previous studies have 
looked at the effect of age and gender on PUFA synthesis capacity in activated PBMCs. The amounts 
of n-3 PUFAs synthesised from [1-13C]18:3n-3 were not found to differ between males and females. 
There were also no gender differences in the mRNA expression levels of FADS2, FADS1 and ELOVL5. 
Furthermore, neither of these measures differed between pre- and post-menopausal women. 
These findings disagree with earlier reports of greater activity of the PUFA synthesis pathway in 
females compared to males (95, 96, 99, 100) and in response to female hormones (102-104). 
Several factors may explain the difference in findings between the present and earlier studies. A 
major difference is represented by the study design; earlier studies measured concentrations of 
labelled n-3 PUFAs in plasma following ingestion of labelled 18:3n-3 whereas the present study 
used a closed culture system. The former does not account for those synthesised PUFAs not 
released into the bloodstream or taken up by target tissues and the latter is an artificial 
environment, which may have had confounding effects. Secondly, the previous studies measured 
the levels of stable isotope labelled n-3 PUFAs at regular intervals over time-periods of 7 days (95) 
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and 21 days (99, 100) compared to a single measurement after 48 h in the present study. Finally, 
activated PBMCs were not found to synthesise 22:6n-3 yet gender differences in n-3 PUFA synthesis 
reported in previous studies were largely attributable to the synthesis of this fatty acid (95, 96, 99, 
100) offering a further explanation for the discrepancy in findings. Despite these explanations, the 
results from this study may indicate that the mechanisms controlling n-3 PUFA synthesis are 
different in activated PBMCs compared with other tissues. Furthermore, it is not known whether 
the activity of alternative delta-8 desaturation pathway is influenced by hormonal factors. 
The effect of age on n-3 PUFA synthesis is less clear with different studies yielding conflicting results 
(97, 100, 117-119). This study showed no clear effects of age on n-3 PUFA synthesis or FADS2, FADS1 
or ELOVL5 mRNA expression. However, when the proportion of activated cells were held constant, 
multiple linear regression analysis predicted a small increase in 20:3n-3 synthesis (0.012 pmol/ µg 
protein per one year increase in age) in females and FADS2 mRNA expression (0.012 units per one 
year increase in age) in males. Whether these values are biologically relevant is not known and 
overall neither gender nor age appeared to influence capacity of n-3 PUFA synthesis in activated 
PBMCs. 
8.6 Thesis limitations 
A limitation of this study that was relevant to all downstream analyses was the use of a 
heterogeneous cell population (PBMCs) as it was unclear which cell types or sub-types were the 
source of detected differences. The use of purified populations of cells would have enabled 
resolution of the cell types responsible for measured changes. However, the large volume of blood 
and time required for purification of single cell populations were not viable in this study. 
Furthermore, a vast number of publications have reported findings from mitogen treated PBMC 
populations as a model for lymphocyte activation.  
The culture period of 48 h may have been another limitation in the study design. A 48 h time period 
was chosen because of previous work in our laboratory (63) and was sufficient to measure 
upregulation of PUFA synthesis in stimulated compared to unstimulated cells. However, a 48 h 
culture period only provided a snapshot of PUFA synthesis capacity and might not have been the 
optimal timeframe for analysis of gender and age differences. Nonetheless, in our previous study, 
a 48 h culture period was sufficient to measure the effect of progesterone treatment on the activity 
of the PUFA synthesis pathway in HepG2 cells and FADS2 mRNA expression in primary hepatocytes 
(104). Measurements at regular intervals over a longer time-period would provide a more complete 
assessment of the activity of the PUFA synthesis pathway. However, as before, the volume of blood 
required for this level of analysis was not feasible in this study. 
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A limitation relating to the analysis PUFA synthesis in pre- and post-menopausal females was the 
number of post-menopausal females recruited (nine) was less than half the number of pre-
menopausal females (twenty-five). This represents a general limitation with recruiting enough 
volunteers within the timeframe of the study and older individuals proved more difficult to recruit. 
Despite this, a major advantage of the present study as a whole was the much higher number of 
participants for comparisons of n-3 PUFA synthesis in unstimulated and stimulated PBMCs and in 
males and females compared with earlier studies (95, 96, 99, 100, 396). Participants in the study 
were asked to limit consumption of oily fish and to cease any consumption of fish-oil supplements 
prior to the study. Compliance has not been verified but this could be done by analysing red blood 
cell fatty n-3 PUFA content as a biomarker of intake (76). 
A major limitation when measuring the effect of inhibiting delta-6 desaturase on lymphocyte 
proliferation was the maximum concentration (200 nM) of the inhibitor (SC-26196) used in the 
experiments did not completely restrict PUFA synthesis, only reduced it. Higher concentrations of 
SC-26196 were avoided to prevent non-specific inhibition of desaturase activities. An alternative 
mechanism to inhibit the pathway using siRNA to knockdown FADS2 expression could be explored 
in future work. 
GC-C-IRMS offers a highly sensitive method for directly measuring the synthesis of labelled n-3 
PUFAs. However, analysis of 22:6n-3 synthesis in Jurkat cells revealed that the detected stable 
isotope enrichment in 22:6n-3 may have been a product of carryover from the large neighbouring 
22:5n-3 peak. This has been previously reported as a limitation of GC-C-IRMS, where isotope 
measurements for compounds eluting immediately after enriched compounds were significantly 
affected due to carryover effects (371). This issue could be resolved by running the samples on a 
low polarity phase, 5% diphenyl/95% dimethyl polysiloxane capillary column (Rtx®-5, Thames 
Restek) that reverses the order in which the fatty acids are eluted. 
5’RACE analysis was conducted to characterise the FADS2 TSS. Initially this was carried out using 
the 5’RLM RACE kit which has the advantage of being specific for mature capped mRNAs. 
Unfortunately, this kit resulted in formation of an artefact, which appeared consistent since the 
same artefact was observed by another researcher. Therefore, 5’RACE was carried out using a 
different kit (SMARTer™ RACE). Successful RACE products were obtained but the SMARTer™ RACE 
kit does not guarantee specificity for full length cDNAs. Eleven independent clones containing the 
gene specific inserts were sequenced (the kit recommends picking at least 8-10 different clones) in 
order to obtain the maximum amount of sequence at the 5’end.  
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8.7 Future work 
The research presented in this thesis has identified a number of novel findings in relation to the 
characterisation and regulation of PUFA synthesis in activated PBMCs. Given more time, future 
experiments could build on the present findings to gain further understanding of the mechanistic 
and functional aspects of this pathway in PBMCs.  
A number of experiments could help answer the unresolved mechanistic questions arising from this 
thesis. Firstly, the identity of the enzyme responsible for catalysing the elongation of 18:3n-3 to 
20:3n-3 in activated PBMCs is not known but was speculated to be elongase-5. To verify this, siRNA 
could be introduced into activated PBMCs to silence ELOVL5 gene expression and synthesis of 
20:3n-3 from 18:3n-3 could then be compared with activated PBMCs in which the ELOVL5 gene is 
functional. Secondly, whether 20:3n-3 was converted to 20:4n-3 and therefore fed back into the 
classical pathway remains unknown. This could be investigated by incubating cells with stable 
isotope labelled 20:3n-3 and measuring enrichment in 20:4n-3 and downstream conversion 
products. Although retro-conversion of 20:3n-3 to 18:3n-3 would have to be accounted for. 
Conversion of 20:3n-3 by delta-5 desaturation to the unusual product 20:4(5,11,14,17) could also 
be investigated using stable isotope labelled 20:3n-3. Lastly, to establish whether limited ELOVL2 
expression underlies the lack of 22:6n-3 synthesis observed in PBMCs, cells could be incubated with 
downstream pathway intermediates (24:5n-3 and 24:6n-3) to determine whether 22:6n-3 synthesis 
is restored.  
Higher n-3 PUFA synthesis and FADS2, FADS1 and ELOVL5 mRNA expression in stimulated compared 
with unstimulated PBMCs strongly indicates that upregulation of the pathway involves increased 
levels of the delta-6 and delta-5 desaturase and elongase-5 enzymes. However, mRNA expression 
levels do not always correlate with the expression of the correspondent protein. The Western blot 
technique would enable confirmation of increased protein levels. This technique could also be used 
to verify whether ELOVL5 was the most highly expressed pathway enzyme in activated PBMCs.  
Functional characterisation of the putative FADS enhancer region represents an interesting area for 
future work. One approach would be to clone the enhancer region into a reporter plasmid construct 
containing a minimal promoter and then introduce the construct into cells for functional analysis. 
The effect of the putative enhancer on the activity of the minimal promoter could be tested by 
comparing the enzymatic activity of the reporter gene in cells transfected with the reporter 
construct either with or without the putative enhancer element. However, a major limitation of this 
technique is there is always the potential that the reporter construct will not completely 
recapitulate the normal functioning of a given promoter or enhancer.  
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Reporter gene assays can also be utilised to investigate the effect of methylation in promoter 
and/or enhancer regions on gene expression. A common method is to add the promoter or 
enhancer elements to a CpG dinucleotide free reporter vector such as PCpGL and methylate the 
whole construct. The absence of CpG dinucleotides in the plasmid backbone limits in vitro CpG 
methylation to the inserted CpG containing elements. Methylated or unmethylated constructs can 
then be transfected into cells and the expression of the reporter gene compared. 
The putative FADS enhancer region was previously reported to have the histone modification 
signature of an enhancer (273). However, this analysis was carried out using ENCODE regulatory 
tracks and such predictive methods do not always translate universally across cell types. Therefore, 
in future experiments histone modifications in the putative FADS enhancer could be profiled 
experimentally, for example in unstimulated and stimulated PBMCs, using Chromatin 
Immunoprecipitation (ChIP). ChIP is a procedure used to examine protein interactions with DNA. 
When examining histone modifications, antibodies against specific histone marks are used to 
isolate the protein-DNA complex of interest and after removal of crosslinks the precipitated DNA 
can be quantified by real-time RT-PCR. Histone modifications associated with active transcription 
include histone H3 acetylation and di- or tri-methylation of histone H3 at lysine 4 (H3K4) whereas 
H3K9 methylation is associated with silent genes. Specifically, active enhancers are marked by 
monomethylation of H3K4 and H3K27 acetylation (397). In addition to profiling histone 
modifications, computational predictions of transcription factor binding sites can be experimentally 
tested using ChIP. Furthermore, binding of transcription factors to, for example, the FADS2 
promoter could be measured under different experimental conditions such as in unstimulated and 
stimulated PBMCs. 
Another technique, named the electrophoretic mobility shift assay (EMSA), has been widely used 
to study DNA-protein interactions. EMSA could be used to investigate the binding of transcription 
factors to the differentially methylated region in the FADS2 and FADS1 promoters and the putative 
FADS enhancer region. This technique is based on the principle that complexes of protein and DNA 
migrate more slowly than free linear DNA fragments through a non-denaturing polyacrylamide gel. 
The assay is performed by incubating a purified or complex mixture of proteins, such as a nuclear 
extract, with a labelled DNA fragment (probe) containing the putative protein binding site. Two 
main approaches are used to determine the specificity of binding and the identity of the protein 
involved: competition with unlabelled competitor DNA and incubation with antibodies specific to 
the putative DNA binding protein (antibody supershifts). Furthermore, methylated and 
unmethylated probes can be employed to determine the effect of methylation on transcription 
factor binding. 
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An important question that remains unanswered is the biological function of activated PUFA 
synthesis in stimulated PBMCs. One hypothesis is that newly synthesised PUFAs are channelled into 
production of lipid signalling molecules such as eicosanoids and resolvins. To test this hypothesis, 
stimulated PBMC cultures could be treated with stable-isotope labelled 18:2n-6 and 18:3n-3 and 
potential enrichment in eicosanoids or resolvins measured using mass spectrometry. This 
hypothesis could be further explored by comparing levels of eicosanoids and resolvins in activated 
PBMCs where the PUFA synthesis pathway is functional, with activated PBMCs where the pathway 
has been inhibited.  Finally, as mentioned earlier, development of siRNA techniques might permit 
greater inhibition of the PUFA pathway, which would enable further characterisation of the 
importance of the pathway in supporting lymphocyte proliferation. 
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A.1 Table of reagents and products 
Reagent/Product Supplier 
37 FAMES Sigma-Aldrich, UK 
 
Agar Sigma-Aldrich, UK 
 
Agarose, BioReagent for molecular biology Sigma-Aldrich, UK 
Ambion FirstChoice™ RLM-RACE Kit Thermo Fisher Scientific, UK 
Aminopropylsilica Cartridges Agilent, USA 
Ampicillin, sodium salt Sigma-Aldrich, UK 
 
BD CellFIX (10X) BD Bioscience, UK 
 
BD CellWASH 
 
BD Bioscience, UK 
 
BDFACSFlow 
 
BD Bioscience, UK 
 
BlueJuice™ Gel Loading Buffer (10X) Thermo Fisher Scientific, UK 
Butylated hydroxytoluene Sigma-Aldrich, UK 
 
CellTiter-Glo® Luminescent Cell Viability Assay Promega, UK 
CFSE Thermo Fisher Scientific, UK 
(ebioscience) 
Chloroform 
 
Sigma-Aldrich, UK 
 
cis-11,14,17-Eicosatrienoic acid Sigma-Aldrich, UK 
 
cis-4,7,10,13,16-Docosapentaenoic acid Sigma-Aldrich, UK 
 
Cis-7,19,13,16-Docosatetraenoic acid Sigma-Aldrich, UK 
 
Concanavalin A Sigma-Aldrich, UK 
CpGenome Universal Methylated DNA Merk Millipore, UK 
CpGenome Universal Unmethylated DNA Merk Millipore, UK 
Custom primers Eurofins Scientific, Luxembourg 
Diheptadecanoyl-sn-glycero-3-phosphocholine Sigma-Aldrich, UK 
 
DMSO Fisher Scientific, UK 
DNeasy® Blood and Tissue Kit Qiagen, UK 
Dulbecco’s Modified Eagle’s Medium – high glucose Sigma-Aldrich, UK 
 
Ethanol Fisher Scientific, UK 
FastDigest Restriction Enzymes Thermo Fisher Scientific, UK 
Fetal Bovine Serum Thermo Fisher Scientific, UK 
FITC Mouse Anti-human CD69 
 
BD Bioscience, UK 
 
FITC Mouse lgG1, K Isotype control 
 
BD Bioscience, UK 
 
FITC Mouse-Anti-human CD19 
 
Bio-Rad, UK 
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FITC Mouse-Anti-human CD3 
 
Bio-Rad, UK 
 
Gel Red nucleic acid stain (10,000X) Cambridge Bioscience, UK 
GeNorm Kit Primerdesign, UK 
GoTaq® Hot Start DNA polymerase Promega, UK 
Halt™ Protease and Phosphatase Inhibitor Cocktail Thermo Fisher Scientific, UK 
HepG2 cells ECACC, UK 
Hexane 
 
Sigma-Aldrich, UK 
 
Human Peripheral Blood Mononuclear cells Stemcell Technologies, Canada 
Jurkat cells ECACC, UK 
KAPA2G Robust Hotstart ReadyMix Kapa Biosystems, USA 
L-Glutamine solution 200 mM Sigma-Aldrich, UK 
 
Linoleic acid Sigma-Aldrich, UK 
 
Linoleic acid-13C18 Sigma-Aldrich, UK 
 
Linolenic Acid Sigma-Aldrich, UK 
 
Linolenic Acid-13C18 Campro Scientific GmbH, Germany 
LIVE/DEAD Fixable Red Dead Cell Stain Kit Thermo Fisher Scientific, UK 
Luria broth Sigma-Aldrich, UK 
 
L-α-phospatidylcholine Sigma-Aldrich, UK 
 
Menhaden Oil Sigma-Aldrich, UK 
 
Methanol Sigma-Aldrich, UK 
 
PCR Nucleotide Mix Promega, UK 
Penicillin-Streptomycin (100X) Sigma-Aldrich, UK 
 
Phosphate buffered saline 
 
Sigma-Aldrich, UK 
 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific, UK 
Potassium bicarbonate Sigma-Aldrich, UK 
 
Potassium carbonate Sigma-Aldrich, UK 
 
PyroMark Annealing Buffer Qiagen, UK 
PyroMark Binding Buffer Qiagen, UK 
PyroMark Denaturation Solution Qiagen, UK 
PyroMark Gold Q96 Reagents Qiagen, UK 
PyroMark Wash Buffer Qiagen, UK 
Qiaprep Spin Miniprep Kit Qiagen, UK 
QuantiFast SYBR Green PCR kit Qiagen, UK 
Quantitect Primer Assays Qiagen, UK 
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Random Nonamers Sigma-Aldrich, UK 
Reference Gene Assays Primerdesign, UK 
RNase and DNase free water Fisher Scientific, UK 
RNase Free DNase Set Qiagen, UK 
RNeasy® Mini Kit Qiagen, UK 
RPE Mouse-Anti-human CD14 
 
Bio-Rad, UK 
 
RPMI, with sodium bicarbonate, without L-glutamine Sigma-Aldrich, UK 
 
SC-26196 Sigma-Aldrich, UK 
SMARTer® RACE 5’/3’ Kit Clontech Laboratories, UK 
Stearidonic acid Sigma-Aldrich, UK 
 
Steptavidin Sepharose High Performance GE Healthcare Life Sciences, UK 
TAE buffer (50X) Thermo Fisher Scientific, UK 
TE Buffer Promega, UK 
Toluene Sigma-Aldrich, UK 
 
TOPO™ TA Cloning™ Kit for Sequencing, with One Shot 
TOP10 Chemically Competent E.coli 
 
Thermo Fisher Scientific, UK 
Zymo Research EZ-96 DNA methylation-Gold™ Kit Cambridge Bioscience, UK 
Zymoclean™ Gel DNA Recovery Kit Cambridge Bioscience, UK 
 
A.2 Cell culture 
A.2.1 Maintenance media 
PBMC medium: 
RPMI-1640 supplemented with 2 mM L-Glutamine, 100 units/ml penicillin and 100 µg/ml 
streptomycin.  This media was supplemented further with 5 % (v/v) autologous plasma or 10 % (v/v) 
fetal bovine serum (FBS) for PBMCs isolated from volunteers’ lithium heparin treated blood and 
purchased cryropreserved PBMCs, respectively.  
Jurkat cell medium: 
RPMI-1640 medium supplemented with 2 mM L-Glutamine, 100 units/ml penicillin and 100 µg/ml 
streptomycin and 10% (v/v) fetal bovine serum (FBS). 
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HepG2 medium: 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 2 mM L-Glutamine, 100 units/ml 
penicillin, 100 µg/ml streptomycin and 10% (v/v) FBS. 
A.2.2 Cell culture treatment compounds 
Stable isotope labelled linoleic acid ([U-13C]18:2n-6): 
10 mM stock solution was made for both [U-13C]18:2n-6 (Sigma-Aldrich) and unlabelled 18:2n-6 
(Sigma-Aldrich) in ethanol. These were then diluted to 1 mM in the appropriate maintenance 
medium. Labelled 18:2n-6 was then diluted 60-fold with unlabelled 18:2n-6 and added to the cell 
culture media at the appropriate concentration always ensuring that the percentage of ethanol in 
the final cell culture medium did not exceed 0.1%. The 60-fold dilution factor was determined 
experimentally (see section 2.12.5.3). 
Stable isotope labelled alpha-linolenic acid ([1-13C]18:3n-3) 
1 ml of ethanol was added to a vial containing 10 mg [1-13C]18:3n-3 (Campro Scientific) and 
vortexed. From this a 1 mM stock was then made in the appropriate growth medium for the cells 
being treated. A 1 mM stock of unlabelled 18:3n-3 (Sigma-Aldrich) was prepared in the same way. 
The 1 mM [1-13C]18:3n-3 was then diluted 10-fold with 1 mM unlabelled 18:3n-3 and added to the 
cell culture medium at the appropriate concentration always ensuring that the percentage of 
ethanol in the final cell culture medium did not exceed 0.1%. The 10-fold dilution factor was 
calculated from the 60-fold required for [U-13C]18:2n-6. 
Concanavalin A 
The T cell mitogen concanavalin A (ConA) was dissolved in PBMC medium to make a 0.5 mg/ml 
stock and added to cells at a final concentration of 5 µg/ml.  
SC-26196 
A 10 mM stock of the delta-6 desaturase inhibitor was prepared in DMSO. A series of 10-fold 
dilutions, the first in DMSO and the second and third in the appropriate maintenance media, were 
made to achieve a 10 µM stock solution. This was then added directly to the cell culture medium at 
the following concentrations: 50 nM, 100 nM, 150 nM and 200 nM. 
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A.3 Instrument settings for flow cytometry analyses 
Instrument Settings    
Detector Voltage AmpGain Mode 
Application: PBMC Phenotyping and CD69 expression 
FSC E00 2.55 Linear 
SSC 407 3.0 Linear 
FL-1 492 1.0 Log 
FL-2 628 1.0 Log 
FL-3 150 1.0 Log 
Compensation    
FL-1 – 0% FL-2  
FL-2 – 39.9% FL-1  
Application: CFSE proliferation and LIVE/DEAD red viability 
FSC E00 1.23 Linear 
SSC 407 2.0 Linear 
FL-1 492 1.0 Log 
FL-2 628 1.0 Log 
FL-3 150 1.0 Log 
Compensation    
FL-1 – 0% FL-2  
FL-2 – 44.1% FL-1  
 
A.4 Coefficients of variation 
A.4.1 COBAS MIRA auto-analyser 
 TG 
(mmol/l) 
Total Cholesterol 
(mmol/l) 
HDL Cholesterol 
(mmol/l) 
Glucose      
(mmol/l) 
Low QC     
n 40 30 11 70 
Mean 1.28 2.71 0.89 4.97 
SD 0.06 0.13 0.03 0.09 
CV (%) 4.90 4.87 3.71 1.89 
High QC     
n 40 30 11 70 
Mean 2.39 5.43 1.78 13.53 
SD 0.10 0.26 0.08 0.36 
CV (%) 4.37 4.74 4.73 2.69 
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A.4.2 GC-C-IRMS δ-value 
The δ-value (raw data) was monitored for unenriched and [13C] enriched 18:3n-3 for all GC-C-IRMS 
runs to calculate an inter-assay CV. In a separate experiment, the δ-value intra-assay CV was 
measured for a [13C] enriched 18:2n-6 sample diluted to achieve different peak areas.  
 Unenriched 18:3n-3 Enriched  18:3n-3 Enriched 18:2n-6    
(peak area of 1 to 2) 
Enriched 18:2n-6   
(peak area <1) 
n 14 14 5 5 
Mean 
(δ-value) 
-32.43 131.53 276.93 245.83 
SD 1.56 7.86 13.08 23.35 
CV (%) 4.80 5.98 4.72 9.50 
 
A.5 Agarose gel electrophoresis DNA ladders 
Thermo Scientific GeneRuler 1 kb Plus (left) and 100 bp Plus (right) DNA ladders. Images are taken 
form the product manual and show the size of the DNA reference bands. 
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B.1 Participant Information Sheet 
 
Participant Information Sheet 
 
Title of study: Epigenetic regulation of omega-3 polyunsaturated fatty acid synthesis 
(The ‘E-PUFA’ study) 
We would like to invite you to take part in our research study. Before you decide whether or 
not you wish to take part it is important that you understand why the research is being done 
and what the research will involve. You are free to decide whether or not to take part in this 
study. Please read the information carefully and discuss it with others if you wish and ask 
us if there is anything that is not clear, or if you would like more information. 
 
What is the purpose of this study? 
Long chain omega-3 fatty acids are believed to be beneficial to human health. They can be 
obtained by eating oily fish. Humans can also make their own long chain omega-3 fatty 
acids in the body from alpha-linolenic acid (ALA), a fatty acid that can only be obtained from 
the diet, for example by eating vegetable oils. Since intake of oily fish is relatively low in the 
UK, this production of long chain omega-3 fatty acids from ALA could be important for 
meeting nutritional requirements. It has been found that increasing levels of long chain 
omega-3 fatty acids can help promote healthy ageing. However, there is limited information 
about our capacity to produce these fatty acids throughout our lives. It has been found that 
women have a greater ability to make long chain omega-3 fatty acids than men but we do 
not fully understand the biological mechanisms behind this.  
We want to find out if the capacity of men and women to make long chain omega-3 fatty 
acids changes with age. If it does then we want to find out how this happens. Specific genes 
can make proteins called enzymes that are responsible for making long chain omega-3 fatty 
acids. In order to do this these genes get copied to a molecule called RNA which is then 
used by cells to build the enzymes. We will be measuring the amount of RNA produced by 
your cells to see if this relates to any changes in the synthesis of omega-3 fatty acids. We 
will also extract DNA from your cells in order to look at a mechanism called epigenetic 
regulation, which is a process that can finely tune the amount of protein that is made by our 
genes. 
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This work is important as it could help us to understand how nutritional requirements for 
long chain omega-3 fatty acids may change for men and women throughout their lives. This 
work could also help us understand how the production of these important fatty acids in the 
body is regulated. In this study we will be measuring long chain omega-3 fatty acids in blood 
and in cheek (buccal) cells. 
 
Can I take part? 
To take part in this study you are required to be a White, Caucasian, male or female, aged 
between 18 and 71 years, healthy and have a BMI between 18.5 and 30. You will not be 
able to take part if any of the following apply to you: 
 You are pregnant 
 You are currently taking the oral contraceptive pill 
 You are receiving hormone replacement therapy 
 You have type 1 or type 2 diabetes 
 You are a smoker 
 You are male and consume more than 28 units of alcohol per week or female and 
consume more than 21 units of alcohol per week 
 You consume more than one portion of oily fish per week 
 You consume fish oil capsules (consumption would have to be terminated 3 months 
prior to the start of the study if you wish to take part) 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
asked to sign a consent form. However, you will still be free to withdraw at any time, and 
without giving a reason. If you do withdraw, you will be asked whether you want us to 
destroy any samples you have given as part of the study. 
 
What would taking part involve?  
Screening and study appointment: 
If you decide that you would like to participate in this study you will have to attend a 
screening appointment before commencing the study. Prior to the screening appointment 
we will send you a basic health and diet questionnaire and you will need to complete and 
return part A of the questionnaire before coming for your appointment. You will need to 
arrive at your appointment fasting (nothing to eat since 10pm the night before, and only 
water to drink). You will be introduced to the study team and we will discuss the project with 
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you. You will be given the opportunity to ask any questions arising from the discussion or 
this information sheet. At this point, if you are happy with all aspects of the study and still 
wish to take part, we will ask you to sign a consent form.  
If your consent is given, your study appointment will follow immediately after your screening 
appointment.  We will measure your height, weight, blood pressure and your percentage 
body fat. You will be introduced to a research nurse or doctor who will take a 40-50 ml blood 
sample. You will also be asked to provide a cheek cell sample, which involves gently 
brushing the inside of your cheek with a brush similar to a toothbrush. The samples you 
give will be used to measure omega-3 fatty acids levels in your cells and the ability of your 
cells to synthesise these fatty acids.  We will also measure blood glucose, triglyceride and 
cholesterol and haemoglobin using the blood sample you have given. A copy of the results 
will be sent to you and your GP. The study appointment will take place at the Cedar Centre, 
Royal Surrey County Hospital. The length of the visit should be approximately 1 hour. We 
will give you a drink and a snack to eat before you leave. 
 
How will the data collected be stored? 
All experimental data will be stored securely according to the data protection act 1998 on 
the password protected university servers (for a period of 10 years) and any information 
you give will be stored separately via a fully anonymous link.  You will be given a trial number 
following recruitment. Sensitive information will not be stored on either personal home 
computers or disks. Electronic data sets will continue to be stored and accessed following 
completion of the study, however, your paper records and sensitive information which could 
identify you will be destroyed on completion of the study. 
 
What will happen to the samples I give? 
If you consent, we would like to keep any unused blood samples for further research related 
to the project. This could be another student project, for example. The samples will be used 
in a completely anonymised way and any use will have an appropriate ethical review. DNA 
samples will not be used for further research projects.  
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What are the possible benefits of taking part? 
You will not receive any direct benefit from taking part in the study. However, you will receive 
a health check.  Knowledge gained from this study will help our research and may ultimately 
be of use to other researchers and to consumers. 
 
What are the possible disadvantages and risks of taking part? 
There is a very small chance of bruising at the site of insertion of the needle for collection 
of blood samples. This risk will be minimised by using fully trained members of staff. You 
may feel a little faint when having your blood sample taken. If this has happened to you 
before then please inform us. 
 
What will happen if anything goes wrong? 
Any complaint or concern about any aspects of the way you have been dealt with during 
the course of the study will be addressed. If you have any concerns about any aspect of the 
study please contact:  
Charlene Sibbons 
Tel: 01483 688642  
Email: c.sibbons@surrey.ac.uk 
 
Alternatively, you can contact the Patient Advice and Liason Service (PALS): 
 
PALS at Royal Surrey County Hospital Egerton Road, Guildford GU2 7XX 
Tel: 01483 402757 
Email: rsc-tr.PALS@nhs.net  
 
Will my taking part in this study remain confidential? 
Your GP will be notified that you are participating in this study, but any information that is 
collected about you during the course of the research will be coded with a study number 
and will be kept strictly confidential.  
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What will happen to the study results? 
We will inform you of the overall results from the study.  The results of this research study 
may be presented at scientific meetings or published in a scientific journal. This may not 
happen until 1 or 2 years after the study is completed and you will not be identified in any 
of these presentations or publications. If you contact the researchers in the future we will let 
you know where you can obtain a copy of the published results.  
 
Will I be reimbursed for my time? 
In recognition of your time and commitment you will be paid an honorarium of £25.  
 
Who is organising and funding the study? 
This study has been organised by the University of Surrey and is funded by the 
Biotechnology and Biological Sciences Research Council Doctoral Training Partnership 
(BBSRC DTP) and the Rank Prize Fund. 
 
Who has reviewed the study? 
This study has been reviewed by the University of Surrey ethics committee and the NHS 
ethics review process. 
 
Contact for further information 
Charlene Sibbons 
Tel: 01483 688642  
Email: c.sibbons@surrey.ac.uk 
 
Thank you for reading this information sheet. If you are interested in being involved 
in the study please contact the study team to arrange a screening appointment 
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B.2 Screening Questionnaire 
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B.3 Consent form 
 
